{"DataElement":{"publicId":"6160592","version":"1","preferredName":"Prior First-Line Therapy Administered Agent Name","preferredDefinition":"A response used to determine which therapeutic agents that produced an effect that is intended to alter or stop a pathologic process was previously given as the preferred standard treatment for a particular condition.","longName":"6133435v1.0:2939030v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"6133435","version":"1","preferredName":"Prior First-Line Therapy Administered","preferredDefinition":"Earlier in time or order._The preferred standard treatment for a particular condition._The act of having given something (e.g., a medication or test).","longName":"5720345v1.0:2233610v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"5720345","version":"1","preferredName":"Prior First-Line Therapy","preferredDefinition":"Earlier in time or order.:The preferred standard treatment for a particular condition.","longName":"C25629:C45792","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"First-Line Therapy","conceptCode":"C45792","definition":"The preferred standard treatment for a particular condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B300A65-90D1-0324-E053-F662850A122E","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"ONEDATA","dateModified":"2017-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"67615C1B-6852-1EA6-E053-F662850ABBAF","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-03-14","modifiedBy":"GARRIDOJ","dateModified":"2018-07-11","changeDescription":"Created for EA5152, 03/14/18 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2939030","version":"1","preferredName":"Prior Therapy Agent Name","preferredDefinition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.","longName":"PRI_TX_AGT_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"MEGF0444A","valueDescription":"MEGF0444A (Humanized IgG1 Antibody)","ValueMeaning":{"publicId":"3076402","version":"1","preferredName":"MEGF0444A (Humanized IgG1 Antibody)","longName":"3076402v1.00","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parsatuzumab","conceptCode":"C90567","definition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C641-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C65A-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Montelukast","valueDescription":"Montelukast Sodium (Singulair)","ValueMeaning":{"publicId":"2578304","version":"1","preferredName":"Montelukast Sodium (Singulair)","longName":"2578304","preferredDefinition":"The monosodium salt of montelukast, a selective and orally active leukotriene receptor antagonist with anti-inflammatory and bronchodilator activity. Montelukast sodium selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, thereby preventing leukotriene D4 from binding to its receptor. This prevents leukotriene-mediated activities, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability and bronchoconstriction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Montelukast Sodium","conceptCode":"C47625","definition":"The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C66F-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Pulmicort","valueDescription":"Budesonide","ValueMeaning":{"publicId":"2576032","version":"1","preferredName":"Budesonide","longName":"2576032","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2012-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C683-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Ipratropium","valueDescription":"Ipratropium","ValueMeaning":{"publicId":"3076449","version":"1","preferredName":"Ipratropium","longName":"3076449","preferredDefinition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipratropium","conceptCode":"C61794","definition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C690-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C6A9-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Levalbuterol","valueDescription":"Levalbuterol (Xopenex)","ValueMeaning":{"publicId":"3076450","version":"1","preferredName":"Levalbuterol (Xopenex)","longName":"3076450v1.00","preferredDefinition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levalbuterol","conceptCode":"C74196","definition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C6B5-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C6CD-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Tiotropium","valueDescription":"Tiotropium Bromide Monohydrate","ValueMeaning":{"publicId":"3076452","version":"1","preferredName":"Tiotropium Bromide Monohydrate","longName":"3076452v1.00","preferredDefinition":"The monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. Upon inhalation, tiotropium binds to and blocks mainly muscarinic M3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tiotropium Bromide Monohydrate","conceptCode":"C61974","definition":"The monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. Upon inhalation, tiotropium binds to and blocks mainly muscarinic M3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C6DB-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C6F4-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Technetium Tc-99m Apcitide","valueDescription":"Technetium Tc-99m Apcitide","ValueMeaning":{"publicId":"2939364","version":"1","preferredName":"Technetium Tc-99m Apcitide","longName":"2939364","preferredDefinition":"A radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99). Apcitide binds to platelet glycoprotein (GP) GPIIb/IIIa receptors on the surface of activated platelets. Labeling apcitide with TC99m allows localization of thrombus formation by gamma-ray imaging equipment and the ability to distinguish between old, inactive thrombi and new, active thrombi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Technetium Tc-99m Apcitide","conceptCode":"C47745","definition":"A radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99). Apcitide binds to platelet glycoprotein (GP) GPIIb/IIIa receptors on the surface of activated platelets. Labeling apcitide with TC99m allows localization of thrombus formation by gamma-ray imaging equipment and the ability to distinguish between old, inactive thrombi and new, active thrombi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7339449B-3976-92A9-E040-BB89AD435E25","latestVersionIndicator":"Yes","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7339449B-398F-92A9-E040-BB89AD435E25","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"ONEDATA","dateModified":"2009-09-10","deletedIndicator":"No"},{"value":"Iodine-131","valueDescription":"Iodine I 131","ValueMeaning":{"publicId":"2939366","version":"1","preferredName":"Iodine I 131","longName":"2939366","preferredDefinition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I-131","conceptCode":"C1639","definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7339449B-399C-92A9-E040-BB89AD435E25","latestVersionIndicator":"Yes","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7339449B-39B5-92A9-E040-BB89AD435E25","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"ONEDATA","dateModified":"2009-09-10","deletedIndicator":"No"},{"value":"Fostamatinib Disodium","valueDescription":"Fostamatinib Disodium","ValueMeaning":{"publicId":"2939032","version":"1","preferredName":"Fostamatinib Disodium","longName":"2939032","preferredDefinition":"An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fostamatinib Disodium","conceptCode":"C69128","definition":"An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4ADE-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72F42843-4AF7-DE11-E040-BB89AD43432F","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"ONEDATA","dateModified":"2009-09-06","deletedIndicator":"No"},{"value":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","valueDescription":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","ValueMeaning":{"publicId":"2958646","version":"1","preferredName":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","longName":"2958646","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Robatumumab","conceptCode":"C71527","definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4414-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-442D-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","valueDescription":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","ValueMeaning":{"publicId":"2958647","version":"1","preferredName":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","longName":"2958647","preferredDefinition":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4437-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-4450-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"TRICOM","valueDescription":"TRICOM","ValueMeaning":{"publicId":"3013193","version":"1","preferredName":"TRICOM","longName":"3013193","preferredDefinition":"TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3).  An immunostimulant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TRICOM","conceptCode":"C2192","definition":"TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3).  An immunostimulant.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF9397D-428B-21AE-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FF9397D-42A4-21AE-E040-BB89AD436688","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"ONEDATA","dateModified":"2010-02-19","deletedIndicator":"No"},{"value":"Ch 14.18 Monoclonal Antibody","valueDescription":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","ValueMeaning":{"publicId":"3021176","version":"1","preferredName":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","longName":"3021176","preferredDefinition":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-59B3-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"817312F9-59CC-37DB-E040-BB89AD437AE8","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"ONEDATA","dateModified":"2010-03-10","deletedIndicator":"No"},{"value":"PG13-CEA_TCR","valueDescription":"PG13-CEA_TCR","ValueMeaning":{"publicId":"3021177","version":"1","preferredName":"PG13-CEA_TCR","longName":"3021177","preferredDefinition":"PG13-CEA_TCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-59D6-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"817312F9-59EF-37DB-E040-BB89AD437AE8","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"ONEDATA","dateModified":"2010-03-10","deletedIndicator":"No"},{"value":"Hsp90 Inhibitor STA-9090","valueDescription":"Hsp90 Inhibitor STA-9090","ValueMeaning":{"publicId":"3061618","version":"1","preferredName":"Hsp90 Inhibitor STA-9090","longName":"3061618","preferredDefinition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor STA-9090 binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganetespib","conceptCode":"C77872","definition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8496A11C-C12A-2BBD-E040-BB89AD4333D9","latestVersionIndicator":"Yes","beginDate":"2010-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8496A11C-C143-2BBD-E040-BB89AD4333D9","beginDate":"2010-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-19","modifiedBy":"ONEDATA","dateModified":"2010-04-19","deletedIndicator":"No"},{"value":"Extracorporeal Photopheresis","valueDescription":"Extracorporeal Photopheresis","ValueMeaning":{"publicId":"2777671","version":"1","preferredName":"Extracorporeal Photopheresis","longName":"2777671","preferredDefinition":"A procedure in which blood is removed from the body and treated with ultraviolet light and drugs that become active when exposed to light. The blood is then returned to the body. It is being studied in the treatment of some blood and bone marrow diseases and graft-vs-host disease (GVHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"554B1B7C-0FF8-6EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A954510-44E8-B49A-E040-BB89AD4331E4","beginDate":"2010-07-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-04","modifiedBy":"ONEDATA","dateModified":"2010-07-04","deletedIndicator":"No"},{"value":"NY-ESO-1 Peptide Vaccine","valueDescription":"NY-ESO-1 Peptide Vaccine","ValueMeaning":{"publicId":"3061104","version":"1","preferredName":"NY-ESO-1 Peptide Vaccine","longName":"3061104","preferredDefinition":"A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NY-ESO-1 Peptide Vaccine","conceptCode":"C2657","definition":"A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8448DBD5-814E-B470-E040-BB89AD433DC3","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8448DBD5-8167-B470-E040-BB89AD433DC3","beginDate":"2010-04-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-15","modifiedBy":"ONEDATA","dateModified":"2010-04-15","deletedIndicator":"No"},{"value":"Albuterol","valueDescription":"Albuterol (Proventil, Ventolin, Volmax)","ValueMeaning":{"publicId":"2575988","version":"1","preferredName":"Albuterol (Proventil, Ventolin, Volmax)","longName":"2575988","preferredDefinition":"A racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol. It is a short-acting beta2-adrenergic agonist with its main clinical use in asthma. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albuterol","conceptCode":"C215","definition":"A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C6FE-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Fluticasone","valueDescription":"Fluticasone Propionate (Flovent)","ValueMeaning":{"publicId":"3076454","version":"1","preferredName":"Fluticasone Propionate (Flovent)","longName":"3076454","preferredDefinition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.: A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone Propionate","conceptCode":"C29061","definition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluticasone","conceptCode":"C61767","definition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C70D-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C726-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin (Zithromax)","ValueMeaning":{"publicId":"3076456","version":"1","preferredName":"Azithromycin (Zithromax)","longName":"3076456","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death. [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C753-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C76B-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine (Ara C, Cytosine Arabinoside)","ValueMeaning":{"publicId":"2960387","version":"1","preferredName":"Cytarabine (Ara C, Cytosine Arabinoside)","longName":"2960387","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE25-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C776-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Oxandrolone","valueDescription":"Oxandrolone (Oxandrin)","ValueMeaning":{"publicId":"3076461","version":"1","preferredName":"Oxandrolone (Oxandrin)","longName":"3076461","preferredDefinition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxandrolone","conceptCode":"C29306","definition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C7A9-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"852693AD-C7F3-32F2-E040-BB89AD436CB9","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"ONEDATA","dateModified":"2010-04-26","deletedIndicator":"No"},{"value":"Reolysin","valueDescription":"Reolysin","ValueMeaning":{"publicId":"3124280","version":"1","preferredName":"Reolysin","longName":"3124280","preferredDefinition":"A serotype 3 Dearing strain (T3D) of reovirus (Respiratory Enteric Orphan VIRUS). Reovirus, a dsRNA virus, is able to replicate specifically in cancer cells bearing an activated Ras pathway. In contrast to normal cells, two-thirds of human cancer cells are Ras-activated, and are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR). In Ras-activated cancer cells, reovirus is able to freely replicate and subsequently cause apoptosis in the tumor cells. Cell lysis frees progeny viral particles to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until no more Ras-activated tumor cells are available. Because the reovirus kills Ras-activated cancer cells, this is a potential therapeutic for malignant glioma, pancreatic, colon and some lung cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pelareorep","conceptCode":"C60774","definition":"An isolate of the oncolytic, human wild-type serotype 3 Dearing (T3D) strain of the double-stranded RNA virus reovirus (Respiratory Enteric Orphan virus), with potential oncolytic activity. Upon administration, pelareorep is able to replicate specifically in cancer cells bearing an activated Ras pathway. This induces apoptosis in Ras-activated tumor cells and subsequently frees progeny viral particles to infect, replicate in and induce cell death of surrounding cancer cells. In addition, viral replication causes the activation of innate and adaptive immune responses, causing a natural killer (NK)-cell-mediated and a cytotoxic T-cell (CTL)-mediated killing of tumor cells, respectively. Ras-activated tumor cells are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D646-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C0EAA9F-D65F-4F99-E040-BB89AD435CFD","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"Foretinib","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","ValueMeaning":{"publicId":"3124282","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","longName":"3124282","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foretinib","conceptCode":"C80058","definition":"An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D66C-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C0EAA9F-D685-4F99-E040-BB89AD435CFD","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"CHK1 Inhibitor PF-477736","valueDescription":"CHK1 Inhibitor PF-477736","ValueMeaning":{"publicId":"3143932","version":"1","preferredName":"CHK1 Inhibitor PF-477736","longName":"3143932","preferredDefinition":"A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHK1 Inhibitor PF-477736","conceptCode":"C68820","definition":"A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167E85F-652E-A82C-E040-BB89AD433534","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9167E85F-6547-A82C-E040-BB89AD433534","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Belagenpumatucel-L","valueDescription":"Belagenpumatucel-L (Lucanix)","ValueMeaning":{"publicId":"3140555","version":"1","preferredName":"Belagenpumatucel-L (Lucanix)","longName":"3140555","preferredDefinition":"A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belagenpumatucel-L","conceptCode":"C73438","definition":"A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90CBCCAD-0C4C-1659-E040-BB89AD434A4C","latestVersionIndicator":"Yes","beginDate":"2010-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90CBCCAD-0C65-1659-E040-BB89AD434A4C","beginDate":"2010-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-21","modifiedBy":"ONEDATA","dateModified":"2010-09-21","deletedIndicator":"No"},{"value":"Recombinant Interleukin-18","valueDescription":"Recombinant Interleukin-18","ValueMeaning":{"publicId":"3147595","version":"1","preferredName":"Recombinant Interleukin-18","longName":"3147595","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, IL-18 displays antitumor effects in vitro and in animal models. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iboctadekin","conceptCode":"C1680","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91EBFE5C-8B39-5E24-E040-BB89AD436F00","latestVersionIndicator":"Yes","beginDate":"2010-10-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91EBFE5C-8B52-5E24-E040-BB89AD436F00","beginDate":"2010-10-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-06","modifiedBy":"ONEDATA","dateModified":"2010-10-06","deletedIndicator":"No"},{"value":"PARP Inhibitor MK4827","valueDescription":"Niraparib","ValueMeaning":{"publicId":"3153580","version":"1","preferredName":"Niraparib","longName":"3153580","preferredDefinition":"An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niraparib","conceptCode":"C80059","definition":"An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5E1E-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":"Updated Long Name to use current NCIt concept name. 4.16.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93AC689E-5E37-5D7A-E040-BB89AD430948","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"ONEDATA","dateModified":"2010-10-28","deletedIndicator":"No"},{"value":"TDL (Tumor Derived Lymphocytes)","valueDescription":"Tumor Derived Lymphocytes","ValueMeaning":{"publicId":"3151136","version":"1","preferredName":"Tumor Derived Lymphocytes","longName":"3151136","preferredDefinition":"A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Allogeneic Lymphocytes","conceptCode":"C28676","definition":"A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92852307-318A-74B4-E040-BB89AD432567","latestVersionIndicator":"Yes","beginDate":"2010-10-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92852307-31A3-74B4-E040-BB89AD432567","beginDate":"2010-10-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-13","modifiedBy":"ONEDATA","dateModified":"2010-10-13","deletedIndicator":"No"},{"value":"XL184","valueDescription":"XL184 (Cabozantinib-S-malate)","ValueMeaning":{"publicId":"3134357","version":"1","preferredName":"XL184 (Cabozantinib-S-malate)","longName":"3134357","preferredDefinition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib S-malate","conceptCode":"C97938","definition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F391D7A-EA3F-2C4D-E040-BB89AD4302AD","latestVersionIndicator":"Yes","beginDate":"2010-09-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F391D7A-EA58-2C4D-E040-BB89AD4302AD","beginDate":"2010-09-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-01","modifiedBy":"ONEDATA","dateModified":"2010-09-01","deletedIndicator":"No"},{"value":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","valueDescription":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","ValueMeaning":{"publicId":"3137490","version":"1","preferredName":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","longName":"3137490","preferredDefinition":"An immunoconjugate consisting of a monoclonal antibody directed against a highly-expressed myeloma cell surface antigen covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-myeloma cell surface antigen immunoconjugate BT-062 binds to an unspecified cell surface antigen highly expressed on myeloma cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of myeloma tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indatuximab Ravtansine","conceptCode":"C78840","definition":"An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1 (CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Upon administration, indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"901534DE-D9AA-2F83-E040-BB89AD43215F","latestVersionIndicator":"Yes","beginDate":"2010-09-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"901534DE-D9C3-2F83-E040-BB89AD43215F","beginDate":"2010-09-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-12","modifiedBy":"ONEDATA","dateModified":"2010-09-12","deletedIndicator":"No"},{"value":"Tivozanib","valueDescription":"Tivozanib (AV-951)","ValueMeaning":{"publicId":"3134818","version":"1","preferredName":"Tivozanib (AV-951)","longName":"3134818","preferredDefinition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tivozanib","conceptCode":"C85444","definition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.  Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F84E9B0-3462-0CFF-E040-BB89AD433A23","latestVersionIndicator":"Yes","beginDate":"2010-09-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F84E9B0-347B-0CFF-E040-BB89AD433A23","beginDate":"2010-09-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-05","modifiedBy":"ONEDATA","dateModified":"2010-09-05","deletedIndicator":"No"},{"value":"Axitinib","valueDescription":"Axitinib","ValueMeaning":{"publicId":"3187559","version":"1","preferredName":"Axitinib","longName":"3187559","preferredDefinition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib","conceptCode":"C38718","definition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9ADBFE58-7699-F1A8-E040-BB89AD436F84","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9ADBFE58-76B1-F1A8-E040-BB89AD436F84","beginDate":"2011-01-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-27","modifiedBy":"ONEDATA","dateModified":"2011-01-27","deletedIndicator":"No"},{"value":"Selumetinib","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A41DC8A8-EBBE-0F50-E040-BB89AD436610","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"ONEDATA","dateModified":"2011-05-25","deletedIndicator":"No"},{"value":"Amrubicin Hydrochloride","valueDescription":"Amrubicin Hydrochloride","ValueMeaning":{"publicId":"3238483","version":"1","preferredName":"Amrubicin Hydrochloride","longName":"3238483","preferredDefinition":"The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amrubicin Hydrochloride","conceptCode":"C47948","definition":"The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBCB-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A41DC8A8-EBE4-0F50-E040-BB89AD436610","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"ONEDATA","dateModified":"2011-05-25","deletedIndicator":"No"},{"value":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","valueDescription":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","ValueMeaning":{"publicId":"3178312","version":"1","preferredName":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","longName":"3178312","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaratumab","conceptCode":"C79825","definition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B5C8B-3348-E22D-E040-BB89AD432202","latestVersionIndicator":"Yes","beginDate":"2010-12-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"985B5C8B-3361-E22D-E040-BB89AD432202","beginDate":"2010-12-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-26","modifiedBy":"ONEDATA","dateModified":"2010-12-26","deletedIndicator":"No"},{"value":"Eribulin Mesylate","valueDescription":"Eribulin Mesylate","ValueMeaning":{"publicId":"3241058","version":"1","preferredName":"Eribulin Mesylate","longName":"3241058","preferredDefinition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eribulin Mesylate","conceptCode":"C26644","definition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A0E2-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A443510D-A0FB-C5AF-E040-BB89AD435D96","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"ONEDATA","dateModified":"2011-05-27","deletedIndicator":"No"},{"value":"Denosumab","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A443510D-A121-C5AF-E040-BB89AD435D96","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"ONEDATA","dateModified":"2011-05-27","deletedIndicator":"No"},{"value":"Urelumab","valueDescription":"Urelumab","ValueMeaning":{"publicId":"3237476","version":"1","preferredName":"Urelumab","longName":"3237476","preferredDefinition":"A humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urelumab","conceptCode":"C62449","definition":"A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-66C4-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3F78E39-66DD-13D6-E040-BB89AD432B2B","beginDate":"2011-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-23","modifiedBy":"ONEDATA","dateModified":"2011-05-23","deletedIndicator":"No"},{"value":"Degarelix","valueDescription":"Degarelix","ValueMeaning":{"publicId":"3240855","version":"1","preferredName":"Degarelix","longName":"3240855","preferredDefinition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix","conceptCode":"C48385","definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4302120-6A24-B554-E040-BB89AD4307C7","latestVersionIndicator":"Yes","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"COOPERM","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4302120-6A3D-B554-E040-BB89AD4307C7","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"ONEDATA","dateModified":"2011-05-26","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A16046E6-D6B9-1B8D-E040-BB89AD434ADA","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"ONEDATA","dateModified":"2011-04-20","deletedIndicator":"No"},{"value":"Sodium Metaarsenite","valueDescription":"Sodium Metaarsenite","ValueMeaning":{"publicId":"3232378","version":"1","preferredName":"Sodium Metaarsenite","longName":"3232378","preferredDefinition":"A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Metaarsenite","conceptCode":"C91098","definition":"A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-07D2-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-07EB-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Ganitumab","valueDescription":"Ganitumab","ValueMeaning":{"publicId":"3232380","version":"1","preferredName":"Ganitumab","longName":"3232380","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganitumab","conceptCode":"C71531","definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-07F8-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-0811-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"CDK2/TRKA Inhibitor PHA-848125 AC","valueDescription":"CDK2/TRKA Inhibitor PHA-848125 AC","ValueMeaning":{"publicId":"3232382","version":"1","preferredName":"CDK2/TRKA Inhibitor PHA-848125 AC","longName":"3232382","preferredDefinition":"An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Milciclib Maleate","conceptCode":"C88312","definition":"The maleate salt form of milciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-081E-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-0837-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Survivin Inhibitor YM155","valueDescription":"Survivin Inhibitor YM155","ValueMeaning":{"publicId":"3232384","version":"1","preferredName":"Survivin Inhibitor YM155","longName":"3232384","preferredDefinition":"A small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sepantronium Bromide","conceptCode":"C61091","definition":"A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-0844-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-085D-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"KSP Inhibitor ARRY-520","valueDescription":"KSP Inhibitor ARRY-520","ValueMeaning":{"publicId":"3232386","version":"1","preferredName":"KSP Inhibitor ARRY-520","longName":"3232386","preferredDefinition":"A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filanesib","conceptCode":"C68937","definition":"A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. Filanesib specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-086A-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-0883-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Polymeric Camptothecin Prodrug XMT-1001","valueDescription":"Polymeric Camptothecin Prodrug XMT-1001","ValueMeaning":{"publicId":"3232388","version":"1","preferredName":"Polymeric Camptothecin Prodrug XMT-1001","longName":"3232388","preferredDefinition":"A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymeric Camptothecin Prodrug XMT-1001","conceptCode":"C69079","definition":"A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-0890-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-08A9-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Checkpoint Kinase Inhibitor AZD7762","valueDescription":"Checkpoint Kinase Inhibitor AZD7762","ValueMeaning":{"publicId":"3232390","version":"1","preferredName":"Checkpoint Kinase Inhibitor AZD7762","longName":"3232390","preferredDefinition":"A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Checkpoint Kinase Inhibitor AZD7762","conceptCode":"C66961","definition":"A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-08B6-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-08CF-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin","valueDescription":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin","ValueMeaning":{"publicId":"3232392","version":"1","preferredName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin","longName":"3232392","preferredDefinition":"A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from polyethyleneglycol-7-ethyl-10-hydroxycamptothecin (PEG-SN38); 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Firtecan Pegol","conceptCode":"C70651","definition":"A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from firtecan pegol; 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-08DC-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1FA4B23-08F5-5DC7-E040-BB89AD4327C7","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","deletedIndicator":"No"},{"value":"Topoisomerase I Inhibitor LMP400","valueDescription":"Topoisomerase I Inhibitor LMP400","ValueMeaning":{"publicId":"3234540","version":"1","preferredName":"Topoisomerase I Inhibitor LMP400","longName":"3234540","preferredDefinition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase I Inhibitor LMP400","conceptCode":"C90594","definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A302FD9A-3D77-C759-E040-BB89AD43422E","latestVersionIndicator":"Yes","beginDate":"2011-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A302FD9A-3D90-C759-E040-BB89AD43422E","beginDate":"2011-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-11","modifiedBy":"ONEDATA","dateModified":"2011-05-11","deletedIndicator":"No"},{"value":"Topoisomerase I Inhibitor LMP776","valueDescription":"Topoisomerase I Inhibitor LMP776","ValueMeaning":{"publicId":"3234542","version":"1","preferredName":"Topoisomerase I Inhibitor LMP776","longName":"3234542","preferredDefinition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase I Inhibitor LMP776","conceptCode":"C90595","definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A302FD9A-3D9D-C759-E040-BB89AD43422E","latestVersionIndicator":"Yes","beginDate":"2011-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A302FD9A-3DB6-C759-E040-BB89AD43422E","beginDate":"2011-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-11","modifiedBy":"ONEDATA","dateModified":"2011-05-11","deletedIndicator":"No"},{"value":"5-Iodo-2-pyrimidinone-2'-deoxyribose","valueDescription":"5-Iodo-2-pyrimidinone-2'-deoxyribose","ValueMeaning":{"publicId":"3191821","version":"1","preferredName":"5-Iodo-2-pyrimidinone-2'-deoxyribose","longName":"3191821","preferredDefinition":"An orally available thymidine analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Ropidoxuridine is efficiently converted to IUdR by a hepatic aldehyde oxidase. IUdR is incorporated into DNA during replication and sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ropidoxuridine","conceptCode":"C48813","definition":"An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C3E7936-E03F-17AE-E040-BB89AD4302F9","latestVersionIndicator":"Yes","beginDate":"2011-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-02-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C3E7936-E058-17AE-E040-BB89AD4302F9","beginDate":"2011-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-02-14","modifiedBy":"ONEDATA","dateModified":"2011-02-14","deletedIndicator":"No"},{"value":"Adenoviral Vector Ad5-CEA(6D) Vaccine","valueDescription":"Adenoviral Vector Ad5-CEA(6D) Vaccine","ValueMeaning":{"publicId":"3203298","version":"1","preferredName":"Adenoviral Vector Ad5-CEA(6D) Vaccine","longName":"3203298","preferredDefinition":"A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral Vector Ad5-CEA(6D) Vaccine","conceptCode":"C91373","definition":"A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8654C5-9B2D-1C49-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8654C5-9B46-1C49-E040-BB89AD432E7C","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"ONEDATA","dateModified":"2011-03-15","deletedIndicator":"No"},{"value":"Hsp90 Inhibitor AT13387","valueDescription":"Hsp90 Inhibitor AT13387","ValueMeaning":{"publicId":"3203300","version":"1","preferredName":"Hsp90 Inhibitor AT13387","longName":"3203300","preferredDefinition":"A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Onalespib","conceptCode":"C85454","definition":"A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8654C5-9B53-1C49-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8654C5-9B6C-1C49-E040-BB89AD432E7C","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"ONEDATA","dateModified":"2011-03-15","deletedIndicator":"No"},{"value":"Aurora A Kinase Inhibitor MLN8237","valueDescription":"Aurora A Kinase Inhibitor MLN8237","ValueMeaning":{"publicId":"3205718","version":"1","preferredName":"Aurora A Kinase Inhibitor MLN8237","longName":"3205718","preferredDefinition":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alisertib","conceptCode":"C71717","definition":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EFD7B87-C0D8-51DF-E040-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9EFD7B87-C0F1-51DF-E040-BB89AD436BE5","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"ONEDATA","dateModified":"2011-03-21","deletedIndicator":"No"},{"value":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","valueDescription":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","ValueMeaning":{"publicId":"3205720","version":"1","preferredName":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","longName":"3205720","preferredDefinition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trebananib","conceptCode":"C91711","definition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EFD7B87-C0FE-51DF-E040-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9EFD7B87-C117-51DF-E040-BB89AD436BE5","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"ONEDATA","dateModified":"2011-03-21","deletedIndicator":"No"},{"value":"Abiraterone","valueDescription":"Abiraterone (Zytiga)","ValueMeaning":{"publicId":"3263351","version":"1","preferredName":"Abiraterone (Zytiga)","longName":"3263351","preferredDefinition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone","conceptCode":"C77333","definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAC9BCD2-6B13-3AEE-E040-BB89AD4375B9","latestVersionIndicator":"Yes","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAC9BCD2-6B2B-3AEE-E040-BB89AD4375B9","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"ONEDATA","dateModified":"2011-08-18","deletedIndicator":"No"},{"value":"Saracatinib","valueDescription":"Saracatinib (AZD0530)","ValueMeaning":{"publicId":"3263353","version":"1","preferredName":"Saracatinib (AZD0530)","longName":"3263353","preferredDefinition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saracatinib","conceptCode":"C48378","definition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAC9BCD2-6B39-3AEE-E040-BB89AD4375B9","latestVersionIndicator":"Yes","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAC9BCD2-6B52-3AEE-E040-BB89AD4375B9","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"ONEDATA","dateModified":"2011-08-18","deletedIndicator":"No"},{"value":"Dimethyl Sulfoxide","valueDescription":"Dimethyl Sulfoxide","ValueMeaning":{"publicId":"3192059","version":"1","preferredName":"Dimethyl Sulfoxide","longName":"3192059","preferredDefinition":"A highly polar organic liquid that is used widely as a chemical solvent and a free radical scavenger. It shows a range of pharmacological activity including analgesia and anti-inflammation. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect cells and tissue during cryopreservation and has been used to treat extravasation damage caused by anthracycline-based chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dimethyl Sulfoxide","conceptCode":"C437","definition":"A highly polar organic liquid that is used widely as a chemical solvent and a free radical scavenger. It shows a range of pharmacological activity including analgesia and anti-inflammation. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect cells and tissue during cryopreservation and has been used to treat extravasation damage caused by anthracycline-based chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C56C67B-19D5-1E23-E040-BB89AD437E85","latestVersionIndicator":"Yes","beginDate":"2011-02-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFAD7A1D-5895-F3EC-E040-BB89AD430E20","beginDate":"2011-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","deletedIndicator":"No"},{"value":"Z-Endoxifen Hydrochloride","valueDescription":"Z-Endoxifen Hydrochloride","ValueMeaning":{"publicId":"3295775","version":"1","preferredName":"Z-Endoxifen Hydrochloride","longName":"3295775","preferredDefinition":"The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endoxifen Hydrochloride","conceptCode":"C95713","definition":"The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFAD7A1D-59CB-F3EC-E040-BB89AD430E20","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFAD7A1D-59E4-F3EC-E040-BB89AD430E20","beginDate":"2011-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","deletedIndicator":"No"},{"value":"BTK Inhibitor PCI-32765","valueDescription":"BTK Inhibitor PCI-32765","ValueMeaning":{"publicId":"3252678","version":"1","preferredName":"BTK Inhibitor PCI-32765","longName":"3252678","preferredDefinition":"An orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. BTK inhibitor PCI-32765 binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7E1ED79-B5B0-3062-E040-BB89AD431105","latestVersionIndicator":"Yes","beginDate":"2011-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7E1ED79-B5C9-3062-E040-BB89AD431105","beginDate":"2011-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-12","modifiedBy":"ONEDATA","dateModified":"2011-07-12","deletedIndicator":"No"},{"value":"Ofatumumab","valueDescription":"Ofatumumab","ValueMeaning":{"publicId":"3243442","version":"1","preferredName":"Ofatumumab","longName":"3243442","preferredDefinition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofatumumab","conceptCode":"C66952","definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3256-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEA13BF1-7349-3ECE-E040-BB89AD4304A8","beginDate":"2011-10-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-06","modifiedBy":"ONEDATA","dateModified":"2011-10-06","deletedIndicator":"No"},{"value":"Dimethane sulfonate (DMS612)","valueDescription":"Dimethane sulfonate (DMS612)","ValueMeaning":{"publicId":"3243438","version":"1","preferredName":"Dimethane sulfonate (DMS612)","longName":"3243438v1.00","preferredDefinition":"A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benzaldehyde Dimethane Sulfonate","conceptCode":"C107164","definition":"A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3208-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A55A32E7-3221-D7C0-E040-BB89AD437508","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"ONEDATA","dateModified":"2011-06-10","deletedIndicator":"No"},{"value":"Steroid 17alpha-monooxygenase TAK-700","valueDescription":"Steroid 17alpha-monooxygenase TAK-700","ValueMeaning":{"publicId":"3259298","version":"1","preferredName":"Steroid 17alpha-monooxygenase TAK-700","longName":"3259298","preferredDefinition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orteronel","conceptCode":"C90582","definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A939DA44-CB85-3822-E040-BB89AD432672","latestVersionIndicator":"Yes","beginDate":"2011-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A939DA44-CB9E-3822-E040-BB89AD432672","beginDate":"2011-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-29","modifiedBy":"ONEDATA","dateModified":"2011-07-29","deletedIndicator":"No"},{"value":"MDV3100","valueDescription":"Selective Androgen Receptor Modulator MDV3100 (Enzalutamide)","ValueMeaning":{"publicId":"3441945","version":"1","preferredName":"Selective Androgen Receptor Modulator MDV3100 (Enzalutamide)","longName":"3441945","preferredDefinition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F3C92-EDA4-5858-E040-BB89AD4304B3","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F3C92-EDBD-5858-E040-BB89AD4304B3","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"ONEDATA","dateModified":"2012-04-23","deletedIndicator":"No"},{"value":"Sipuleucel-T","valueDescription":"APC8015 Vaccine","ValueMeaning":{"publicId":"3439565","version":"1","preferredName":"APC8015 Vaccine","longName":"3439565v1.00","preferredDefinition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sipuleucel-T","conceptCode":"C1985","definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1C2E-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"GDEEN","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F3C92-EDC7-5858-E040-BB89AD4304B3","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"ONEDATA","dateModified":"2012-04-23","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"3378061","version":"1","preferredName":"Pentostatin","longName":"3378061","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B900BC0D-BE80-CD46-E040-BB89AD434DBB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BE99-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CBDCA","valueDescription":"CBDCA (Carboplatin)","ValueMeaning":{"publicId":"2576636","version":"1","preferredName":"CBDCA (Carboplatin)","longName":"2576636","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F869-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-7348-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CAT-8015","valueDescription":"Moxetumomab Pasudotox","ValueMeaning":{"publicId":"3378204","version":"1","preferredName":"Moxetumomab Pasudotox","longName":"3378204","preferredDefinition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moxetumomab Pasudotox","conceptCode":"C68819","definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-7355-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"HARTLEYG","dateModified":"2021-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-736E-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CHOP","valueDescription":"CHOP Regimen","ValueMeaning":{"publicId":"3378205","version":"1","preferredName":"CHOP Regimen","longName":"3378205","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-737A-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-7393-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CAMFTP","valueDescription":"Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen","ValueMeaning":{"publicId":"3378207","version":"1","preferredName":"Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen","longName":"3378207","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen","conceptCode":"C10113","definition":"A combination of agents containing conjugated estrogens, cyclophosphamide, doxorubicin, fluorouracil, methotrexate and tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-73A0-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-73B9-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CAI/Paclitaxel","valueDescription":"Carboxyamidotriazole/Paclitaxel","ValueMeaning":{"publicId":"3378209","version":"1","preferredName":"Carboxyamidotriazole/Paclitaxel","longName":"3378209","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxyamidotriazole/Paclitaxel","conceptCode":"C10924","definition":"A combination of agents containing carboxyamidotriazole and paclitaxel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-73C6-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-73DF-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CAI","valueDescription":"Carboxyamidotriazole","ValueMeaning":{"publicId":"3378211","version":"1","preferredName":"Carboxyamidotriazole","longName":"3378211","preferredDefinition":"An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxyamidotriazole","conceptCode":"C1141","definition":"An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-73EC-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-7405-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CAF","valueDescription":"CAF Regimen","ValueMeaning":{"publicId":"3378213","version":"1","preferredName":"CAF Regimen","longName":"3378213","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, doxorubicin hdrochloride (Adriamycin), and fluorouracil, which may be used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAF Regimen","conceptCode":"C9533","definition":"A chemotherapy regimen consisting of oral cyclophosphamide, doxorubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-7412-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-742B-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BuMelt","valueDescription":"Busulfan/Melphalan/Thiotepa","ValueMeaning":{"publicId":"3378215","version":"1","preferredName":"Busulfan/Melphalan/Thiotepa","longName":"3378215","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan/Melphalan/Thiotepa","conceptCode":"C10791","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-7438-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-7451-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bromocriptine","valueDescription":"Bromocriptine","ValueMeaning":{"publicId":"2577766","version":"1","preferredName":"Bromocriptine","longName":"2577766","preferredDefinition":"Bromocriptine belongs to the group of medicines known as ergot alkaloids. It acts as a dopamine agonist primarily activating the dopamine D2 receptors. It blocks release of prolactin from the pituitary gland, and is used in the therapy of amenorrhea, infertility in women, abnormal breast milk discharge, hypogonadism, Parkinsons disease, and acromegaly. It is also used in the treatment of pituitary prolactinoma, neuroleptic malignant syndrome, cocaine addiction, and painful breast condition. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bromocriptine Mesylate","conceptCode":"C317","definition":"The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. This agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-745B-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bendamustine HCl","valueDescription":"Bendamustine Hydrochloride","ValueMeaning":{"publicId":"3378217","version":"1","preferredName":"Bendamustine Hydrochloride","longName":"3378217","preferredDefinition":"The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine Hydrochloride","conceptCode":"C61565","definition":"The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-7468-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-7481-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bactrim","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-748B-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bacillus Calmette-Guerin (BCG)","valueDescription":"Bacillus Calmette-Guerin Antigen","ValueMeaning":{"publicId":"3378219","version":"1","preferredName":"Bacillus Calmette-Guerin Antigen","longName":"3378219v1.00","preferredDefinition":"An antigen preparation derived from Bacillus Calmette-Guerin, used as a component of BCG vaccine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacillus Calmette-Guerin Antigen","conceptCode":"C77178","definition":"An antigen preparation derived from Bacillus Calmette-Guerin, used as a component of BCG vaccine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-7498-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-74B1-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BMT, Autologous","valueDescription":"Autologous Bone Marrow Transplantation","ValueMeaning":{"publicId":"3378221","version":"1","preferredName":"Autologous Bone Marrow Transplantation","longName":"3378221","preferredDefinition":"Bone marrow transfer in which the patient is his own donor.  Bone marrow is removed prior to bone marrow ablation treatment and then returned to reconstitute the hematopoietic system. Prior to reinfusion the bone marrow is often treated to purge it of residual tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Bone Marrow Transplantation","conceptCode":"C15395","definition":"Bone marrow transfer in which the patient is his own donor.  Bone marrow is removed prior to bone marrow ablation treatment and then returned to reconstitute the hematopoietic system. Prior to reinfusion the bone marrow is often treated to purge it of residual tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-74BE-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-74D7-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CpG","valueDescription":"CpG Dinucleotide","ValueMeaning":{"publicId":"3378866","version":"1","preferredName":"CpG Dinucleotide","longName":"3378866","preferredDefinition":"A dinucleotide consisting of cytosine followed by guanine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CpG Dinucleotide","conceptCode":"C67101","definition":"A dinucleotide consisting of cytosine followed by guanine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3E25-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3E3E-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroids","ValueMeaning":{"publicId":"2578061","version":"1","preferredName":"Corticosteroids","longName":"2578061","preferredDefinition":"Hormones that have antitumor activity in lymphomas and lymphoid leukemias; in addition, corticosteroids (steroids) may be used for hormone replacement and for the management of some of the complications of cancer and its treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Corticosteroid","conceptCode":"C211","definition":"Any steroid hormone made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDFA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-01","modifiedBy":"CAMPBELB","dateModified":"2013-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3E48-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Combivir","valueDescription":"Lamivudine/Zidovudine","ValueMeaning":{"publicId":"2577823","version":"1","preferredName":"Lamivudine/Zidovudine","longName":"2577823","preferredDefinition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine/Zidovudine","conceptCode":"C28939","definition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3E53-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Colesevelam HCl","valueDescription":"Colesevelam Hydrochloride","ValueMeaning":{"publicId":"3378867","version":"1","preferredName":"Colesevelam Hydrochloride","longName":"3378867","preferredDefinition":"A polymeric synthetic polyallylamine derivative cross-linked with epichlorohydrin, Colesevelam Hydrochloride is a non-absorbed, water-insoluble, lipid-lowering, hydrophilic agent that binds intestinal bile acids and impedes their reabsorption. Used alone or with other medications, Colesevelam increases cholesterol metabolism and decreases its plasma concentration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colesevelam Hydrochloride","conceptCode":"C28937","definition":"A hydrochloride salt form of colesevelam, a non-absorbed polymer that binds bile acids in the intestine and lowers serum lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3E5F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3E77-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Co-trimoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3E82-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cloretazine","valueDescription":"Laromustine","ValueMeaning":{"publicId":"3378869","version":"1","preferredName":"Laromustine","longName":"3378869","preferredDefinition":"A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laromustine","conceptCode":"C2653","definition":"A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3E8F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3EA8-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Paclitax/Cyclophos/Thalidomide","valueDescription":"Cisplatin Paclitaxel Cyclophosphamide Thalidomide Treatment Regimen","ValueMeaning":{"publicId":"3378870","version":"1","preferredName":"Cisplatin Paclitaxel Cyclophosphamide Thalidomide Treatment Regimen","longName":"3378870","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  Thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3EB8-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3ED1-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Pacli/Cyclo/GCSF","valueDescription":"Cisplatin Paclitaxel Cyclophosphamide Granulocyte Colony Stimulating Factor Measurement Treatment Regimen","ValueMeaning":{"publicId":"3378872","version":"1","preferredName":"Cisplatin Paclitaxel Cyclophosphamide Granulocyte Colony Stimulating Factor Measurement Treatment Regimen","longName":"3378872","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): The determination of the amount of granulocyte colony stimulating factor present in a sample.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Granulocyte Colony Stimulating Factor Measurement","conceptCode":"C82018","definition":"The determination of the amount of granulocyte colony stimulating factor present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3EE2-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3EFB-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Interferon","valueDescription":"Cisplatin Interferon Treatment Regimen","ValueMeaning":{"publicId":"3378873","version":"1","preferredName":"Cisplatin Interferon Treatment Regimen","longName":"3378873","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3F09-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3F22-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Etoposide","valueDescription":"Cisplatin Etoposide Treatment Regimen","ValueMeaning":{"publicId":"3378874","version":"1","preferredName":"Cisplatin Etoposide Treatment Regimen","longName":"3378874","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3F30-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3F49-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Doxorubicin","valueDescription":"Cisplatin Doxorubicin Treatment Regimen","ValueMeaning":{"publicId":"3378875","version":"1","preferredName":"Cisplatin Doxorubicin Treatment Regimen","longName":"3378875","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3F57-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3F70-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Cyclophosphamide","valueDescription":"Cisplatin Cyclophosphamide Treatment Regimen","ValueMeaning":{"publicId":"3378876","version":"1","preferredName":"Cisplatin Cyclophosphamide Treatment Regimen","longName":"3378876","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3F7E-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3F97-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Paclitaxel/Cyclophosphamide","valueDescription":"Cisplatin/Cyclophosphamide/Paclitaxel","ValueMeaning":{"publicId":"3378878","version":"1","preferredName":"Cisplatin/Cyclophosphamide/Paclitaxel","longName":"3378878","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Cyclophosphamide/Paclitaxel","conceptCode":"C10604","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3FA4-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3FBD-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Vinblastine","valueDescription":"Cisplatin/Vinblastine","ValueMeaning":{"publicId":"3378880","version":"1","preferredName":"Cisplatin/Vinblastine","longName":"3378880","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Vinblastine","conceptCode":"C10263","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3FCA-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-3FE3-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Topotecan","valueDescription":"Cisplatin/Topotecan","ValueMeaning":{"publicId":"3378882","version":"1","preferredName":"Cisplatin/Topotecan","longName":"3378882","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Topotecan","conceptCode":"C10653","definition":"A combination of agents containing cisplatin and topotecan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3FF0-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-4009-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Paclitaxel","valueDescription":"Cisplatin/Paclitaxel","ValueMeaning":{"publicId":"3378884","version":"1","preferredName":"Cisplatin/Paclitaxel","longName":"3378884","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Paclitaxel","conceptCode":"C10228","definition":"A combination of agents containing cisplatin and paclitaxel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-4016-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-402F-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin/Gemcitabine","valueDescription":"Cisplatin/gemcitabine Treatment Regimen","ValueMeaning":{"publicId":"3378885","version":"1","preferredName":"Cisplatin/gemcitabine Treatment Regimen","longName":"3378885","preferredDefinition":"Definition not available.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/gemcitabine","conceptCode":"C11117","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-4039-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-4052-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-17DF-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carfilzomib","valueDescription":"Carfilzomib","ValueMeaning":{"publicId":"3378843","version":"1","preferredName":"Carfilzomib","longName":"3378843","preferredDefinition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carfilzomib","conceptCode":"C52196","definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17EC-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1805-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carprofen","valueDescription":"Carprofen","ValueMeaning":{"publicId":"3270054","version":"1","preferredName":"Carprofen","longName":"3270054v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities, used exclusively in veterinary medicine. Carprofen inhibits the activity of the enzymes cyclo-oxygenase (COX) I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This inhibits the formation of prostaglandins, by prostaglandin synthase, that are involved in pain, inflammation and fever. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carprofen","conceptCode":"C65290","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities, used exclusively in veterinary medicine. Carprofen inhibits the activity of the enzymes cyclo-oxygenase (COX) I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This inhibits the formation of prostaglandins, by prostaglandin synthase, that are involved in pain, inflammation and fever. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-90F3-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-180F-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"3225735","version":"1","preferredName":"Cisplatin","longName":"3225735","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E93-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1819-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cimetidine","valueDescription":"Cimetidine","ValueMeaning":{"publicId":"2577816","version":"1","preferredName":"Cimetidine","longName":"2577816","preferredDefinition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cimetidine","conceptCode":"C374","definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1824-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cilengitide","valueDescription":"Cilengitide","ValueMeaning":{"publicId":"3378845","version":"1","preferredName":"Cilengitide","longName":"3378845","preferredDefinition":"A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cilengitide","conceptCode":"C1834","definition":"A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1831-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-184A-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cidofovir","valueDescription":"Cidofovir","ValueMeaning":{"publicId":"2577815","version":"1","preferredName":"Cidofovir","longName":"2577815","preferredDefinition":"A synthetic nucleotide analog with antiviral activity against cytomegalovirus (CMV).  After conversion to the active metabolite cidofovir diphosphate, cidofovir selectively inhibits CMV DNA polymerase and incorporates into the growing viral DNA chain ultimately inhibiting viral DNA synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cidofovir","conceptCode":"C1600","definition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD04-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1854-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Chlorambucil","valueDescription":"Chlorambucil","ValueMeaning":{"publicId":"2577804","version":"1","preferredName":"Chlorambucil","longName":"2577804","preferredDefinition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil","conceptCode":"C362","definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-185E-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Catumaxomab","valueDescription":"Catumaxomab","ValueMeaning":{"publicId":"3378847","version":"1","preferredName":"Catumaxomab","longName":"3378847","preferredDefinition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Catumaxomab","conceptCode":"C62445","definition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-186B-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1884-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cediranib","valueDescription":"Cediranib","ValueMeaning":{"publicId":"3378849","version":"1","preferredName":"Cediranib","longName":"3378849v1.00","preferredDefinition":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cediranib","conceptCode":"C80867","definition":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1891-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-18AA-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cefadroxil","valueDescription":"Cefadroxil","ValueMeaning":{"publicId":"3134035","version":"1","preferredName":"Cefadroxil","longName":"3134035","preferredDefinition":"A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefadroxil","conceptCode":"C28912","definition":"A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9997-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-18B4-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DMP-266","valueDescription":"(DMP-266) Efavirenz","ValueMeaning":{"publicId":"2576812","version":"1","preferredName":"(DMP-266) Efavirenz","longName":"2576812","preferredDefinition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral loads, therefore retarding or preventing damage to the immune system, and reducing the risk of developing AIDS.  Efavirenz induces activity of the cytochrome P450 system, thereby accelerating its own metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz","conceptCode":"C29027","definition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F919-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2B8D-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DMAC","valueDescription":"Dexamethasone Melphalan Cytarabine Treatment Regimen","ValueMeaning":{"publicId":"3378919","version":"1","preferredName":"Dexamethasone Melphalan Cytarabine Treatment Regimen","longName":"3378919","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]: An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2B9C-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2BB5-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DHAP","valueDescription":"Cisplatin/Cytarabine/Dexamethasone","ValueMeaning":{"publicId":"3378921","version":"1","preferredName":"Cisplatin/Cytarabine/Dexamethasone","longName":"3378921","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Cytarabine/Dexamethasone","conceptCode":"C9583","definition":"A combination of agents containing cisplatin, cytarabine and dexamethasone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2BC2-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2BDB-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DES","valueDescription":"Diethylstilbestrol","ValueMeaning":{"publicId":"2577843","version":"1","preferredName":"Diethylstilbestrol","longName":"2577843","preferredDefinition":"DES; the acronym for diethylstilbestrol, a synthetic, nonsteroidal form of estrogen.  A well-known teratogen and carcinogen, DES inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diethylstilbestrol","conceptCode":"C433","definition":"A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD20-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2BE5-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"D4T","valueDescription":"Stavudine","ValueMeaning":{"publicId":"3378923","version":"1","preferredName":"Stavudine","longName":"3378923","preferredDefinition":"A nucleoside reverse transcriptase inhibitor analog of thymidine. Stavudine has been recommended to undergo phase-out management due to its long-term, irreversible side-effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stavudine","conceptCode":"C1428","definition":"A nucleoside reverse transcriptase inhibitor analog of thymidine. Stavudine has been recommended to undergo phase-out management due to its long-term, irreversible side-effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2BF2-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2C0B-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"D1694","valueDescription":"Raltitrexed","ValueMeaning":{"publicId":"3378925","version":"1","preferredName":"Raltitrexed","longName":"3378925","preferredDefinition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltitrexed","conceptCode":"C1804","definition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2C18-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907AE08-2C31-59CE-E040-BB89AD436C6D","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Fowlpox/Tyrosinase HDL 2","valueDescription":"Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine","ValueMeaning":{"publicId":"3379038","version":"1","preferredName":"Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine","longName":"3379038","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine","conceptCode":"C11610","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1EFC-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1F15-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FUDR","valueDescription":"Floxuridine","ValueMeaning":{"publicId":"3379039","version":"1","preferredName":"Floxuridine","longName":"3379039","preferredDefinition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Floxuridine","conceptCode":"C504","definition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1F1F-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1F38-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FOLFOX","valueDescription":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","ValueMeaning":{"publicId":"3171720","version":"1","preferredName":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","longName":"3171720","preferredDefinition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX Regimen","conceptCode":"C11197","definition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD02F2-6DAB-8DB6-E040-BB89AD430E72","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1F42-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FOLFIRI/Bevacizumab","valueDescription":"Bevacizumab FOLFIRI Regimen","ValueMeaning":{"publicId":"3379041","version":"1","preferredName":"Bevacizumab FOLFIRI Regimen","longName":"3379041","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.: An abbreviation for a chemotherapy combination used to treat advanced colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and irinotecan hydrochloride.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"FOLFIRI Regimen","conceptCode":"C63593","definition":"A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of ampullary, appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1F50-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1F69-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FLT3-Ligand","valueDescription":"FLT3 Ligand","ValueMeaning":{"publicId":"3379042","version":"1","preferredName":"FLT3 Ligand","longName":"3379042","preferredDefinition":"Flt3 ligand is a novel hematopoietic growth factor ligand for the FLT3 tyrosine kinase receptor.  This growth factor stimulates the proliferation of hematopoietic progenitor cells.  FLT3 (FLK2) is a tyrosine kinase receptor structurally related to CSF1 and KIT.  (from OMIM 600007 and NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fms-Related Tyrosine Kinase 3 Ligand","conceptCode":"C20492","definition":"Fms-related tyrosine kinase 3 ligand (235 aa, ~26 kDa) is encoded by the human FLT3LG gene. This protein is involved in the positive regulation of hematopoietic cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1F77-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1F90-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FLAC","valueDescription":"Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin Calcium","ValueMeaning":{"publicId":"3379044","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin Calcium","longName":"3379044","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLAC Regimen","conceptCode":"C10223","definition":"A chemotherapy regimen consisting of fluorouracil, leucovorin, doxorubicin, and cyclophosphamide for the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1F9D-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1FB6-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FDG","valueDescription":"Fludeoxyglucose F 18","ValueMeaning":{"publicId":"3379045","version":"1","preferredName":"Fludeoxyglucose F 18","longName":"3379045","preferredDefinition":"The radioactive form of glucose used in positron emission tomography (PET), a diagnostic imaging procedure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludeoxyglucose F-18","conceptCode":"C964","definition":"A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1FC0-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-1FD9-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FAC","valueDescription":"Fluorouracil Doxorubicin Cyclophosphamide Treatment Regimen","ValueMeaning":{"publicId":"3379046","version":"1","preferredName":"Fluorouracil Doxorubicin Cyclophosphamide Treatment Regimen","longName":"3379046","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1FE8-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2001-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"F-ddA","valueDescription":"2'-Fluoro-2',3'-Dideoxyadenosine","ValueMeaning":{"publicId":"3379047","version":"1","preferredName":"2'-Fluoro-2',3'-Dideoxyadenosine","longName":"3379047","preferredDefinition":"A fluoro-substituted analog of dideoxyadenosine that inhibits reverse transcriptase, thereby inhibiting telomerase activity and subsequent cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lodenosine","conceptCode":"C1499","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine. Lodenosine is a synthetic purine fluoro-dideoxyadenosine derivative that was rationally designed to have improved chemical and enzymatic stability. It has shown activity against clinical isolates and cell lines that are resistant to AZT, dideoxyinosine, and dideoxycytosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-200B-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2024-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Etretinate","valueDescription":"Etretinate","ValueMeaning":{"publicId":"3379048","version":"1","preferredName":"Etretinate","longName":"3379048","preferredDefinition":"A synthetic oral retinoid that is a prodrug of acitretin.  Etretinate activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  Etretinate is no longer commercially available in the U.S. due to the extended potential for teratogenic effects related to its long half-life. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etretinate","conceptCode":"C29036","definition":"A synthetic oral retinoid that is a prodrug of acitretin.  Etretinate activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  Etretinate is no longer commercially available in the U.S. due to the extended potential for teratogenic effects related to its long half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-202E-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2047-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Etop/Cyt/Vcr/Mtx/Ifo/Dxm","valueDescription":"Etoposide Cyclophosphamide Vincristine Methotrexate Ifosfamide Dexamethasone Treatment Regimen","ValueMeaning":{"publicId":"3379049","version":"1","preferredName":"Etoposide Cyclophosphamide Vincristine Methotrexate Ifosfamide Dexamethasone Treatment Regimen","longName":"3379049","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04): A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04): A synthetic adrenal corticostero","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-2059-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2072-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ethambutol HCl","valueDescription":"Ethambutol Hydrochloride","ValueMeaning":{"publicId":"3379050","version":"1","preferredName":"Ethambutol Hydrochloride","longName":"3379050","preferredDefinition":"The hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethambutol Hydrochloride","conceptCode":"C29033","definition":"The hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-207C-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2094-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Estrogen","valueDescription":"Estrogen","ValueMeaning":{"publicId":"3379051","version":"1","preferredName":"Estrogen","longName":"3379051","preferredDefinition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen","conceptCode":"C2293","definition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-209F-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20B8-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Etanercept","valueDescription":"Etanercept","ValueMeaning":{"publicId":"2567429","version":"1","preferredName":"Etanercept","longName":"2567429","preferredDefinition":"A dimeric fusion protein comprised of a recombinant form of the extracellular ligand-binding portion of the human 75-kilodalton tumor necrosis factor receptor linked to the Fc portion of human immunoglobulin G1 (IgG1).  Clinical Use: Juvenile Arthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.  Clinical Trial: Bone Marrow Transplant and Adjuvant use for Caner-related Anorexia, Cachexia, and Stomatitis.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D472-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20C2-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"3145843","version":"1","preferredName":"Exemestane","longName":"3145843","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A3AC-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20CD-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20D7-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Famciclovir","valueDescription":"Famciclovir","ValueMeaning":{"publicId":"2575683","version":"1","preferredName":"Famciclovir","longName":"2575683","preferredDefinition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famciclovir","conceptCode":"C29044","definition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20E1-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fazarabine","valueDescription":"Fazarabine","ValueMeaning":{"publicId":"2576848","version":"1","preferredName":"Fazarabine","longName":"2576848","preferredDefinition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fazarabine","conceptCode":"C1096","definition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20EB-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fenretinide","valueDescription":"Fenretinide","ValueMeaning":{"publicId":"2565816","version":"1","preferredName":"Fenretinide","longName":"2565816v1.00","preferredDefinition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fenretinide","conceptCode":"C1098","definition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CE25-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-03-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-20F6-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"BMT, Allogeneic","valueDescription":"Allogeneic Bone Marrow Transplantation","ValueMeaning":{"publicId":"3378222","version":"1","preferredName":"Allogeneic Bone Marrow Transplantation","longName":"3378222","preferredDefinition":"(AL-o-jen-AY-ik) A procedure in which a person receives stem cells, the cells from which all blood cell develop, from a compatible, though not genetically identical, donor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-74E1-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-74FA-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BMS 247550","valueDescription":"BMS 247550 (Ixabepilone)","ValueMeaning":{"publicId":"3145834","version":"1","preferredName":"BMS 247550 (Ixabepilone)","longName":"3145834","preferredDefinition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixabepilone","conceptCode":"C37452","definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A257-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9057ADC-750E-46E9-E040-BB89AD432383","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Estramustine/Vinblastine","valueDescription":"Estramustine Vinblastine Treatment Regimen","ValueMeaning":{"publicId":"3379010","version":"1","preferredName":"Estramustine Vinblastine Treatment Regimen","longName":"3379010","preferredDefinition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estramustine","conceptCode":"C479","definition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-5617-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-5630-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Estradiol","valueDescription":"Estradiol","ValueMeaning":{"publicId":"2576827","version":"1","preferredName":"Estradiol","longName":"2576827","preferredDefinition":"Estradiol (E2). beta-estradiol; 17 beta-estradiol; 1,3,5(10)-estratriene-3,17 beta-diol; the most potent naturally occurring estrogen in mammals, formed by the ovary, placenta, testis, and possibly the adrenal cortex; therapeutic indications for estradiol are those typical of an estrogen. alpha-Estradiol, (17 alpha-estradiol), exhibits considerably less biologic activity. Estradiol is used in the treatment of menstrual disorders, menopause problems, etc. SYN estrogenic hormone, oestradiol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estradiol","conceptCode":"C2295","definition":"The most potent form of the naturally occurring steroid sex hormone in humans, produced by ovary, placenta, testis, and in small amount by adrenal cortex. Estradiol binds to a specific intracellular estrogen receptor located in female organs, breasts, hypothalamus and pituitary. The receptor-ligand complex promotes gene expression necessary for the maintenance of fertility and secondary sexual characteristics in females. In addition, estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Estradiol, the principal intracellular human estrogen, is substantially more active at the cellular level than its metabolites, estrone and estriol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F928-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-563C-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Epothilone D","valueDescription":"Epothilone D","ValueMeaning":{"publicId":"3379012","version":"1","preferredName":"Epothilone D","longName":"3379012","preferredDefinition":"A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epothilone D","conceptCode":"C2672","definition":"A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-564A-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-5663-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Epidermal Growth Factor (EGFR)","valueDescription":"Epidermal Growth Factor","ValueMeaning":{"publicId":"3379014","version":"1","preferredName":"Epidermal Growth Factor","longName":"3379014","preferredDefinition":"Epidermal Growth Factor, encoded by the EGF gene, has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells of both ectodermal and mesodermal origin. The EGF precursor is believed to exist as a membrane-bound molecule that is proteolytically cleaved to generate the 53-amino acid peptide hormone that stimulates cells to divide. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermal Growth Factor","conceptCode":"C20425","definition":"Epidermal growth factor (53 aa, ~6 kDa) is encoded by the human EGF gene. This protein is involved in mitogenesis and magnesium reabsorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-5670-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-5689-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MGCD265","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor MGCD265","ValueMeaning":{"publicId":"3434560","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor MGCD265","longName":"3434560","preferredDefinition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor MGCD265 binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glesatinib","conceptCode":"C77876","definition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD3F6081-657D-1C16-E040-BB89AD431E82","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD3F6081-6596-1C16-E040-BB89AD431E82","beginDate":"2012-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-09","modifiedBy":"ONEDATA","dateModified":"2012-04-09","deletedIndicator":"No"},{"value":"Enfuvirtide","valueDescription":"Enfuvirtide","ValueMeaning":{"publicId":"3379016","version":"1","preferredName":"Enfuvirtide","longName":"3379016","preferredDefinition":"A short polypeptide with activity against human immunodeficiency virus (HIV). Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 viral envelope glycoprotein, thereby preventing conformational changes required for fusion of viral and cellular membranes and preventing the virus from entering a host cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enfuvirtide","conceptCode":"C2105","definition":"A short polypeptide with activity against human immunodeficiency virus (HIV). Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 viral envelope glycoprotein, thereby preventing conformational changes required for fusion of viral and cellular membranes and preventing the virus from entering a host cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-5696-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-56AF-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Efavirenz/Emtricitabine/Tenofovir","valueDescription":"Efavirenz Emtricitabine Tenofovir Treatment Regimen","ValueMeaning":{"publicId":"3379017","version":"1","preferredName":"Efavirenz Emtricitabine Tenofovir Treatment Regimen","longName":"3379017","preferredDefinition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral loads, therefore retarding or preventing damage to the immune system, and reducing the risk of developing AIDS.  Efavirenz induces activity of the cytochrome P450 system, thereby accelerating its own metabolism. (NCI04): A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).: A synthetic antiviral acyclic nucleotide analogue of adenosine 5-monophosphate.  Tenofovir is incorporated into human immunodeficiency viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT), an RNA-dependent DNA polymerase, and resulting in DNA chain termination and impairment of viral replication and propagation.  This agent prevents HIV from reproducing in uninfected cells only.  Tenofovir exhibits activity against the hepatitis B virus (HBV). (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz","conceptCode":"C29027","definition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Emtricitabine","conceptCode":"C47509","definition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tenofovir","conceptCode":"C29490","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-56BE-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-56D7-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Epzicom","valueDescription":"Epzicom","ValueMeaning":{"publicId":"3282242","version":"1","preferredName":"Epzicom","longName":"3282242v1.00","preferredDefinition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate/Lamivudine","conceptCode":"C157405","definition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-72A1-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-56E1-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-56EB-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Estramustine","valueDescription":"Estramustine","ValueMeaning":{"publicId":"3379018","version":"1","preferredName":"Estramustine","longName":"3379018","preferredDefinition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estramustine","conceptCode":"C479","definition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9116403-56F8-BDD4-E040-BB89AD434D9A","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9116403-5711-BDD4-E040-BB89AD434D9A","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"rhuMAB 2C4","valueDescription":"Pertuzumab","ValueMeaning":{"publicId":"3378887","version":"1","preferredName":"Pertuzumab","longName":"3378887","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pertuzumab","conceptCode":"C38692","definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-405F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-4078-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cladribine","valueDescription":"Cladribine","ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-4082-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Clofarabine","valueDescription":"Clofarabine","ValueMeaning":{"publicId":"3378889","version":"1","preferredName":"Clofarabine","longName":"3378889","preferredDefinition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofarabine","conceptCode":"C26638","definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-408F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-40A8-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Clofazimine","valueDescription":"Clofazimine","ValueMeaning":{"publicId":"3378890","version":"1","preferredName":"Clofazimine","longName":"3378890","preferredDefinition":"A phenazine dye with anti-mycobacterial and anti-inflammatory activity. The exact mechanism through which clofazime exerts its effect is unknown.  However, it binds preferentially to mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Clofazimine has a slow bactericidal effect on Mycobacterium leprae and is active against various other Mycobacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofazimine","conceptCode":"C47456","definition":"A phenazine dye with anti-mycobacterial and anti-inflammatory activities. The exact mechanism through which clofazimine exerts its effect is unknown.  However, it binds preferentially to mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Clofazimine has a slow bactericidal effect on Mycobacterium leprae and is active against various other Mycobacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-40B2-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-40CB-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Colchicine","valueDescription":"Colchicine","ValueMeaning":{"publicId":"2577831","version":"1","preferredName":"Colchicine","longName":"2577831","preferredDefinition":"An alkaloid isolated from Colchicum autumnale L. and in other Colchicum species. Colchicine binds to tubulin, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colchicine","conceptCode":"C385","definition":"An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activities. The exact mechanism of action by which colchicines exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals.  Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90729CF-40D5-B0E0-E040-BB89AD436B58","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"PS IL-10/Placebo","valueDescription":"PS IL-10/Placebo","ValueMeaning":{"publicId":"3443980","version":"1","preferredName":"PS IL-10/Placebo","longName":"3443980","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PS IL-10/Placebo","conceptCode":"C29336","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-915B-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9174-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Pred/Cyclo/Etop/Dox (PACE)","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","ValueMeaning":{"publicId":"3379493","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","longName":"3379493","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","conceptCode":"C10861","definition":"A combination of agents containing cyclophosphamide, doxorubicin, etoposide and prednisone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2670-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9188-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"S-1/Cisplatin","valueDescription":"SI/ Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"3443978","version":"1","preferredName":"SI/ Cisplatin Treatment Regimen","longName":"3443978","preferredDefinition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.: An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tegafur-gimeracil-oteracil Potassium","conceptCode":"C1833","definition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-9135-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-914E-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Hycaptmn","valueDescription":"Hycaptmn","ValueMeaning":{"publicId":"3443981","version":"1","preferredName":"Hycaptmn","longName":"3443981","preferredDefinition":"Hycaptmn","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-9192-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-91AB-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Humanized AntiTac Toxin","valueDescription":"LMB-2 Immunotoxin","ValueMeaning":{"publicId":"3379076","version":"1","preferredName":"LMB-2 Immunotoxin","longName":"3379076","preferredDefinition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LMB-2 Immunotoxin","conceptCode":"C2513","definition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-54AA-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-91BF-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"GMX177","valueDescription":"Teglarinad Chloride","ValueMeaning":{"publicId":"3443983","version":"1","preferredName":"Teglarinad Chloride","longName":"3443983","preferredDefinition":"A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teglarinad Chloride","conceptCode":"C68931","definition":"A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-91CC-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-91E5-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Finasteride","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2100-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Flavopiridol","valueDescription":"Flavopiridol","ValueMeaning":{"publicId":"2576859","version":"1","preferredName":"Flavopiridol","longName":"2576859","preferredDefinition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.  This agent is also a competitive inhibitor of adenosine triphosphate activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvocidib Hydrochloride","conceptCode":"C1571","definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F948-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-210A-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":"Fludarabine","ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2115-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fluocinonide","valueDescription":"Fluocinonide","ValueMeaning":{"publicId":"2576865","version":"1","preferredName":"Fluocinonide","longName":"2576865v1.00","preferredDefinition":"A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluocinonide","conceptCode":"C29056","definition":"A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2120-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Flutamide","valueDescription":"Flutamide","ValueMeaning":{"publicId":"3379052","version":"1","preferredName":"Flutamide","longName":"3379052","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-212B-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2144-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fluoxymesterone","valueDescription":"Fluoxymesterone","ValueMeaning":{"publicId":"2576869","version":"1","preferredName":"Fluoxymesterone","longName":"2576869","preferredDefinition":"An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxymesterone","conceptCode":"C507","definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F952-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-214E-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"FOLFIRI","valueDescription":"FOLFIRI Regimen","ValueMeaning":{"publicId":"3379053","version":"1","preferredName":"FOLFIRI Regimen","longName":"3379053","preferredDefinition":"An abbreviation for a chemotherapy combination used to treat advanced colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and irinotecan hydrochloride.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFIRI Regimen","conceptCode":"C63593","definition":"A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of ampullary, appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-2179-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-2192-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fortovase","valueDescription":"Fortovase (Saquinavir)","ValueMeaning":{"publicId":"2575710","version":"1","preferredName":"Fortovase (Saquinavir)","longName":"2575710","preferredDefinition":"A synthetic antiviral agent.  Saquinavir, a peptide-like substrate, selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saquinavir","conceptCode":"C29444","definition":"A peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914931D-21A6-28A3-E040-BB89AD437288","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Tipranavir","valueDescription":"Tipranavir","ValueMeaning":{"publicId":"3380209","version":"1","preferredName":"Tipranavir","longName":"3380209","preferredDefinition":"A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tipranavir","conceptCode":"C66603","definition":"A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97AFB37-88DF-FE51-E040-BB89AD435FA0","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-88F8-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tipifarnib (Zarnestra)","valueDescription":"Tipifarnib","ValueMeaning":{"publicId":"3379529","version":"1","preferredName":"Tipifarnib","longName":"3379529","preferredDefinition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tipifarnib","conceptCode":"C1703","definition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-32E0-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-890C-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Thyrotropin Alfa","valueDescription":"Recombinant Thyrotropin Alfa","ValueMeaning":{"publicId":"3380211","version":"1","preferredName":"Recombinant Thyrotropin Alfa","longName":"3380211","preferredDefinition":"A form of thyroid-stimulating hormone (TSH) that is made in the laboratory. It is used to test for remaining or recurring cancer cells in patients who have been treated for thyroid cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Thyrotropin Alfa","conceptCode":"C61322","definition":"A recombinant form of the human anterior pituitary glycoprotein thyroid stimulating hormone (TSH) with use in the diagnostic setting. With an amino acid sequence identical to that of human TSH, thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or well-differentiated thyroid cancer cells, stimulating iodine uptake and organification, synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97AFB37-8919-FE51-E040-BB89AD435FA0","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-8932-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"2739553","version":"1","preferredName":"Thiotepa","longName":"2739553","preferredDefinition":"A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0294-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-893C-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Theratope Vaccine","valueDescription":"Sialyl Tn-KLH Vaccine","ValueMeaning":{"publicId":"3380213","version":"1","preferredName":"Sialyl Tn-KLH Vaccine","longName":"3380213","preferredDefinition":"A vaccine composed of a substance that enhances immunity plus an antigen found on some tumors of the colon, breast, lung, ovary, pancreas, and stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sialyl Tn-KLH Vaccine","conceptCode":"C1690","definition":"A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97AFB37-8949-FE51-E040-BB89AD435FA0","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-8962-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tetrathiomylybdate (TM)","valueDescription":"Ammonium Tetrathiomolybdate","ValueMeaning":{"publicId":"3380215","version":"1","preferredName":"Ammonium Tetrathiomolybdate","longName":"3380215","preferredDefinition":"An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tiomolibdate Diammonium","conceptCode":"C74001","definition":"An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97AFB37-896F-FE51-E040-BB89AD435FA0","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-8988-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Teniposide (VM-26)","valueDescription":"Teniposide","ValueMeaning":{"publicId":"2739552","version":"1","preferredName":"Teniposide","longName":"2739552","preferredDefinition":"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teniposide","conceptCode":"C857","definition":"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-026F-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97AFB37-899C-FE51-E040-BB89AD435FA0","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Pyrazinamide","valueDescription":"Pyrazinamide","ValueMeaning":{"publicId":"3379510","version":"1","preferredName":"Pyrazinamide","longName":"3379510","preferredDefinition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrazinamide","conceptCode":"C29395","definition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92A1160-3554-5002-E040-BB89AD4338DD","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92A1160-356D-5002-E040-BB89AD4338DD","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"EPOCH/FR","valueDescription":"EPOCH Regimen Fludarabine Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3443984","version":"1","preferredName":"EPOCH Regimen Fludarabine Rituximab Treatment Regimen","longName":"3443984","preferredDefinition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.: A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  : A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-91F4-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-920D-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Emtric/Tenof Dis Fumarate (Truvada)","valueDescription":"Emtricitabine Tenofovir Disoproxil Fumarate Treatment Regimen","ValueMeaning":{"publicId":"3443985","version":"1","preferredName":"Emtricitabine Tenofovir Disoproxil Fumarate Treatment Regimen","longName":"3443985","preferredDefinition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).: A pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine","conceptCode":"C47509","definition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tenofovir Disoproxil Fumarate","conceptCode":"C47747","definition":"A pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-921B-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9234-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"CGN-15/Taxotere","valueDescription":"CGN-15/Taxotere","ValueMeaning":{"publicId":"3443986","version":"1","preferredName":"CGN-15/Taxotere","longName":"3443986","preferredDefinition":"CGN-15/Taxotere","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-923E-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9257-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Carboplatin/Gemcitabine","valueDescription":"Carboplatin/Gemcitabine","ValueMeaning":{"publicId":"3443988","version":"1","preferredName":"Carboplatin/Gemcitabine","longName":"3443988","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Gemcitabine","conceptCode":"C11469","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-9264-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-927D-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"BMS 599626","valueDescription":"pan-HER Kinase Inhibitor AC480","ValueMeaning":{"publicId":"3443990","version":"1","preferredName":"pan-HER Kinase Inhibitor AC480","longName":"3443990","preferredDefinition":"An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pan-HER Kinase Inhibitor AC480","conceptCode":"C48380","definition":"An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-928A-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-92A3-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"5-Fluorodeoxycytadine","valueDescription":"5-Fluorodeoxycytadine","ValueMeaning":{"publicId":"3443991","version":"1","preferredName":"5-Fluorodeoxycytadine","longName":"3443991","preferredDefinition":"5-Fluorodeoxycytadine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-92AD-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-92C6-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Vemurafenib","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-92DA-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Thalidomide/Placebo","valueDescription":"Thalidomide Placebo Treatment Regimen","ValueMeaning":{"publicId":"3443996","version":"1","preferredName":"Thalidomide Placebo Treatment Regimen","longName":"3443996","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  Thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. (NCI04): An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-92E8-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9301-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Study Med 98C0118","valueDescription":"StudyMed 98C0118","ValueMeaning":{"publicId":"3443997","version":"1","preferredName":"StudyMed 98C0118","longName":"3443997","preferredDefinition":"StudyMed 98C0118","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-930B-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9324-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Study Med 00C0080","valueDescription":"StudyMed 00C0080","ValueMeaning":{"publicId":"3443998","version":"1","preferredName":"StudyMed 00C0080","longName":"3443998","preferredDefinition":"StudyMed 00C0080","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA8F7F7-932E-E83B-E040-BB89AD4330DE","latestVersionIndicator":"Yes","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA8F7F7-9347-E83B-E040-BB89AD4330DE","beginDate":"2012-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"Strontium","valueDescription":"Strontium","ValueMeaning":{"publicId":"3380158","version":"1","preferredName":"Strontium","longName":"3380158","preferredDefinition":"An element with atomic symbol Sr, atomic number 38, and atomic weight 87.62.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strontium","conceptCode":"C846","definition":"An element with atomic symbol Sr, atomic number 38, and atomic weight 87.62.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9581-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-959A-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Streptozocin","valueDescription":"Streptozocin","ValueMeaning":{"publicId":"3380160","version":"1","preferredName":"Streptozocin","longName":"3380160","preferredDefinition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Streptozocin","conceptCode":"C845","definition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-95A7-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-95C0-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Stem Cell Transplant","valueDescription":"Stem Cell Transplantation","ValueMeaning":{"publicId":"3380161","version":"1","preferredName":"Stem Cell Transplantation","longName":"3380161","preferredDefinition":"A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-95CA-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-95E3-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Sorafenib (Nexavar)","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-962B-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"SS1(dsFv)-PE38","valueDescription":"SS1(dsFv)-PE38 Immunotoxin","ValueMeaning":{"publicId":"3380163","version":"1","preferredName":"SS1(dsFv)-PE38 Immunotoxin","longName":"3380163","preferredDefinition":"A recombinant immunotoxin consisting of the single chain anti-mesothelin monoclonal antibody SS1(dsFv) linked to Pseudomonas exotoxin PE-38. The monoclonal antibody moiety of the agent binds to cells that express mesothelin, a cell surface glycoprotein which may be overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas; after internalization, the exotoxin moiety inactivates eukaryotic translation elongation factor 2, thereby disrupting tumor cell protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SS1(dsFv)-PE38 Immunotoxin","conceptCode":"C2609","definition":"A recombinant immunotoxin consisting of the single chain anti-mesothelin monoclonal antibody SS1(dsFv) linked to Pseudomonas exotoxin PE-38. The monoclonal antibody moiety of the agent binds to cells that express mesothelin, a cell surface glycoprotein which may be overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas; after internalization, the exotoxin moiety inactivates eukaryotic translation elongation factor 2, thereby disrupting tumor cell protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-95F0-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-9609-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"SNX-6522 (Mesylate)","valueDescription":"Hsp90 Inhibitor SNX-5422 Mesylate","ValueMeaning":{"publicId":"3380166","version":"1","preferredName":"Hsp90 Inhibitor SNX-5422 Mesylate","longName":"3380166","preferredDefinition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hsp90 Inhibitor SNX-5422 Mesylate","conceptCode":"C91068","definition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9639-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-9652-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Sulfasalazine","valueDescription":"Sulfasalazine","ValueMeaning":{"publicId":"3380168","version":"1","preferredName":"Sulfasalazine","longName":"3380168","preferredDefinition":"A synthetic salicylic acid derivative with affinity for connective tissues containing elastin and formulated as a prodrug, antiinflammatory Sulfasalazine acts locally in the intestine through its active metabolites, sulfamide 5-aminosalicylic acid and salicylic acid, by a mechanism that is not clear. It appears inhibit cyclooxygenase and prostaglandin production and is used in the management of inflammatory bowel diseases. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulfasalazine","conceptCode":"C29469","definition":"A synthetic salicylic acid derivative with affinity for connective tissues containing elastin and formulated as a prodrug, antiinflammatory Sulfasalazine acts locally in the intestine through its active metabolites, sulfamide 5-aminosalicylic acid and salicylic acid, by a mechanism that is not clear. It appears inhibit cyclooxygenase and prostaglandin production and is used in the management of inflammatory bowel diseases. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-965F-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-9678-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Sunitinib Malate","valueDescription":"Sunitinib Malate","ValueMeaning":{"publicId":"2679054","version":"1","preferredName":"Sunitinib Malate","longName":"2679054","preferredDefinition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib Malate","conceptCode":"C26673","definition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"399116D7-83EA-5962-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-09-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-968C-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Suramin","valueDescription":"Suramin","ValueMeaning":{"publicId":"3380170","version":"1","preferredName":"Suramin","longName":"3380170","preferredDefinition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Suramin","conceptCode":"C853","definition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9699-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-96B2-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Suramin/HC","valueDescription":"Hydrocortisone/Suramin","ValueMeaning":{"publicId":"3380172","version":"1","preferredName":"Hydrocortisone/Suramin","longName":"3380172","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocortisone/Suramin","conceptCode":"C10154","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-96BF-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-96D8-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Suramin/AGT/HC","valueDescription":"Aminoglutethimide/Hydrocortisone/Suramin","ValueMeaning":{"publicId":"3380174","version":"1","preferredName":"Aminoglutethimide/Hydrocortisone/Suramin","longName":"3380174","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide/Hydrocortisone/Suramin","conceptCode":"C29471","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-96E5-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A2A6B-96FE-1351-E040-BB89AD432684","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"WR2721","valueDescription":"Amifostine","ValueMeaning":{"publicId":"3380282","version":"1","preferredName":"Amifostine","longName":"3380282","preferredDefinition":"A phosphorylated aminosulfhydryl compound. After dephosphorylation by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, amifostine binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amifostine","conceptCode":"C488","definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A3FA-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A412-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"dHER2+ASCI","valueDescription":"dHER2 + AS15 candidate Antigen-Specific Cancer Imunotherapeutic (ASCI)","ValueMeaning":{"publicId":"3377293","version":"1","preferredName":"dHER2 + AS15 candidate Antigen-Specific Cancer Imunotherapeutic (ASCI)","longName":"3377293","preferredDefinition":"dHER2 + AS15 candidate Antigen-Specific Cancer Imunotherapeutic (ASCI)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DB02B7-E82A-9AB0-E040-BB89AD434779","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DB02B7-E843-9AB0-E040-BB89AD434779","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Vinblastine/Lomustine","valueDescription":"Vinblastine Lomustine Treatment Regimen","ValueMeaning":{"publicId":"3380284","version":"1","preferredName":"Vinblastine Lomustine Treatment Regimen","longName":"3380284","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A449-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A462-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vinblastine/Lomustine/Pred","valueDescription":"Vinblastine Lomustine Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3380283","version":"1","preferredName":"Vinblastine Lomustine Prednisone Treatment Regimen","longName":"3380283","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A422-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A43B-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vinblastine/Etoposide/Pred","valueDescription":"Etoposide/Prednisone/Vinblastine","ValueMeaning":{"publicId":"3380286","version":"1","preferredName":"Etoposide/Prednisone/Vinblastine","longName":"3380286","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Prednisone/Vinblastine","conceptCode":"C29542","definition":"A combination of agents containing etoposide, prednisone and vinblastine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A46F-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A488-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vinblastine","valueDescription":"Vinblastine","ValueMeaning":{"publicId":"3380287","version":"1","preferredName":"Vinblastine","longName":"3380287","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A492-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A4AB-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VAC","valueDescription":"Cyclophosphamide/Doxorubicin/Vincristine","ValueMeaning":{"publicId":"3380289","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Vincristine","longName":"3380289","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Doxorubicin/Vincristine","conceptCode":"C9540","definition":"A chemotherapy combination consisting of cyclophosphamide, doxorubicin, and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A4B8-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A4D1-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Ursodeoxycholic acid","valueDescription":"Ursodiol","ValueMeaning":{"publicId":"3380290","version":"1","preferredName":"Ursodiol","longName":"3380290","preferredDefinition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ursodiol","conceptCode":"C1818","definition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A4DB-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A4F4-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"UVB","valueDescription":"Ultraviolet B Radiation","ValueMeaning":{"publicId":"3380292","version":"1","preferredName":"Ultraviolet B Radiation","longName":"3380292","preferredDefinition":"Ultraviolet B Radiation is the 290 to 320 nanometers portion of the sun's radiant electromagnetic energy spectrum, partially absorbed by the Earth's protective stratospheric ozone layer. Recent ozone depletion has permitted more UVB to reach the Earth's surface with a wide range of potentially damaging health effects related to skin, eyes, and immune system. Evidence shows a dose-response relationship between nonmelanoma skin cancer and cumulative exposure to UVB radiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ultraviolet B Radiation","conceptCode":"C27987","definition":"Ultraviolet B Radiation is the 290 to 320 nanometers portion of the sun's radiant electromagnetic energy spectrum, partially absorbed by the Earth's protective stratospheric ozone layer. Recent ozone depletion has permitted more UVB to reach the Earth's surface with a wide range of potentially damaging health effects related to skin, eyes, and immune system. Evidence shows a dose-response relationship between nonmelanoma skin cancer and cumulative exposure to UVB radiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A501-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A51A-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Warburg Therapy","valueDescription":"Warburg Therapy","ValueMeaning":{"publicId":"3380294","version":"1","preferredName":"Warburg Therapy","longName":"3380294","preferredDefinition":"The cornerstone of oxygenation therapy is the presumption that human disease, including cancer, is caused by a deficit of tissue oxygen. According to proponents, hypoxia results in anaerobic fermentation, a loss of capacity for oxidative detoxification of toxins and metabolic products, and failure of immune killing of invading bacteria and viruses. To restore ability to carry out these functions, oxygenation promoters propose using chemicals they claim will release oxygen in tissue or act as germicides in vivo.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warburg Therapy","conceptCode":"C29545","definition":"The cornerstone of oxygenation therapy is the presumption that human disease, including cancer, is caused by a deficit of tissue oxygen. According to proponents, hypoxia results in anaerobic fermentation, a loss of capacity for oxidative detoxification of toxins and metabolic products, and failure of immune killing of invading bacteria and viruses. To restore ability to carry out these functions, oxygenation promoters propose using chemicals they claim will release oxygen in tissue or act as germicides in vivo.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A527-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A540-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Adefovir","valueDescription":"Adefovir","ValueMeaning":{"publicId":"2575649","version":"1","preferredName":"Adefovir","longName":"2575649v1.00","preferredDefinition":"A nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adefovir","conceptCode":"C61526","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9DAB-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Epothilone B","valueDescription":"Epothilone B","ValueMeaning":{"publicId":"3013195","version":"1","preferredName":"Epothilone B","longName":"3013195","preferredDefinition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, epothilone B induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Epothilone B may cause complete cell-cycle arrest. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patupilone","conceptCode":"C1623","definition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF9397D-42B1-21AE-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9D7E-1E33-E040-BB89AD43040B","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Abacavir Sulfate/Lamivudine","valueDescription":"Abacavir Sulfate Lamivudine Combination","ValueMeaning":{"publicId":"3377403","version":"1","preferredName":"Abacavir Sulfate Lamivudine Combination","longName":"3377403","preferredDefinition":"The sulfate salt form of abacavir, a synthetic carbocyclic nucleoside analog. In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.: A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04): A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate","conceptCode":"C28804","definition":"A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9E46-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9E5F-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Abacavir","valueDescription":"Abacavir","ValueMeaning":{"publicId":"2575647","version":"1","preferredName":"Abacavir","longName":"2575647","preferredDefinition":"A synthetic carbocyclic nucleoside analog.  In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles.  This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir","conceptCode":"C61523","definition":"A nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9DB5-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Abacavir/AZT/3TC","valueDescription":"Abacavir Zidovudine Lamivudine Combination","ValueMeaning":{"publicId":"3377402","version":"1","preferredName":"Abacavir Zidovudine Lamivudine Combination","longName":"3377402","preferredDefinition":"A synthetic carbocyclic nucleoside analog.  In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles.  This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.: A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04): A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04): A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir","conceptCode":"C61523","definition":"A nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Zidovudine","conceptCode":"C947","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9E1F-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9E38-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"AZT (Zidovudine)","valueDescription":"Zidovudine","ValueMeaning":{"publicId":"3128742","version":"1","preferredName":"Zidovudine","longName":"3128742","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zidovudine","conceptCode":"C947","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E76-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9E73-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Advair","valueDescription":"Fluticasone Salmeterol Combination","ValueMeaning":{"publicId":"3377405","version":"1","preferredName":"Fluticasone Salmeterol Combination","longName":"3377405","preferredDefinition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.: A highly selective, long-acting beta-2 adrenergic agonist with bronchodilatory activity. Salmeterol's benzene moiety resembles the structure of catecholamines, and occupies the active site of beta-2 adrenergic receptor, while the long, lipophilic side chain of salmeterol, binds to the so called 'exosite' near the beta-2 adrenergic receptors. The binding at the exosite allows the active portion of the molecule to remain at the receptor site and continually engage and disengage with the receptor, therefore providing a long duration of action. This agent stimulates intracellular adenyl cyclase to catalyze the conversion of adenosine triphosphate to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels result in relaxation of bronchiolar smooth muscle, bronchodilation and increased bronchial airflow.: A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone","conceptCode":"C61767","definition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Salmeterol","conceptCode":"C29443","definition":"A highly selective, long-acting beta-2 adrenergic agonist with bronchodilatory activity. Salmeterol's benzene moiety resembles the structure of catecholamines, and occupies the active site of beta-2 adrenergic receptor, while the long, lipophilic side chain of salmeterol, binds to the so called 'exosite' near the beta-2 adrenergic receptors. The binding at the exosite allows the active portion of the molecule to remain at the receptor site and continually engage and disengage with the receptor, therefore providing a long duration of action. This agent stimulates intracellular adenyl cyclase to catalyze the conversion of adenosine triphosphate to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels result in relaxation of bronchiolar smooth muscle, bronchodilation and increased bronchial airflow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9E82-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9E9B-1E33-E040-BB89AD43040B","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Alphavirus Vector CEA","valueDescription":"Vector Carcinoembryonic Antigen Alphavirus","ValueMeaning":{"publicId":"3377406","version":"1","preferredName":"Vector Carcinoembryonic Antigen Alphavirus","longName":"3377406","preferredDefinition":"A single dimensional array.: Carcinoembryonic antigen. A substance that is sometimes found in an increased amount in the blood of people with certain cancers.: A genus of TOGAVIRIDAE, also known as Group A arboviruses, serologically related to each other but not to other Togaviridae. The viruses are transmitted by mosquitoes. The type species is the SINDBIS VIRUS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vector","conceptCode":"C54169","definition":"A single dimensional array.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Carcinoembryonic Antigen","conceptCode":"C25159","definition":"A cancer-specific antigen associated with both tumors and the developing fetus. The main use of this antigen is as a tumor marker, especially with respect to intestinal cancers. Production of the antigen ceases shortly before birth, but may reappear in people who develop certain types of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Alphavirus","conceptCode":"C0002331","definition":"A genus of TOGAVIRIDAE, also known as Group A arboviruses, serologically related to each other but not to other Togaviridae. The viruses are transmitted by mosquitoes. The type species is the SINDBIS VIRUS.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9EA9-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9EC2-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"AZD8055","valueDescription":"mTOR Kinase Inhibitor AZD8055","ValueMeaning":{"publicId":"3377408","version":"1","preferredName":"mTOR Kinase Inhibitor AZD8055","longName":"3377408","preferredDefinition":"An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"mTOR Kinase Inhibitor AZD8055","conceptCode":"C78856","definition":"An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9ECF-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9EE8-1E33-E040-BB89AD43040B","beginDate":"2011-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Cabazitaxel","valueDescription":"Cabizitaxel","ValueMeaning":{"publicId":"2939033","version":"1","preferredName":"Cabizitaxel","longName":"2939033v1.00","preferredDefinition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabazitaxel","conceptCode":"C66937","definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4B01-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9EF2-1E33-E040-BB89AD43040B","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Lexatumumb","valueDescription":"Lexatumumb","ValueMeaning":{"publicId":"3377401","version":"1","preferredName":"Lexatumumb","longName":"3377401","preferredDefinition":"Lexatumumb","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9D88-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F06-1E33-E040-BB89AD43040B","beginDate":"2009-12-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Acetylcysteine","valueDescription":"Acetylcysteine","ValueMeaning":{"publicId":"3128727","version":"1","preferredName":"Acetylcysteine","longName":"3128727","preferredDefinition":"A synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, a precursor of the antioxidant enzyme glutathione.  Acetylcysteine regenerates liver stores of glutathione. This agent also reduces disulfide bonds in mucoproteins, resulting in liquification of mucus.  Some evidence suggests that acetylcysteine may exert an anti-apoptotic effect due to its antioxidant activity, possibly preventing cancer cell development or growth.  In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetylcysteine","conceptCode":"C200","definition":"A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BEDD-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F10-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Acitretin","valueDescription":"Acitretin","ValueMeaning":{"publicId":"2576902","version":"1","preferredName":"Acitretin","longName":"2576902","preferredDefinition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acitretin","conceptCode":"C985","definition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F973-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F1A-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Acivicin","valueDescription":"Acivicin","ValueMeaning":{"publicId":"3377410","version":"1","preferredName":"Acivicin","longName":"3377410","preferredDefinition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acivicin","conceptCode":"C986","definition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9F28-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F41-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Aminoglutethimide/Hydrocortisone","valueDescription":"Aminoglutethimide Cortisol Combination","ValueMeaning":{"publicId":"3377427","version":"1","preferredName":"Aminoglutethimide Cortisol Combination","longName":"3377427","preferredDefinition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.: The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.: A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide","conceptCode":"C233","definition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cortisol","conceptCode":"C2290","definition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9F50-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F69-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Alpha-1, 3-galactosyltransferase","valueDescription":"Alpha-1, 3-galactosyltransferase","ValueMeaning":{"publicId":"3377428","version":"1","preferredName":"Alpha-1, 3-galactosyltransferase","longName":"3377428","preferredDefinition":"Alpha-1, 3-galactosyltransferase","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9F73-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9F8C-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"BACOD","valueDescription":"Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine","ValueMeaning":{"publicId":"3377430","version":"1","preferredName":"Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine","longName":"3377430","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BACOD Regimen","conceptCode":"C9698","definition":"A chemotherapy regimen consisting of bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone for treating patients with non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9F99-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9FB2-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"B3 (Monoclonal Antibody B3)","valueDescription":"Monoclonal Antibody B3","ValueMeaning":{"publicId":"3377432","version":"1","preferredName":"Monoclonal Antibody B3","longName":"3377432","preferredDefinition":"A murine IgG1 monoclonal antibody directed against Lewis Y antigen and related carbohydrate antigens of cell surface glycoproteins found in many tumor cells.  Monoclonal antibody B3 can be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing these carbohydrate antigens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody B3","conceptCode":"C2726","definition":"A murine IgG1 monoclonal antibody directed against Lewis Y antigen and related carbohydrate antigens of cell surface glycoproteins found in many tumor cells.  Monoclonal antibody B3 can be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing these carbohydrate antigens. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9FBF-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9FD8-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Antineoplaston","valueDescription":"Antineoplaston Agent","ValueMeaning":{"publicId":"3377434","version":"1","preferredName":"Antineoplaston Agent","longName":"3377434","preferredDefinition":"A peptide, amino acid derivative, and/or organic acid extracted from blood serum, urine, or synthesized chemically, that inhibits the methylation of nucleic acids and the incorporation of L-glutamine into tumor-cell proteins. These agents also intercalate into DNA, leading to cell cycle arrest in the G1 phase and inhibition of mitosis and terminal cell differentiation. In addition, antineoplastons may inhibit RAS oncogene expression and activate the tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antineoplaston Agent","conceptCode":"C2500","definition":"A peptide, amino acid derivative, and/or organic acid extracted from blood serum, urine, or synthesized chemically, that inhibits the methylation of nucleic acids and the incorporation of L-glutamine into tumor-cell proteins. These agents also intercalate into DNA, leading to cell cycle arrest in the G1 phase and inhibition of mitosis and terminal cell differentiation. In addition, antineoplastons may inhibit RAS oncogene expression and activate the tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9FE5-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-9FFE-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Altretamine","valueDescription":"Hexamethylmelamine (Altretamine)","ValueMeaning":{"publicId":"2576918","version":"1","preferredName":"Hexamethylmelamine (Altretamine)","longName":"2576918","preferredDefinition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Altretamine","conceptCode":"C544","definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F983-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A008-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Alternative Therapy","valueDescription":"Alternative Medicine, Indirect","ValueMeaning":{"publicId":"3377436","version":"1","preferredName":"Alternative Medicine, Indirect","longName":"3377436","preferredDefinition":"Medical substance or procedure in the process of becoming accepted by orthodox western medicine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alternative Medicine, Indirect","conceptCode":"C19937","definition":"Medical substance or procedure in the process of becoming accepted by orthodox western medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A016-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A02F-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Aldesleukin","valueDescription":"Aldesleukin","ValueMeaning":{"publicId":"2737463","version":"1","preferredName":"Aldesleukin","longName":"2737463","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous human cytokine interleukin-2 with potential antineoplastic activity.  Aldesleukin enhances lymphocyte mitogenesis, stimulates long-term growth of human IL-2 dependent cell lines, enhances lymphocyte cytotoxicity, induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities, and induces expression of interferon-gamma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldesleukin","conceptCode":"C1498","definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C2DF-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A039-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Vincristine","valueDescription":"Vincristine","ValueMeaning":{"publicId":"3380295","version":"1","preferredName":"Vincristine","longName":"3380295","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A54A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A563-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vindesine","valueDescription":"Vindesine","ValueMeaning":{"publicId":"3380296","version":"1","preferredName":"Vindesine","longName":"3380296","preferredDefinition":"Vinblastine derivative with antineoplastic activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus, head, and neck, and Hodgkin's and non-Hodgkin's lymphomas. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vindesine","conceptCode":"C934","definition":"A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A56D-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A586-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vinorelbine","valueDescription":"Vinorelbine","ValueMeaning":{"publicId":"2576638","version":"1","preferredName":"Vinorelbine","longName":"2576638","preferredDefinition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A590-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vitamin B12","valueDescription":"Vitamin B12","ValueMeaning":{"publicId":"2577835","version":"1","preferredName":"Vitamin B12","longName":"2577835","preferredDefinition":"A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobalamin","conceptCode":"C939","definition":"An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A5A4-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vorinostat","valueDescription":"Vorinostat","ValueMeaning":{"publicId":"3380298","version":"1","preferredName":"Vorinostat","longName":"3380298","preferredDefinition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorinostat","conceptCode":"C1796","definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5B1-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A5CA-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"ddI","valueDescription":"Didanosine","ValueMeaning":{"publicId":"2576104","version":"1","preferredName":"Didanosine","longName":"2576104","preferredDefinition":"A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F655-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A64D-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VNP 20009","valueDescription":"Salmonella VNP20009","ValueMeaning":{"publicId":"3380351","version":"1","preferredName":"Salmonella VNP20009","longName":"3380351","preferredDefinition":"A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Salmonella VNP20009","conceptCode":"C2556","definition":"A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A65A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A673-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VEGF","valueDescription":"Recombinant Vascular Endothelial Growth Factor","ValueMeaning":{"publicId":"3380352","version":"1","preferredName":"Recombinant Vascular Endothelial Growth Factor","longName":"3380352","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Vascular Endothelial Growth Factor","conceptCode":"C1272","definition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A67F-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A698-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VEG102616 (Pazopanib)","valueDescription":"Pazopanib Hydrochloride","ValueMeaning":{"publicId":"3380354","version":"1","preferredName":"Pazopanib Hydrochloride","longName":"3380354","preferredDefinition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib Hydrochloride","conceptCode":"C60779","definition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6A5-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A6BE-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VEG10006","valueDescription":"Pazopanib","ValueMeaning":{"publicId":"3380355","version":"1","preferredName":"Pazopanib","longName":"3380355","preferredDefinition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6CA-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A6E2-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VAD","valueDescription":"VAD Regimen","ValueMeaning":{"publicId":"3380357","version":"1","preferredName":"VAD Regimen","longName":"3380357","preferredDefinition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for multiple myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAD Regimen","conceptCode":"C63498","definition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6F0-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A709-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VATH","valueDescription":"Doxorubicin/Fluoxymesterone/Thiotepa/Vinblastine","ValueMeaning":{"publicId":"3380359","version":"1","preferredName":"Doxorubicin/Fluoxymesterone/Thiotepa/Vinblastine","longName":"3380359","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VATH Regimen","conceptCode":"C9638","definition":"A chemotherapy regimen consisting of fluoxymesterone, thiotepa, doxorubicin, and vinblastine that may be used in the treatment of advanced breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A716-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A72F-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VACOP","valueDescription":"Etoposide Doxorubicin Cyclophosphamide Vincristine Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3380360","version":"1","preferredName":"Etoposide Doxorubicin Cyclophosphamide Vincristine Prednisone Treatment Regimen","longName":"3380360","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and a","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A740-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97CA559-A759-BAA9-E040-BB89AD430252","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Yttrium 90","valueDescription":"Yttrium 90","ValueMeaning":{"publicId":"3380782","version":"1","preferredName":"Yttrium 90","longName":"3380782","preferredDefinition":"Radioactive isotope of yttrium.  A beta/gamma-emitter with a half life of 2.7 days.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yttrium Y-90","conceptCode":"C1641","definition":"Radioactive isotope of yttrium.  A beta/gamma-emitter with a half life of 2.7 days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B1D-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5B36-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Y90-B3","valueDescription":"Yttrium Y 90 Monoclonal Antibody B3","ValueMeaning":{"publicId":"3378152","version":"1","preferredName":"Yttrium Y 90 Monoclonal Antibody B3","longName":"3378152","preferredDefinition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yttrium Y 90 Monoclonal Antibody B3","conceptCode":"C2614","definition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C6B-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5B4A-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Zoladex","valueDescription":"Goserelin Acetate","ValueMeaning":{"publicId":"3380783","version":"1","preferredName":"Goserelin Acetate","longName":"3380783","preferredDefinition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin Acetate","conceptCode":"C1417","definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B54-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5B6C-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"XR9576","valueDescription":"Tariquidar","ValueMeaning":{"publicId":"3380784","version":"1","preferredName":"Tariquidar","longName":"3380784","preferredDefinition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tariquidar","conceptCode":"C2246","definition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B79-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5B92-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"XL999","valueDescription":"XL999","ValueMeaning":{"publicId":"3380786","version":"1","preferredName":"XL999","longName":"3380786v1.00","preferredDefinition":"A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","conceptCode":"C116894","definition":"A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B9F-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5BB8-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Folate Receptor-Targeted Vinca Alkaloid EC0489","valueDescription":"Folate Receptor-Targeted Vinca Alkaloid EC0489","ValueMeaning":{"publicId":"3380788","version":"1","preferredName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","longName":"3380788","preferredDefinition":"A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","conceptCode":"C81935","definition":"A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5BC5-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5BDE-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vesanoid","valueDescription":"ATRA","ValueMeaning":{"publicId":"2764385","version":"1","preferredName":"ATRA","longName":"2764385","preferredDefinition":"A naturally-occurring acid of retinol.  Vitamin A acid binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some cancer cell types.  The oral form of vitamin A acid has teratogenic and embryotoxic properties.(NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"519B9CC5-5DF0-3C2A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5BF2-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vbl/Cyt/Etop/Dxm","valueDescription":"Vinblastine Cyclophosphamide Etoposide Dexamethasone Treatment Regimen","ValueMeaning":{"publicId":"3380789","version":"1","preferredName":"Vinblastine Cyclophosphamide Etoposide Dexamethasone Treatment Regimen","longName":"3380789","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5C02-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C1B-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Valganciclovir","valueDescription":"Valganciclovir","ValueMeaning":{"publicId":"2575724","version":"1","preferredName":"Valganciclovir","longName":"2575724","preferredDefinition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valganciclovir","conceptCode":"C2629","definition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C25-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Valacyclovir HCl","valueDescription":"Valacyclovir Hydrochloride","ValueMeaning":{"publicId":"3380791","version":"1","preferredName":"Valacyclovir Hydrochloride","longName":"3380791","preferredDefinition":"The hydrochloride salt of valacyclovir. Valacyclovir is an acyclovir prodrug that, after metabolization, inhibits viral DNA replication. It is used in the management of herpes simplex and varicella zoster infections, as well as prophylactically for human cytomegalovirus infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valacyclovir Hydrochloride","conceptCode":"C29535","definition":"The hydrochloride salt of valacyclovir. Valacyclovir is an acyclovir prodrug that, after metabolization, inhibits viral DNA replication. It is used in the management of herpes simplex and varicella zoster infections, as well as prophylactically for human cytomegalovirus infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5C32-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C4A-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vaccinia/Tyrosinase","valueDescription":"Vaccinia Virus Tyrosinase Treatment Regimen","ValueMeaning":{"publicId":"3380794","version":"1","preferredName":"Vaccinia Virus Tyrosinase Treatment Regimen","longName":"3380794","preferredDefinition":"DNA viruses used in several biotechnology applications, including expression vector systems.: A group of copper proteins that also catalyze the reaction of EC 1.10.3.1 catechol oxidase, if only 1,2-benzenediols are available as substrate. (from IUBMB): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccinia Virus","conceptCode":"C14281","definition":"DNA viruses used in several biotechnology applications, including expression vector systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tyrosinase","conceptCode":"C17226","definition":"Tyrosinase (529 aa, ~60 kDa) is encoded by the human TYR gene. This protein is involved in pigment biosynthesis, eye development and the metabolism of both tyrosine and L-dopa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5C5A-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C73-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Vaccine","valueDescription":"Vaccine","ValueMeaning":{"publicId":"2958076","version":"1","preferredName":"Vaccine","longName":"2958076","preferredDefinition":"Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"779FFFA3-EFE3-61A0-E040-BB89AD433786","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C7D-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"VELCAP","valueDescription":"Etoposide Doxorubicin Cyclophosphamide Vincristine Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3380795","version":"1","preferredName":"Etoposide Doxorubicin Cyclophosphamide Vincristine Prednisone Treatment Regimen","longName":"3380795","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and a","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5C87-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5C9F-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Hyper-CVAD","valueDescription":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","ValueMeaning":{"publicId":"3378831","version":"1","preferredName":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","longName":"3378831","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","conceptCode":"C10131","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-16D4-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5CB5-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"p53","valueDescription":"Tumor Protein p53","ValueMeaning":{"publicId":"2669809","version":"1","preferredName":"Tumor Protein p53","longName":"2669809","preferredDefinition":"A homo-tetrameric, DNA-binding, trans-activator of genes involved in cell division. p53 induces growth arrest or apoptosis and is mutated or inactivated in about 60% of cancers. JNK-p53 and mdm2-p53 complexes regulate ubiquitination and degradation of p53. (from SWISS-PROT P04637, OMIM 191170, and NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Tumor Antigen p53","conceptCode":"C17387","definition":"Cellular tumor antigen p53 (393 aa, ~44 kDa) is encoded by the human TP53 gene. This protein plays a role in the regulation of both the cell cycle and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36934AAA-BFBF-3C59-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5CBF-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"gp-120","valueDescription":"gp-120 Antigen","ValueMeaning":{"publicId":"3380797","version":"1","preferredName":"gp-120 Antigen","longName":"3380797","preferredDefinition":"A recombinant HIV gp120 envelope protein with potential use in HIV vaccine therapy. Gp-120 antigen is used to elicit a gp120-specific T-cell response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"gp-120 Antigen","conceptCode":"C29554","definition":"A recombinant HIV gp120 envelope protein with potential use in HIV vaccine therapy. Gp-120 antigen is used to elicit a gp120-specific T-cell response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5CCD-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5CE6-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"ERB-38","valueDescription":"ERB-38 Immunotoxin","ValueMeaning":{"publicId":"3380799","version":"1","preferredName":"ERB-38 Immunotoxin","longName":"3380799","preferredDefinition":"A bivalent fusion protein consisting of disulfide-stabilized Fv fragments of an anti-HER2 (erbB2) monoclonal antibody (e23) and a truncated version of the M(r) 38 fragment of Pseudomonas exotoxin that lacks the toxin's cell binding domain. ERB-38 immunotoxin binds specifically to cells that overexpress HER2, the antigenic target of the monoclonal antibody; the exotoxin portion of the immunotoxin then lyses the cells bound by the antibody portion. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ERB-38 Immunotoxin","conceptCode":"C2453","definition":"A bivalent fusion protein consisting of disulfide-stabilized Fv fragments of an anti-HER2 (erbB2) monoclonal antibody (e23) and a truncated version of the M(r) 38 fragment of Pseudomonas exotoxin that lacks the toxin's cell binding domain. ERB-38 immunotoxin binds specifically to cells that overexpress HER2, the antigenic target of the monoclonal antibody; the exotoxin portion of the immunotoxin then lyses the cells bound by the antibody portion. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5CF3-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D0C-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"ddc","valueDescription":"Zalcitabine","ValueMeaning":{"publicId":"2576782","version":"1","preferredName":"Zalcitabine","longName":"2576782","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zalcitabine","conceptCode":"C430","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D20-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Zoledronic Acid","valueDescription":"Zoledronate","ValueMeaning":{"publicId":"2576643","version":"1","preferredName":"Zoledronate","longName":"2576643","preferredDefinition":"A drug that belongs to the family of drugs called bisphosphonates. It is used to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D34-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Zinc Finger","valueDescription":"Zinc-Binding, DNA-Binding Motif","ValueMeaning":{"publicId":"3380801","version":"1","preferredName":"Zinc-Binding, DNA-Binding Motif","longName":"3380801","preferredDefinition":"Zinc-binding, DNA-binding motifs in proteins contain amino acids that are folded into a single DNA-binding structural unit around a zinc atom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc-Binding, DNA-Binding Motif","conceptCode":"C13427","definition":"Zinc-binding, DNA-binding motifs in proteins contain amino acids that are folded into a single DNA-binding structural unit around a zinc atom.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5D41-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D5A-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"ZD6474","valueDescription":"Vandetanib","ValueMeaning":{"publicId":"3380803","version":"1","preferredName":"Vandetanib","longName":"3380803","preferredDefinition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vandetanib","conceptCode":"C2737","definition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5D67-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D80-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"ZD1839","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B980D66E-5D94-FB86-E040-BB89AD43770B","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Akt Inhibitor MK2206","valueDescription":"Akt Inhibitor MK2206","ValueMeaning":{"publicId":"3374409","version":"1","preferredName":"Akt Inhibitor MK2206","longName":"3374409","preferredDefinition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Akt Inhibitor MK2206","conceptCode":"C90581","definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B87BD737-997B-575D-E040-BB89AD434B6E","latestVersionIndicator":"Yes","beginDate":"2012-02-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B87BD737-9994-575D-E040-BB89AD434B6E","beginDate":"2012-02-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-08","modifiedBy":"ONEDATA","dateModified":"2012-02-08","deletedIndicator":"No"},{"value":"177 Lu-CC49","valueDescription":"Lutetium Lu 177 Monoclonal Antibody CC49","ValueMeaning":{"publicId":"3377412","version":"1","preferredName":"Lutetium Lu 177 Monoclonal Antibody CC49","longName":"3377412","preferredDefinition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lutetium Lu 177 Monoclonal Antibody CC49","conceptCode":"C2598","definition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1B7C-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1B95-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"17-DMAG","valueDescription":"17-Dimethylaminoethylamino-17-Demethoxygeldanamycin","ValueMeaning":{"publicId":"3377414","version":"1","preferredName":"17-Dimethylaminoethylamino-17-Demethoxygeldanamycin","longName":"3377414","preferredDefinition":"An analogue of the benzoquinone antineoplastic antibiotic geldanamycin.  17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins.  Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvespimycin","conceptCode":"C38142","definition":"An analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1BA2-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1BBB-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"131-I-TM-601","valueDescription":"Iodine I 131 Tositumomab","ValueMeaning":{"publicId":"3377416","version":"1","preferredName":"Iodine I 131 Tositumomab","longName":"3377416","preferredDefinition":"A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I 131 Tositumomab","conceptCode":"C2444","definition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1BC8-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1BE1-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"111 In-B3","valueDescription":"In 111 Monoclonal Antibody B3","ValueMeaning":{"publicId":"3377418","version":"1","preferredName":"In 111 Monoclonal Antibody B3","longName":"3377418","preferredDefinition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 labeled with Indium 111 (In-111). MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits gamma radiation and X-Ray photons that can be captured by gamma camera, allowing imaging of Lewis Y expressing tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In 111 Monoclonal Antibody B3","conceptCode":"C2615","definition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 labeled with Indium 111 (In-111). MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits gamma radiation and X-Ray photons that can be captured by gamma camera, allowing imaging of Lewis Y expressing tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1BEE-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C07-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"ABVD","valueDescription":"ABVD Regimen","ValueMeaning":{"publicId":"3377419","version":"1","preferredName":"ABVD Regimen","longName":"3377419","preferredDefinition":"A chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ABVD Regimen","conceptCode":"C9509","definition":"A regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C13-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C2C-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"5-Fluorouracil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"2561703","version":"1","preferredName":"Fluorouracil","longName":"2561703","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"REEVESD","dateModified":"2009-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C36-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"ARQ 197 (Tivantinib)","valueDescription":"Tivantinib","ValueMeaning":{"publicId":"3377421","version":"1","preferredName":"Tivantinib","longName":"3377421","preferredDefinition":"An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tivantinib","conceptCode":"C62437","definition":"An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C43-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C5C-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"ATS (Anti-Thymocyte Globulin)","valueDescription":"Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"3253646","version":"1","preferredName":"Anti-Thymocyte Globulin","longName":"3253646","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7AB2-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C70-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"9-AC (Aminocamptothecin)","valueDescription":"Aminocamptothecin","ValueMeaning":{"publicId":"2576886","version":"1","preferredName":"Aminocamptothecin","longName":"2576886","preferredDefinition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminocamptothecin","conceptCode":"C1488","definition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F963-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1C84-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"AZD2281","valueDescription":"Olaparib","ValueMeaning":{"publicId":"3377423","version":"1","preferredName":"Olaparib","longName":"3377423","preferredDefinition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaparib","conceptCode":"C71721","definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C92-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1CAB-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"AZD6244","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1CBF-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Acyclovir","valueDescription":"Acyclovir","ValueMeaning":{"publicId":"2575648","version":"1","preferredName":"Acyclovir","longName":"2575648","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses.  After conversion in vitro to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1CC9-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Alprostadil","valueDescription":"Alprostadil","ValueMeaning":{"publicId":"2576910","version":"1","preferredName":"Alprostadil","longName":"2576910","preferredDefinition":"The naturally occuring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions.  Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alprostadil","conceptCode":"C28816","definition":"The naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions.  Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A043-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Amifostine","valueDescription":"Amifostine","ValueMeaning":{"publicId":"2568062","version":"1","preferredName":"Amifostine","longName":"2568062v1.00","preferredDefinition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amifostine","conceptCode":"C488","definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A04E-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Aminoglutethimide","valueDescription":"Aminoglutethimide","ValueMeaning":{"publicId":"2576921","version":"1","preferredName":"Aminoglutethimide","longName":"2576921","preferredDefinition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide","conceptCode":"C233","definition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F986-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A058-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Amprenavir","valueDescription":"Amprenavir","ValueMeaning":{"publicId":"2576927","version":"1","preferredName":"Amprenavir","longName":"2576927","preferredDefinition":"A synthetic antiviral agent.  As a derivative of hydroxyethylamine sulfonamide, amprenavir selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amprenavir","conceptCode":"C28824","definition":"A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A062-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anastrozole","valueDescription":"Anastrozole","ValueMeaning":{"publicId":"3145842","version":"1","preferredName":"Anastrozole","longName":"3145842","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A37F-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A06C-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anthralin","valueDescription":"Anthralin","ValueMeaning":{"publicId":"2567421","version":"1","preferredName":"Anthralin","longName":"2567421","preferredDefinition":"An anti-inflammatory anthracene derivative used for the treatment of dermatoses, especially psoriasis. It may cause folliculitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthralin","conceptCode":"C28827","definition":"A natural anthraquinone derivative, anti-psoriatic and anti-inflammatory Anthralin (dithranol) controls skin growth by reducing DNA synthesis and mitotic activity in the hyperplastic epidermis, restoring a normal rate of cell proliferation and keratinization. Used topically in the treatment of psoriasis, dermatoses, and alopecia areata, it is also used in biomedical research due to its effect on EGFR autophosphorylation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A076-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Antibody","valueDescription":"Antibody","ValueMeaning":{"publicId":"3377437","version":"1","preferredName":"Antibody","longName":"3377437","preferredDefinition":"(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A081-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A09A-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Apolizumab","valueDescription":"Apolizumab","ValueMeaning":{"publicId":"2576004","version":"1","preferredName":"Apolizumab","longName":"2576004","preferredDefinition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apolizumab","conceptCode":"C2228","definition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5F1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A0A4-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Arsenic Trioxide","valueDescription":"Arsenic Trioxide","ValueMeaning":{"publicId":"3377438","version":"1","preferredName":"Arsenic Trioxide","longName":"3377438","preferredDefinition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic Trioxide","conceptCode":"C1005","definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0B0-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A0C9-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Asparaginase","valueDescription":"Asparaginase","ValueMeaning":{"publicId":"3377440","version":"1","preferredName":"Asparaginase","longName":"3377440","preferredDefinition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase","conceptCode":"C286","definition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0D6-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A0EF-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Atazanavir Sulfate","valueDescription":"Atazanavir Sulfate","ValueMeaning":{"publicId":"2577678","version":"1","preferredName":"Atazanavir Sulfate","longName":"2577678","preferredDefinition":"A synthetic antiviral agent.  As a symmetric azapeptide agent structurally different from other HIV protease inhibitors, atazanavir selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions.  This agent does not elevate serum lipids, a common problem with other protease inhibitors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atazanavir Sulfate","conceptCode":"C28835","definition":"A sulfate salt form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-14","modifiedBy":"ONEDATA","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A103-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Azacitidine","valueDescription":"Azacitidine","ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A10D-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":"Azathioprine","ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A117-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Alendronate","valueDescription":"Alendronic Acid","ValueMeaning":{"publicId":"3377442","version":"1","preferredName":"Alendronic Acid","longName":"3377442","preferredDefinition":"A second generation bisphosphonate and synthetic analog of pyrophosphate with anti-bone-resorption activity. Alendronic acid binds to and inhibits the activity of farnesyl pyrophosphate synthetase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronic Acid","conceptCode":"C61625","definition":"A second generation bisphosphonate and synthetic analog of pyrophosphate with anti-bone-resorption activity. Alendronic acid binds to and inhibits the activity of farnesyl pyrophosphate synthetase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A124-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A13D-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"BFM 90","valueDescription":"NHL-BFM-90 Regimen","ValueMeaning":{"publicId":"3377444","version":"1","preferredName":"NHL-BFM-90 Regimen","longName":"3377444","preferredDefinition":"A regimen used for the treatment of localized aggressive forms of childhood B-cell non-Hodgkin's lymphoma, including lymphoblastic lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NHL-BFM-90 Regimen","conceptCode":"C67197","definition":"A regimen used for the treatment of localized aggressive forms of childhood B-cell non-Hodgkin lymphoma, including lymphoblastic lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1CE5-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1CFE-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"BEAM","valueDescription":"Carmustine/Cytarabine/Etoposide/Melphalan","ValueMeaning":{"publicId":"3377446","version":"1","preferredName":"Carmustine/Cytarabine/Etoposide/Melphalan","longName":"3377446","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine/Cytarabine/Etoposide/Melphalan","conceptCode":"C11103","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1D0B-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1D24-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"BEACOPP","valueDescription":"BEACOPP Regimen","ValueMeaning":{"publicId":"3377448","version":"1","preferredName":"BEACOPP Regimen","longName":"3377448","preferredDefinition":"A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BEACOPP Regimen","conceptCode":"C11638","definition":"A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1D31-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1D4A-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anti CD3","valueDescription":"Antibody CD3 Complex","ValueMeaning":{"publicId":"3377449","version":"1","preferredName":"Antibody CD3 Complex","longName":"3377449","preferredDefinition":"(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.: Consisting of cell surface type I membrane Delta, Epsilon, Gamma, Zeta, and Eta protein subunits with ITAM domains and noncovalently associated with the disulfide bound heterodimeric alpha/beta and gamma/delta TCR, the CD3 complex couples receptor antigen recognition to signal transduction pathways during T-cell activation. During TCR engagement with MHC-associated antigen on host cell surfaces and synapse formation, CD3 activity leads to Tyr-phosphorylated CD3 subunits, Tyr phosphorylation of LAT colocalized in lipid rafts, and MAPK activation. CD3 signal transduction appears to involve LCK, ZAP70, Nck, SLA, SLA2, and DOCK2. CD3 subunits may also associate with the cytoskeleton. CD3 also mediates TCR signal transduction during the developmental transition through positive selection of immature thymocytes to mature CD4+ or CD8+ T cells. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CD3 Complex","conceptCode":"C38897","definition":"A protein complex comprised of one T-cell surface glycoprotein CD3 delta chain (CD3D), one T-cell surface glycoprotein CD3 gamma chain (CD3G) and two T-cell surface glycoprotein CD3 epsilon chains (CD3E). CD3D, CD3G and CD3E are transmembrane proteins with one extracellular immunoglobulin domain and one intracellular ITAM domain. The CD3 complex is a T-cell co-receptor that noncovalently associates with either the disulfide bound heterodimeric alpha/beta T-cell receptor (TCR) or gamma/delta TCR and two copies of the accessory protein, T-cell surface glycoprotein CD3 zeta chain (CD247), which is a transmembrane protein with three ITAM domains. The TCR moiety of the TCR-CD3 complex binds to MHC and processed antigens on antigen presenting cells, which triggers phosphorylation of and cellular propagation of the signal by CD247 and the CD3 complex.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1D57-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1D70-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anti-MUC-1","valueDescription":"Anti-MUC-1 Monoclonal Antibody","ValueMeaning":{"publicId":"3377451","version":"1","preferredName":"Anti-MUC-1 Monoclonal Antibody","longName":"3377451","preferredDefinition":"A monoclonal antibody recognizing human mucin, a cell surface antigen encoded by the MUC-1 gene. In normal tissue, mucin exists as heavily glycosylated form, while tumor-associated mucin molecules are hypo-glycosylated. Hypo-glycosylation exposes the normally cryptic tandem peptide repeats in cancer-associated mucin, thereby allows antigen-antibody interaction with MUC-1 antibody. As a result, the MUC-1 antibody inhibits the initiation of the immunosuppressive cascade triggered by mucin, including production and secretion of prostaglandin E2 (PGE2), followed by VEGF induction and suppression of natural killer cell, lymphokine-activated killer cell and cytotoxic T cell activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-MUC-1 Monoclonal Antibody","conceptCode":"C29983","definition":"A monoclonal antibody recognizing human mucin, a cell surface antigen encoded by the MUC-1 gene. In normal tissue, mucin exists as heavily glycosylated form, while tumor-associated mucin molecules are hypo-glycosylated. Hypo-glycosylation exposes the normally cryptic tandem peptide repeats in cancer-associated mucin, thereby allows antigen-antibody interaction with MUC-1 antibody. As a result, the MUC-1 antibody inhibits the initiation of the immunosuppressive cascade triggered by mucin, including production and secretion of prostaglandin E2 (PGE2), followed by VEGF induction and suppression of natural killer cell, lymphokine-activated killer cell and cytotoxic T cell activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1D7D-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1D96-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anti B4bR","valueDescription":"Anti-B4 Blocked Ricin Immunotoxin","ValueMeaning":{"publicId":"3377453","version":"1","preferredName":"Anti-B4 Blocked Ricin Immunotoxin","longName":"3377453","preferredDefinition":"An immunotoxin comprised of an anti-B4 (anti-CD19) murine monoclonal antibody linked to the modified plant-derived toxin blocked ricin. The antibody moiety of anti-B4 blocked ricin immunotoxin binds to B lymphocytes that express B4; after internalization of the immunotoxin by the B4-expressing B cell, the ricin moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in the B lymphocyte 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death. Blocked ricin is ricin which has been chemically modified such that the lectin binding sites of the B chain (galactose-binding sites) have been blocked by covalent attachment of affinity ligands, leaving the ribosome-inactivating activity of the ricin A chain intact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-B4 Blocked Ricin Immunotoxin","conceptCode":"C2380","definition":"An immunotoxin comprised of an anti-B4 (anti-CD19) murine monoclonal antibody linked to the modified plant-derived toxin blocked ricin. The antibody moiety of anti-B4 blocked ricin immunotoxin binds to B lymphocytes that express B4; after internalization of the immunotoxin by the B4-expressing B cell, the ricin moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in the B lymphocyte 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death. Blocked ricin is ricin which has been chemically modified such that the lectin binding sites of the B chain (galactose-binding sites) have been blocked by covalent attachment of affinity ligands, leaving the ribosome-inactivating activity of the ricin A chain intact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1DA3-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DFB740-1DBC-299D-E040-BB89AD430A5E","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anti-Tac","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"2576091","version":"1","preferredName":"Daclizumab","longName":"2576091","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8DF6309-A152-1E33-E040-BB89AD43040B","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"ONEDATA","dateModified":"2012-02-13","deletedIndicator":"No"},{"value":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","valueDescription":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","ValueMeaning":{"publicId":"3422118","version":"1","preferredName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","longName":"3422118","preferredDefinition":"A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","conceptCode":"C68930","definition":"A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-33E8-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3ACCEE-3401-DAF6-E040-BB89AD433B37","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"Crenolanib","valueDescription":"Crenolanib","ValueMeaning":{"publicId":"3422120","version":"1","preferredName":"Crenolanib","longName":"3422120","preferredDefinition":"An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. PDGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crenolanib","conceptCode":"C64639","definition":"An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3413-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3ACCEE-342C-DAF6-E040-BB89AD433B37","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"Gemtuzumab Ozogamicin","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B904A837-DC66-3230-E040-BB89AD4349C9","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CBDCA/GM-CSF/IL-6","valueDescription":"Carboplatin/Interleukin-6/Sargramostim","ValueMeaning":{"publicId":"3378372","version":"1","preferredName":"Carboplatin/Interleukin-6/Sargramostim","longName":"3378372","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Interleukin-6/Sargramostim","conceptCode":"C10829","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2EB9-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2ED2-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CC5013","valueDescription":"CC 5013 (Lenalidomide)","ValueMeaning":{"publicId":"2662266","version":"1","preferredName":"CC 5013 (Lenalidomide)","longName":"2662266","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"34857986-EB02-1CED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2E88-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CBDCA/Paclitaxel","valueDescription":"Carboplatin/Paclitaxel","ValueMeaning":{"publicId":"3378370","version":"1","preferredName":"Carboplatin/Paclitaxel","longName":"3378370","preferredDefinition":"Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Paclitaxel","conceptCode":"C10662","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2E93-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2EAB-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CBDCA/Cyclophosphamide/Thiotepa","valueDescription":"Carboplatin Cyclophosphamide Thiotepa Treatment Regimen","ValueMeaning":{"publicId":"3378373","version":"1","preferredName":"Carboplatin Cyclophosphamide Thiotepa Treatment Regimen","longName":"3378373","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2EE1-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2EFA-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CBDCA/Cyclophosphamide","valueDescription":"Carboplatin Cyclophosphamide Treatment Regimen","ValueMeaning":{"publicId":"3378374","version":"1","preferredName":"Carboplatin Cyclophosphamide Treatment Regimen","longName":"3378374","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F08-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2F21-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bay 43-9006","valueDescription":"Sorafenib Tosylate","ValueMeaning":{"publicId":"3378376","version":"1","preferredName":"Sorafenib Tosylate","longName":"3378376","preferredDefinition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib Tosylate","conceptCode":"C2194","definition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F2E-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2F47-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Batracylin","valueDescription":"Daniquidone","ValueMeaning":{"publicId":"3378378","version":"1","preferredName":"Daniquidone","longName":"3378378","preferredDefinition":"A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daniquidone","conceptCode":"C66984","definition":"A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F54-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2F6D-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BVCPP","valueDescription":"Carmustine/Cyclophosphamide/Prednisone/Procarbazine/Vinblastine","ValueMeaning":{"publicId":"3378380","version":"1","preferredName":"Carmustine/Cyclophosphamide/Prednisone/Procarbazine/Vinblastine","longName":"3378380","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCVPP Regimen","conceptCode":"C9530","definition":"A chemotherapy regimen consisting of carmustine, cyclophosphamide, vinblastine, procarbazine and prednisone for the treatment of Hodgkin Lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F7A-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2F93-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BUDr (Bromodeoxyuridine)","valueDescription":"Bromodeoxyuridine","ValueMeaning":{"publicId":"3378381","version":"1","preferredName":"Bromodeoxyuridine","longName":"3378381","preferredDefinition":"A halogenated pyrimidine analogue that has been investigated for antineoplastic and radiosenstizing activities.  Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and inhibition of cell proliferation.  As a radiosensitizer, this agent induces the formation of reactive uracil radicals, resulting in DNA strand breaks and, ultimately, disruption of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broxuridine","conceptCode":"C318","definition":"A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F9D-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2FB6-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BOPP","valueDescription":"Carmustine Vincristine Sulfate Procarbazine Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"3378383","version":"1","preferredName":"Carmustine Vincristine Sulfate Procarbazine Cisplatin Treatment Regimen","longName":"3378383","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04): The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.: A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.: An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Vincristine Sulfate","conceptCode":"C1739","definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2FC7-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B905A965-2FE0-08AF-E040-BB89AD430955","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Chemotherapy Embolization","valueDescription":"Chemoembolization","ValueMeaning":{"publicId":"3225721","version":"1","preferredName":"Chemoembolization","longName":"3225721","preferredDefinition":"A procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This permits a higher concentration of drug to be in contact with the tumor for a longer period of time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemoembolization","conceptCode":"C15752","definition":"A procedure that introduces chemotherapy to blood vessels adjacent to a tumor, for the purpose of both treating the tumor and interrupt blood flow to the tumor, which serves both to trap the chemotherapeutic agent at the tumor and to decrease the amount of nutrients flowing to the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8D6D-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1537-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1541-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cerivastatin Sodium","valueDescription":"Cerivastatin Sodium","ValueMeaning":{"publicId":"2577803","version":"1","preferredName":"Cerivastatin Sodium","longName":"2577803","preferredDefinition":"The sodium salt of a synthetic lipid-lowering agent.  Cerivastatin sodium competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerivastatin Sodium","conceptCode":"C28919","definition":"The sodium salt of cerivastatin, a synthetic lipid-lowering agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-154B-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Celecoxib (Celebrex)","valueDescription":"Celecoxib","ValueMeaning":{"publicId":"2577801","version":"1","preferredName":"Celecoxib","longName":"2577801","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-155F-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carmustine/Polifeprosan 20","valueDescription":"Polifeprosan 20 with Carmustine Implant","ValueMeaning":{"publicId":"3378822","version":"1","preferredName":"Polifeprosan 20 with Carmustine Implant","longName":"3378822","preferredDefinition":"A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine Implant","conceptCode":"C2487","definition":"A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-156C-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1585-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carmustine (BCNU)","valueDescription":"Carmustine","ValueMeaning":{"publicId":"3378823","version":"1","preferredName":"Carmustine","longName":"3378823","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-158F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-15A7-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin/Taxotere","valueDescription":"Carboplatin Docetaxel Treatment Regimen","ValueMeaning":{"publicId":"3378824","version":"1","preferredName":"Carboplatin Docetaxel Treatment Regimen","longName":"3378824","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-15B6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-15CF-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel/Doxorubicin","valueDescription":"Carboplatin Paclitaxel Doxorubicin Treatment Regimen","ValueMeaning":{"publicId":"3378825","version":"1","preferredName":"Carboplatin Paclitaxel Doxorubicin Treatment Regimen","longName":"3378825","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-15DE-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-15F7-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin/Gemcitabine/Paclitaxel","valueDescription":"Carboplatin Gemcitabine Paclitaxel Treatment Regimen","ValueMeaning":{"publicId":"3378826","version":"1","preferredName":"Carboplatin Gemcitabine Paclitaxel Treatment Regimen","longName":"3378826","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1606-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-161F-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Darboplatin/Gemcitabine","valueDescription":"Carboplatin Gemcitabine Treatment Regimen","ValueMeaning":{"publicId":"3378827","version":"1","preferredName":"Carboplatin Gemcitabine Treatment Regimen","longName":"3378827","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-162D-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1646-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin/Cisplatin","valueDescription":"Carboplatin Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"3378828","version":"1","preferredName":"Carboplatin Cisplatin Treatment Regimen","longName":"3378828","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1654-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-166D-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel","valueDescription":"Carboplatin/Paclitaxel","ValueMeaning":{"publicId":"3378370","version":"1","preferredName":"Carboplatin/Paclitaxel","longName":"3378370","preferredDefinition":"Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Paclitaxel","conceptCode":"C10662","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2E93-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1681-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Capecitabine/Radiation","valueDescription":"Capecitabine Radiation Therapy Treatment Regimen","ValueMeaning":{"publicId":"3378829","version":"1","preferredName":"Capecitabine Radiation Therapy Treatment Regimen","longName":"3378829","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04): Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-168F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-16A8-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CVP","valueDescription":"CVP Regimen","ValueMeaning":{"publicId":"3366718","version":"1","preferredName":"CVP Regimen","longName":"3366718","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine and prednisone used to treat indolent forms of non-Hodgkin's lymphoma; also used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CVP Regimen","conceptCode":"C9573","definition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-531B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-16C6-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CVAD","valueDescription":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","ValueMeaning":{"publicId":"3378831","version":"1","preferredName":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","longName":"3378831","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","conceptCode":"C10131","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-16D4-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-16ED-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CT-322","valueDescription":"Pegdinetanib","ValueMeaning":{"publicId":"3378833","version":"1","preferredName":"Pegdinetanib","longName":"3378833","preferredDefinition":"A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegdinetanib","conceptCode":"C62791","definition":"A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-16FA-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1713-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CPE-C","valueDescription":"Cyclopentenyl Cytosine","ValueMeaning":{"publicId":"3378835","version":"1","preferredName":"Cyclopentenyl Cytosine","longName":"3378835","preferredDefinition":"A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclopentenyl Cytosine","conceptCode":"C1359","definition":"A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1720-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1739-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"rhGH","valueDescription":"Somatropin","ValueMeaning":{"publicId":"3378837","version":"1","preferredName":"Somatropin","longName":"3378837","preferredDefinition":"A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Somatropin","conceptCode":"C837","definition":"A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1746-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-175F-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cabergoline","valueDescription":"Cabergoline","ValueMeaning":{"publicId":"3378839","version":"1","preferredName":"Cabergoline","longName":"3378839","preferredDefinition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabergoline","conceptCode":"C47428","definition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-176C-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-1785-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Calcipotriene","valueDescription":"Calcipotriene","ValueMeaning":{"publicId":"3378840","version":"1","preferredName":"Calcipotriene","longName":"3378840","preferredDefinition":"A synthetic vitamin D derivative usually formulated for topical dermatological use, antipsoriatic Calcipotriene (calcipotriol) competes equally with active 1,25-hydroxy-2D3 (the natural form of vitamin D) for 1,25-hydroxy-2D3 receptors in regulating cell proliferation and differentiation. It induces differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and leads to normalization of epidermal growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcipotriene","conceptCode":"C28900","definition":"A synthetic vitamin D derivative usually formulated for topical dermatological use, antipsoriatic Calcipotriene (calcipotriol) competes equally with active 1,25-hydroxy-2D3 (the natural form of vitamin D) for 1,25-hydroxy-2D3 receptors in regulating cell proliferation and differentiation. It induces differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and leads to normalization of epidermal growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-178F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-17A8-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Calcitriol","valueDescription":"Calcitriol","ValueMeaning":{"publicId":"2577779","version":"1","preferredName":"Calcitriol","longName":"2577779","preferredDefinition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcitriol","conceptCode":"C330","definition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-17B2-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"Capecitabine","ValueMeaning":{"publicId":"2718478","version":"1","preferredName":"Capecitabine","longName":"2718478","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D79B0B-217A-74F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906B2BD-17BC-3273-E040-BB89AD431F7C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"2-Deosycoformycin","valueDescription":"2-Deoxycoformycin (Pentostatin)","ValueMeaning":{"publicId":"2576783","version":"1","preferredName":"2-Deoxycoformycin (Pentostatin)","longName":"2576783","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BDEA-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"REEVESD","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"4-HPR","valueDescription":" 4-HPR (Fenretinide)","ValueMeaning":{"publicId":"3378059","version":"1","preferredName":" 4-HPR (Fenretinide)","longName":"3378059","preferredDefinition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties.(NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fenretinide","conceptCode":"C1098","definition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B900BC0D-BE26-CD46-E040-BB89AD434DBB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BE3E-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5-Fluoro-2-Deoxycytidine","valueDescription":"5-Fluoro-2-Deoxycytidine","ValueMeaning":{"publicId":"3378058","version":"1","preferredName":"5-Fluoro-2-Deoxycytidine","longName":"3378058","preferredDefinition":"An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5-Fluoro-2-Deoxycytidine","conceptCode":"C62785","definition":"An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B900BC0D-BDF8-CD46-E040-BB89AD434DBB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BE11-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"3TC","valueDescription":"Lamivudine","ValueMeaning":{"publicId":"3378060","version":"1","preferredName":"Lamivudine","longName":"3378060","preferredDefinition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B900BC0D-BE49-CD46-E040-BB89AD434DBB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BE62-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"2CDA","valueDescription":"Cladribine","ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B900BC0D-BE76-CD46-E040-BB89AD434DBB","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"MOPP","valueDescription":"MOPP Regimen","ValueMeaning":{"publicId":"3379269","version":"1","preferredName":"MOPP Regimen","longName":"3379269","preferredDefinition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MOPP Regimen","conceptCode":"C9619","definition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91AC57E-1E84-187B-E040-BB89AD4329C2","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91AC57E-1E9D-187B-E040-BB89AD4329C2","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MINE","valueDescription":"Etoposide/Ifosfamide/Mesna/Mitoxantrone","ValueMeaning":{"publicId":"3379270","version":"1","preferredName":"Etoposide/Ifosfamide/Mesna/Mitoxantrone","longName":"3379270","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Ifosfamide/Mesna/Mitoxantrone","conceptCode":"C11137","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91AC57E-1EA9-187B-E040-BB89AD4329C2","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91AC57E-1EC2-187B-E040-BB89AD4329C2","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MAVE","valueDescription":"Doxorubicin/Etoposide/Mitotane/Vincristine","ValueMeaning":{"publicId":"3379271","version":"1","preferredName":"Doxorubicin/Etoposide/Mitotane/Vincristine","longName":"3379271","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin/Etoposide/Mitotane/Vincristine","conceptCode":"C10800","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C555-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C56E-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MORab-0003","valueDescription":"Farletuzumab","ValueMeaning":{"publicId":"3379273","version":"1","preferredName":"Farletuzumab","longName":"3379273","preferredDefinition":"A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Farletuzumab","conceptCode":"C61503","definition":"A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C57C-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C595-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MS-275","valueDescription":"Entinostat","ValueMeaning":{"publicId":"3379275","version":"1","preferredName":"Entinostat","longName":"3379275","preferredDefinition":"A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entinostat","conceptCode":"C1863","definition":"A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5A2-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C5BB-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MVAC","valueDescription":"Cisplatin/Doxorubicin/Methotrexate/Vinblastine Treatment Regimen (MVAC)","ValueMeaning":{"publicId":"3379277","version":"1","preferredName":"Cisplatin/Doxorubicin/Methotrexate/Vinblastine Treatment Regimen (MVAC)","longName":"3379277v1.00","preferredDefinition":"A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MVAC Regimen","conceptCode":"C63486","definition":"A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5C8-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C5E1-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Medroxyprogesterone","valueDescription":"Medroxyprogesterone","ValueMeaning":{"publicId":"2578261","version":"1","preferredName":"Medroxyprogesterone","longName":"2578261","preferredDefinition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medroxyprogesterone","conceptCode":"C629","definition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C5EB-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Megace","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"3379278","version":"1","preferredName":"Megestrol Acetate","longName":"3379278","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5F5-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C60D-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Oxymorphone","valueDescription":"Oxymorphone","ValueMeaning":{"publicId":"3379280","version":"1","preferredName":"Oxymorphone","longName":"3379280","preferredDefinition":"A semisynthetic narcotic analgesic related to hydromorphone and other opiates, Oxymorphone, hydroxy-dihydromorphinone, affects the central nervous system and smooth muscles by activation of specific opiate receptors. Similar to morphine, but more potent and without cough suppressant activity, it is used in treatment of moderate to severe pain, including obstetrical pain, or as an adjunct to anaesthesia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxymorphone","conceptCode":"C29314","definition":"A semisynthetic narcotic analgesic related to hydromorphone and other opiates, Oxymorphone, hydroxy-dihydromorphinone, affects the central nervous system and smooth muscles by activation of specific opiate receptors. Similar to morphine, but more potent and without cough suppressant activity, it is used in treatment of moderate to severe pain, including obstetrical pain, or as an adjunct to anaesthesia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C61C-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C635-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Oxygen","valueDescription":"Oxygen","ValueMeaning":{"publicId":"2569674","version":"1","preferredName":"Oxygen","longName":"2569674","preferredDefinition":"use this term only for elemental or gaseous oxygen (02); for other compounds see OXYGEN COMPOUND.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD37-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-26","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C63F-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C649-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Octreotide","valueDescription":"Octreotide","ValueMeaning":{"publicId":"3379281","version":"1","preferredName":"Octreotide","longName":"3379281","preferredDefinition":"The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide","conceptCode":"C711","definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C655-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C66E-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Oblimersen Sodium","valueDescription":"Oblimersen Sodium","ValueMeaning":{"publicId":"3379282","version":"1","preferredName":"Oblimersen Sodium","longName":"3379282","preferredDefinition":"The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oblimersen Sodium","conceptCode":"C66722","definition":"The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C67A-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C693-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Methotrexate/Cytarabine","valueDescription":"Methotrexate Cytarabine Treatment Regimen","ValueMeaning":{"publicId":"3379283","version":"1","preferredName":"Methotrexate Cytarabine Treatment Regimen","longName":"3379283","preferredDefinition":"An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C70D-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C726-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Melphalan/Prednisone","valueDescription":"Melphalan Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3379284","version":"1","preferredName":"Melphalan Prednisone Treatment Regimen","longName":"3379284","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C734-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C74D-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Melphalan/Cisplatin","valueDescription":"Melphalan Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"3379285","version":"1","preferredName":"Melphalan Cisplatin Treatment Regimen","longName":"3379285","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04): An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C75B-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C774-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Melanoma Vaccine","valueDescription":"Melanoma Vaccine","ValueMeaning":{"publicId":"3379287","version":"1","preferredName":"Melanoma Vaccine","longName":"3379287","preferredDefinition":"A cancer vaccine prepared from human melanoma cancer cells. It can be used alone or with other therapy in treating melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma Vaccine","conceptCode":"C2517","definition":"A cancer vaccine prepared from human melanoma cancer cells. It can be used alone or with other therapy in treating melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C781-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C79A-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mechlorethamine HCl","valueDescription":"Nitrogen Mustard","ValueMeaning":{"publicId":"2567424","version":"1","preferredName":"Nitrogen Mustard","longName":"2567424","preferredDefinition":"A vesicant and necrotizing irritant destructive to mucous membranes. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mechlorethamine Hydrochloride","conceptCode":"C627","definition":"The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that alkylates DNA, particularly the 7 nitrogen of guanine residues, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C7AE-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mab 131l mel-14F(ab') 2","valueDescription":"131l mel-14F(ab') 2 mAb","ValueMeaning":{"publicId":"3379288","version":"1","preferredName":"131l mel-14F(ab') 2 mAb","longName":"3379288","preferredDefinition":"131l mel-14F(ab') 2 Monoclonal Antibody","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C7B9-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C7D2-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mab 123l Mu81c6","valueDescription":"131I-mu81C6 mAb","ValueMeaning":{"publicId":"3379289","version":"1","preferredName":"131I-mu81C6 mAb","longName":"3379289","preferredDefinition":"131I-mu81C6 Monoclonal Antibody","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C7DC-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C7F5-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Melphalan","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C7FF-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mercaptopurine","valueDescription":"Mercaptopurine","ValueMeaning":{"publicId":"3379290","version":"1","preferredName":"Mercaptopurine","longName":"3379290","preferredDefinition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C80B-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C824-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mesna","valueDescription":"Mesna","ValueMeaning":{"publicId":"2578266","version":"1","preferredName":"Mesna","longName":"2578266","preferredDefinition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesna","conceptCode":"C192","definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C82E-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"2567426","version":"1","preferredName":"Methotrexate","longName":"2567426","preferredDefinition":"An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C838-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C842-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hsp90 Inhibitor PU-H71","valueDescription":"Heat shock protein 90 (Hsp90) inhibitor PU-H71","ValueMeaning":{"publicId":"3431123","version":"1","preferredName":"Heat shock protein 90 (Hsp90) inhibitor PU-H71","longName":"3431123v1.00","preferredDefinition":"Any agent that inhibits heat shock protein (Hsp) 90.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HSP90 Inhibitor","conceptCode":"C156880","definition":"Any agent that inhibits heat shock protein (Hsp) 90.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB82F9C-52EE-31A6-E040-BB89AD436C2A","latestVersionIndicator":"Yes","beginDate":"2012-04-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCB82F9C-5307-31A6-E040-BB89AD436C2A","beginDate":"2012-04-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"ONEDATA","dateModified":"2012-04-02","deletedIndicator":"No"},{"value":"AQ4N (Banoxantrone)","valueDescription":"Banoxantrone","ValueMeaning":{"publicId":"3378138","version":"1","preferredName":"Banoxantrone","longName":"3378138","preferredDefinition":"A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Banoxantrone","conceptCode":"C79528","definition":"A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6B61-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6B7A-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"AP23573","valueDescription":"Ridaforolimus","ValueMeaning":{"publicId":"3378140","version":"1","preferredName":"Ridaforolimus","longName":"3378140","preferredDefinition":"A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ridaforolimus","conceptCode":"C49061","definition":"A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6B87-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6BA0-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"AMG 102","valueDescription":"Rilotumumab","ValueMeaning":{"publicId":"3378142","version":"1","preferredName":"Rilotumumab","longName":"3378142","preferredDefinition":"A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilotumumab","conceptCode":"C67079","definition":"A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6BAD-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6BC6-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"AGN 195183","valueDescription":"AGN 195183","ValueMeaning":{"publicId":"3378144","version":"1","preferredName":"AGN 195183","longName":"3378144","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AGN 195183","conceptCode":"C1527761","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6BD3-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6BEC-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"AEE788","valueDescription":"AEE788","ValueMeaning":{"publicId":"3378146","version":"1","preferredName":"AEE788","longName":"3378146","preferredDefinition":"An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multikinase Inhibitor AEE788","conceptCode":"C48369","definition":"An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6BF9-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6C12-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"ABT-888","valueDescription":"Veliparib","ValueMeaning":{"publicId":"3378148","version":"1","preferredName":"Veliparib","longName":"3378148","preferredDefinition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Veliparib","conceptCode":"C60768","definition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C1F-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6C38-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"ABT-263","valueDescription":"Navitoclax","ValueMeaning":{"publicId":"3378150","version":"1","preferredName":"Navitoclax","longName":"3378150","preferredDefinition":"An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Navitoclax","conceptCode":"C64776","definition":"An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C45-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6C5E-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"90 Y-B3","valueDescription":"Yttrium Y 90 Monoclonal Antibody B3","ValueMeaning":{"publicId":"3378152","version":"1","preferredName":"Yttrium Y 90 Monoclonal Antibody B3","longName":"3378152","preferredDefinition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yttrium Y 90 Monoclonal Antibody B3","conceptCode":"C2614","definition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C6B-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6C84-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"9-cis-Retinoic Acid","valueDescription":"Alitretinoin","ValueMeaning":{"publicId":"3378153","version":"1","preferredName":"Alitretinoin","longName":"3378153","preferredDefinition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alitretinoin","conceptCode":"C1574","definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C8E-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6CA7-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"BL22","valueDescription":"BL22 Immunotoxin","ValueMeaning":{"publicId":"3378155","version":"1","preferredName":"BL22 Immunotoxin","longName":"3378155","preferredDefinition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BL22 Immunotoxin","conceptCode":"C1842","definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6CB5-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6CCE-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Belinostat","valueDescription":"Belinostat","ValueMeaning":{"publicId":"3378157","version":"1","preferredName":"Belinostat","longName":"3378157","preferredDefinition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belinostat","conceptCode":"C48812","definition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6CDB-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6CF4-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6CFE-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bleomycin","valueDescription":"Bleomycin","ValueMeaning":{"publicId":"2739540","version":"1","preferredName":"Bleomycin","longName":"2739540","preferredDefinition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBF7-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D08-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bexarotene","valueDescription":"Bexarotene","ValueMeaning":{"publicId":"2567420","version":"1","preferredName":"Bexarotene","longName":"2567420","preferredDefinition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bexarotene","conceptCode":"C1635","definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D469-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"COOPERM","dateModified":"2017-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D12-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bicalutamide","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D1C-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"2738485","version":"1","preferredName":"Bortezomib","longName":"2738485","preferredDefinition":"A modified dipeptidyl boronic acid with antineoplastic activity. Via boronic acid moiety, bortezomib reversibly binds to the 26S proteasome, where degradation of ubiquinated proteins occurs. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis.  Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F951-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D26-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Brimonidine","valueDescription":"Brimonidine","ValueMeaning":{"publicId":"3378159","version":"1","preferredName":"Brimonidine","longName":"3378159","preferredDefinition":"An imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine also enhances the uveoscleral outflow of aqueous humor. This reduces intraocular pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brimonidine","conceptCode":"C65269","definition":"An imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine also enhances the uveoscleral outflow of aqueous humor. This reduces intraocular pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6D33-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D4C-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Brivanib Alaninate","valueDescription":"Brivanib Alaninate","ValueMeaning":{"publicId":"3378161","version":"1","preferredName":"Brivanib Alaninate","longName":"3378161","preferredDefinition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brivanib Alaninate","conceptCode":"C53397","definition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6D59-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D72-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90390BA-6D7C-6B71-E040-BB89AD432BAA","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"rhIGH-1","valueDescription":"IGF1R Gene ","ValueMeaning":{"publicId":"3378851","version":"1","preferredName":"IGF1R Gene ","longName":"3378851","preferredDefinition":"This gene is involved in the regulation of apoptosis and cell proliferation and plays a role in cellular transformation and malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IGF1R Gene","conceptCode":"C20135","definition":"This gene is involved in the regulation of apoptosis and cell proliferation and plays a role in cellular transformation and malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906C410-2635-470B-E040-BB89AD4320DF","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SOKKERL","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906C410-264E-470B-E040-BB89AD4320DF","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"rCD4/IgG","valueDescription":"Recombinant Soluble Human CD4 Protein IgG Treatment Regimen","ValueMeaning":{"publicId":"3378853","version":"1","preferredName":"Recombinant Soluble Human CD4 Protein IgG Treatment Regimen","longName":"3378853","preferredDefinition":"A recombinant human soluble CD4 with antiviral activity. Recombinant human soluble CD4 has the amino terminus but not the T-cell binding domain of the endogenous CD4 antigen. This soluble CD4 protein competitively binds to envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) resulting in inhibition of interaction between gp120 and the endogenous CD4 antigen, thereby blocking viral recognition of CD4 and subsequent entry of HIV into CD4 bearing cells.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Soluble Human CD4 Protein","conceptCode":"C2342","definition":"A recombinant human soluble CD4 with antiviral activity. Recombinant human soluble CD4 has the amino terminus but not the T-cell binding domain of the endogenous CD4 antigen. This soluble CD4 protein competitively binds to envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) resulting in inhibition of interaction between gp120 and the endogenous CD4 antigen, thereby blocking viral recognition of CD4 and subsequent entry of HIV into CD4 bearing cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906C410-265D-470B-E040-BB89AD4320DF","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B906C410-2676-470B-E040-BB89AD4320DF","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Thiotepa/Carboplatin","valueDescription":"Cyclophosphamide Thiotepa Carboplatin Treatment Regimen","ValueMeaning":{"publicId":"3378896","version":"1","preferredName":"Cyclophosphamide Thiotepa Carboplatin Treatment Regimen","longName":"3378896","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04): A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F559-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F572-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Pentostatin","valueDescription":"Cyclophosphamide Pentostatin Treatment Regimen","ValueMeaning":{"publicId":"3378897","version":"1","preferredName":"Cyclophosphamide Pentostatin Treatment Regimen","longName":"3378897","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F580-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F599-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Gemcitabine","valueDescription":"Cyclophosphamide Gemcitabine Treatment Regimen","ValueMeaning":{"publicId":"3378898","version":"1","preferredName":"Cyclophosphamide Gemcitabine Treatment Regimen","longName":"3378898","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An anticancer drug that belongs to the family of drugs called antimetabolites.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F5A7-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F5C0-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CyVE","valueDescription":"Cytarabine/Etoposide","ValueMeaning":{"publicId":"3378900","version":"1","preferredName":"Cytarabine/Etoposide","longName":"3378900","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CYVE Regimen","conceptCode":"C10239","definition":"A rregimen consisting of cytarabine and etoposide that may be used in the treatment of central nervous system (CNS) lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F5CD-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F5E6-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Fludarabine/Genasense","valueDescription":"Cyclophosphamide Fludarabine Oblimersen Sodium Treatment Regimen","ValueMeaning":{"publicId":"3378902","version":"1","preferredName":"Cyclophosphamide Fludarabine Oblimersen Sodium Treatment Regimen","longName":"3378902","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  : The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oblimersen Sodium","conceptCode":"C66722","definition":"The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F5F6-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F60F-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Daunomycin","valueDescription":"Cyclophosphamide Daunorubicin Treatment Regimen","ValueMeaning":{"publicId":"3378903","version":"1","preferredName":"Cyclophosphamide Daunorubicin Treatment Regimen","longName":"3378903","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F61D-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F636-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"rhuMabVEGF","valueDescription":"Recombinant Vascular Endothelial Growth Factor Monoclonal Antibody","ValueMeaning":{"publicId":"3378905","version":"1","preferredName":"Recombinant Vascular Endothelial Growth Factor Monoclonal Antibody","longName":"3378905","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04): An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Vascular Endothelial Growth Factor","conceptCode":"C1272","definition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F644-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F65D-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"y2B8","valueDescription":"IDEC-Y2B8 Monoclonal Antibody/Rituximab","ValueMeaning":{"publicId":"3378907","version":"1","preferredName":"IDEC-Y2B8 Monoclonal Antibody/Rituximab","longName":"3378907","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IDEC-Y2B8 Monoclonal Antibody/Rituximab","conceptCode":"C12167","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F66A-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F683-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Vincristine","valueDescription":"Cyclophosphamide/Vincristine","ValueMeaning":{"publicId":"3378909","version":"1","preferredName":"Cyclophosphamide/Vincristine","longName":"3378909","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Vincristine","conceptCode":"C10313","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F690-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F6A9-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Prednisone","valueDescription":"Cyclophosphamide/Prednisone","ValueMeaning":{"publicId":"3378911","version":"1","preferredName":"Cyclophosphamide/Prednisone","longName":"3378911","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Prednisone","conceptCode":"C10163","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F6B6-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F6CF-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide/Fludarabine","valueDescription":"Cyclophosphamide/Fludarabine","ValueMeaning":{"publicId":"3378913","version":"1","preferredName":"Cyclophosphamide/Fludarabine","longName":"3378913","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Fludarabine","conceptCode":"C10489","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F6DC-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F6F5-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F6FF-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Cyclosporine","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"3253643","version":"1","preferredName":"Cyclosporine","longName":"3253643","preferredDefinition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7A3A-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F709-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Daclizumab","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"2576091","version":"1","preferredName":"Daclizumab","longName":"2576091","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F713-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dactinomycin","valueDescription":"Dactinomycin","ValueMeaning":{"publicId":"3378914","version":"1","preferredName":"Dactinomycin","longName":"3378914","preferredDefinition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dactinomycin","conceptCode":"C412","definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F71D-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F736-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Darbepoetin Alfa","valueDescription":"Darbepoetin Alfa","ValueMeaning":{"publicId":"2577851","version":"1","preferredName":"Darbepoetin Alfa","longName":"2577851","preferredDefinition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darbepoetin Alfa","conceptCode":"C1878","definition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD28-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F740-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Darunavir","valueDescription":"Darunavir","ValueMeaning":{"publicId":"3270588","version":"1","preferredName":"Darunavir","longName":"3270588v1.00","preferredDefinition":"A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir","conceptCode":"C65364","definition":"A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A517-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F74A-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Decitabine","valueDescription":"Decitabine","ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F754-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Delavirdine Mesylate","valueDescription":"Delavirdine Mesylate","ValueMeaning":{"publicId":"2577853","version":"1","preferredName":"Delavirdine Mesylate","longName":"2577853","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Delavirdine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with at least two other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in the majority of patients.  As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of those co-administered protease inhibitors metabolized by the cytochrome P450 system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delavirdine Mesylate","conceptCode":"C28974","definition":"A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in patients. As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of co-administered protease inhibitors metabolized by the cytochrome P450 system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F75E-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F768-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dexrazoxane","valueDescription":"Dexrazoxane","ValueMeaning":{"publicId":"3378916","version":"1","preferredName":"Dexrazoxane","longName":"3378916","preferredDefinition":"A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexrazoxane","conceptCode":"C1333","definition":"A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F775-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F78E-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Didanosine","valueDescription":"Didanosine","ValueMeaning":{"publicId":"2576104","version":"1","preferredName":"Didanosine","longName":"2576104","preferredDefinition":"A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F655-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F798-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Diaziquone","valueDescription":"Diaziquone","ValueMeaning":{"publicId":"3378918","version":"1","preferredName":"Diaziquone","longName":"3378918","preferredDefinition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diaziquone","conceptCode":"C1363","definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F7A5-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9078B1E-F7BE-89BB-E040-BB89AD432908","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Doxorubicin","valueDescription":"Docetaxel/Doxorubicin","ValueMeaning":{"publicId":"3378927","version":"1","preferredName":"Docetaxel/Doxorubicin","longName":"3378927","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel/Doxorubicin Regimen","conceptCode":"C11218","definition":"A regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CC4B-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CC64-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"EM-1421","valueDescription":"Terameprocol","ValueMeaning":{"publicId":"3378929","version":"1","preferredName":"Terameprocol","longName":"3378929","preferredDefinition":"A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Terameprocol","conceptCode":"C61441","definition":"A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CC71-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CC8A-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Denileukin Diftitox","valueDescription":"Denileukin Diftitox","ValueMeaning":{"publicId":"2577847","version":"1","preferredName":"Denileukin Diftitox","longName":"2577847","preferredDefinition":"A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denileukin Diftitox","conceptCode":"C1476","definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD24-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CC9E-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dendritic Cell Therapy","valueDescription":"Dendritic Cell Therapeutic Procedure","ValueMeaning":{"publicId":"3378930","version":"1","preferredName":"Dendritic Cell Therapeutic Procedure","longName":"3378930","preferredDefinition":"A special type of antigen-presenting cell (APC) that activates T lymphocytes.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dendritic Cell","conceptCode":"C12583","definition":"Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CCAB-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CCC4-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Daunorubicin Citrate Liposome","valueDescription":"Liposomal Daunorubicin Citrate","ValueMeaning":{"publicId":"3378931","version":"1","preferredName":"Liposomal Daunorubicin Citrate","longName":"3378931","preferredDefinition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Daunorubicin Citrate","conceptCode":"C2213","definition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CCCE-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CCE7-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dasatinib (Sprycel)","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CCF1-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Sulindac","valueDescription":"Sulindac","ValueMeaning":{"publicId":"3340618","version":"1","preferredName":"Sulindac","longName":"3340618","preferredDefinition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulindac","conceptCode":"C850","definition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B551BC76-E230-0DCA-E040-BB89AD431CC3","latestVersionIndicator":"Yes","beginDate":"2011-12-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B551BC76-E249-0DCA-E040-BB89AD431CC3","beginDate":"2011-12-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-30","modifiedBy":"ONEDATA","dateModified":"2011-12-30","deletedIndicator":"No"},{"value":"c-Met Inhibitor LY2801653","valueDescription":"c-Met Inhibitor LY2801653","ValueMeaning":{"publicId":"3395962","version":"1","preferredName":"c-Met Inhibitor LY2801653","longName":"3395962","preferredDefinition":"An orally available, small molecule inhibitor of the proto-oncogene c-Met (mesenchymal-epithelial transition, also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. c-Met inhibitor LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Merestinib","conceptCode":"C95729","definition":"An orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA2FCF52-DB36-114F-E040-BB89AD4355CF","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA2FCF52-DB4F-114F-E040-BB89AD4355CF","beginDate":"2012-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","deletedIndicator":"No"},{"value":"Interleukin-15","valueDescription":"Interleukin-15","ValueMeaning":{"publicId":"3316598","version":"1","preferredName":"Interleukin-15","longName":"3316598","preferredDefinition":"Interleukin-15, encoded by the IL15 gene, is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukin 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other's activity. The number of CD8+ memory cells is controlled by a balance between this cytokine and IL2. This cytokine induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. Three alternatively spliced transcript variants of this gene encoding two distinct isoforms have been reported. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-15","conceptCode":"C20517","definition":"Interleukin-15 (162 aa, ~18 kDa) is encoded by the human IL15 gene. This protein plays a role in the regulation of both proliferation and activation of both T-cells and natural killer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F483BF-275E-ADF2-E040-BB89AD4327EB","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2F483BF-2777-ADF2-E040-BB89AD4327EB","beginDate":"2011-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-30","modifiedBy":"ONEDATA","dateModified":"2011-11-30","deletedIndicator":"No"},{"value":"Anti-PD-1 Human Monoclonal Antibody MDX-1106","valueDescription":"Anti-PD-1 Human Monoclonal Antibody (Anti-PD-1 Human Monoclonal Antibody MDX-1106)","ValueMeaning":{"publicId":"3316600","version":"1","preferredName":"Anti-PD-1 Human Monoclonal Antibody (Anti-PD-1 Human Monoclonal Antibody MDX-1106)","longName":"3316600","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Anti-PD-1 human monoclonal antibody MDX-1106 binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F483BF-2784-ADF2-E040-BB89AD4327EB","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2F483BF-279D-ADF2-E040-BB89AD4327EB","beginDate":"2011-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-30","modifiedBy":"ONEDATA","dateModified":"2011-11-30","deletedIndicator":"No"},{"value":"Dartmouth Regimen","valueDescription":"Dartmouth Regimen","ValueMeaning":{"publicId":"3378933","version":"1","preferredName":"Dartmouth Regimen","longName":"3378933","preferredDefinition":"A regimen consisting of tamoxifen, cisplatin, dacarbazine and carmustine used for the treatment of advanced-stage or metastatic malignant melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dartmouth Regimen","conceptCode":"C63781","definition":"A regimen consisting of tamoxifen, cisplatin, dacarbazine and carmustine used for the treatment of advanced-stage or metastatic melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CCFE-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CD17-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DTPACE","valueDescription":"Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide/Thalidomide","ValueMeaning":{"publicId":"3378935","version":"1","preferredName":"Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide/Thalidomide","longName":"3378935","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide/Thalidomide","conceptCode":"C28969","definition":"A combination of agents containing cisplatin, cyclophosphamide, dexamethasone, doxorubicin, etoposide and thalidomide.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD24-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CD3D-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DTIC/Mesna","valueDescription":"Dacarbazine/Mesna","ValueMeaning":{"publicId":"3378937","version":"1","preferredName":"Dacarbazine/Mesna","longName":"3378937","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine/Mesna","conceptCode":"C28967","definition":"A combination of agents containing dacarbazine and mesna.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD4A-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CD63-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dacarbazine (DTIC)","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CD86-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"DSAP","valueDescription":"Anti-Dopamine-b-Hydroxylase Monoclonal Antibody-Saporin","ValueMeaning":{"publicId":"3378940","version":"1","preferredName":"Anti-Dopamine-b-Hydroxylase Monoclonal Antibody-Saporin","longName":"3378940","preferredDefinition":"An immunoconjugate of the anti-dopamine-b-hydroxylase monoclonal antibody covalently linked to the ribosome-inactivating protein (RIP) saporin derived from Saponaria officinalis. The monoclonal antibody component recognizes and attaches to the membrane-associated antigen, dopamine-b-hydroxylase, resulting in the conjugate being internalized by receptor-mediated endocytosis. The saporin toxin is then released from the complex, and binds to ribosomal subunits, thereby halts protein synthesis, and results in cell death. This immunoconjugate targets the dopamine-beta-hydroxylase enzyme localized on adrenergic nerves in the brainstem particular medulla and pons, thereby could be used to study neurodegenerative disorders and/or address fundamental neurobiological questions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Dopamine-b-Hydroxylase Monoclonal Antibody-Saporin","conceptCode":"C28966","definition":"An immunoconjugate of the anti-dopamine-b-hydroxylase monoclonal antibody covalently linked to the ribosome-inactivating protein (RIP) saporin derived from Saponaria officinalis. The monoclonal antibody component recognizes and attaches to the membrane-associated antigen, dopamine-b-hydroxylase, resulting in the conjugate being internalized by receptor-mediated endocytosis. The saporin toxin is then released from the complex, and binds to ribosomal subunits, thereby halts protein synthesis, and results in cell death. This immunoconjugate targets the dopamine-beta-hydroxylase enzyme localized on adrenergic nerves in the brainstem particular medulla and pons, thereby could be used to study neurodegenerative disorders and/or address fundamental neurobiological questions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD93-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CDAC-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CDB6-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Deoxythioguanosine","valueDescription":"Beta-Thioguanine Deoxyriboside","ValueMeaning":{"publicId":"3378942","version":"1","preferredName":"Beta-Thioguanine Deoxyriboside","longName":"3378942","preferredDefinition":"A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Thioguanine Deoxyriboside","conceptCode":"C1350","definition":"A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CDC3-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CDDC-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Depsipeptide","valueDescription":"Depsipeptide Antineoplastic Antibiotic","ValueMeaning":{"publicId":"3378944","version":"1","preferredName":"Depsipeptide Antineoplastic Antibiotic","longName":"3378944","preferredDefinition":"A bicyclic peptide antibiotic with one or more amide bonds replaced by ester bonds. Depsipeptide antibiotics act as histone deacetylase inhibitors and regulate chromatin structure and transcription by increasing histone acetylation, thereby resulting in alterations in gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Depsipeptide Antineoplastic Antibiotic","conceptCode":"C1976","definition":"A bicyclic peptide antibiotic with one or more amide bonds replaced by ester bonds. Depsipeptide antibiotics act as histone deacetylase inhibitors and regulate chromatin structure and transcription by increasing histone acetylation, thereby resulting in alterations in gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CDE9-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE02-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Di-dgA-RFB4","valueDescription":"Di-dgA-RFB4 Immunotoxin","ValueMeaning":{"publicId":"3378946","version":"1","preferredName":"Di-dgA-RFB4 Immunotoxin","longName":"3378946","preferredDefinition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Di-dgA-RFB4 Immunotoxin","conceptCode":"C2334","definition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CE0F-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE28-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE32-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Diphencyprone","valueDescription":"Diphencyprone","ValueMeaning":{"publicId":"2576111","version":"1","preferredName":"Diphencyprone","longName":"2576111v1.00","preferredDefinition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphencyprone","conceptCode":"C28994","definition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F65C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE3C-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dorzolamide","valueDescription":"Dorzolamide","ValueMeaning":{"publicId":"3378948","version":"1","preferredName":"Dorzolamide","longName":"3378948","preferredDefinition":"An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dorzolamide","conceptCode":"C62026","definition":"An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CE49-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE62-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2744954","version":"1","preferredName":"Doxorubicin","longName":"2744954","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-8077-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE6C-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dutasteride","valueDescription":"Dutasteride","ValueMeaning":{"publicId":"2576806","version":"1","preferredName":"Dutasteride","longName":"2576806","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F913-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE76-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Gemcitabine","valueDescription":"Docetaxel-Gemcitabine Regimen","ValueMeaning":{"publicId":"3378950","version":"1","preferredName":"Docetaxel-Gemcitabine Regimen","longName":"3378950","preferredDefinition":"A regimen consisting of docetaxel and gemcitabine used to treat advanced-stage non-small cell lung cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel-Gemcitabine Regimen","conceptCode":"C63760","definition":"A regimen consisting of docetaxel and gemcitabine used to treat advanced-stage non-small cell lung cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CE84-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B907F9D9-CE9D-F916-E040-BB89AD435222","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin/Ifosfamide","valueDescription":"Doxorubicin Ifosfamide Treatment Regimen","ValueMeaning":{"publicId":"3378957","version":"1","preferredName":"Doxorubicin Ifosfamide Treatment Regimen","longName":"3378957","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-30DF-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-30F8-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dox/Vcr/Cyt/Etop/Dxm","valueDescription":"Doxorubicin Vincristine Cyclophosphamide Etoposide Dexamethasone Treatment Regimen","ValueMeaning":{"publicId":"3378958","version":"1","preferredName":"Doxorubicin Vincristine Cyclophosphamide Etoposide Dexamethasone Treatment Regimen","longName":"3378958","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation a","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3109-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3122-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin/Dacarbazine","valueDescription":"Doxorubicin Dacarbazine Treatment Regimen","ValueMeaning":{"publicId":"3378959","version":"1","preferredName":"Doxorubicin Dacarbazine Treatment Regimen","longName":"3378959","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3130-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3149-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin/Cyclophosphamide","valueDescription":"Doxorubicin Cyclophosphamide Treatment Regimen","ValueMeaning":{"publicId":"3378960","version":"1","preferredName":"Doxorubicin Cyclophosphamide Treatment Regimen","longName":"3378960","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3157-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3170-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin Lipos/RFA","valueDescription":"Doxorubicin Hydrochloride Liposome Radiofrequency Ablation Treatment Regimen","ValueMeaning":{"publicId":"3378961","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome Radiofrequency Ablation Treatment Regimen","longName":"3378961","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04): A therapeutic procedure to eradicate or reduce small tumors using radiowaves to generate heat. The procedure is performed by the insertion of a thin needle through the skin and into a tumor, which is guided by computed tomography (CT) or ultrasound. Electrical energy delivered through this needle (electrode) heats and destroys the tumor. This therapeutic option is widely utilized by patients that have inoperable cancers, or are unsuitable chemotherapy candidates.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiofrequency Ablation","conceptCode":"C15666","definition":"A therapeutic procedure to kill tissue using radiowaves to generate heat. The procedure is performed by the insertion of an electrode into a target tissue. Electrical energy delivered to the electrode heats and destroys the tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-317E-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3197-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin/Gemcitabine","valueDescription":"Doxorubicin/Gemcitabine","ValueMeaning":{"publicId":"3378963","version":"1","preferredName":"Doxorubicin/Gemcitabine","longName":"3378963","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin/Gemcitabine Regimen","conceptCode":"C11312","definition":"A regimen consisting of doxorubicin and gemcitabine that may be used in the treatment of certain types of renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-31A4-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-31BD-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin Liposome","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"2576633","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"2576633","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F866-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-31D1-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Doxorubicin Liposomal/Gemcitabine","valueDescription":"Doxorubicin Hcl Liposome/Gemcitabine","ValueMeaning":{"publicId":"3378965","version":"1","preferredName":"Doxorubicin Hcl Liposome/Gemcitabine","longName":"3378965","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin Hcl Liposome/Gemcitabine","conceptCode":"C11851","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-31DE-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-31F7-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Donor Lymphocyte Infusion (DLI)","valueDescription":"Donor Leukocyte Infusion","ValueMeaning":{"publicId":"2866902","version":"1","preferredName":"Donor Leukocyte Infusion","longName":"2866902","preferredDefinition":"A type of therapy in which lymphocytes from the blood of a donor are given to a patient who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Donor lymphocyte infusion is used to treat chronic myelogenous leukemia (CML) that has come back and myeloma. It is being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Lymphocyte Infusion","conceptCode":"C16145","definition":"The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68DF7602-9A6D-3F9A-E040-BB89AD43599F","latestVersionIndicator":"Yes","beginDate":"2009-05-01","endDate":null,"createdBy":"CZECHS","dateCreated":"2009-05-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-320B-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Flavopiridol","valueDescription":"Docetaxel Flavopiridol Treatment Regimen","ValueMeaning":{"publicId":"3378966","version":"1","preferredName":"Docetaxel Flavopiridol Treatment Regimen","longName":"3378966","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.  This agent is also a competitive inhibitor of adenosine triphosphate activity. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alvocidib Hydrochloride","conceptCode":"C1571","definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3219-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3232-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Vaccine","valueDescription":"Docetaxel Vaccine Treatment Regimen","ValueMeaning":{"publicId":"3378967","version":"1","preferredName":"Docetaxel Vaccine Treatment Regimen","longName":"3378967","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3240-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3259-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Tariquidar (XR9576)","valueDescription":"Docetaxel Tariquidar Treatment Regimen","ValueMeaning":{"publicId":"3378969","version":"1","preferredName":"Docetaxel Tariquidar Treatment Regimen","longName":"3378969","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tariquidar","conceptCode":"C2246","definition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3268-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3281-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Docetaxel/Trastuzumab","valueDescription":"Docetaxel/Trastuzumab","ValueMeaning":{"publicId":"3378971","version":"1","preferredName":"Docetaxel/Trastuzumab","longName":"3378971","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel/Trastuzumab","conceptCode":"C11800","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-328E-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-32A7-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"ESHAP","valueDescription":"Cisplatin/Cytarabine/Etoposide/Methylprednisolone","ValueMeaning":{"publicId":"3378978","version":"1","preferredName":"Cisplatin/Cytarabine/Etoposide/Methylprednisolone","longName":"3378978","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Cytarabine/Etoposide/Methylprednisolone","conceptCode":"C9720","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-337A-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3393-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"EPOCH/R","valueDescription":"EPOCH Regimen Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3378979","version":"1","preferredName":"EPOCH Regimen Rituximab Treatment Regimen","longName":"3378979","preferredDefinition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-33A1-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-33BA-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"EPOCH","valueDescription":"EPOCH Regimen","ValueMeaning":{"publicId":"3378980","version":"1","preferredName":"EPOCH Regimen","longName":"3378980","preferredDefinition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-33C6-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-33DF-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Efavirenz","valueDescription":"Efavirenz","ValueMeaning":{"publicId":"3378981","version":"1","preferredName":"Efavirenz","longName":"3378981","preferredDefinition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral loads, therefore retarding or preventing damage to the immune system, and reducing the risk of developing AIDS.  Efavirenz induces activity of the cytochrome P450 system, thereby accelerating its own metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz","conceptCode":"C29027","definition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-33E9-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3402-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Emtricitabine","valueDescription":"Emtricitabine","ValueMeaning":{"publicId":"3282251","version":"1","preferredName":"Emtricitabine","longName":"3282251","preferredDefinition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine","conceptCode":"C47509","definition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-735C-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-340C-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Enzastaurin","valueDescription":"Enzastaurin","ValueMeaning":{"publicId":"3378983","version":"1","preferredName":"Enzastaurin","longName":"3378983","preferredDefinition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzastaurin","conceptCode":"C77392","definition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-3419-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3432-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Epirubicin","valueDescription":"Epirubicin","ValueMeaning":{"publicId":"2757913","version":"1","preferredName":"Epirubicin","longName":"2757913","preferredDefinition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin","conceptCode":"C62028","definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-841F-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-343C-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Epoetin Alfa","valueDescription":"Epoetin Alfa","ValueMeaning":{"publicId":"2576817","version":"1","preferredName":"Epoetin Alfa","longName":"2576817","preferredDefinition":"A colony-stimulating factor that is made in the laboratory. It increases the production of red blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epoetin Alfa","conceptCode":"C2695","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9086113-3446-38C1-E040-BB89AD43581C","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"HGS-ETR2","valueDescription":"HGS-ETR2 (Lexatumumab)","ValueMeaning":{"publicId":"3379055","version":"1","preferredName":"HGS-ETR2 (Lexatumumab)","longName":"3379055","preferredDefinition":"A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lexatumumab","conceptCode":"C64621","definition":"A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AC9E-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ACB7-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"HeFi-1","valueDescription":"Monoclonal Antibody HeFi-1","ValueMeaning":{"publicId":"3379057","version":"1","preferredName":"Monoclonal Antibody HeFi-1","longName":"3379057","preferredDefinition":"A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody HeFi-1","conceptCode":"C2505","definition":"A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-ACC4-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ACDD-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Gene Therapy","valueDescription":"Gene Therapy","ValueMeaning":{"publicId":"3082843","version":"1","preferredName":"Gene Therapy","longName":"3082843","preferredDefinition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.  The genetic material as 'naked' DNA can be delivered into the cells alone or can be delivered into cells by different types of vectors such as viruses which may contain DNA or RNA.  Gene therapy techniques attempt to replace a faulty/missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.  Gene therapies are designed to deliver genetic material into somatic cells and not germ cells, so that only cells of patients and not those of their offspring contain and express the genetic material delivered. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Therapy","conceptCode":"C15238","definition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85F4380C-67AF-77C6-E040-BB89AD4310D6","latestVersionIndicator":"Yes","beginDate":"2010-05-06","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-05-06","modifiedBy":"ONEDATA","dateModified":"2010-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ACF1-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Herceptin","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD05-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Gallium Nitrate","valueDescription":"Gallium Nitrate","ValueMeaning":{"publicId":"3379059","version":"1","preferredName":"Gallium Nitrate","longName":"3379059","preferredDefinition":"A hydrated nitrate salt of the group IIIa element gallium with potential use in the treatment of malignancy-associated hypercalcemia.  Gallium nitrate localizes preferentially to areas of bone resorption and remodeling and inhibits osteoclast-mediated resorption by enhancing hydroxyapatite crystallization and reduction of bone mineral solubility.  This agent also increases calcium and phosphorous deposition into bone and may increase collagen synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallium Nitrate","conceptCode":"C1109","definition":"A hydrated nitrate salt of the group IIIa element gallium with potential use in the treatment of malignancy-associated hypercalcemia.  Gallium nitrate localizes preferentially to areas of bone resorption and remodeling and inhibits osteoclast-mediated resorption by enhancing hydroxyapatite crystallization and reduction of bone mineral solubility.  This agent also increases calcium and phosphorous deposition into bone and may increase collagen synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD12-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD2B-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"GC1008","valueDescription":"Fresolimumab","ValueMeaning":{"publicId":"3379061","version":"1","preferredName":"Fresolimumab","longName":"3379061","preferredDefinition":"A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fresolimumab","conceptCode":"C63546","definition":"A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD38-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD51-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"GM-CSF","ValueMeaning":{"publicId":"2576458","version":"1","preferredName":"GM-CSF","longName":"2576458","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C1288","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-07","modifiedBy":"SHIDED","dateModified":"2013-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD5B-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fosamprenavir Calcium","valueDescription":"Fosamprenavir Calcium","ValueMeaning":{"publicId":"3282277","version":"1","preferredName":"Fosamprenavir Calcium","longName":"3282277","preferredDefinition":"The calcium salt form of fosamprenavir, prodrug of amprenavir, and a human immunodeficiency virus (HIV) protease inhibitor with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine. Then amprenavir binds to the active site of HIV-1 protease, thereby preventing the proteolytic cleavage of viral Gag-Pol polypeptide into individual functional proteins, thereby leading to the formation of immature non-infectious viral particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosamprenavir Calcium","conceptCode":"C61771","definition":"The calcium salt form of fosamprenavir, prodrug of amprenavir, and a human immunodeficiency virus (HIV) protease inhibitor with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine. Then amprenavir binds to the active site of HIV-1 protease, thereby preventing the proteolytic cleavage of viral Gag-Pol polypeptide into individual functional proteins, thereby leading to the formation of immature non-infectious viral particles.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-683A-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD65-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Foscarnet","valueDescription":"Foscarnet","ValueMeaning":{"publicId":"2794945","version":"1","preferredName":"Foscarnet","longName":"2794945","preferredDefinition":"A synthetic organic analogue of inorganic pyrophosphate with antiviral properties.  Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.  Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foscarnet","conceptCode":"C71630","definition":"A synthetic organic analog of inorganic pyrophosphate with activity against several types of viruses, but primarily used for the treatment of cytomegalovirus retinitis. Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-3095-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD6F-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD79-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"G-CSF","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"3379062","version":"1","preferredName":"Filgrastim","longName":"3379062","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD83-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AD9B-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ganciclovir","valueDescription":"Ganciclovir","ValueMeaning":{"publicId":"2575684","version":"1","preferredName":"Ganciclovir","longName":"2575684","preferredDefinition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganciclovir","conceptCode":"C517","definition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ADA6-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ADB0-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"3145831","version":"1","preferredName":"Gemcitabine","longName":"3145831","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A1DB-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ADBA-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Goserelin","valueDescription":"Goserelin","ValueMeaning":{"publicId":"2921026","version":"1","preferredName":"Goserelin","longName":"2921026","preferredDefinition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin","conceptCode":"C1374","definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD2F-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ADC4-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hexamethylmelamine","valueDescription":"Hexamethylmelamine (Altretamine)","ValueMeaning":{"publicId":"2576918","version":"1","preferredName":"Hexamethylmelamine (Altretamine)","longName":"2576918","preferredDefinition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Altretamine","conceptCode":"C544","definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F983-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-ADDF-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"HIV Peptide Vaccine","valueDescription":"HIV Peptide Vaccine","ValueMeaning":{"publicId":"3379064","version":"1","preferredName":"HIV Peptide Vaccine","longName":"3379064","preferredDefinition":"A vaccine containing one or more peptides derived from the human immunodeficiency virus (HIV). As a vaccine antigen, an HIV peptide may stimulate the host immune response against HIV, thereby preventing or treating HIV infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HIV Peptide Vaccine","conceptCode":"C29085","definition":"A vaccine containing one or more peptides derived from the human immunodeficiency virus (HIV). As a vaccine antigen, an HIV peptide may stimulate the host immune response against HIV, thereby preventing or treating HIV infection. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-ADEC-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AE05-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Gemcitabine/Vinorelbine Tartrate","valueDescription":"Gemcitabine Vinorelbine Treatment Regimen","ValueMeaning":{"publicId":"3379065","version":"1","preferredName":"Gemcitabine Vinorelbine Treatment Regimen","longName":"3379065","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.: A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AE13-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AE2C-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IFN/5FU/IL2","valueDescription":"Interferon Fluorouracil Interleukin-2 Treatment Regimen","ValueMeaning":{"publicId":"3379066","version":"1","preferredName":"Interferon Fluorouracil Interleukin-2 Treatment Regimen","longName":"3379066","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AE45-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AE5E-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IFN/5FU","valueDescription":"Interferon Fluorouracil Treatment Regimen","ValueMeaning":{"publicId":"3379067","version":"1","preferredName":"Interferon Fluorouracil Treatment Regimen","longName":"3379067","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AE6C-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AE85-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-2","valueDescription":"Interleukin-2","ValueMeaning":{"publicId":"2578198","version":"1","preferredName":"Interleukin-2","longName":"2578198","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AE8F-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-13","valueDescription":"Interleukin-13","ValueMeaning":{"publicId":"3379069","version":"1","preferredName":"Interleukin-13","longName":"3379069","preferredDefinition":"Interleukin-13, encoded by the IL13 gene, is an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. Interleukin-13 is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-13","conceptCode":"C20515","definition":"Interleukin-13 (146 aa, ~16 kDa) is encoded by the human IL13 gene. This protein plays a role in the negative regulation of cytokine production and the positive regulation of B-cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AE9C-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AEB5-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-12","valueDescription":"Interleukin-12","ValueMeaning":{"publicId":"2578188","version":"1","preferredName":"Interleukin-12","longName":"2578188","preferredDefinition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-12","conceptCode":"C20514","definition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AEC9-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-10","valueDescription":"Interleukin-10","ValueMeaning":{"publicId":"3259396","version":"1","preferredName":"Interleukin-10","longName":"3259396","preferredDefinition":"Expressed primarily in monocytes and less in lymphocytes by human IL10 Gene, Interleukin-10 is a cytokine with pleiotropic effects in immunoregulation and inflammation. It down-regulates expression of Th1 cytokines, MHC class II antigens, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Studies in mice suggest that this cytokine as an essential immunoregulator in the intestinal tract. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-10","conceptCode":"C20512","definition":"Interleukin-10 (178 aa, ~21 kDa) is encoded by the human IL10 gene. This protein plays a role in the negative regulation of cytokine expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9739EF2-B046-0BB4-E040-BB89AD43078C","latestVersionIndicator":"Yes","beginDate":"2011-08-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-01","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AEDD-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-1","valueDescription":"Interleukin-1","ValueMeaning":{"publicId":"2578187","version":"1","preferredName":"Interleukin-1","longName":"2578187","preferredDefinition":"Human interleukin-1 protein (271 aa, 31 kD precursor) is encoded by the human interleukin-1 (IL1) gene. This soluble protein is produced primarily by monocytes and macrophages. It activates and potentiates T-lymphocyte responses to mitogens or antigens. This protein is also capable of replacing macrophage requirements for T-cell activation","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-1","conceptCode":"C20506","definition":"Interleukin-1 (endogenous pyrogen), produced primarily by monocytes, is an important pro-inflammatory cytokine that mediates the acute phase host response.  The biologic activities of IL1 are properties of a protein derived from a larger precursor.  Inflammation causes induction of COX2, leading to release of prostanoids, which sensitize peripheral nociceptor terminals and produce local pain hypersensitivity.  Inflammation also generates sensitivity in neighboring tissue, muscle and joint pain, fever, lethargy, and anorexia.  COX2 induction in regions of the CNS is mediated by IL1B.  Interleukin-1-beta also stimulates bone resorption.  IL1RN is a competitive inhibitor of IL1B.  Mature IL1-beta levels are a sensitive and specific indicator of caspase-1 activation.  (from OMIM 147720 and NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE78-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AEE8-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"ICE","valueDescription":"ICE Regimen","ValueMeaning":{"publicId":"3366711","version":"1","preferredName":"ICE Regimen","longName":"3366711","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5264-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AEF2-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"I131-COL1","valueDescription":"I131-COL1","ValueMeaning":{"publicId":"3379071","version":"1","preferredName":"I131-COL1","longName":"3379071","preferredDefinition":"A radioimmunoconjugate of a murine monoclonal antibody (MoAb) COL1, labeled with iodine 131 (I-131). COL1 recognizes an epitope of carcinoembryonic antigen (CEA), which is over-expressed in many tumor cell types. I-131 MoAb COL1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express CEA, thereby allowing imaging and/or treatment of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"I131-COL1","conceptCode":"C29106","definition":"A radioimmunoconjugate of a murine monoclonal antibody (MoAb) COL1, labeled with iodine 131 (I-131). COL1 recognizes an epitope of carcinoembryonic antigen (CEA), which is over-expressed in many tumor cell types. I-131 MoAb COL1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express CEA, thereby allowing imaging and/or treatment of cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF00-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AF19-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AF23-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hydrocortisone","valueDescription":"Cortisol","ValueMeaning":{"publicId":"3303092","version":"1","preferredName":"Cortisol","longName":"3303092","preferredDefinition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortisol","conceptCode":"C2290","definition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B165DCF6-0287-5175-E040-BB89AD432D3B","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-10","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AF37-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hydrazine","valueDescription":"Hydrazine","ValueMeaning":{"publicId":"3379073","version":"1","preferredName":"Hydrazine","longName":"3379073","preferredDefinition":"A highly reactive base and reducing agent used in many industrial and medical applications.  In biological applications, hydrazine and its derivatives exhibit antidepressant properties by inhibiting monoamine oxidase (MAO), an enzyme that catalyzes the deamination and inactivation of certain stimulatory neurotransmitters such as norepinephrine and dopamine.  In psychiatry, the use of hydrazine derivatives is limited due to the emergence of the tricyclic antidepressants. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrazine","conceptCode":"C29097","definition":"A highly reactive base and reducing agent used in many industrial and medical applications.  In biological applications, hydrazine and its derivatives exhibit antidepressant properties by inhibiting monoamine oxidase (MAO), an enzyme that catalyzes the deamination and inactivation of certain stimulatory neurotransmitters such as norepinephrine and dopamine.  In psychiatry, the use of hydrazine derivatives is limited due to the emergence of the tricyclic antidepressants. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF45-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AF5E-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Hydroxychloroquine","valueDescription":"Hydroxychloroquine","ValueMeaning":{"publicId":"3379074","version":"1","preferredName":"Hydroxychloroquine","longName":"3379074","preferredDefinition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxychloroquine","conceptCode":"C557","definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF6A-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B914C2F8-AF83-3067-E040-BB89AD433056","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LMB-2","valueDescription":"LMB-2 Immunotoxin","ValueMeaning":{"publicId":"3379076","version":"1","preferredName":"LMB-2 Immunotoxin","longName":"3379076","preferredDefinition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LMB-2 Immunotoxin","conceptCode":"C2513","definition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-54AA-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-54C3-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Interferon gamma (IFN-G)","valueDescription":"Interferon Gamma","ValueMeaning":{"publicId":"2578177","version":"1","preferredName":"Interferon Gamma","longName":"2578177","preferredDefinition":"Interferon gamma (IFNg) is produced by activated T cells and is an important immunoregulatory molecule, particularly in allergic diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Gamma","conceptCode":"C20496","definition":"Interferon gamma (166 aa, ~19 kDa) is encoded by the human IFNG gene. This protein is involved in antiviral activity, macrophage activation, antiproliferative activity and immunopotentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-54D7-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Interferon beta (IFN-B)","valueDescription":"Interferon Beta","ValueMeaning":{"publicId":"2578175","version":"1","preferredName":"Interferon Beta","longName":"2578175","preferredDefinition":"A class of interferon elaborated by fibroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Beta","conceptCode":"C20495","definition":"Interferon beta (187 aa, ~22 kDa) is encoded by the human IFNB1 gene. This protein plays a role in interferon signaling and host defense.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-54EB-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Interferon alfa (IFN-A)","valueDescription":"Interferon Alpha","ValueMeaning":{"publicId":"2578176","version":"1","preferredName":"Interferon Alpha","longName":"2578176","preferredDefinition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha","conceptCode":"C20494","definition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-54FF-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-7","valueDescription":"Interleukin-7","ValueMeaning":{"publicId":"3379078","version":"1","preferredName":"Interleukin-7","longName":"3379078","preferredDefinition":"Encoded by human IL7 Gene, Interleukin-7 is an important cytokine for B and T cell development. This cytokine and HGF form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL7 is a cofactor for V(D)J rearrangement of T cell receptor beta (TCRB) during early T cell development. IL7 can be produced locally by intestinal epithelial and epithelial goblet cells, and may be a regulatory factor for intestinal mucosal lymphocytes. Studies in mice suggest that IL7 plays an essential role in lymphoid cell survival. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-7","conceptCode":"C20510","definition":"Interleukin-7 (177 aa, ~20 kDa) is encoded by the human IL7 gene. This protein plays a role in lymphocyte proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-550C-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5525-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-6","valueDescription":"Interleukin-6","ValueMeaning":{"publicId":"2578190","version":"1","preferredName":"Interleukin-6","longName":"2578190","preferredDefinition":"Interleukin-6 (IL-6), a glycoprotein produced by activated T-cells and a variety of other cells, induces the production of IgM by B-cells and can be used to replace feeder cells for the growth and maintenance of B-cell hybridomas in vitro.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-6","conceptCode":"C20451","definition":"Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-552F-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL-3","valueDescription":"Interleukin-3","ValueMeaning":{"publicId":"2578189","version":"1","preferredName":"Interleukin-3","longName":"2578189","preferredDefinition":"Human interleukin-3 (152 aa, 17 kDa precursor) is encoded by the human interleukin-3 (IL3) gene. This protein is a potent growth-promoting cytokine that enhances the ability of the immune system to fight tumor cells. IL-3 supports proliferation of many hematopoietic cell types. It is involved in cell growth, differentiation and apoptosis in addition to possessing neurotrophic activity. Abnormalities in this protein may be associated with neurologic disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-3","conceptCode":"C20439","definition":"Interleukin-3 (152 aa, ~17 kDa) is encoded by the human IL3 gene. This protein plays a role in neurotrophic activity and the proliferation of several types of hematopoietic lineage cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5539-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IFN/5FU/IL2/Leucovorin","valueDescription":"Interferon Fluorouracil Interleukin-2 Leucovorin Calcium Treatment Regimen","ValueMeaning":{"publicId":"3379079","version":"1","preferredName":"Interferon Fluorouracil Interleukin-2 Leucovorin Calcium Treatment Regimen","longName":"3379079","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Leucovorin Calcium","conceptCode":"C607","definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5549-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5562-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IFN/5FU/Leucovorin","valueDescription":"Interferon Fluorouracil Leucovorin Calcium Treatment Regimen","ValueMeaning":{"publicId":"3379080","version":"1","preferredName":"Interferon Fluorouracil Leucovorin Calcium Treatment Regimen","longName":"3379080","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Leucovorin Calcium","conceptCode":"C607","definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5571-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-558A-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Humanized MiK-beta-1","valueDescription":"Monoclonal Antibody Mik-Beta-1","ValueMeaning":{"publicId":"3379082","version":"1","preferredName":"Monoclonal Antibody Mik-Beta-1","longName":"3379082","preferredDefinition":"A murine monoclonal antibody directed against of the beta subunit of interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types.  Monoclonal antibody Mik-Beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody Mik-Beta-1","conceptCode":"C2669","definition":"A murine monoclonal antibody directed against of the beta subunit of interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types.  Monoclonal antibody Mik-Beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5597-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55B0-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55BA-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ifosfamide","valueDescription":"Ifosfamide","ValueMeaning":{"publicId":"2739548","version":"1","preferredName":"Ifosfamide","longName":"2739548","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01A4-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55C4-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Imetelstat","valueDescription":"Imetelstat","ValueMeaning":{"publicId":"3379084","version":"1","preferredName":"Imetelstat","longName":"3379084","preferredDefinition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imetelstat","conceptCode":"C49084","definition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-55D1-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55EA-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Imatinib Mesylate","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55F4-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Indinavir","valueDescription":"Indinavir","ValueMeaning":{"publicId":"2575686","version":"1","preferredName":"Indinavir","longName":"2575686v1.00","preferredDefinition":"A synthetic hydroxyaminopentane amide agent that selectively inhibits the protease of both human immunodeficiency virus 1 and 2. The incorporation of a basic amine into the hydroxyethylene backbone improves its aqueous solubility and its oral bioavailability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indinavir","conceptCode":"C66877","definition":"A synthetic hydroxyaminopentane amide agent that selectively inhibits the protease of both human immunodeficiency virus 1 and 2. The incorporation of a basic amine into the hydroxyethylene backbone improves its aqueous solubility and its oral bioavailability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-55FE-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":"Infliximab","ValueMeaning":{"publicId":"2567430","version":"1","preferredName":"Infliximab","longName":"2567430","preferredDefinition":"A monoclonal antibody that inhibits the function of TNF-alpha.  It is used in the treatment of rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D473-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5608-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Irofulven","valueDescription":"Irofulven","ValueMeaning":{"publicId":"3379086","version":"1","preferredName":"Irofulven","longName":"3379086","preferredDefinition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irofulven","conceptCode":"C1717","definition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5615-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-562E-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Isotretinoin","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5651-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ispinesib","valueDescription":"Ispinesib","ValueMeaning":{"publicId":"3379089","version":"1","preferredName":"Ispinesib","longName":"3379089","preferredDefinition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ispinesib","conceptCode":"C38131","definition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-565E-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5677-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ixabepilone","valueDescription":"Ixabepilone","ValueMeaning":{"publicId":"3379090","version":"1","preferredName":"Ixabepilone","longName":"3379090","preferredDefinition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixabepilone","conceptCode":"C37452","definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5681-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-569A-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"KNI-272","valueDescription":"KNI-272","ValueMeaning":{"publicId":"3379092","version":"1","preferredName":"KNI-272","longName":"3379092","preferredDefinition":"A synthetic peptide-based antiviral agent.  As a peptidomimetic substrate containing an unnatural amino acid, allophenylnorstatine, KNI-272 selectively binds to and inhibits the human immunodeficiency virus (HIV) 1 and 2 proteases, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"KNI-272","conceptCode":"C29140","definition":"A synthetic peptide-based antiviral agent.  As a peptidomimetic substrate containing an unnatural amino acid, allophenylnorstatine, KNI-272 selectively binds to and inhibits the human immunodeficiency virus (HIV) 1 and 2 proteases, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-56A7-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-56C0-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ketoconazole","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-56CA-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LMB-1","valueDescription":"LMB-1 Immunotoxin","ValueMeaning":{"publicId":"3379094","version":"1","preferredName":"LMB-1 Immunotoxin","longName":"3379094","preferredDefinition":"A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LMB-1 Immunotoxin","conceptCode":"C2499","definition":"A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-56D7-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-56F0-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL2/IFN","valueDescription":"Interleukin-2 Interferon Treatment Regimen","ValueMeaning":{"publicId":"3379095","version":"1","preferredName":"Interleukin-2 Interferon Treatment Regimen","longName":"3379095","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink): Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-56FF-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5718-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Irinotecan HCl","valueDescription":"Irinotecan Hydrochloride","ValueMeaning":{"publicId":"2579326","version":"1","preferredName":"Irinotecan Hydrochloride","longName":"2579326","preferredDefinition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan Hydrochloride","conceptCode":"C1381","definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-18","modifiedBy":"ONEDATA","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-572C-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL2/LAK","valueDescription":"Interleukin-2/Lymphokine-Activated Killer Cells","ValueMeaning":{"publicId":"3379097","version":"1","preferredName":"Interleukin-2/Lymphokine-Activated Killer Cells","longName":"3379097","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2/Lymphokine-Activated Killer Cells","conceptCode":"C10246","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5739-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B915D7F9-5752-D77C-E040-BB89AD4330BD","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Id Lymph Skin test vaccine","valueDescription":"Skin Test Lymphoma Vaccine","ValueMeaning":{"publicId":"3379102","version":"1","preferredName":"Skin Test Lymphoma Vaccine","longName":"3379102","preferredDefinition":"A preparation of an antigenic component of an infectious agent that is administered to a patient in order to determine whether previous exposure to the agent has occurred, and/or to assess the integrity of the patient's cellular immune system.  Depending on the clinical situation, the appearance of a delayed (cellular) hypersensitivity response, which manifests as an area of induration and erythema at the injection site, i.e. a positive test result, may indicate previous exposure to a particular infectious agent. (NCI04): A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.: Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Test","conceptCode":"C17137","definition":"A preparation of an antigenic component of an infectious agent that is administered to a patient in order to determine whether previous exposure to the agent has occurred, and/or to assess the integrity of the patient's cellular immune system.  Depending on the clinical situation, the appearance of a delayed (cellular) hypersensitivity response, which manifests as an area of induration and erythema at the injection site, i.e. a positive test result, may indicate previous exposure to a particular infectious agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-AAF4-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AB0D-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Id KLH Myeloma","valueDescription":"Intradermal Plasma Cell Myeloma Keyhole Limpet Hemocyanin","ValueMeaning":{"publicId":"3379103","version":"1","preferredName":"Intradermal Plasma Cell Myeloma Keyhole Limpet Hemocyanin","longName":"3379103","preferredDefinition":"Within the dermis, which is the layer of skin below the epidermis (outermost layer).: A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001): A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intradermal","conceptCode":"C28213","definition":"Within the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Keyhole Limpet Hemocyanin","conceptCode":"C1139","definition":"A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-AB1B-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AB34-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Id KLH Lymphoma","valueDescription":"Intradermal Lymphoma Keyhole Limpet Hemocyanin","ValueMeaning":{"publicId":"3379104","version":"1","preferredName":"Intradermal Lymphoma Keyhole Limpet Hemocyanin","longName":"3379104","preferredDefinition":"Within the dermis, which is the layer of skin below the epidermis (outermost layer).: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.: A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intradermal","conceptCode":"C28213","definition":"Within the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Keyhole Limpet Hemocyanin","conceptCode":"C1139","definition":"A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-AB42-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AB5B-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ibritumomab Tiuxetan","valueDescription":"Ibritumomab Tiuxetan","ValueMeaning":{"publicId":"2741549","version":"1","preferredName":"Ibritumomab Tiuxetan","longName":"2741549","preferredDefinition":"ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan.  This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90.  The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes one infusion of Rituximab preceding In-111 ZEVALIN. Step 2 follows Step 1 by seven to nine days and consists of a second infusion of Rituximab followed by Y-90 ZEVALIN.  ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibritumomab Tiuxetan","conceptCode":"C29981","definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-461A-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AB6F-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IUdr","valueDescription":"Idoxuridine","ValueMeaning":{"publicId":"3379106","version":"1","preferredName":"Idoxuridine","longName":"3379106","preferredDefinition":"An iodinated analog of deoxyuridine originally developed as a chemotherapeutic agent, but more commonly used as a treatment for conditions of herpes virus infection. Idoxuridine inhibits thymidylate phosphorylase and viral DNA polymerases. It is converted in vivo to its mono-, di-, and triphosphate forms and is incorporated into DNA by competition with thymidine. Once incorporated into DNA it creates a faulty template and disrupts viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idoxuridine","conceptCode":"C563","definition":"An iodinated analogue of deoxyuridine, with antiviral activity against herpes simplex virus (HSV) and potential radiosensitizing activities. Upon ocular administration, idoxuridine (IUdR) is converted to its mono-, di-, and triphosphate forms, is incorporated into DNA and disrupts viral replication. Upon oral administration of the idoxuridine prodrug ropidoxuridine and hepatic conversion by aldehyde oxidase into idoxuridine, this agent incorporates into DNA and sensitizes cells to ionizing radiation by increasing DNA strand breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-AB7C-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AB95-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"INO-1001","valueDescription":"INO-1001","ValueMeaning":{"publicId":"3379108","version":"1","preferredName":"INO-1001","longName":"3379108","preferredDefinition":"A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"INO-1001","conceptCode":"C61315","definition":"A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-ABA2-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-ABBB-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IMC-A12","valueDescription":"Cixutumumab","ValueMeaning":{"publicId":"3379110","version":"1","preferredName":"Cixutumumab","longName":"3379110","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cixutumumab","conceptCode":"C79828","definition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-ABC8-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-ABE1-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL2/MDX","valueDescription":"Interleukin-2 Monoclonal Antibody Treatment Regimen","ValueMeaning":{"publicId":"3379111","version":"1","preferredName":"Interleukin-2 Monoclonal Antibody Treatment Regimen","longName":"3379111","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink): An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-ABEF-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AC08-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IL2/LAK/IFN","valueDescription":"Interleukin-2 Lymphokine-Activated Killer Cells Interferon Treatment Regimen","ValueMeaning":{"publicId":"3379113","version":"1","preferredName":"Interleukin-2 Lymphokine-Activated Killer Cells Interferon Treatment Regimen","longName":"3379113","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink): Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2).  Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins.  LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage.: Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lymphokine-Activated Killer Cells","conceptCode":"C13008","definition":"Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2).  Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins.  LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-AC18-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9163F61-AC31-188C-E040-BB89AD435BED","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LY573636","valueDescription":"Tasisulam","ValueMeaning":{"publicId":"3379119","version":"1","preferredName":"Tasisulam","longName":"3379119","preferredDefinition":"An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tasisulam","conceptCode":"C62794","definition":"An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E82B-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E844-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LY317615","valueDescription":"Enzastaurin Hydrochloride","ValueMeaning":{"publicId":"3379121","version":"1","preferredName":"Enzastaurin Hydrochloride","longName":"3379121","preferredDefinition":"The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzastaurin Hydrochloride","conceptCode":"C26658","definition":"The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E851-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E86A-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LMB-7","valueDescription":"LMB-7 Immunotoxin","ValueMeaning":{"publicId":"3379123","version":"1","preferredName":"LMB-7 Immunotoxin","longName":"3379123","preferredDefinition":"A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LMB-7 Immunotoxin","conceptCode":"C1619","definition":"A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E877-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E890-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"LMB-9","valueDescription":"LMB-9 Immunotoxin","ValueMeaning":{"publicId":"3379125","version":"1","preferredName":"LMB-9 Immunotoxin","longName":"3379125","preferredDefinition":"A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LMB-9 Immunotoxin","conceptCode":"C2472","definition":"A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E89D-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E8B6-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ketoconazole/Prednisone","valueDescription":"Ketoconazole Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3379126","version":"1","preferredName":"Ketoconazole Prednisone Treatment Regimen","longName":"3379126","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E8C4-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E8DD-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Karenitecin","valueDescription":"Cositecan","ValueMeaning":{"publicId":"3379128","version":"1","preferredName":"Cositecan","longName":"3379128","preferredDefinition":"A drug being studied in the treatment of cancer.  It belongs to a family of drugs called topoisomerase inhibitors. It is related to the anticancer drug camptothecin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cositecan","conceptCode":"C1877","definition":"A synthetic silicon-containing agent related to camptothecin with antineoplastic properties.  Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis.  Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E8EA-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E903-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Kaletra (Lopinavir/Ritonavir)","valueDescription":"Lopinavir/Ritonavir","ValueMeaning":{"publicId":"2578201","version":"1","preferredName":"Lopinavir/Ritonavir","longName":"2578201","preferredDefinition":"A combination anti-HIV protease inhibitor from Abbott Laboratories.  Brand name is Kaletra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir/Ritonavir","conceptCode":"C2096","definition":"A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E917-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IgG-RFB4-SMPT-dgA","valueDescription":"Di-dgA-RFB4 Immunotoxin","ValueMeaning":{"publicId":"3378946","version":"1","preferredName":"Di-dgA-RFB4 Immunotoxin","longName":"3378946","preferredDefinition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Di-dgA-RFB4 Immunotoxin","conceptCode":"C2334","definition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CE0F-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E92B-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"IgG-HD37-SMPT-dgA","valueDescription":"Monoclonal Antibody HD37-SMPT-dgA Immunotoxin","ValueMeaning":{"publicId":"3379130","version":"1","preferredName":"Monoclonal Antibody HD37-SMPT-dgA Immunotoxin","longName":"3379130","preferredDefinition":"An immunotoxin consisting of the murine anti-CD19 monoclonal antibody HD37 conjugated to a deglycosylated ricin A chain (dgA) via the linking molecule N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene (SMPT).  The HD37 component binds to CD19, a B-cell restricted antigen, thereby targeting the delivery of the cytotoxic ricin A chain to B-cells. The ricin A chain component binds to B-cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody HD37-SMPT-dgA Immunotoxin","conceptCode":"C29222","definition":"An immunotoxin consisting of the murine anti-CD19 monoclonal antibody HD37 conjugated to a deglycosylated ricin A chain (dgA) via the linking molecule N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene (SMPT).  The HD37 component binds to CD19, a B-cell restricted antigen, thereby targeting the delivery of the cytotoxic ricin A chain to B-cells. The ricin A chain component binds to B-cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E938-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E951-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Irinotecan/Cetuximab","valueDescription":"Irinotecan Cetuximab Treatment Regimen","ValueMeaning":{"publicId":"3379132","version":"1","preferredName":"Irinotecan Cetuximab Treatment Regimen","longName":"3379132","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.: A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan","conceptCode":"C62040","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E960-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E979-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Ifosfa/Mesna/Etop","valueDescription":"Ifosfamide Mesna Etoposide Treatment Regimen","ValueMeaning":{"publicId":"3379133","version":"1","preferredName":"Ifosfamide Mesna Etoposide Treatment Regimen","longName":"3379133","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04): A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Mesna","conceptCode":"C192","definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E988-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E9A1-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Idarubicin HCl","valueDescription":"Idarubicin Hydrochloride","ValueMeaning":{"publicId":"3379135","version":"1","preferredName":"Idarubicin Hydrochloride","longName":"3379135","preferredDefinition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin Hydrochloride","conceptCode":"C1587","definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E9AE-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E9C7-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Id/IL-2 vaccine","valueDescription":"Interleukin-2 Vaccine","ValueMeaning":{"publicId":"3379136","version":"1","preferredName":"Interleukin-2 Vaccine","longName":"3379136","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink): Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E9D4-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-E9ED-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Id MM Skin test vaccine","valueDescription":"Skin Test Plasma Cell Myeloma Vaccine","ValueMeaning":{"publicId":"3379137","version":"1","preferredName":"Skin Test Plasma Cell Myeloma Vaccine","longName":"3379137","preferredDefinition":"A preparation of an antigenic component of an infectious agent that is administered to a patient in order to determine whether previous exposure to the agent has occurred, and/or to assess the integrity of the patient's cellular immune system.  Depending on the clinical situation, the appearance of a delayed (cellular) hypersensitivity response, which manifests as an area of induration and erythema at the injection site, i.e. a positive test result, may indicate previous exposure to a particular infectious agent. (NCI04): A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001): Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Test","conceptCode":"C17137","definition":"A preparation of an antigenic component of an infectious agent that is administered to a patient in order to determine whether previous exposure to the agent has occurred, and/or to assess the integrity of the patient's cellular immune system.  Depending on the clinical situation, the appearance of a delayed (cellular) hypersensitivity response, which manifests as an area of induration and erythema at the injection site, i.e. a positive test result, may indicate previous exposure to a particular infectious agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E9FB-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA14-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Laetrille","valueDescription":"Laetrille","ValueMeaning":{"publicId":"2578215","version":"1","preferredName":"Laetrille","longName":"2578215","preferredDefinition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laetrile","conceptCode":"C29149","definition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE94-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA1E-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"Letrozole","ValueMeaning":{"publicId":"2921027","version":"1","preferredName":"Letrozole","longName":"2921027","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD52-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA28-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Leucovorin Calcium","valueDescription":"Leucovorin Calcium","ValueMeaning":{"publicId":"2576876","version":"1","preferredName":"Leucovorin Calcium","longName":"2576876","preferredDefinition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin Calcium","conceptCode":"C607","definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F959-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA32-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Leuprolide","valueDescription":"Leuprolide","ValueMeaning":{"publicId":"2921029","version":"1","preferredName":"Leuprolide","longName":"2921029","preferredDefinition":"The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide","conceptCode":"C62042","definition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD78-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA3C-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Levamisole","valueDescription":"Levamisole","ValueMeaning":{"publicId":"2578219","version":"1","preferredName":"Levamisole","longName":"2578219","preferredDefinition":"An anthelmintic drug. Co-administered with fluorouracil in the treatment of Dukes' stage C colon cancer, levamisole restores immune function through stimulating antibody formation, enhancing T-cell activity, and potentiating macrophage function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levamisole Hydrochloride","conceptCode":"C610","definition":"The hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. In immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating T-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA46-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Levobunolol","valueDescription":"Levobunolol","ValueMeaning":{"publicId":"3379139","version":"1","preferredName":"Levobunolol","longName":"3379139","preferredDefinition":"A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levobunolol","conceptCode":"C62043","definition":"A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EA53-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA6C-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Liarozole","valueDescription":"Liarozole","ValueMeaning":{"publicId":"3379141","version":"1","preferredName":"Liarozole","longName":"3379141","preferredDefinition":"An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liarozole","conceptCode":"C1433","definition":"An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EA79-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EA92-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Liposomal Daunorubicin","valueDescription":"Liposomal Daunorubicin Citrate","ValueMeaning":{"publicId":"3379142","version":"1","preferredName":"Liposomal Daunorubicin Citrate","longName":"3379142","preferredDefinition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Daunorubicin Citrate","conceptCode":"C2213","definition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EA9C-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"COLBERTM","dateModified":"2023-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EAB4-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Liposomal Doxorubicin","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"3379143","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"3379143","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EABF-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B917C4ED-EAD7-F265-E040-BB89AD435210","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lapatinib","valueDescription":"Lapatinib","ValueMeaning":{"publicId":"2647015","version":"1","preferredName":"Lapatinib","longName":"2647015","preferredDefinition":"The ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3229BE13-DB27-00BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B009-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MOPP/ABVD","valueDescription":"MOPP Regimen ABVD Regimen Treatment Regimen","ValueMeaning":{"publicId":"3379182","version":"1","preferredName":"MOPP Regimen ABVD Regimen Treatment Regimen","longName":"3379182","preferredDefinition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.: A chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MOPP Regimen","conceptCode":"C9619","definition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"ABVD Regimen","conceptCode":"C9509","definition":"A regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B018-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B031-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MONO dgA RFB4","valueDescription":"Di-dgA-RFB4 Immunotoxin","ValueMeaning":{"publicId":"3378946","version":"1","preferredName":"Di-dgA-RFB4 Immunotoxin","longName":"3378946","preferredDefinition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Di-dgA-RFB4 Immunotoxin","conceptCode":"C2334","definition":"An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CE0F-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B047-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MK-0158 (Raltegravir)","valueDescription":"Raltegravir","ValueMeaning":{"publicId":"3282746","version":"1","preferredName":"Raltegravir","longName":"3282746v1.00","preferredDefinition":"A small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltegravir","conceptCode":"C72837","definition":"A small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-17AD-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B051-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MINE/ESHAP","valueDescription":"Etoposide/Ifosfamide/Mesna/Mitoxantrone Cisplatin/Cytarabine/Etoposide/Methylprednisolone Treatment Regimen","ValueMeaning":{"publicId":"3379184","version":"1","preferredName":"Etoposide/Ifosfamide/Mesna/Mitoxantrone Cisplatin/Cytarabine/Etoposide/Methylprednisolone Treatment Regimen","longName":"3379184","preferredDefinition":"No Value Exists: No Value Exists: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Ifosfamide/Mesna/Mitoxantrone","conceptCode":"C11137","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin/Cytarabine/Etoposide/Methylprednisolone","conceptCode":"C9720","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B060-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B079-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MIME","valueDescription":"Etoposide/Ifosfamide/Methotrexate/Mitoguazone","ValueMeaning":{"publicId":"3379186","version":"1","preferredName":"Etoposide/Ifosfamide/Methotrexate/Mitoguazone","longName":"3379186","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Ifosfamide/Methotrexate/Mitoguazone","conceptCode":"C9615","definition":"A combination of agents containing etoposide, ifosfamide, methotrexate and mitoguazone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B088-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B0A1-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MICE","valueDescription":"Cytarabine Etoposide Everolimus Idarubicin Mitoxantrone Treatment Regimen","ValueMeaning":{"publicId":"3379187","version":"1","preferredName":"Cytarabine Etoposide Everolimus Idarubicin Mitoxantrone Treatment Regimen","longName":"3379187","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05): A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04): An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Idarubicin","conceptCode":"C562","definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B0B2-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B0CB-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MGI-114","valueDescription":"Irofulven","ValueMeaning":{"publicId":"3379086","version":"1","preferredName":"Irofulven","longName":"3379086","preferredDefinition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irofulven","conceptCode":"C1717","definition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5615-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B0DF-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MGCD0103 HDAC","valueDescription":"Mocetinostat","ValueMeaning":{"publicId":"3379189","version":"1","preferredName":"Mocetinostat","longName":"3379189","preferredDefinition":"A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mocetinostat","conceptCode":"C62521","definition":"A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B0EC-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B105-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MEDI-547","valueDescription":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","ValueMeaning":{"publicId":"3379191","version":"1","preferredName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","longName":"3379191","preferredDefinition":"An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","conceptCode":"C79836","definition":"An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B112-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B12B-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MEDI-507","valueDescription":"Siplizumab","ValueMeaning":{"publicId":"3379193","version":"1","preferredName":"Siplizumab","longName":"3379193","preferredDefinition":"A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siplizumab","conceptCode":"C38685","definition":"A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B138-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B151-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MDX-H210","valueDescription":"Bispecific Antibody MDX-H210","ValueMeaning":{"publicId":"3379195","version":"1","preferredName":"Bispecific Antibody MDX-H210","longName":"3379195","preferredDefinition":"A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bispecific Antibody MDX-H210","conceptCode":"C1578","definition":"A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B15E-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B177-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MDX-CTLA","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B18B-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mab 211At-ch81C6","valueDescription":"At 211 Monoclonal Antibody 81C6","ValueMeaning":{"publicId":"3379197","version":"1","preferredName":"At 211 Monoclonal Antibody 81C6","longName":"3379197","preferredDefinition":"A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"At 211 Monoclonal Antibody 81C6","conceptCode":"C2490","definition":"A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B198-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B1B1-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mab 131I-mu81C6","valueDescription":"Iodine I 131 Monoclonal Antibody 81C6","ValueMeaning":{"publicId":"3379199","version":"1","preferredName":"Iodine I 131 Monoclonal Antibody 81C6","longName":"3379199","preferredDefinition":"A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I 131 Monoclonal Antibody 81C6","conceptCode":"C2488","definition":"A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B1BE-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B1D7-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mab 131I-ch81C6","valueDescription":"(131)I-ch81C6","ValueMeaning":{"publicId":"3379201","version":"1","preferredName":"(131)I-ch81C6","longName":"3379201","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"(131)I-ch81C6","conceptCode":"C1723325","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B1E4-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B1FD-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MAVE/Taraquidar (XR9576)","valueDescription":"Doxorubicin/Etoposide/Mitotane/Vincristine Tariquidar Treatment Regimen","ValueMeaning":{"publicId":"3379203","version":"1","preferredName":"Doxorubicin/Etoposide/Mitotane/Vincristine Tariquidar Treatment Regimen","longName":"3379203","preferredDefinition":"No Value Exists: An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin/Etoposide/Mitotane/Vincristine","conceptCode":"C10800","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tariquidar","conceptCode":"C2246","definition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B20C-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B225-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MAID","valueDescription":"Dacarbazine/Doxorubicin/Ifosfamide/Mesna","ValueMeaning":{"publicId":"3379205","version":"1","preferredName":"Dacarbazine/Doxorubicin/Ifosfamide/Mesna","longName":"3379205","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine/Doxorubicin/Ifosfamide/Mesna","conceptCode":"C11179","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B234-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B24D-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"MACOP-B","valueDescription":"MACOP-B Regimen","ValueMeaning":{"publicId":"3366705","version":"1","preferredName":"MACOP-B Regimen","longName":"3366705","preferredDefinition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MACOP-B Regimen","conceptCode":"C63457","definition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51B2-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B257-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lopinavir/Ritonavir","valueDescription":"Lopinavir/Ritonavir","ValueMeaning":{"publicId":"2578201","version":"1","preferredName":"Lopinavir/Ritonavir","longName":"2578201","preferredDefinition":"A combination anti-HIV protease inhibitor from Abbott Laboratories.  Brand name is Kaletra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir/Ritonavir","conceptCode":"C2096","definition":"A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B262-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lonafarnib (Sch66336)","valueDescription":"Lonafarnib","ValueMeaning":{"publicId":"3379207","version":"1","preferredName":"Lonafarnib","longName":"3379207","preferredDefinition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lonafarnib","conceptCode":"C1829","definition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B26F-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B288-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lomustine/Prednisone","valueDescription":"Lomustine Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3379208","version":"1","preferredName":"Lomustine Prednisone Treatment Regimen","longName":"3379208","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B296-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B2AF-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lomustine (BCNU)","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B2C3-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Micellar Paclitaxel","valueDescription":"Micellar Paclitaxel","ValueMeaning":{"publicId":"3379292","version":"1","preferredName":"Micellar Paclitaxel","longName":"3379292","preferredDefinition":"A systemic administered polymeric micelle containing paclitaxel that may be used for chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. Paclitaxel, a toxoid, binds to and stabilizes tubulin and inhibits the disassembly of microtubules, thereby inhibiting cell division. Paclitaxel also inhibits metalloproteinase, thereby blocking the activities of matrix metalloproteinases (MMPs) and preventing collagen degradation in cartilage and bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micellar Paclitaxel","conceptCode":"C29256","definition":"A systemic administered polymeric micelle containing paclitaxel that may be used for chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. Paclitaxel, a toxoid, binds to and stabilizes tubulin and inhibits the disassembly of microtubules, thereby inhibiting cell division. Paclitaxel also inhibits metalloproteinase, thereby blocking the activities of matrix metalloproteinases (MMPs) and preventing collagen degradation in cartilage and bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C84F-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C868-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mitomycin","valueDescription":"Mitomycin C","ValueMeaning":{"publicId":"3379293","version":"1","preferredName":"Mitomycin C","longName":"3379293","preferredDefinition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C872-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C88A-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mitotane","valueDescription":"Mitotane","ValueMeaning":{"publicId":"2578300","version":"1","preferredName":"Mitotane","longName":"2578300","preferredDefinition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotane","conceptCode":"C664","definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C895-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mitoxantrone","valueDescription":"Mitoxantrone","ValueMeaning":{"publicId":"2739550","version":"1","preferredName":"Mitoxantrone","longName":"2739550v1.00","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0217-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C89F-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mometasone Furoate","valueDescription":"Mometasone Furoate","ValueMeaning":{"publicId":"3379294","version":"1","preferredName":"Mometasone Furoate","longName":"3379294","preferredDefinition":"The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression.  This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mometasone Furoate","conceptCode":"C29268","definition":"The furoate ester form of mometasone, a synthetic topical glucocorticoid receptor (GR) agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Upon administration, mometasone binds to cytoplasmic GRs and subsequently activates GR-mediated gene expression. This results in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, mometasone appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C8A9-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8C2-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil","valueDescription":"Mycophenolate Mofetil","ValueMeaning":{"publicId":"2567431","version":"1","preferredName":"Mycophenolate Mofetil","longName":"2567431","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D474-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8CC-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Nelfinavir","valueDescription":"Nelfinavir","ValueMeaning":{"publicId":"2575692","version":"1","preferredName":"Nelfinavir","longName":"2575692","preferredDefinition":"A synthetic antiviral agent.  Nelfinavir selectively inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions.  In vivo, this agent exhibits broad tissue distribution compared to related agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelfinavir","conceptCode":"C29285","definition":"A synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8D7-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Nevirapine","valueDescription":"Nevirapine","ValueMeaning":{"publicId":"2578318","version":"1","preferredName":"Nevirapine","longName":"2578318","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Nevirapine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevirapine","conceptCode":"C29277","definition":"A benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8E1-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Oatmeal Powder","valueDescription":"Oatmeal Powder","ValueMeaning":{"publicId":"2577718","version":"1","preferredName":"Oatmeal Powder","longName":"2577718","preferredDefinition":"Colloidal oatmeal, whole oats milled to a fine powder, with anti-pruritic activity. Oatmeal powder, especially when added to a warm bath, is used to provide temporary relief of itching and irritation caused by insect bites, eczema, sun burns, reactions to poisonous plants and various other skin rashes and allergies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oatmeal Powder","conceptCode":"C29298","definition":"Colloidal oatmeal, whole oats milled to a fine powder, with anti-pruritic activity. Oatmeal powder, especially when added to a warm bath, is used to provide temporary relief of itching and irritation caused by insect bites, eczema, sun burns, reactions to poisonous plants and various other skin rashes and allergies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8F5-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C8FF-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Nilutamide","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"3335142","version":"1","preferredName":"Nilutamide","longName":"3335142","preferredDefinition":"A drug that blocks the effects of male hormones in the body.  It belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED69-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C909-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Noscapine","valueDescription":"Noscapine","ValueMeaning":{"publicId":"3293803","version":"1","preferredName":"Noscapine","longName":"3293803","preferredDefinition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Noscapine","conceptCode":"C80589","definition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D80E-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C913-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"O6-Benzylguanine","valueDescription":"O6-Benzylguanine","ValueMeaning":{"publicId":"3379296","version":"1","preferredName":"O6-Benzylguanine","longName":"3379296","preferredDefinition":"A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"O6-Benzylguanine","conceptCode":"C1306","definition":"A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C920-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C939-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"ON 01910.Na","valueDescription":"Polo-like kinase 1 Inhibitor ON 01910.Na","ValueMeaning":{"publicId":"3379298","version":"1","preferredName":"Polo-like kinase 1 Inhibitor ON 01910.Na","longName":"3379298","preferredDefinition":"A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like kinase1 (Plk1), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rigosertib Sodium","conceptCode":"C71355","definition":"The sodium salt form of rigosertib, a synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C946-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B91A08CE-C95F-784E-E040-BB89AD435DD1","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"TNF","valueDescription":"Tumor Necrosis Factor Therapy","ValueMeaning":{"publicId":"3380176","version":"1","preferredName":"Tumor Necrosis Factor Therapy","longName":"3380176v1.00","preferredDefinition":"A biological therapy that involves the use of anti-tumor necrosis factor antagonists. It results in the inhibition of tumor necrosis factor and the decrease of the inflammatory response in autoimmune disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Necrosis Factor Therapy","conceptCode":"C15507","definition":"A biological therapy that involves the use of anti-tumor necrosis factor antagonists. It results in the inhibition of tumor necrosis factor and the decrease of the inflammatory response in autoimmune disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D4B3-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D4CC-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TMC-125 (Etravirine)","valueDescription":"Etravirine","ValueMeaning":{"publicId":"3380178","version":"1","preferredName":"Etravirine","longName":"3380178","preferredDefinition":"A diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etravirine","conceptCode":"C73195","definition":"A diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D4D9-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D4F2-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TIL/DTIC/Cisplat/Tam/IFN","valueDescription":"Tumor Infiltrating Lymphocyte Dacarbazine Cisplatin Tamoxifen Interferon Treatment Regimen","ValueMeaning":{"publicId":"3380179","version":"1","preferredName":"Tumor Infiltrating Lymphocyte Dacarbazine Cisplatin Tamoxifen Interferon Treatment Regimen","longName":"3380179","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.: A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04): An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04): Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D503-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D51C-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TH2 cells","valueDescription":"Type 2 Helper Cell","ValueMeaning":{"publicId":"3380181","version":"1","preferredName":"Type 2 Helper Cell","longName":"3380181","preferredDefinition":"Type 2 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type 2 Helper Cell","conceptCode":"C12540","definition":"Type 2 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D529-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D542-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TAS-106","valueDescription":"3'-C-ethynylcytidine","ValueMeaning":{"publicId":"3380183","version":"1","preferredName":"3'-C-ethynylcytidine","longName":"3380183","preferredDefinition":"A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"3'-C-ethynylcytidine","conceptCode":"C29475","definition":"A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D54F-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D568-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Suramin/HC/Flut","valueDescription":"Flutamide/Hydrocortisone/Suramin","ValueMeaning":{"publicId":"3380186","version":"1","preferredName":"Flutamide/Hydrocortisone/Suramin","longName":"3380186","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide/Hydrocortisone/Suramin","conceptCode":"C29472","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D59C-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D5B5-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Comtrex","valueDescription":"Comtrex","ValueMeaning":{"publicId":"3380187","version":"1","preferredName":"Comtrex","longName":"3380187v1.00","preferredDefinition":"A combination preparation containing the analgesic acetaminophen and a combination of one or more of the following agents: an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride or phenylephrine hydrochloride. These preparations are used to relieve symptoms of cold, cough and flu.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen-based Oral Cough and Cold Preparation","conceptCode":"C28940","definition":"A combination preparation containing the analgesic acetaminophen and a combination of one or more of the following agents: an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride or phenylephrine hydrochloride. These preparations are used to relieve symptoms of cold, cough and flu.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D5C0-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D5D8-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"O-Chloroacetylcarbamoylfumagillol","valueDescription":"O-Chloroacetylcarbamoylfumagillol","ValueMeaning":{"publicId":"3380189","version":"1","preferredName":"O-Chloroacetylcarbamoylfumagillol","longName":"3380189","preferredDefinition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"O-Chloroacetylcarbamoylfumagillol","conceptCode":"C1298","definition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D5E6-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D5FF-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tazarotene","valueDescription":"Tazarotene","ValueMeaning":{"publicId":"3380191","version":"1","preferredName":"Tazarotene","longName":"3380191","preferredDefinition":"A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tazarotene","conceptCode":"C29487","definition":"A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D60D-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D626-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tandutinib","valueDescription":"Tandutinib","ValueMeaning":{"publicId":"3380193","version":"1","preferredName":"Tandutinib","longName":"3380193","preferredDefinition":"A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tandutinib","conceptCode":"C48404","definition":"A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D633-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D64C-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tamsulosin HCl","valueDescription":"Tamsulosin Hydrochloride","ValueMeaning":{"publicId":"3380195","version":"1","preferredName":"Tamsulosin Hydrochloride","longName":"3380195","preferredDefinition":"The hydrochloride salt of tamsulosin, a sulfonamide derivative with adrenergic antagonist activity. Tamsulosin selectivity binds to and blocks the activity of alpha1 adrenoreceptors in the human prostate and bladder neck; blockade of these adrenoceptors can cause smooth muscle in the prostate and bladder neck to relax, resulting in an improvement in urinary flow rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamsulosin Hydrochloride","conceptCode":"C29486","definition":"The hydrochloride salt of tamsulosin, a sulfonamide derivative with adrenergic antagonist activity. Tamsulosin selectivity binds to and blocks the activity of alpha1 adrenoreceptors in the human prostate and bladder neck; blockade of these adrenoceptors can cause smooth muscle in the prostate and bladder neck to relax, resulting in an improvement in urinary flow rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D659-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D672-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"Tamoxifen","ValueMeaning":{"publicId":"2897675","version":"1","preferredName":"Tamoxifen","longName":"2897675","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB2B-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D67C-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Talampanel","valueDescription":"Talampanel","ValueMeaning":{"publicId":"3380197","version":"1","preferredName":"Talampanel","longName":"3380197","preferredDefinition":"A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talampanel","conceptCode":"C38139","definition":"A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D689-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D6A2-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Talactoferrin alfa","valueDescription":"Talactoferrin","ValueMeaning":{"publicId":"3380199","version":"1","preferredName":"Talactoferrin","longName":"3380199","preferredDefinition":"A drug being studied in the treatment of kidney cancer that has spread. It is also being studied in the treatment of other types of cancer and other conditions. Talactoferrin increases the activity of dendritic cells (a type of immune cell) to help kill cancer cells. It is a form of human lactoferrin (a protein found in milk, tears, mucus, bile, and some white blood cells) that is made in the laboratory. Talactoferrin is a type of recombinant protein and a type of immunomodulatory protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talactoferrin Alfa","conceptCode":"C78460","definition":"An orally bioavailable recombinant human lactoferrin produced in the fungus Aspergillus niger with potential antineoplastic and immunomodulating activities. Upon oral administration, talactoferrin is transported into small intestinal Peyer's patches of the gut-associated lymphoreticular tissues (GALT), where it recruits circulating immature dendritic cells (DCs) bearing tumor antigens and induces their maturation. In the GALT, DC maturation in the presence of tumor antigens and lymphoid effector cells may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells; activation of tumor-draining lymph nodes, cellular infiltration of distant tumors, and tumor-cell death may follow. Raising the initial immune response in the GALT, distant from the primary tumor, may counter local tumor-mediated immunosuppression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D6AF-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D6C8-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TP-38","valueDescription":"TGFa-PE38 Immunotoxin","ValueMeaning":{"publicId":"3380201","version":"1","preferredName":"TGFa-PE38 Immunotoxin","longName":"3380201","preferredDefinition":"A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TGFa-PE38 Immunotoxin","conceptCode":"C29483","definition":"A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D6D5-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D6EE-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"TNP-470","valueDescription":"O-Chloroacetylcarbamoylfumagillol","ValueMeaning":{"publicId":"3380189","version":"1","preferredName":"O-Chloroacetylcarbamoylfumagillol","longName":"3380189","preferredDefinition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"O-Chloroacetylcarbamoylfumagillol","conceptCode":"C1298","definition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D5E6-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D702-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tacrolimus","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D70C-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D730-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Lopinavir","valueDescription":"Lopinavir","ValueMeaning":{"publicId":"2575688","version":"1","preferredName":"Lopinavir","longName":"2575688","preferredDefinition":"An anti-HIV protease inhibitor","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir","conceptCode":"C2095","definition":"A peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B2CD-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lovastatin","valueDescription":"Lovastatin","ValueMeaning":{"publicId":"3379209","version":"1","preferredName":"Lovastatin","longName":"3379209","preferredDefinition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering activity and potential antineoplastic activity. Lovastatin is hydrolyszed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the cholesterol biosynthesis.  In addition, this agent may inhibit tumor cell proliferation and reduce tumor cell invasiveness, thereby decreasing tumor metastatic potential; induce tumor cell apoptosis, possibly by inhibiting protein geranylgeranylation and; arrest cells in the G1 phase of the cell cycle, an effect that sensitizes tumor cells to the cytotoxic effects of ionizing radiation.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lovastatin","conceptCode":"C620","definition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2D7-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B2F0-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Lenalidomide (Revlimid)","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B918227F-B313-6EA7-E040-BB89AD434A76","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"ONEDATA","dateModified":"2012-02-16","deletedIndicator":"No"},{"value":"Temsirolimus","valueDescription":"Temsirolimus","ValueMeaning":{"publicId":"3380203","version":"1","preferredName":"Temsirolimus","longName":"3380203","preferredDefinition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temsirolimus","conceptCode":"C1844","definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D73C-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D755-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Testosterone","valueDescription":"Testosterone","ValueMeaning":{"publicId":"2579543","version":"1","preferredName":"Testosterone","longName":"2579543","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-03C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-06-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D75F-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tenofovir","valueDescription":"Tenofovir","ValueMeaning":{"publicId":"2575715","version":"1","preferredName":"Tenofovir","longName":"2575715","preferredDefinition":"A synthetic antiviral acyclic nucleotide analogue of adenosine 5-monophosphate.  Tenofovir is incorporated into human immunodeficiency viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT), an RNA-dependent DNA polymerase, and resulting in DNA chain termination and impairment of viral replication and propagation.  This agent prevents HIV from reproducing in uninfected cells only.  Tenofovir exhibits activity against the hepatitis B virus (HBV). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tenofovir","conceptCode":"C29490","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D76A-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tenofovir Disoproxil Fumarate","valueDescription":"Tenofovir Disoproxil Fumarate","ValueMeaning":{"publicId":"3380205","version":"1","preferredName":"Tenofovir Disoproxil Fumarate","longName":"3380205","preferredDefinition":"A pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tenofovir Disoproxil Fumarate","conceptCode":"C47747","definition":"A pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D777-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D790-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tetrahydrouridine","valueDescription":"Tetrahydrouridine","ValueMeaning":{"publicId":"3380207","version":"1","preferredName":"Tetrahydrouridine","longName":"3380207","preferredDefinition":"A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetrahydrouridine","conceptCode":"C868","definition":"A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D79D-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D7B6-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Thalidomide","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"3253641","version":"1","preferredName":"Thalidomide","longName":"3253641","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  Thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-79AE-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D7C0-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Thioguanine","valueDescription":"Thioguanine","ValueMeaning":{"publicId":"2744957","version":"1","preferredName":"Thioguanine","longName":"2744957","preferredDefinition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thioguanine","conceptCode":"C876","definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80FC-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97A755C-D7D4-40C9-E040-BB89AD4320DE","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"PEP-3-KLH (CDX-110)","valueDescription":"Rindopepimut","ValueMeaning":{"publicId":"3379398","version":"1","preferredName":"Rindopepimut","longName":"3379398","preferredDefinition":"A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with anti-EGFRvIII vaccine CDX-110 may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rindopepimut","conceptCode":"C69076","definition":"A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1DDF-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1DF8-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pentostatin/Rituximab","valueDescription":"Pentostatin/Rituximab","ValueMeaning":{"publicId":"3379400","version":"1","preferredName":"Pentostatin/Rituximab","longName":"3379400","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin/Rituximab","conceptCode":"C12074","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E05-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1E1E-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pentosan","valueDescription":"Pentosan Polysulfate Sodium","ValueMeaning":{"publicId":"3379402","version":"1","preferredName":"Pentosan Polysulfate Sodium","longName":"3379402","preferredDefinition":"The sodium salt of a semisynthetic heparin-like glucosaminoglycan.  Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentosan Polysulfate Sodium","conceptCode":"C946","definition":"The sodium salt of a semisynthetic heparin-like glucosaminoglycan.  Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. In addition, pentosan polysulfate may block endothelial P-selectin and increase microvascular blood flow in sickle cell disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E2B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1E44-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Peginterferon Alfa-2a","valueDescription":"Peginterferon Alfa-2a","ValueMeaning":{"publicId":"3379404","version":"1","preferredName":"Peginterferon Alfa-2a","longName":"3379404","preferredDefinition":"A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peginterferon Alfa-2a","conceptCode":"C33987","definition":"A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E51-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1E6A-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Peginterferon Alfa-2b","valueDescription":"Peginterferon Alfa-2b","ValueMeaning":{"publicId":"3379406","version":"1","preferredName":"Peginterferon Alfa-2b","longName":"3379406","preferredDefinition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peginterferon Alfa-2b","conceptCode":"C1845","definition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E77-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1E90-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pegamotecan","valueDescription":"pegamotecan","ValueMeaning":{"publicId":"3379408","version":"1","preferredName":"pegamotecan","longName":"3379408","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pegamotecan","conceptCode":"C0758797","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E9D-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1EB6-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Panzem (2-Methoxyestradiol )","valueDescription":"2-Methoxyestradiol","ValueMeaning":{"publicId":"3379409","version":"1","preferredName":"2-Methoxyestradiol","longName":"3379409","preferredDefinition":"An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"2-Methoxyestradiol","conceptCode":"C965","definition":"An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1EC0-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1ED9-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Paclitaxel Protein-Bound (Abraxane)","valueDescription":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","ValueMeaning":{"publicId":"3379411","version":"1","preferredName":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","longName":"3379411","preferredDefinition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nab-paclitaxel","conceptCode":"C2688","definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1EE6-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1EFF-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Paclitaxel (Taxol)","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1F13-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PUVA","valueDescription":"PUVA Photochemotherapy","ValueMeaning":{"publicId":"3379412","version":"1","preferredName":"PUVA Photochemotherapy","longName":"3379412v1.00","preferredDefinition":"Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PUVA Photochemotherapy","conceptCode":"C29973","definition":"Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1F1F-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1F38-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PTK-787/ZK-222584 (Vatalanib)","valueDescription":"Vatalanib","ValueMeaning":{"publicId":"3379414","version":"1","preferredName":"Vatalanib","longName":"3379414","preferredDefinition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vatalanib","conceptCode":"C1868","definition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1F45-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1F5E-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PSC/Vinblastine","valueDescription":"PSC 833/Vinblastine","ValueMeaning":{"publicId":"3379416","version":"1","preferredName":"PSC 833/Vinblastine","longName":"3379416","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSC 833/Vinblastine","conceptCode":"C10691","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1F6B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1F84-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PSC/Paclitaxel","valueDescription":"Paclitaxel/PSC 833 Treatment Regimen","ValueMeaning":{"publicId":"3379418","version":"1","preferredName":"Paclitaxel/PSC 833 Treatment Regimen","longName":"3379418","preferredDefinition":"No Value Exists: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel/PSC 833","conceptCode":"C10855","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1F92-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1FAB-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PSC 833","valueDescription":"Valspodar","ValueMeaning":{"publicId":"3379420","version":"1","preferredName":"Valspodar","longName":"3379420","preferredDefinition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valspodar","conceptCode":"C1405","definition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1FB8-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1FD1-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PSA Vaccine/GMCSF","valueDescription":"PSA RNA-Pulsed Dendritic Cell Vaccine Colony Stimulating Factor 2 Treatment Regimen","ValueMeaning":{"publicId":"3379422","version":"1","preferredName":"PSA RNA-Pulsed Dendritic Cell Vaccine Colony Stimulating Factor 2 Treatment Regimen","longName":"3379422","preferredDefinition":"An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.: An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSA RNA-Pulsed Dendritic Cell Vaccine","conceptCode":"C2236","definition":"An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C20545","definition":"Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1FE0-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-1FF9-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PMEA","valueDescription":"Adefovir","ValueMeaning":{"publicId":"3134027","version":"1","preferredName":"Adefovir","longName":"3134027","preferredDefinition":"An acyclic nucleotide adenine analogue of adenosine monophosphate and reverse transcriptase inhibitor with potent antiviral activity against hepatitis B virus (HBV). Adefovir is activated in vivo to a diphosphate metabolite by cellular kinases. In turn, adefovir diphosphate competes with the natural substrate deoxyadenosine triphosphate (dATP) for incorporation into viral DNA by competing with the natural substrate deoxyadenosine triphosphate (dATP), leading to viral RNA-dependent HBV DNA polymerase inhibition, DNA chain termination and impairment of viral replication.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adefovir","conceptCode":"C61526","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9873-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-200D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PIXY","valueDescription":"Milodistim","ValueMeaning":{"publicId":"3379424","version":"1","preferredName":"Milodistim","longName":"3379424","preferredDefinition":"A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Milodistim","conceptCode":"C1477","definition":"A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-201A-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2033-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PF-00299804","valueDescription":"Dacomitinib","ValueMeaning":{"publicId":"3379426","version":"1","preferredName":"Dacomitinib","longName":"3379426","preferredDefinition":"A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacomitinib","conceptCode":"C53398","definition":"A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2040-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2059-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PEG-L-asparaginase","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-207F-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PCLUS 6.1-18MN","valueDescription":"PCLUS 6.1-18MN","ValueMeaning":{"publicId":"3379430","version":"1","preferredName":"PCLUS 6.1-18MN","longName":"3379430","preferredDefinition":"A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PCLUS 6.1-18MN","conceptCode":"C2787","definition":"A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-208C-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-20A5-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PCLUS 3-18MN","valueDescription":"PCLUS 3-18MN","ValueMeaning":{"publicId":"3379432","version":"1","preferredName":"PCLUS 3-18MN","longName":"3379432","preferredDefinition":"A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PCLUS 3-18MN","conceptCode":"C2786","definition":"A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-20B2-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-20CB-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PCK3145","valueDescription":"PSP-94-Derived Peptide PCK3145","ValueMeaning":{"publicId":"3379434","version":"1","preferredName":"PSP-94-Derived Peptide PCK3145","longName":"3379434","preferredDefinition":"A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tigapotide","conceptCode":"C78474","definition":"A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-20D8-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-20F1-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PC-SPES","valueDescription":"PC-SPES","ValueMeaning":{"publicId":"3379436","version":"1","preferredName":"PC-SPES","longName":"3379436","preferredDefinition":"An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","conceptCode":"C1828","definition":"An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-20FE-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2117-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PBSCT, Autologous","valueDescription":"Autologous Peripheral Blood Stem Cell Transplantation","ValueMeaning":{"publicId":"3379437","version":"1","preferredName":"Autologous Peripheral Blood Stem Cell Transplantation","longName":"3379437","preferredDefinition":"(aw-TAHL-o-gus) Taken from an individual's own tissues, cells, or DNA.: Similar to bone marrow transplantation, peripheral stem cell transplantation is a method of replacing the blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells. Certain immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.  Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous","conceptCode":"C28000","definition":"Taken from an individual's own tissues, cells, or DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Peripheral Blood Stem Cell Transplantation","conceptCode":"C15430","definition":"A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2124-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-213D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PCV","valueDescription":"Lomustine/Procarbazine/Vincristine","ValueMeaning":{"publicId":"3379439","version":"1","preferredName":"Lomustine/Procarbazine/Vincristine","longName":"3379439","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine/Procarbazine/Vincristine","conceptCode":"C9627","definition":"A combination of agents containing lomustine, procarbazine and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-214A-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2163-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Panretin","valueDescription":"Alitretinoin","ValueMeaning":{"publicId":"3378153","version":"1","preferredName":"Alitretinoin","longName":"3378153","preferredDefinition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alitretinoin","conceptCode":"C1574","definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C8E-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2177-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Panitumumab (ABX-EGF)","valueDescription":"Panitumumab","ValueMeaning":{"publicId":"3379440","version":"1","preferredName":"Panitumumab","longName":"3379440","preferredDefinition":"A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panitumumab","conceptCode":"C1857","definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2183-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-219C-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PANVAC-V/PANVAC-F/GM-CSF","valueDescription":"Falimarev Inalimarev Recombinant Granulocyte-Macrophage Colony-Stimulating Factor Treatment Regimen","ValueMeaning":{"publicId":"3379443","version":"1","preferredName":"Falimarev Inalimarev Recombinant Granulocyte-Macrophage Colony-Stimulating Factor Treatment Regimen","longName":"3379443","preferredDefinition":"A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.: A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.: Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Falimarev","conceptCode":"C29316","definition":"A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Inalimarev","conceptCode":"C29317","definition":"A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C1288","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-21AD-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-21C6-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PS-341","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"2738485","version":"1","preferredName":"Bortezomib","longName":"2738485","preferredDefinition":"A modified dipeptidyl boronic acid with antineoplastic activity. Via boronic acid moiety, bortezomib reversibly binds to the 26S proteasome, where degradation of ubiquinated proteins occurs. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis.  Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F951-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-21DA-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PALA","valueDescription":"Sparfosic Acid","ValueMeaning":{"publicId":"3379445","version":"1","preferredName":"Sparfosic Acid","longName":"3379445","preferredDefinition":"A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sparfosic Acid","conceptCode":"C1398","definition":"A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-21E7-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2200-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PACE BOM","valueDescription":"Prednisolone Doxorubicin Cyclophosphamide Etoposide Bleomycin Vincristine Methotrexate Treatment Regimen","ValueMeaning":{"publicId":"3379446","version":"1","preferredName":"Prednisolone Doxorubicin Cyclophosphamide Etoposide Bleomycin Vincristine Methotrexate Treatment Regimen","longName":"3379446","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals w","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2213-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-222C-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"P6 Regimen","valueDescription":"Radiation Therapy Thiotepa Carboplatin Autologous Stem Cell Rescue Treatment Regimen","ValueMeaning":{"publicId":"3379447","version":"1","preferredName":"Radiation Therapy Thiotepa Carboplatin Autologous Stem Cell Rescue Treatment Regimen","longName":"3379447","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04): A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A type of autologous hematopoietic stem cell\r\ntransplantation designed to promote recovery if a prior hematopoietic stem cell transplantation fails or is not adequate.\r\n: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Autologous Stem Cell Rescue","conceptCode":"C82054","definition":"A type of autologous hematopoietic stem cell transplantation designed to promote recovery if a prior hematopoietic stem cell transplantation fails or is not adequate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-223C-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2255-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"P-32","valueDescription":"Phosphorus P-32","ValueMeaning":{"publicId":"3379449","version":"1","preferredName":"Phosphorus P-32","longName":"3379449","preferredDefinition":"A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phosphorus P-32","conceptCode":"C1698","definition":"A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2262-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-227B-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"OSI 774 (Tarceva)","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3379450","version":"1","preferredName":"Erlotinib","longName":"3379450","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib Hydrochloride","conceptCode":"C2693","definition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2285-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-229D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Nutritional supplement","valueDescription":"Supplements","ValueMeaning":{"publicId":"3335130","version":"1","preferredName":"Supplements/Vitamins","longName":"3335130v1.00","preferredDefinition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites._Used to indicate that either or both of two items or options may be valid._A group of organic food substances found in animals and plants in small quantities. They must be supplied in diet or dietary supplement and are essential for normal metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dietary Supplement","conceptCode":"C1505","definition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vitamin","conceptCode":"C944","definition":"A group of organic food substances found in animals and plants in small quantities. They must be supplied in diet or dietary supplement and are essential for normal metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC63-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-22B2-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Nitrocamptothecin","valueDescription":"Rubitecan","ValueMeaning":{"publicId":"3379452","version":"1","preferredName":"Rubitecan","longName":"3379452","preferredDefinition":"A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rubitecan","conceptCode":"C1485","definition":"A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-22BF-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-22D8-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"MoAB","valueDescription":"Monoclonal Antibody","ValueMeaning":{"publicId":"2829937","version":"1","preferredName":"Monoclonal Antibody","longName":"2829937","preferredDefinition":"An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"618DC679-B100-32DD-E040-BB89AD43461A","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-22EC-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Mitoxantrone/Prednisone","valueDescription":"Mitoxantrone Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3379453","version":"1","preferredName":"Mitoxantrone Prednisone Treatment Regimen","longName":"3379453","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.: A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-22FA-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2313-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Mini-BEAM","valueDescription":"Carmustine/Cytarabine/Etoposide/Melphalan","ValueMeaning":{"publicId":"3377446","version":"1","preferredName":"Carmustine/Cytarabine/Etoposide/Melphalan","longName":"3377446","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine/Cytarabine/Etoposide/Melphalan","conceptCode":"C11103","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1D0B-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2327-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Panobinostat","valueDescription":"Panobinostat","ValueMeaning":{"publicId":"3379455","version":"1","preferredName":"Panobinostat","longName":"3379455","preferredDefinition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panobinostat","conceptCode":"C66948","definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2334-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-234D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Clarithromycin","valueDescription":"Clarithromycin","ValueMeaning":{"publicId":"2577826","version":"1","preferredName":"Clarithromycin","longName":"2577826","preferredDefinition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clarithromycin","conceptCode":"C1054","definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B35A9198-AEDF-CBB0-E040-BB89AD435648","beginDate":"2011-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-05","modifiedBy":"ONEDATA","dateModified":"2011-12-05","deletedIndicator":"No"},{"value":"Rifabutin","valueDescription":"Rifabutin","ValueMeaning":{"publicId":"2575707","version":"1","preferredName":"Rifabutin","longName":"2575707","preferredDefinition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifabutin","conceptCode":"C1408","definition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B35A9198-AEE9-CBB0-E040-BB89AD435648","beginDate":"2011-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-05","modifiedBy":"ONEDATA","dateModified":"2011-12-05","deletedIndicator":"No"},{"value":"Amikacin","valueDescription":"Amikacin","ValueMeaning":{"publicId":"2575651","version":"1","preferredName":"Amikacin","longName":"2575651","preferredDefinition":"A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and , misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amikacin","conceptCode":"C61615","definition":"A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F490-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B35A9198-AEF3-CBB0-E040-BB89AD435648","beginDate":"2011-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-05","modifiedBy":"ONEDATA","dateModified":"2011-12-05","deletedIndicator":"No"},{"value":"Ciprofloxacin","valueDescription":"Ciprofloxacin","ValueMeaning":{"publicId":"2577817","version":"1","preferredName":"Ciprofloxacin","longName":"2577817","preferredDefinition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciprofloxacin","conceptCode":"C375","definition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD06-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B35A9198-AEFD-CBB0-E040-BB89AD435648","beginDate":"2011-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-05","modifiedBy":"ONEDATA","dateModified":"2011-12-05","deletedIndicator":"No"},{"value":"Pamidronate Disodium","valueDescription":"Pamidronate Disodium","ValueMeaning":{"publicId":"2576642","version":"1","preferredName":"Pamidronate Disodium","longName":"2576642","preferredDefinition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronate Disodium","conceptCode":"C1345","definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2357-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PNU-214565","valueDescription":"PNU-214565","ValueMeaning":{"publicId":"3379457","version":"1","preferredName":"PNU-214565","longName":"3379457","preferredDefinition":"A recombinant fusion protein of the bacterial superantigen Staphylococcal enterotoxin A (SEA) and the variable Fab fragment of the C242 monoclonal antibody. Upon administering PNU-214565, the Fab fragment binds to Lewis antigen, a glycoprotein overexpressed in human colon and pancreatic carcinoma cell surfaces, thereby directing PNU-214565 to the tumor target area and providing tumor specificity. Superantigen staphylococcal enterotoxin A (SEA) promotes the crosslinking of T-cell receptor (TCR) Vb regions with major histocompatibility complex (MHC) class II molecules on antigen presenting cells, thereby enhancing cytotoxic T-lymphocyte activation, cytokine production and tumor cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nacolomab Tafenatox","conceptCode":"C29328","definition":"A recombinant fusion protein of the bacterial superantigen Staphylococcal enterotoxin A (SEA) and the variable Fab fragment of the C242 monoclonal antibody. Upon administering nacolomab tafenatox, the Fab fragment binds to Lewis antigen, a glycoprotein overexpressed in human colon and pancreatic carcinoma cell surfaces, thereby directing PNU-214565 to the tumor target area and providing tumor specificity. Superantigen staphylococcal enterotoxin A (SEA) promotes the crosslinking of T-cell receptor (TCR) Vb regions with major histocompatibility complex (MHC) class II molecules on antigen presenting cells, thereby enhancing cytotoxic T-lymphocyte activation, cytokine production and tumor cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2364-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-237D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pazopanib","valueDescription":"Pazopanib","ValueMeaning":{"publicId":"3107591","version":"1","preferredName":"Pazopanib","longName":"3107591v1.00","preferredDefinition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-1138-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2387-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pegfilgrastim","valueDescription":"Pegfilgrastim","ValueMeaning":{"publicId":"2775105","version":"1","preferredName":"Pegfilgrastim","longName":"2775105","preferredDefinition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegfilgrastim","conceptCode":"C1854","definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D3AA38-DF52-52EA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-239B-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pemetrexed","valueDescription":"Pemetrexed","ValueMeaning":{"publicId":"3237462","version":"1","preferredName":"Pemetrexed","longName":"3237462","preferredDefinition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6570-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-23A5-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pentoxifylline","valueDescription":"Pentoxifylline","ValueMeaning":{"publicId":"3379459","version":"1","preferredName":"Pentoxifylline","longName":"3379459","preferredDefinition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentoxifylline","conceptCode":"C733","definition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-23B2-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-23CB-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Paclitaxel/Doxorubicin","valueDescription":"Doxorubicin/Paclitaxel","ValueMeaning":{"publicId":"3379461","version":"1","preferredName":"Doxorubicin/Paclitaxel","longName":"3379461","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin/Paclitaxel","conceptCode":"C10476","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-23D8-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-23F1-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Paclitaxel/Cyclophosphamide","valueDescription":"Cyclophosphamide/Paclitaxel","ValueMeaning":{"publicId":"3379463","version":"1","preferredName":"Cyclophosphamide/Paclitaxel","longName":"3379463","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Paclitaxel","conceptCode":"C10655","definition":"A combination of agents containing cyclophosphamide and paclitaxel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-23FE-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2417-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Paclitaxel/Vinorelbine Tartrate","valueDescription":"Paclitaxel/Vinorelbine","ValueMeaning":{"publicId":"3379465","version":"1","preferredName":"Paclitaxel/Vinorelbine","longName":"3379465","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel/Vinorelbine","conceptCode":"C11115","definition":"A combination of agents containing paclitaxel and vinorelbine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2424-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-243D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Perifosine","valueDescription":"Perifosine","ValueMeaning":{"publicId":"3379467","version":"1","preferredName":"Perifosine","longName":"3379467","preferredDefinition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perifosine","conceptCode":"C1727","definition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-244B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2464-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Peripheral Blood Stem Cell Transplantation","valueDescription":"Peripheral Blood Stem Cell Transplantation","ValueMeaning":{"publicId":"3379468","version":"1","preferredName":"Peripheral Blood Stem Cell Transplantation","longName":"3379468","preferredDefinition":"Similar to bone marrow transplantation, peripheral stem cell transplantation is a method of replacing the blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells. Certain immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.  Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Blood Stem Cell Transplantation","conceptCode":"C15430","definition":"A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2470-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2489-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pertuzumab","valueDescription":"Pertuzumab","ValueMeaning":{"publicId":"3378887","version":"1","preferredName":"Pertuzumab","longName":"3378887","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pertuzumab","conceptCode":"C38692","definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-405F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-249D-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Petrolatum Hydrophilic","valueDescription":"Petrolatum Hydrophilic","ValueMeaning":{"publicId":"3379470","version":"1","preferredName":"Petrolatum Hydrophilic","longName":"3379470","preferredDefinition":"A non-polar semi-solid mixture of hydrocarbons that is derived from petroleum. This agent has application as a lubricant, emollient, and a carrier for other agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Petrolatum Hydrophilic","conceptCode":"C29356","definition":"A non-polar semi-solid mixture of hydrocarbons that is derived from petroleum. This agent has application as a lubricant, emollient, and a carrier for other agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-24AA-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Adding current NCIt definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-24C3-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pheniramine Maleate","valueDescription":"Pheniramine Maleate","ValueMeaning":{"publicId":"3379472","version":"1","preferredName":"Pheniramine Maleate","longName":"3379472","preferredDefinition":"The maleate salt form of pheniramine, an alkylamine derivative with antihistaminic and vasodilatory properties. Pheniramine maleate binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP (cGMP) levels, thereby inhibiting constriction of smooth muscle tissue, and decreased capillary permeability and histamine-activated allergic reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pheniramine Maleate","conceptCode":"C29358","definition":"The maleate salt form of pheniramine, an alkylamine derivative with antihistaminic and vasodilatory properties. Pheniramine maleate binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP (cGMP) levels, thereby inhibiting constriction of smooth muscle tissue, and decreased capillary permeability and histamine-activated allergic reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-24D0-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-24E9-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Phenoxodiol","valueDescription":"Idronoxil","ValueMeaning":{"publicId":"3379474","version":"1","preferredName":"Idronoxil","longName":"3379474","preferredDefinition":"A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idronoxil","conceptCode":"C2642","definition":"A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-24F6-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-250F-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Phenylacetate","valueDescription":"Phenylacetate","ValueMeaning":{"publicId":"3379476","version":"1","preferredName":"Phenylacetate","longName":"3379476","preferredDefinition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenyl Acetate","conceptCode":"C1501","definition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-251C-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2535-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Phenylbutyrate","valueDescription":"Sodium Phenylbutyrate","ValueMeaning":{"publicId":"3379478","version":"1","preferredName":"Sodium Phenylbutyrate","longName":"3379478","preferredDefinition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Phenylbutyrate","conceptCode":"C1440","definition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2542-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-255B-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pirfenidone","valueDescription":"Pirfenidone","ValueMeaning":{"publicId":"3379480","version":"1","preferredName":"Pirfenidone","longName":"3379480","preferredDefinition":"An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pirfenidone","conceptCode":"C2635","definition":"An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2568-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2581-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Piritrexim","valueDescription":"Piritrexim","ValueMeaning":{"publicId":"3379482","version":"1","preferredName":"Piritrexim","longName":"3379482","preferredDefinition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piritrexim","conceptCode":"C1031","definition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-258E-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-25A7-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Piroxicam","valueDescription":"Piroxicam","ValueMeaning":{"publicId":"3379484","version":"1","preferredName":"Piroxicam","longName":"3379484","preferredDefinition":"A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piroxicam","conceptCode":"C751","definition":"A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-25B4-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-25CD-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Plicamycin","valueDescription":"Plicamycin","ValueMeaning":{"publicId":"3379486","version":"1","preferredName":"Plicamycin","longName":"3379486","preferredDefinition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plicamycin","conceptCode":"C658","definition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-25DA-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-25F3-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Poly ICLC","valueDescription":"Poly ICLC","ValueMeaning":{"publicId":"3379488","version":"1","preferredName":"Poly ICLC","longName":"3379488","preferredDefinition":"A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Poly ICLC","conceptCode":"C1198","definition":"A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2600-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2619-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pralatrexate","valueDescription":"10-Propargyl-10-Deazaaminopterin","ValueMeaning":{"publicId":"3379489","version":"1","preferredName":"10-Propargyl-10-Deazaaminopterin","longName":"3379489","preferredDefinition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pralatrexate","conceptCode":"C2250","definition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2623-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-263C-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Pravastatin","valueDescription":"Pravastatin","ValueMeaning":{"publicId":"3379491","version":"1","preferredName":"Pravastatin","longName":"3379491","preferredDefinition":"A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pravastatin","conceptCode":"C62070","definition":"A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-264A-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2663-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"PACE (Cyclophosphamide/Doxorubicin/Etoposide/Prednisone)","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","ValueMeaning":{"publicId":"3379493","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","longName":"3379493","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Doxorubicin/Etoposide/Prednisone","conceptCode":"C10861","definition":"A combination of agents containing cyclophosphamide, doxorubicin, etoposide and prednisone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2670-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2689-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2693-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Prednisone/Etoposide","valueDescription":"Etoposide/Prednisone","ValueMeaning":{"publicId":"3379495","version":"1","preferredName":"Etoposide/Prednisone","longName":"3379495","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Prednisone","conceptCode":"C29376","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26A0-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-26B9-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"ProMACE","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone","ValueMeaning":{"publicId":"3379497","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone","longName":"3379497","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Regimen","conceptCode":"C9771","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26C6-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-26DF-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":"Procarbazine","ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-2702-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Psoralen","valueDescription":"Psoralen","ValueMeaning":{"publicId":"3293804","version":"1","preferredName":"Psoralen","longName":"3293804","preferredDefinition":"A furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division.  Psoralen is used in Photochemotherapy or PUVA (Psoralen with high-intensity long-wavelength UVA irradiation). (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoralen","conceptCode":"C2586","definition":"A furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division. Psoralen is used in Photochemotherapy with high-intensity long-wavelength UVA irradiation. Psoralens are tricyclic furocumarins and have a strong tendency to intercalate with DNA base pairs. Irradiation of nucleic acids in the presence of psoralen with long wave UV (~360 nm) results in the 2+2 cyclo- addition of either of its two photoreactive sites with 5,6-carbon bonds of pyrimidines resulting in crosslinking double-stranded nucleic acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D831-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9293EA5-270C-3D6D-E040-BB89AD4348A8","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoids","valueDescription":"Retinoid","ValueMeaning":{"publicId":"3379512","version":"1","preferredName":"Retinoid","longName":"3379512","preferredDefinition":"Class of compounds consisting of four isoprenoid units joined in a head-to-tail manner and customarily containing five conjugated double bonds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoid","conceptCode":"C68299","definition":"Class of compounds consisting of four isoprenoid units joined in a head-to-tail manner and customarily containing five conjugated double bonds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-314F-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3168-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoic acid, trans-","valueDescription":"ATRA","ValueMeaning":{"publicId":"2764385","version":"1","preferredName":"ATRA","longName":"2764385","preferredDefinition":"A naturally-occurring acid of retinol.  Vitamin A acid binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some cancer cell types.  The oral form of vitamin A acid has teratogenic and embryotoxic properties.(NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"519B9CC5-5DF0-3C2A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-317C-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoic acid, cis-","valueDescription":"Retinoic Acid Binding","ValueMeaning":{"publicId":"3379514","version":"1","preferredName":"Retinoic Acid Binding","longName":"3379514","preferredDefinition":"Retinoic Acid Binding consists of a biophysical interaction between retinoic acid (ligand) and a biological molecule, such as specific steroid receptor-like transcriptional regulator proteins containing an N-terminal modulating domain, a DNA-binding domain, and a C-terminal ligand-binding domain. The ligand-activated receptor complexes selectively bind as homodimers or heterodimers (with other steroid family receptors) to DNA response elements in target gene promoters, enhance transcriptional activity with coactivators, and mediate tissue growth and differentiation in embryogenesis, organogenesis, limb development, bone growth, and maintenance of normal epithelia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoic Acid Binding","conceptCode":"C26052","definition":"Retinoic Acid Binding consists of a biophysical interaction between retinoic acid (ligand) and a biological molecule, such as specific steroid receptor-like transcriptional regulator proteins containing an N-terminal modulating domain, a DNA-binding domain, and a C-terminal ligand-binding domain. The ligand-activated receptor complexes selectively bind as homodimers or heterodimers (with other steroid family receptors) to DNA response elements in target gene promoters, enhance transcriptional activity with coactivators, and mediate tissue growth and differentiation in embryogenesis, organogenesis, limb development, bone growth, and maintenance of normal epithelia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3189-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-31A2-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoic acid, 13-cis","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-31B6-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoic acid, 9-cis","valueDescription":"Alitretinoin","ValueMeaning":{"publicId":"3378153","version":"1","preferredName":"Alitretinoin","longName":"3378153","preferredDefinition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alitretinoin","conceptCode":"C1574","definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C8E-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-31CA-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Vaccinia-CEA","valueDescription":"Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine","ValueMeaning":{"publicId":"3379516","version":"1","preferredName":"Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine","longName":"3379516","preferredDefinition":"A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine","conceptCode":"C2619","definition":"A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-31D7-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-31F0-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Vaccinia-PSA","valueDescription":"Recombinant Vaccinia PSA Vaccine","ValueMeaning":{"publicId":"3379518","version":"1","preferredName":"Recombinant Vaccinia PSA Vaccine","longName":"3379518","preferredDefinition":"A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Vaccinia PSA Vaccine","conceptCode":"C2433","definition":"A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-31FD-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3216-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Vaccinia-B7.1","valueDescription":"Recombinant Vaccinia-B7.1 Vaccine","ValueMeaning":{"publicId":"3379520","version":"1","preferredName":"Recombinant Vaccinia-B7.1 Vaccine","longName":"3379520","preferredDefinition":"A recombinant vaccinia virus encoding the T-cell co-stimulatory molecule B7-1. Co-administration of recombinant vaccinia-B7.1 and a tumor-associated antigen vaccine may enhance tumor-associated antigen-specific T-cell responses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Vaccinia-B7.1 Vaccine","conceptCode":"C2237","definition":"A recombinant vaccinia virus encoding the T-cell co-stimulatory molecule B7-1. Co-administration of recombinant vaccinia-B7.1 and a tumor-associated antigen vaccine may enhance tumor-associated antigen-specific T-cell responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3223-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-323C-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Raloxifene HCl","valueDescription":"Raloxifene Hydrochloride","ValueMeaning":{"publicId":"3379522","version":"1","preferredName":"Raloxifene Hydrochloride","longName":"3379522","preferredDefinition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene Hydrochloride","conceptCode":"C1762","definition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3249-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3262-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Ras","valueDescription":"RAS Family Oncogene","ValueMeaning":{"publicId":"3379524","version":"1","preferredName":"RAS Family Oncogene","longName":"3379524","preferredDefinition":"Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein. Critically involved in cell activation and replication in many cell types, and disruption of its regulation can lead to uncontrolled growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RAS Family Oncogene","conceptCode":"C17061","definition":"A family of oncogenes that are highly homologous with the retrovirus-associated DNA sequences (ras) originally isolated from Harvey and Kirsten murine sarcoma viruses. Mutated or overexpressed forms of the human ras genes are associated with constitutive ras GTPase activity, increased cellular proliferation, and cell transformation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-326F-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3288-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"RAD001 (Everolimus)","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-32AD-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"R1507","valueDescription":"Anti-IGF-1R Monoclonal Antibody R1507","ValueMeaning":{"publicId":"3379527","version":"1","preferredName":"Anti-IGF-1R Monoclonal Antibody R1507","longName":"3379527","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R human monoclonal antibody R1507 binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teprotumumab","conceptCode":"C71697","definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R human monoclonal antibody R1507 binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-32BA-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-32D3-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"R115777","valueDescription":"Tipifarnib","ValueMeaning":{"publicId":"3379529","version":"1","preferredName":"Tipifarnib","longName":"3379529","preferredDefinition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tipifarnib","conceptCode":"C1703","definition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-32E0-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-32F9-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"R/ICE","valueDescription":"Rituximab ICE Regimen Treatment Regimen","ValueMeaning":{"publicId":"3379530","version":"1","preferredName":"Rituximab ICE Regimen Treatment Regimen","longName":"3379530","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3307-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3320-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"R-Verapamil","valueDescription":"Verapamil","ValueMeaning":{"publicId":"3128735","version":"1","preferredName":"Verapamil","longName":"3128735","preferredDefinition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verapamil","conceptCode":"C928","definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1DCB-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3334-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"R-Verap/EPOCH","valueDescription":"Verapamil EPOCH Regimen Treatment Regimen","ValueMeaning":{"publicId":"3379531","version":"1","preferredName":"Verapamil EPOCH Regimen Treatment Regimen","longName":"3379531","preferredDefinition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04): A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verapamil","conceptCode":"C928","definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3342-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-335B-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"ProMACE/MOPP","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone MOPP Regimen Treatment Regimen","ValueMeaning":{"publicId":"3379532","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone MOPP Regimen Treatment Regimen","longName":"3379532v1.00","preferredDefinition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL)._A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Regimen","conceptCode":"C9771","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"MOPP Regimen","conceptCode":"C9619","definition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3369-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3382-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"ProMACE/Cytabom","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone Bleomycin/Cytarabine/Methotrexate/Vincristine Treatment Regimen","ValueMeaning":{"publicId":"3379534","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone Bleomycin/Cytarabine/Methotrexate/Vincristine Treatment Regimen","longName":"3379534v1.00","preferredDefinition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL)._A chemotherapy regimen consisting of cytarabine, bleomycin, methotrexate, and vincristine for the treatment of non-Hodgkin lymphoma (NHL)._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Regimen","conceptCode":"C9771","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"CytaBOM Regimen","conceptCode":"C10007","definition":"A chemotherapy regimen consisting of cytarabine, bleomycin, methotrexate, and vincristine for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3391-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-33AA-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"ProMACE/Cyclophosphamide","valueDescription":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone Cyclophosphamide Treatment Regimen","ValueMeaning":{"publicId":"3379535","version":"1","preferredName":"Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone Cyclophosphamide Treatment Regimen","longName":"3379535v1.00","preferredDefinition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL)._A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Regimen","conceptCode":"C9771","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-33B8-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-33D1-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Rebeccamycin","valueDescription":"Rebeccamycin","ValueMeaning":{"publicId":"3379537","version":"1","preferredName":"Rebeccamycin","longName":"3379537","preferredDefinition":"An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rebeccamycin","conceptCode":"C1213","definition":"An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-33DE-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-33F7-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Fowlpox-PSA","valueDescription":"Recombinant Fowlpox-Prostate Specific Antigen Vaccine","ValueMeaning":{"publicId":"3379539","version":"1","preferredName":"Recombinant Fowlpox-Prostate Specific Antigen Vaccine","longName":"3379539","preferredDefinition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Fowlpox-Prostate Specific Antigen Vaccine","conceptCode":"C2675","definition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3404-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-341D-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Fowlpox-GM-CSF","valueDescription":"Recombinant Fowlpox GM-CSF Vaccine Adjuvant","ValueMeaning":{"publicId":"3379541","version":"1","preferredName":"Recombinant Fowlpox GM-CSF Vaccine Adjuvant","longName":"3379541","preferredDefinition":"A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Fowlpox GM-CSF Vaccine Adjuvant","conceptCode":"C2686","definition":"A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-342A-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3443-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Recombinant Fowlpox-CEA","valueDescription":"Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine","ValueMeaning":{"publicId":"3379543","version":"1","preferredName":"Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine","longName":"3379543","preferredDefinition":"A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine","conceptCode":"C2620","definition":"A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3450-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3469-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Retinoic Acid","valueDescription":"Retinoic Acid","ValueMeaning":{"publicId":"3379545","version":"1","preferredName":"Retinoic Acid","longName":"3379545","preferredDefinition":"Retinoid with a carboxylic acid group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoic Acid","conceptCode":"C68301","definition":"Retinoid with a carboxylic acid group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3476-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-348F-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Ritonavir","valueDescription":"Ritonavir","ValueMeaning":{"publicId":"2575709","version":"1","preferredName":"Ritonavir","longName":"2575709","preferredDefinition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ritonavir","conceptCode":"C1609","definition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3499-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-34A3-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Saquinavir","valueDescription":"Saquinavir","ValueMeaning":{"publicId":"3379546","version":"1","preferredName":"Saquinavir","longName":"3379546","preferredDefinition":"A synthetic antiviral agent.  Saquinavir, a peptide-like substrate, selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saquinavir","conceptCode":"C29444","definition":"A peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-34AD-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-34C6-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Satraplatin","valueDescription":"Satraplatin","ValueMeaning":{"publicId":"3379548","version":"1","preferredName":"Satraplatin","longName":"3379548","preferredDefinition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Satraplatin","conceptCode":"C1493","definition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-34D3-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-34EC-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"2760061","version":"1","preferredName":"Sirolimus","longName":"2760061","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE455C3-3ABF-5319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-34F6-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"STI571","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-370F-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"SKI-606","valueDescription":"Bosutinib","ValueMeaning":{"publicId":"3379565","version":"1","preferredName":"Bosutinib","longName":"3379565","preferredDefinition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bosutinib","conceptCode":"C60809","definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-371C-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3735-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"SCAB","valueDescription":"Bleomycin/Doxorubicin/Lomustine/Streptozocin","ValueMeaning":{"publicId":"3379567","version":"1","preferredName":"Bleomycin/Doxorubicin/Lomustine/Streptozocin","longName":"3379567","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SCAB Regimen","conceptCode":"C9637","definition":"A chemotherapy regimen consisting of streptozocin, lomustine, doxorubicin, and bleomycin that may be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3742-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-375B-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Ricin Conjugate Murine MCA","valueDescription":"Murine MCA Ricin Conjugate","ValueMeaning":{"publicId":"3379569","version":"1","preferredName":"Murine MCA Ricin Conjugate","longName":"3379569","preferredDefinition":"An immunotoxin consisting of a murine monoclonal antibody (MCA) conjugated to the toxin ricin. The monoclonal antibody component binds to cell surface antigens, thereby targeting delivery of cytotoxic ricin to a specific cell type. The ricin component binds to cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Murine MCA Ricin Conjugate","conceptCode":"C29415","definition":"An immunotoxin consisting of a murine monoclonal antibody (MCA) conjugated to the toxin ricin. The monoclonal antibody component binds to cell surface antigens, thereby targeting delivery of cytotoxic ricin to a specific cell type. The ricin component binds to cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3768-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3781-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Samarium","valueDescription":"Samarium","ValueMeaning":{"publicId":"3379571","version":"1","preferredName":"Samarium","longName":"3379571","preferredDefinition":"Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Samarium","conceptCode":"C0036147","definition":"Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-378E-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-37A7-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Somatuline","valueDescription":"Lanreotide","ValueMeaning":{"publicId":"3379573","version":"1","preferredName":"Lanreotide","longName":"3379573","preferredDefinition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lanreotide","conceptCode":"C1523","definition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-37B4-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-37CD-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"UCN-01","valueDescription":"7-Hydroxystaurosporine","ValueMeaning":{"publicId":"3380221","version":"1","preferredName":"7-Hydroxystaurosporine","longName":"3380221","preferredDefinition":"A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"7-Hydroxystaurosporine","conceptCode":"C1271","definition":"A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-14F4-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-150D-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Triptorelin","valueDescription":"Triptorelin","ValueMeaning":{"publicId":"3380222","version":"1","preferredName":"Triptorelin","longName":"3380222","preferredDefinition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1517-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-1530-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Trimetrexate Glucuronate","valueDescription":"Trimetrexate Glucuronate","ValueMeaning":{"publicId":"3380224","version":"1","preferredName":"Trimetrexate Glucuronate","longName":"3380224","preferredDefinition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimetrexate Glucuronate","conceptCode":"C1265","definition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-153D-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-1556-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Trastuzumab/Gemcitabine","valueDescription":"Gemcitabine/Trastuzumab","ValueMeaning":{"publicId":"3380226","version":"1","preferredName":"Gemcitabine/Trastuzumab","longName":"3380226","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine/Trastuzumab Regimen","conceptCode":"C37808","definition":"A regimen consisting of gemcitabine and trastuzumab that may be used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1563-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-157C-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Trastuzumab/Vinorelbine","valueDescription":"Trastuzumab/Vinorelbine","ValueMeaning":{"publicId":"3380228","version":"1","preferredName":"Trastuzumab/Vinorelbine","longName":"3380228","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab/Vinorelbine","conceptCode":"C11959","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1589-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-15A2-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Trastuzumab","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-15AC-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tramadol","valueDescription":"Tramadol","ValueMeaning":{"publicId":"3380229","version":"1","preferredName":"Tramadol","longName":"3380229","preferredDefinition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tramadol","conceptCode":"C29507","definition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15B8-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-15D1-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Trabectedin","valueDescription":"Trabectedin","ValueMeaning":{"publicId":"3380231","version":"1","preferredName":"Trabectedin","longName":"3380231","preferredDefinition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trabectedin","conceptCode":"C1691","definition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15DE-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Yondelis as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-15F7-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Tositumomab","valueDescription":"Tositumomab","ValueMeaning":{"publicId":"2741550","version":"1","preferredName":"Tositumomab","longName":"2741550","preferredDefinition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tositumomab","conceptCode":"C2543","definition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-4641-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-160B-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Toremifene","valueDescription":"Toremifene","ValueMeaning":{"publicId":"3145844","version":"1","preferredName":"Toremifene","longName":"3145844","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene","conceptCode":"C1256","definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A3E3-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-1615-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Topotecan/Vinorelbine Tartrate","valueDescription":"Topotecan Vinorelbine Tartrate Treatment Regimen","ValueMeaning":{"publicId":"3380232","version":"1","preferredName":"Topotecan Vinorelbine Tartrate Treatment Regimen","longName":"3380232","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.: The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinorelbine Tartrate","conceptCode":"C1395","definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1623-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-163C-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Topotecan","valueDescription":"Topotecan","ValueMeaning":{"publicId":"3380233","version":"1","preferredName":"Topotecan","longName":"3380233","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1648-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-1661-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"Topical Corticosteroids","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"2563882","version":"1","preferredName":"Corticosteroid","longName":"2563882v1.00","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C697-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B97B8401-1675-113F-E040-BB89AD431AAC","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"ONEDATA","dateModified":"2012-02-21","deletedIndicator":"No"},{"value":"STAMP V","valueDescription":"Carmustine/Cisplatin/Cyclophosphamide","ValueMeaning":{"publicId":"3379575","version":"1","preferredName":"Carmustine/Cisplatin/Cyclophosphamide","longName":"3379575","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CBP Regimen","conceptCode":"C9783","definition":"A chemotherapy regimen consisting of carmustine, cyclophosphamide, and cisplatin that may be used in the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-37DA-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-37F3-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Campath","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9F90292-DEF8-0332-E040-BB89AD437624","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-27","modifiedBy":"ONEDATA","dateModified":"2012-02-27","deletedIndicator":"No"},{"value":"Suramin/Somatuline","valueDescription":"Suramin Lanreotide Treatment Regimen","ValueMeaning":{"publicId":"3380184","version":"1","preferredName":"Suramin Lanreotide Treatment Regimen","longName":"3380184","preferredDefinition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04): A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Suramin","conceptCode":"C853","definition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lanreotide","conceptCode":"C1523","definition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D576-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9F90292-DF0C-0332-E040-BB89AD437624","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-27","modifiedBy":"ONEDATA","dateModified":"2012-02-27","deletedIndicator":"No"},{"value":"Crizotinib","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B89EC9E2-4A0E-54C4-E040-BB89AD432648","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"ONEDATA","dateModified":"2012-02-10","deletedIndicator":"No"},{"value":"5FU/Leucovorin/Irinotecan","valueDescription":"Fluorouracil/Irinotecan/Leucovorin Calcium","ValueMeaning":{"publicId":"3378078","version":"1","preferredName":"Fluorouracil/Irinotecan/Leucovorin Calcium","longName":"3378078","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil/Irinotecan/Leucovorin Calcium","conceptCode":"C10836","definition":"A combination of agents containing fluorouracil, irinotecan and leucovorin calcium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-3484-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-349D-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Leucovorin/Levamasole","valueDescription":"Fluorouracil/Leucovorin Calcium/Levamasole","ValueMeaning":{"publicId":"3378080","version":"1","preferredName":"Fluorouracil/Leucovorin Calcium/Levamasole","longName":"3378080","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil/Leucovorin Calcium/Levamisole","conceptCode":"C9813","definition":"A combination of agents containing fluorouracil, leucovorin calcium, levamisole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-34AA-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-34C3-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Levamisole","valueDescription":"Fluorouracil/Levamisole","ValueMeaning":{"publicId":"3378082","version":"1","preferredName":"Fluorouracil/Levamisole","longName":"3378082","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil/Levamisole Regimen","conceptCode":"C9981","definition":"A chemotherapy regimen consisting of fluorouracil and levamisole that may be used in the treatment of colon cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-34D0-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-34E9-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Interferon","valueDescription":"Fluorouracil/Interferon Alfa","ValueMeaning":{"publicId":"3378084","version":"1","preferredName":"Fluorouracil/Interferon Alfa","longName":"3378084","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil/Interferon Alfa","conceptCode":"C10987","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-34F6-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-350F-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Leucovorin","valueDescription":"FU-LV Regimen","ValueMeaning":{"publicId":"3378086","version":"1","preferredName":"FU-LV Regimen","longName":"3378086","preferredDefinition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FU-LV Regimen","conceptCode":"C63388","definition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-351C-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-3535-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Leucovorin/Gemcitabine","valueDescription":"Fluorouracil/Gemcitabine/Leucovorin Calcium","ValueMeaning":{"publicId":"3378088","version":"1","preferredName":"Fluorouracil/Gemcitabine/Leucovorin Calcium","longName":"3378088","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil/Gemcitabine/Leucovorin Calcium","conceptCode":"C11313","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-3542-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-355B-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Epirubicin/Cyclophosphamide (FEC)","valueDescription":"Cyclophosphamide/Epirubicin/Fluorouracil","ValueMeaning":{"publicId":"3378089","version":"1","preferredName":"Cyclophosphamide/Epirubicin/Fluorouracil","longName":"3378089","preferredDefinition":"A combination chemotherapy comprised of the agents cyclophosphamide, epirubicin and fluorouracil that has been used in the treatment of breast cancer.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FEC Regimen","conceptCode":"C9595","definition":"A chemotherapy regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-3565-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-357D-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"5FU/Cisplatin","valueDescription":"Fluorouracil Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"3378090","version":"1","preferredName":"Fluorouracil Cisplatin Treatment Regimen","longName":"3378090","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04): An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-358C-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-35A5-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"506U78","valueDescription":"Nelarabine","ValueMeaning":{"publicId":"3378092","version":"1","preferredName":"Nelarabine","longName":"3378092","preferredDefinition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelarabine","conceptCode":"C1704","definition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-35B2-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B90208C1-35CB-0101-E040-BB89AD434367","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"COPP","valueDescription":"COPP Regimen","ValueMeaning":{"publicId":"3368104","version":"1","preferredName":"COPP Regimen","longName":"3368104","preferredDefinition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin's lymphoma. Also used for the treatment of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COPP Regimen","conceptCode":"C9567","definition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7D59407-7E14-B72A-E040-BB89AD432902","latestVersionIndicator":"Yes","beginDate":"2012-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F472-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"COPAdM","valueDescription":"Cyclophosphamide Vincristine Prednisolone Doxorubicin Methotrexate Treatment Regimen","ValueMeaning":{"publicId":"3378645","version":"1","preferredName":"Cyclophosphamide Vincristine Prednisolone Doxorubicin Methotrexate Treatment Regimen","longName":"3378645","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidy","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F484-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F49D-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"COP","valueDescription":"Cyclophosphamide Vincristine Sulfate Prednisone Treatment Regimen","ValueMeaning":{"publicId":"3378646","version":"1","preferredName":"Cyclophosphamide Vincristine Sulfate Prednisone Treatment Regimen","longName":"3378646","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.: A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vincristine Sulfate","conceptCode":"C1739","definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F4AC-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F4C5-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"COL-3","valueDescription":"Incyclinide","ValueMeaning":{"publicId":"3378648","version":"1","preferredName":"Incyclinide","longName":"3378648","preferredDefinition":"A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Incyclinide","conceptCode":"C2454","definition":"A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F4D2-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F4EB-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"COL-1","valueDescription":"Monoclonal Antibody COL-1","ValueMeaning":{"publicId":"3378650","version":"1","preferredName":"Monoclonal Antibody COL-1","longName":"3378650","preferredDefinition":"A recombinant immunoglobulin antibody directed against the tumor-associated antigen carcinoembryonic antigen (CEA). CEA is a cell surface glycoprotein expressed at high levels in embryonic and fetal digestive epithelial tissue, breast carcinoma, and squamous cell carcinoma of the head and neck. Except for some reactivity to skin and gastric and colon mucosa, monoclonal antibody COL-1COL-1 does not appear to react with normal tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody COL-1","conceptCode":"C28893","definition":"A recombinant immunoglobulin antibody directed against the tumor-associated antigen carcinoembryonic antigen (CEA). CEA is a cell surface glycoprotein expressed at high levels in embryonic and fetal digestive epithelial tissue, breast carcinoma, and squamous cell carcinoma of the head and neck. Except for some reactivity to skin and gastric and colon mucosa, monoclonal antibody COL-1COL-1 does not appear to react with normal tissues. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F4F8-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F511-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CODOX-MIVAC","valueDescription":"CODOX-M/IVAC Regimen","ValueMeaning":{"publicId":"3378652","version":"1","preferredName":"CODOX-M/IVAC Regimen","longName":"3378652","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) alternating with ifosfamide, etoposide and high-dose cytarabine (IVAC), used as a treatment for aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment for AIDS-related and high-risk Burkitt's lymphoma.  Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CODOX-M Alternating with IVAC Regimen","conceptCode":"C63448","definition":"A regimen that alternates cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) with ifosfamide, etoposide and high-dose cytarabine (IVAC), and can be used in the treatment of Burkitt lymphoma and Burkitt-like lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F51E-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F537-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CNOP/Rituximab","valueDescription":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3378653","version":"1","preferredName":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine Rituximab Treatment Regimen","longName":"3378653","preferredDefinition":"No Value Exists: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","conceptCode":"C10211","definition":"A combination of agents containing cyclophosphamide, mitoxantrone, prednisone and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F545-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F55E-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CMOPP","valueDescription":"Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine","ValueMeaning":{"publicId":"3378654","version":"1","preferredName":"Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine","longName":"3378654","preferredDefinition":"A chemotherapy combination consisting of cyclophosphamide, mechlorethamine, prednisone, procarbazine, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine","conceptCode":"C28890","definition":"A chemotherapy combination consisting of cyclophosphamide, mechlorethamine, prednisone, procarbazine, and vincristine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F568-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F581-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CMFVP","valueDescription":"Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine","ValueMeaning":{"publicId":"3378656","version":"1","preferredName":"Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine","longName":"3378656","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CMFVP Regimen","conceptCode":"C9557","definition":"A chemotherapy regimen consisting of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone that may be used in the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F58E-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F5A7-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CMFP","valueDescription":"Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone","ValueMeaning":{"publicId":"3378658","version":"1","preferredName":"Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone","longName":"3378658","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone","conceptCode":"C9555","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F5B4-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F5CD-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CMF","valueDescription":"Cyclophosphamide/Fluorouracil/Methotrexate","ValueMeaning":{"publicId":"3378659","version":"1","preferredName":"Cyclophosphamide/Fluorouracil/Methotrexate","longName":"3378659","preferredDefinition":"A combination drug therapy used in the treatment of breast cancer. The treatment is administrated over a four-week cycle. On days 1 and 8 methotraxate and 5-FU are given as injections. Cyclophosphamide may be also administered intravenously in conjunction with these drugs, or may be taken as an oral tablet, taken once every-day for the first 14 days of each cycle.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CMF Regimen","conceptCode":"C9874","definition":"A chemotherapy regimen consisting of cyclophosphamide, methotrexate and fluorouracil, used as a neoadjuvant or adjuvant treatment for breast cancer; also used for the treatment of recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F5D9-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F5F2-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CHOP/R","valueDescription":"CHOP Regimen Rituximab Treatment Regimen","ValueMeaning":{"publicId":"3378660","version":"1","preferredName":"CHOP Regimen Rituximab Treatment Regimen","longName":"3378660","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F600-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F619-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"CHOP/R/Bleomycin","valueDescription":"CHOP Regimen Rituximab Bleomycin Treatment Regimen","ValueMeaning":{"publicId":"3378661","version":"1","preferredName":"CHOP Regimen Rituximab Bleomycin Treatment Regimen","longName":"3378661","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F628-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9065DDB-F641-EA21-E040-BB89AD43659B","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"ONEDATA","dateModified":"2012-02-15","deletedIndicator":"No"},{"value":"Dual PI3 Kinase/mTOR Inhibitor GDC-0980","valueDescription":"Dual PI3 Kinase/mTOR Inhibitor GDC-0980","ValueMeaning":{"publicId":"3630833","version":"1","preferredName":"Dual PI3 Kinase/mTOR Inhibitor GDC-0980","longName":"3630833","preferredDefinition":"An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor GDC-0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apitolisib","conceptCode":"C91731","definition":"An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF91478D-07D2-DC32-E040-BB89AD436F05","latestVersionIndicator":"Yes","beginDate":"2012-11-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF91478D-07EB-DC32-E040-BB89AD436F05","beginDate":"2012-11-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-28","modifiedBy":"ONEDATA","dateModified":"2012-11-28","deletedIndicator":"No"},{"value":"Trebananib","valueDescription":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","ValueMeaning":{"publicId":"3205720","version":"1","preferredName":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","longName":"3205720","preferredDefinition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trebananib","conceptCode":"C91711","definition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EFD7B87-C0FE-51DF-E040-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFB7C2C4-91EA-7469-E040-BB89AD4323F7","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"ONEDATA","dateModified":"2012-11-30","deletedIndicator":"No"},{"value":"GM-K562 Cell Vaccine","valueDescription":"GM-K562 Cell Vaccine","ValueMeaning":{"publicId":"3631678","version":"1","preferredName":"GM-K562 Cell Vaccine","longName":"3631678","preferredDefinition":"A cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. Vaccination with GM-K562 cells may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. K562 cells are derived from the human erythroleukemia cell line K562. GM-CSF (also known as sagramostim) expressed by vaccine cells binds to specific cell surface receptors, modulating the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. GM-CSF also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GM-K562 Cell Vaccine","conceptCode":"C52190","definition":"A cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. Vaccination with GM-K562 cells may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. K562 cells are derived from the human erythroleukemia cell line K562. GM-CSF (also known as sagramostim) expressed by vaccine cells binds to specific cell surface receptors, modulating the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. GM-CSF also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB7C2C4-91F7-7469-E040-BB89AD4323F7","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFB7C2C4-9210-7469-E040-BB89AD4323F7","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"ONEDATA","dateModified":"2012-11-30","deletedIndicator":"No"},{"value":"ST1306","valueDescription":"ST1306","ValueMeaning":{"publicId":"3462017","version":"1","preferredName":"ST1306","longName":"3462017","preferredDefinition":"ST1306","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08C0B11-12F6-C470-E040-BB89AD4333AE","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08C0B11-130F-C470-E040-BB89AD4333AE","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"Linsitinib","valueDescription":"Linsitinib","ValueMeaning":{"publicId":"3444804","version":"1","preferredName":"Linsitinib","longName":"3444804","preferredDefinition":"An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Linsitinib","conceptCode":"C70982","definition":"An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEEAB74C-03F3-084A-E040-BB89AD4354F7","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEEAB74C-040C-084A-E040-BB89AD4354F7","beginDate":"2012-04-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"AZD7451","valueDescription":"Tropomyosin Receptor Kinase Inhibitor AZD7451","ValueMeaning":{"publicId":"3444806","version":"1","preferredName":"Tropomyosin Receptor Kinase Inhibitor AZD7451","longName":"3444806","preferredDefinition":"A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. AZD7451 binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Utatrectinib","conceptCode":"C99161","definition":"A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. Upon administration, utatrectinib binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEEAB74C-0419-084A-E040-BB89AD4354F7","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEEAB74C-0432-084A-E040-BB89AD4354F7","beginDate":"2012-04-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"VB-111","valueDescription":"VB-111","ValueMeaning":{"publicId":"3461372","version":"1","preferredName":"VB-111","longName":"3461372v1.00","preferredDefinition":"A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature.  Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells.  Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofranergene Obadenovec","conceptCode":"C71539","definition":"A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature.  Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells.  Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0189925-0C75-5E86-E040-BB89AD431853","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0189925-0C8E-5E86-E040-BB89AD431853","beginDate":"2012-05-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-15","modifiedBy":"ONEDATA","dateModified":"2012-05-15","deletedIndicator":"No"},{"value":"IAP Inhibitor AT-406","valueDescription":"IAP Inhibitor AT-406","ValueMeaning":{"publicId":"3614156","version":"1","preferredName":"IAP Inhibitor AT-406","longName":"3614156","preferredDefinition":"An orally bioavailable inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins with potential apoptotic inducing and antineoplastic activity. IAP inhibitor AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). This may restore and promote the induction of apoptosis through apoptotic signaling pathways. AT-406 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Xevinapant","conceptCode":"C90574","definition":"An orally available mimetic of the natural second mitochondrial-derived activator of caspases (Smac) and inhibitor of Inhibitor of Apoptosis Proteins (IAPs), with potential immunomodulating, apoptotic-inducing, chemo-radio-sensitizing and antineoplastic activities. Upon oral administration,xevinapant targets and binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP), and the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This inhibits the activities of these IAPs and promotes the induction of apoptosis. Additionally, as xevinapant inhibits the activity of IAPs, it may work synergistically with cytotoxic drugs and/or radiation to overcome tumor cell resistance to apoptosis. As IAPs regulate nuclear factor-kappa B (NFkB) signaling pathways, which drives the expression of genes involved in immune and inflammatory responses, xevinapant may enhance anti-tumor immune responses when administered with certain immunomodulating agents, such as immune checkpoint inhibitors. IAPs are overexpressed by many cancer cell types and suppress both intrinsic and extrinsic apoptosis by binding to and inhibiting active caspases via their baculoviral lAP repeat (BIR) domains. They contribute to chemo-radio-resistance of cancer cells to certain cytotoxic agents and radiation, promote tumor cell survival and are associated with poor prognosis in certain types of cancer. SMAC, a pro-apoptotic mitochondrial protein, is an endogenous inhibitor of the IAPs family of cellular proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC30A674-8D9E-B756-E040-BB89AD4314E4","latestVersionIndicator":"Yes","beginDate":"2012-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CC30A674-8DB7-B756-E040-BB89AD4314E4","beginDate":"2012-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-16","modifiedBy":"ONEDATA","dateModified":"2012-10-16","deletedIndicator":"No"},{"value":"Anti-Endosialin Monoclonal Antibody MORAb-004","valueDescription":"Anti-Endosialin Monoclonal Antibody MORAb-004","ValueMeaning":{"publicId":"3614158","version":"1","preferredName":"Anti-Endosialin Monoclonal Antibody MORAb-004","longName":"3614158","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Anti-endosialin/TEM1 monoclonal antibody MORAb-004 binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ontuxizumab","conceptCode":"C82406","definition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC30A674-8DC4-B756-E040-BB89AD4314E4","latestVersionIndicator":"Yes","beginDate":"2012-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CC30A674-8DDD-B756-E040-BB89AD4314E4","beginDate":"2012-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-16","modifiedBy":"ONEDATA","dateModified":"2012-10-16","deletedIndicator":"No"},{"value":"Simvastatin (Zocor)","valueDescription":"Simvastatin","ValueMeaning":{"publicId":"3626719","version":"1","preferredName":"Simvastatin","longName":"3626719","preferredDefinition":"A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus.  Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Simvastatin","conceptCode":"C29454","definition":"A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus.  Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEA077E7-17C6-0C78-E040-BB89AD43075F","latestVersionIndicator":"Yes","beginDate":"2012-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEA077E7-17DF-0C78-E040-BB89AD43075F","beginDate":"2012-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-16","modifiedBy":"ONEDATA","dateModified":"2012-11-16","deletedIndicator":"No"},{"value":"PD-0332991","valueDescription":"PD-0332991","ValueMeaning":{"publicId":"3564160","version":"1","preferredName":"PD-0332991","longName":"3564160","preferredDefinition":"An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8B81-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7DBA78C-8B9A-5111-E040-BB89AD4317C1","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"ONEDATA","dateModified":"2012-08-22","deletedIndicator":"No"},{"value":"Ramucirumab","valueDescription":"Ramucirumab","ValueMeaning":{"publicId":"3553252","version":"1","preferredName":"Ramucirumab","longName":"3553252","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BB9C1D-7980-2974-E040-BB89AD430E5E","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BB9C1D-7999-2974-E040-BB89AD430E5E","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Thapsigargin Prodrug G-202","valueDescription":"Thapsigargin Prodrug G-202","ValueMeaning":{"publicId":"3461702","version":"1","preferredName":"Thapsigargin Prodrug G-202","longName":"3461702","preferredDefinition":"A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, the non-toxic prodrug targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. G-202 is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mipsagargin","conceptCode":"C90554","definition":"A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03C496A-BCC8-0EBD-E040-BB89AD431ABD","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03C496A-BCE1-0EBD-E040-BB89AD431ABD","beginDate":"2012-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","valueDescription":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","ValueMeaning":{"publicId":"3461704","version":"1","preferredName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","longName":"3461704","preferredDefinition":"A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","conceptCode":"C74055","definition":"A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03C496A-BCEE-0EBD-E040-BB89AD431ABD","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03C496A-BD07-0EBD-E040-BB89AD431ABD","beginDate":"2012-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"ICT-107","valueDescription":"ICT-107","ValueMeaning":{"publicId":"3515397","version":"1","preferredName":"ICT-107","longName":"3515397v1.00","preferredDefinition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","conceptCode":"C124054","definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F0AA9F-F95B-DEFE-E040-BB89AD4374B9","latestVersionIndicator":"Yes","beginDate":"2012-07-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-03","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F0AA9F-F974-DEFE-E040-BB89AD4374B9","beginDate":"2012-07-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-03","modifiedBy":"ONEDATA","dateModified":"2012-07-03","deletedIndicator":"No"},{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F59E-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"BIBW2992 (Afatinib)","valueDescription":"Afatinib","ValueMeaning":{"publicId":"3462019","version":"1","preferredName":"Afatinib","longName":"3462019","preferredDefinition":"An orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Afatinib irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afatinib","conceptCode":"C66940","definition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F5AC-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F5C5-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"PEPvIII loaded Dendritic Cell (DC) vaccine","valueDescription":"Dendritic Cell Tumor Peptide Vaccine","ValueMeaning":{"publicId":"3462021","version":"1","preferredName":"Dendritic Cell Tumor Peptide Vaccine","longName":"3462021","preferredDefinition":"A vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dendritic Cell Tumor Peptide Vaccine","conceptCode":"C1987","definition":"A vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F5D2-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F5EB-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"Brain Tumor Stem Cell (BTSC)/total tumor RNA Dendritic Cell (ttRNA DC) vaccine","valueDescription":"Brain Tumor Stem Cell (BTSC)/total tumor RNA Dendritic Cell (ttRNA DC) vaccine","ValueMeaning":{"publicId":"3462022","version":"1","preferredName":"Brain Tumor Stem Cell (BTSC)/total tumor RNA Dendritic Cell (ttRNA DC) vaccine","longName":"3462022","preferredDefinition":"Brain Tumor Stem Cell (BTSC)/total tumor RNA Dendritic Cell (ttRNA DC) vaccine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F5F5-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F60E-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"Total tumor RNA Dendritic cell (ttRNA DC) vaccine with antigen specific ALT","valueDescription":"Total tumor RNA Dendritic cell (ttRNA DC) vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","ValueMeaning":{"publicId":"3462023","version":"1","preferredName":"Total tumor RNA Dendritic cell (ttRNA DC) vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","longName":"3462023","preferredDefinition":"Total tumor RNA Dendritic cell (ttRNA DC) vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F618-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F631-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"pp65 DC vaccine with antigen specific ALT","valueDescription":"pp65 DC vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","ValueMeaning":{"publicId":"3462024","version":"1","preferredName":"pp65 DC vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","longName":"3462024","preferredDefinition":"pp65 DC vaccine with antigen specific Autologous Lymphocyte Transfer (ALT)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F63B-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F654-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"pp65 DC vaccine","valueDescription":"pp65 DC vaccine","ValueMeaning":{"publicId":"3462025","version":"1","preferredName":"pp65 DC vaccine","longName":"3462025","preferredDefinition":"pp65 DC vaccine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F65E-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C08DE349-F677-1829-E040-BB89AD430889","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"ONEDATA","dateModified":"2012-05-21","deletedIndicator":"No"},{"value":"Vadimezan","valueDescription":"Vadimezan","ValueMeaning":{"publicId":"3481458","version":"1","preferredName":"Vadimezan","longName":"3481458","preferredDefinition":"A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vadimezan","conceptCode":"C2504","definition":"A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2D5B875-4C1B-266D-E040-BB89AD43176B","latestVersionIndicator":"Yes","beginDate":"2012-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2D5B875-4C34-266D-E040-BB89AD43176B","beginDate":"2012-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-06-19","modifiedBy":"ONEDATA","dateModified":"2012-06-19","deletedIndicator":"No"},{"value":"Immunocytokine NHS-IL12","valueDescription":"Immunocytokine NHS-IL12","ValueMeaning":{"publicId":"3595594","version":"1","preferredName":"Immunocytokine NHS-IL12","longName":"3595594","preferredDefinition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunocytokine NHS-IL12","conceptCode":"C97961","definition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA68E09A-F6F0-E0A9-E040-BB89AD4338DB","latestVersionIndicator":"Yes","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA68E09A-F709-E0A9-E040-BB89AD4338DB","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"ONEDATA","dateModified":"2012-09-23","deletedIndicator":"No"},{"value":"Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343","valueDescription":"Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343","ValueMeaning":{"publicId":"3595596","version":"1","preferredName":"Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343","longName":"3595596","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin antibody-drug conjugate BAY 94-9343 targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anetumab Ravtansine","conceptCode":"C98293","definition":"A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anetumab ravtansine targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA68E09A-F716-E0A9-E040-BB89AD4338DB","latestVersionIndicator":"Yes","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA68E09A-F72F-E0A9-E040-BB89AD4338DB","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"ONEDATA","dateModified":"2012-09-23","deletedIndicator":"No"},{"value":"Hsp90 Inhibitor AUY922","valueDescription":"Hsp90 Inhibitor AUY922","ValueMeaning":{"publicId":"3523218","version":"1","preferredName":"Hsp90 Inhibitor AUY922","longName":"3523218","preferredDefinition":"A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luminespib","conceptCode":"C71467","definition":"A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Luminespib has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-456A-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4A309D0-4583-6212-E040-BB89AD4364ED","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"ONEDATA","dateModified":"2012-07-12","deletedIndicator":"No"},{"value":"Trametinib","valueDescription":"Trametinib","ValueMeaning":{"publicId":"3523220","version":"1","preferredName":"Trametinib","longName":"3523220","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-4590-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4A309D0-45A9-6212-E040-BB89AD4364ED","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"ONEDATA","dateModified":"2012-07-12","deletedIndicator":"No"},{"value":"K-562","valueDescription":"K-562","ValueMeaning":{"publicId":"3673376","version":"1","preferredName":"K-562","longName":"3673376","preferredDefinition":"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises. The K562 line is composed of undifferentiated blast cells that are rich in glycophorin and may be induced to produce fetal and embryonic hemoglobin in the presence of hemin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"K-562","conceptCode":"C19437","definition":"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises. The K562 line is composed of undifferentiated blast cells that are rich in glycophorin and may be induced to produce fetal and embryonic hemoglobin in the presence of hemin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D496E198-04C4-B770-E040-BB89AD432058","latestVersionIndicator":"Yes","beginDate":"2013-01-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D496E198-04DD-B770-E040-BB89AD432058","beginDate":"2013-01-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-31","modifiedBy":"ONEDATA","dateModified":"2013-01-31","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D68C2697-3E4F-5AFE-E040-BB89AD431E18","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"ONEDATA","dateModified":"2013-02-25","deletedIndicator":"No"},{"value":"Anti-Endoglin Chimeric Monoclonal Antibody TRC105","valueDescription":"Anti-Endoglin Chimeric Monoclonal Antibody TRC105","ValueMeaning":{"publicId":"3690105","version":"1","preferredName":"Anti-Endoglin Chimeric Monoclonal Antibody TRC105","longName":"3690105","preferredDefinition":"A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Anti-endoglin monoclonal antibody TRC105 binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carotuximab","conceptCode":"C74010","definition":"A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E5C-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D68C2697-3E75-5AFE-E040-BB89AD431E18","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"ONEDATA","dateModified":"2013-02-25","deletedIndicator":"No"},{"value":"MEK inhibitor GDC-0973","valueDescription":"MEK inhibitor GDC-0973","ValueMeaning":{"publicId":"3653958","version":"1","preferredName":"MEK inhibitor GDC-0973","longName":"3653958","preferredDefinition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobimetinib","conceptCode":"C68923","definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E1EFE4-45EB-52B6-E040-BB89AD431E3D","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3E1EFE4-4604-52B6-E040-BB89AD431E3D","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"ONEDATA","dateModified":"2013-01-22","deletedIndicator":"No"},{"value":"PI3K Inhibitor GDC-0941 Bismesylate","valueDescription":"PI3K Inhibitor GDC-0941 Bismesylate","ValueMeaning":{"publicId":"3653960","version":"1","preferredName":"PI3K Inhibitor GDC-0941 Bismesylate","longName":"3653960","preferredDefinition":"The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway; inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations may result. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pictilisib Bismesylate","conceptCode":"C82380","definition":"The orally bioavailable bismesylate salt of pictilisib, a small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E1EFE4-4611-52B6-E040-BB89AD431E3D","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3E1EFE4-462A-52B6-E040-BB89AD431E3D","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"ONEDATA","dateModified":"2013-01-22","deletedIndicator":"No"},{"value":"Anti-KIR Monoclonal Antibody IPH 2101","valueDescription":"Anti-KIR Monoclonal Antibody IPH 2101","ValueMeaning":{"publicId":"3640461","version":"1","preferredName":"Anti-KIR Monoclonal Antibody IPH 2101","longName":"3640461","preferredDefinition":"A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-KIR Monoclonal Antibody IPH 2101","conceptCode":"C78464","definition":"A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D094D3FB-1887-9B9C-E040-BB89AD43042A","latestVersionIndicator":"Yes","beginDate":"2012-12-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D094D3FB-18A0-9B9C-E040-BB89AD43042A","beginDate":"2012-12-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-12-11","modifiedBy":"ONEDATA","dateModified":"2012-12-11","deletedIndicator":"No"},{"value":"Anti-MART-1 F5 Cells","valueDescription":"Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes","ValueMeaning":{"publicId":"3673373","version":"1","preferredName":"Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes","longName":"3673373","preferredDefinition":"Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes","conceptCode":"C38587","definition":"Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D494EBFD-6B1F-C624-E040-BB89AD43166F","latestVersionIndicator":"Yes","beginDate":"2013-01-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D494EBFD-6B38-C624-E040-BB89AD43166F","beginDate":"2013-01-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-31","modifiedBy":"ONEDATA","dateModified":"2013-01-31","deletedIndicator":"No"},{"value":"MART-1 Antigen","valueDescription":"MART-1 Antigen","ValueMeaning":{"publicId":"3653298","version":"1","preferredName":"MART-1 Antigen","longName":"3653298","preferredDefinition":"A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MART-1 Antigen","conceptCode":"C28724","definition":"A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D38F2894-80EB-1E17-E040-BB89AD432177","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D38F2894-8104-1E17-E040-BB89AD432177","beginDate":"2013-01-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"},{"value":"TIL","valueDescription":"Tumor Infiltrating Lymphocyte","ValueMeaning":{"publicId":"3534177","version":"1","preferredName":"Tumor Infiltrating Lymphocyte","longName":"3534177","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5482261-1F39-4429-E040-BB89AD435AFB","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBC039D1-0A13-F767-E040-BB89AD4315AA","beginDate":"2013-05-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-02","modifiedBy":"ONEDATA","dateModified":"2013-05-02","deletedIndicator":"No"},{"value":"Neratinib","valueDescription":"Neratinib","ValueMeaning":{"publicId":"3720773","version":"1","preferredName":"Neratinib","longName":"3720773","preferredDefinition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neratinib","conceptCode":"C49094","definition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA06151A-148F-0504-E040-BB89AD437F71","latestVersionIndicator":"Yes","beginDate":"2013-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA06151A-14A8-0504-E040-BB89AD437F71","beginDate":"2013-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-10","modifiedBy":"ONEDATA","dateModified":"2013-04-10","deletedIndicator":"No"},{"value":"Iodine I 124-labeled Hsp90 Inhibitor PUH71","valueDescription":"Iodine I 124-labeled Hsp90 Inhibitor PUH71","ValueMeaning":{"publicId":"3698433","version":"1","preferredName":"Iodine I 124-labeled Hsp90 Inhibitor PUH71","longName":"3698433","preferredDefinition":"A radioconjugate containing the purine scaffold heat shock protein 90 (Hsp90) inhibitor PUH71 labeled with the radioisotope iodine I 124, with positron emitting activity. Hsp90 inhibitor PUH71 is thought to bind to cytosolic Hsp90 and the endoplasmic reticulum paralogue gp96 (HSP90B1), thereby inhibiting its molecular chaperone function and promoting the degradation of the oncogenic signaling proteins. This induces caspase-dependent apoptosis. The iodine I 124 moiety can be visualized using Positron emission tomography (PET) imaging, thereby allowing an assessment of the accumulation of PUH71 in vivo, particularly in tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I 124-labeled Hsp90 Inhibitor PUH71","conceptCode":"C95711","definition":"A radioconjugate containing the purine scaffold heat shock protein 90 (Hsp90) inhibitor PUH71 labeled with the radioisotope iodine I 124, with positron emitting activity. Hsp90 inhibitor PUH71 is thought to bind to cytosolic Hsp90 and the endoplasmic reticulum paralogue gp96 (HSP90B1), thereby inhibiting its molecular chaperone function and promoting the degradation of the oncogenic signaling proteins. This induces caspase-dependent apoptosis. The iodine I 124 moiety can be visualized using Positron emission tomography (PET) imaging, thereby allowing an assessment of the accumulation of PUH71 in vivo, particularly in tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D836BEEA-5948-3EB4-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2013-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D836BEEA-5961-3EB4-E040-BB89AD437846","beginDate":"2013-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-18","modifiedBy":"ONEDATA","dateModified":"2013-03-18","deletedIndicator":"No"},{"value":"Plerixafor","valueDescription":"Plerixafor","ValueMeaning":{"publicId":"3631680","version":"1","preferredName":"Plerixafor","longName":"3631680","preferredDefinition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plerixafor","conceptCode":"C1777","definition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC50-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D8FBE825-2DFC-4063-E040-BB89AD4375D6","beginDate":"2013-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-28","modifiedBy":"ONEDATA","dateModified":"2013-03-28","deletedIndicator":"No"},{"value":"Levofloxacin","valueDescription":"Levofloxacin","ValueMeaning":{"publicId":"2575687","version":"1","preferredName":"Levofloxacin","longName":"2575687","preferredDefinition":"A type of quinolone antibiotic. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levofloxacin","conceptCode":"C1586","definition":"A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD33D016-58E6-8C70-E040-BB89AD432AB2","beginDate":"2013-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-21","modifiedBy":"ONEDATA","dateModified":"2013-05-21","deletedIndicator":"No"},{"value":"Linezolid","valueDescription":"Linezolid","ValueMeaning":{"publicId":"2578237","version":"1","preferredName":"Linezolid","longName":"2578237","preferredDefinition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Linezolid","conceptCode":"C29158","definition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD33D016-58F0-8C70-E040-BB89AD432AB2","beginDate":"2013-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-21","modifiedBy":"ONEDATA","dateModified":"2013-05-21","deletedIndicator":"No"},{"value":"Moxifloxacin","valueDescription":"Moxifloxacin","ValueMeaning":{"publicId":"2743466","version":"1","preferredName":"Moxifloxacin","longName":"2743466","preferredDefinition":"A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moxifloxacin","conceptCode":"C62052","definition":"A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B4DB-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD33D016-5904-8C70-E040-BB89AD432AB2","beginDate":"2013-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-21","modifiedBy":"ONEDATA","dateModified":"2013-05-21","deletedIndicator":"No"},{"value":"Rifampin","valueDescription":"Rifampin","ValueMeaning":{"publicId":"2575708","version":"1","preferredName":"Rifampin","longName":"2575708","preferredDefinition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifampin","conceptCode":"C811","definition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD33D016-590E-8C70-E040-BB89AD432AB2","beginDate":"2013-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-21","modifiedBy":"ONEDATA","dateModified":"2013-05-21","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"3693066","version":"1","preferredName":"Ruxolitinib","longName":"3693066","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib pecifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D73077EB-0B13-8CEF-E040-BB89AD43494E","latestVersionIndicator":"Yes","beginDate":"2013-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D73077EB-0B2C-8CEF-E040-BB89AD43494E","beginDate":"2013-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-05","modifiedBy":"ONEDATA","dateModified":"2013-03-05","deletedIndicator":"No"},{"value":"Anti-PD-L1 Monoclonal Antibody MDX-1105","valueDescription":"Anti-PD-L1 Monoclonal Antibody MDX-1105","ValueMeaning":{"publicId":"3773962","version":"1","preferredName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","longName":"3773962","preferredDefinition":"A fully human monoclonal antibody directed against the protein ligand PD-L1 (Programmed Death-1 Ligand 1) with immunomodulating and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor, PD-1 (Programmed Death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation in chronic infectious disease.  PD-L1 is expressed broadly on hematopoietic and parenchymal tissues; PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","conceptCode":"C78852","definition":"A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE063EDC-2D9C-BDC2-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2013-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE063EDC-2DB5-BDC2-E040-BB89AD432073","beginDate":"2013-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Regorafenib","valueDescription":"Regorafenib","ValueMeaning":{"publicId":"3729312","version":"1","preferredName":"Regorafenib","longName":"3729312","preferredDefinition":"An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regorafenib","conceptCode":"C78204","definition":"The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0A510A-06A5-547A-E040-BB89AD436C02","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB0A510A-06BE-547A-E040-BB89AD436C02","beginDate":"2013-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-23","modifiedBy":"ONEDATA","dateModified":"2013-04-23","deletedIndicator":"No"},{"value":"Retaspimycin","valueDescription":"Retaspimycin","ValueMeaning":{"publicId":"3813173","version":"1","preferredName":"Retaspimycin","longName":"3813173","preferredDefinition":"A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retaspimycin","conceptCode":"C80378","definition":"A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DC2A43-2ADB-EAC1-E040-BB89AD43563F","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DC2A43-2AF4-EAC1-E040-BB89AD43563F","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"ONEDATA","dateModified":"2013-07-19","deletedIndicator":"No"},{"value":"Gamma Secretase Inhibitor PF-03084014","valueDescription":"Gamma Secretase Inhibitor PF-03084014","ValueMeaning":{"publicId":"3813175","version":"1","preferredName":"Gamma Secretase Inhibitor PF-03084014","longName":"3813175","preferredDefinition":"A selective gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors; Notch signaling pathway inhibition may follow, which may result in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nirogacestat","conceptCode":"C82383","definition":"A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DC2A43-2B01-EAC1-E040-BB89AD43563F","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DC2A43-2B1A-EAC1-E040-BB89AD43563F","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"ONEDATA","dateModified":"2013-07-19","deletedIndicator":"No"},{"value":"Dovitinib Lactate","valueDescription":"Dovitinib Lactate","ValueMeaning":{"publicId":"3813177","version":"1","preferredName":"Dovitinib Lactate","longName":"3813177","preferredDefinition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dovitinib Lactate","conceptCode":"C62435","definition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DC2A43-2B28-EAC1-E040-BB89AD43563F","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DC2A43-2B41-EAC1-E040-BB89AD43563F","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"ONEDATA","dateModified":"2013-07-19","deletedIndicator":"No"},{"value":"WEE1 Inhibitor MK-1775","valueDescription":"Adavosertib","ValueMeaning":{"publicId":"3718072","version":"1","preferredName":"Adavosertib","longName":"3718072","preferredDefinition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adavosertib","conceptCode":"C91725","definition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9A00243-390D-1772-E040-BB89AD43098A","latestVersionIndicator":"Yes","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":"Updated Long Name to current NCIt concept name.  Added previous Long Name as alternate VM. 4.16.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9A00243-3926-1772-E040-BB89AD43098A","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Choline Kinase Alpha Inhibitor TCD-717","valueDescription":"Choline Kinase Alpha Inhibitor TCD-717","ValueMeaning":{"publicId":"3718074","version":"1","preferredName":"Choline Kinase Alpha Inhibitor TCD-717","longName":"3718074","preferredDefinition":"A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choline Kinase Alpha Inhibitor TCD-717","conceptCode":"C94213","definition":"A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9A00243-3933-1772-E040-BB89AD43098A","latestVersionIndicator":"Yes","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9A00243-394C-1772-E040-BB89AD43098A","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Tumor Infiltrating Lymphocyte","valueDescription":"Tumor Infiltrating Lymphocyte","ValueMeaning":{"publicId":"3534177","version":"1","preferredName":"Tumor Infiltrating Lymphocyte","longName":"3534177","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5482261-1F39-4429-E040-BB89AD435AFB","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB321644-EBA7-7538-E040-BB89AD4353DB","beginDate":"2013-04-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-25","modifiedBy":"ONEDATA","dateModified":"2013-04-25","deletedIndicator":"No"},{"value":"AAV-DC-CTL Tumor Cell Targeting Therapy (ACTL)","valueDescription":"AAV-DC-CTL Tumor Cell Targeting Therapy","ValueMeaning":{"publicId":"3855951","version":"1","preferredName":"AAV-DC-CTL Tumor Cell Targeting Therapy","longName":"3855951v1.00","preferredDefinition":"A tumor-targeted therapy consisting of cytotoxic T lymphocytes (CTLs) that are exposed ex vivo to dendritic cells (DCs) transfected with a recombinant adeno-associated virus (rAAV) encoding a specific tumor associated antigen (TAA) gene. Autologous peripheral blood mononuclear cells (PBMC) are collected and separated into monocytes and lymphocytes. The monocytes are infected with the rAAV that carries the TAA gene; this is followed by co-culture of the monocyte-derived, mature rAAV-transfected DCs and the isolated lymphocytes to generate CTLs against the specific TAA. These CTLs are transfused back into the patient for cancer therapy. The CTLs specifically kill tumor cells expressing the TAA, which results in a reduction of tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AAV-DC-CTL Tumor Cell Targeting Therapy","conceptCode":"C107677","definition":"A tumor-targeted therapy consisting of cytotoxic T lymphocytes (CTLs) that are exposed ex vivo to dendritic cells (DCs) transfected with a recombinant adeno-associated virus (rAAV) encoding a specific tumor associated antigen (TAA) gene. Autologous peripheral blood mononuclear cells (PBMC) are collected and separated into monocytes and lymphocytes. The monocytes are infected with the rAAV that carries the TAA gene; this is followed by co-culture of the monocyte-derived, mature rAAV-transfected DCs and the isolated lymphocytes to generate CTLs against the specific TAA. These CTLs are transfused back into the patient for cancer therapy. The CTLs specifically kill tumor cells expressing the TAA, which results in a reduction of tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4005F1C-4903-DA3F-E040-BB89AD43336B","latestVersionIndicator":"Yes","beginDate":"2013-08-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4005F1C-491C-DA3F-E040-BB89AD43336B","beginDate":"2013-08-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-15","modifiedBy":"ONEDATA","dateModified":"2013-08-15","deletedIndicator":"No"},{"value":"Dicycloplatin","valueDescription":"Dicycloplatin","ValueMeaning":{"publicId":"3855895","version":"1","preferredName":"Dicycloplatin","longName":"3855895v1.00","preferredDefinition":"A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential  antineoplastic activity.  Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks.  This mechanism results in the induction of apoptosis and cell growth inhibition.  Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dicycloplatin","conceptCode":"C107676 ","definition":"A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential  antineoplastic activity.  Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks.  This mechanism results in the induction of apoptosis and cell growth inhibition.  Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3FF937D-A155-EC4E-E040-BB89AD43511E","latestVersionIndicator":"Yes","beginDate":"2013-08-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3FF937D-A16E-EC4E-E040-BB89AD43511E","beginDate":"2013-08-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-15","modifiedBy":"ONEDATA","dateModified":"2013-08-15","deletedIndicator":"No"},{"value":"Ziv-Aflibercept","valueDescription":"Aflibercept","ValueMeaning":{"publicId":"3880514","version":"1","preferredName":"Aflibercept","longName":"3880514v1.00","preferredDefinition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ziv-Aflibercept","conceptCode":"C2682","definition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B6AC0C-2D46-A8F1-E040-BB89AD43573C","latestVersionIndicator":"Yes","beginDate":"2013-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-06","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5B6AC0C-2D5F-A8F1-E040-BB89AD43573C","beginDate":"2013-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-06","modifiedBy":"ONEDATA","dateModified":"2013-09-06","deletedIndicator":"No"},{"value":"IL-2 Recombinant Fusion Protein ALT-801","valueDescription":"IL-2 Recombinant Fusion Protein ALT-801","ValueMeaning":{"publicId":"3896160","version":"1","preferredName":"IL-2 Recombinant Fusion Protein ALT-801","longName":"3896160","preferredDefinition":"A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IL-2 Recombinant Fusion Protein ALT-801","conceptCode":"C71743","definition":"A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64364A0-929C-41BB-E040-BB89AD4328F8","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E64364A0-92B5-41BB-E040-BB89AD4328F8","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"ONEDATA","dateModified":"2013-09-13","deletedIndicator":"No"},{"value":"Autologous Dendritic Cell-Adenovirus P53 Vaccine","valueDescription":"Autologous Dendritic Cell-Adenovirus P53 Vaccine","ValueMeaning":{"publicId":"3911935","version":"1","preferredName":"Autologous Dendritic Cell-Adenovirus P53 Vaccine","longName":"3911935","preferredDefinition":"An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Dendritic Cell-Adenovirus P53 Vaccine","conceptCode":"C26445","definition":"An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ADABE2-6EC8-4B56-E040-BB89AD435E85","latestVersionIndicator":"Yes","beginDate":"2013-10-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-10-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ADABE2-6EE1-4B56-E040-BB89AD435E85","beginDate":"2013-10-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-10-01","modifiedBy":"ONEDATA","dateModified":"2013-10-01","deletedIndicator":"No"},{"value":"Lambrolizumab","valueDescription":"Lambrolizumab","ValueMeaning":{"publicId":"3911937","version":"1","preferredName":"Lambrolizumab","longName":"3911937","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ADABE2-6EEE-4B56-E040-BB89AD435E85","latestVersionIndicator":"Yes","beginDate":"2013-10-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-10-01","modifiedBy":"COOPERM","dateModified":"2020-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ADABE2-6F07-4B56-E040-BB89AD435E85","beginDate":"2013-10-01","endDate":"2020-12-10","createdBy":"REEVESD","dateCreated":"2013-10-01","modifiedBy":"COOPERM","dateModified":"2020-12-10","deletedIndicator":"No"},{"value":"Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells","valueDescription":"Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells","ValueMeaning":{"publicId":"4037975","version":"1","preferredName":"Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells","longName":"4037975","preferredDefinition":"Allogeneic natural killer (NK) cells transduced with an mRNA expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. NK cells from haploidentical donors are expanded in culture and electroporated with the CAR mRNA. Upon transfusion of the transduced cultured cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic NK cells bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Its inclusion may also increase antitumor activity, when compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells","conceptCode":"C112179","definition":"Allogeneic natural killer (NK) cells transduced with an mRNA expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. NK cells from haploidentical donors are expanded in culture and electroporated with the CAR mRNA. Upon transfusion of the transduced cultured cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic NK cells bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Its inclusion may also increase antitumor activity, when compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EED5F15C-EFC5-2DEC-E040-BB89AD43588C","latestVersionIndicator":"Yes","beginDate":"2013-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EED5F15C-EFDE-2DEC-E040-BB89AD43588C","beginDate":"2013-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-12-31","modifiedBy":"ONEDATA","dateModified":"2013-12-31","deletedIndicator":"No"},{"value":"Dacetuzumab","valueDescription":"Dacetuzumab","ValueMeaning":{"publicId":"3950197","version":"1","preferredName":"Dacetuzumab","longName":"3950197","preferredDefinition":"A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacetuzumab","conceptCode":"C62179","definition":"A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAB139C1-9166-AC26-E040-BB89AD437812","latestVersionIndicator":"Yes","beginDate":"2013-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAB139C1-917F-AC26-E040-BB89AD437812","beginDate":"2013-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-08","modifiedBy":"ONEDATA","dateModified":"2013-11-08","deletedIndicator":"No"},{"value":"Talaporfin Sodium","valueDescription":"Talaporfin Sodium","ValueMeaning":{"publicId":"3977275","version":"1","preferredName":"Talaporfin Sodium","longName":"3977275","preferredDefinition":"An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talaporfin Sodium","conceptCode":"C26675","definition":"An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECC9490F-3E6F-9A44-E040-BB89AD434414","latestVersionIndicator":"Yes","beginDate":"2013-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECC9490F-3E88-9A44-E040-BB89AD434414","beginDate":"2013-12-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-12-05","modifiedBy":"ONEDATA","dateModified":"2013-12-05","deletedIndicator":"No"},{"value":"Amrubicin","valueDescription":"Amrubicin","ValueMeaning":{"publicId":"4076475","version":"1","preferredName":"Amrubicin","longName":"4076475","preferredDefinition":"A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amrubicin","conceptCode":"C80089","definition":"A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EFDBD23B-B1B3-C2B6-E040-BB89AD431A2F","latestVersionIndicator":"Yes","beginDate":"2014-01-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EFDBD23B-B1CC-C2B6-E040-BB89AD431A2F","beginDate":"2014-01-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-01-13","modifiedBy":"ONEDATA","dateModified":"2014-01-13","deletedIndicator":"No"},{"value":"Anti-human GITR Monoclonal Antibody TRX518","valueDescription":"Anti-human GITR Monoclonal Antibody TRX518","ValueMeaning":{"publicId":"3944882","version":"1","preferredName":"Anti-human GITR Monoclonal Antibody TRX518","longName":"3944882","preferredDefinition":"A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-human GITR Monoclonal Antibody TRX518","conceptCode":"C95023","definition":"A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F15F-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA60336B-F178-AE12-E040-BB89AD435C63","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"ONEDATA","dateModified":"2013-11-04","deletedIndicator":"No"},{"value":"Valrubicin","valueDescription":"Valrubicin","ValueMeaning":{"publicId":"4337185","version":"1","preferredName":"Valrubicin","longName":"4337185","preferredDefinition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valrubicin","conceptCode":"C1340","definition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA7C1A6F-1DB2-C2AB-E040-BB89AD436686","latestVersionIndicator":"Yes","beginDate":"2014-05-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-05-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA7C1A6F-1DCB-C2AB-E040-BB89AD436686","beginDate":"2014-05-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-05-28","modifiedBy":"ONEDATA","dateModified":"2014-05-28","deletedIndicator":"No"},{"value":"Methoxyamine","valueDescription":"Methoxyamine","ValueMeaning":{"publicId":"4255112","version":"1","preferredName":"Methoxyamine","longName":"4255112","preferredDefinition":"An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methoxyamine","conceptCode":"C78084","definition":"An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AA2DE6-BE22-4E55-E040-BB89AD43059A","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AA2DE6-BE3B-4E55-E040-BB89AD43059A","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"Trastuzumab Emtansine","valueDescription":"Trastuzumab Emtansine","ValueMeaning":{"publicId":"4255113","version":"1","preferredName":"Trastuzumab Emtansine","longName":"4255113","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab Emtansine","conceptCode":"C82492","definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AA2DE6-BE47-4E55-E040-BB89AD43059A","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AA2DE6-BE60-4E55-E040-BB89AD43059A","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"Programmed Cell Death 1 Ligand 1","valueDescription":"Programmed Cell Death 1 Ligand 1","ValueMeaning":{"publicId":"3377565","version":"1","preferredName":"Programmed Cell Death 1 Ligand 1","longName":"3377565","preferredDefinition":"Programmed cell death 1 ligand 1 (290 aa, ~33 kDa) is encoded by the human CD274 gene. This protein is involved in the mediation of both the activation and proliferation of T cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Programmed Cell Death 1 Ligand 1","conceptCode":"C96024","definition":"Programmed cell death 1 ligand 1 (290 aa, ~33 kDa) is encoded by the human CD274 gene. This protein is involved in the mediation of both the activation and proliferation of T cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8EE339F-EFCB-4316-E040-BB89AD4372AB","latestVersionIndicator":"Yes","beginDate":"2012-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8E59F29-42A5-D35F-E040-BB89AD436240","beginDate":"2014-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-05-08","modifiedBy":"ONEDATA","dateModified":"2014-05-08","deletedIndicator":"No"},{"value":"Rucaparib Phosphate","valueDescription":"Rucaparib Phosphate","ValueMeaning":{"publicId":"4273832","version":"1","preferredName":"Rucaparib Phosphate","longName":"4273832","preferredDefinition":"A tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP1 catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rucaparib Phosphate","conceptCode":"C78186","definition":"The phosphate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F73B077B-A32F-E0E0-E040-BB89AD4363DE","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F73B077B-A348-E0E0-E040-BB89AD4363DE","beginDate":"2014-04-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-17","modifiedBy":"ONEDATA","dateModified":"2014-04-17","deletedIndicator":"No"},{"value":"Afatinib","valueDescription":"Afatinib","ValueMeaning":{"publicId":"4713538","version":"1","preferredName":"Afatinib","longName":"4713538","preferredDefinition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afatinib","conceptCode":"C66940","definition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EAD2857-C172-13C9-E050-BB89AD432E00","latestVersionIndicator":"Yes","beginDate":"2015-02-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAD2857-C18A-13C9-E050-BB89AD432E00","beginDate":"2015-02-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-09","modifiedBy":"ONEDATA","dateModified":"2015-02-09","deletedIndicator":"No"},{"value":"Dabrafenib","valueDescription":"Dabrafenib","ValueMeaning":{"publicId":"4539014","version":"1","preferredName":"Dabrafenib","longName":"4539014","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059E8F71-D4FF-7062-E050-BB89AD435032","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"059E8F71-D518-7062-E050-BB89AD435032","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","deletedIndicator":"No"},{"value":"PG13-CD19-H3","valueDescription":"PG13-CD19-H3 (anti-CD19 CAR)","ValueMeaning":{"publicId":"4865851","version":"1","preferredName":"PG13-CD19-H3 (anti-CD19 CAR)","longName":"4865851","preferredDefinition":"PG13-CD19-H3 (anti-CD19 CAR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"188F2161-90B9-CACD-E050-BB89AD4303DD","latestVersionIndicator":"Yes","beginDate":"2015-06-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"188F2161-90D2-CACD-E050-BB89AD4303DD","beginDate":"2015-06-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-15","modifiedBy":"ONEDATA","dateModified":"2015-06-15","deletedIndicator":"No"},{"value":"Glutaminase Inhibitor CB-839","valueDescription":"Glutaminase Inhibitor CB-839","ValueMeaning":{"publicId":"4783196","version":"1","preferredName":"Glutaminase Inhibitor CB-839","longName":"4783196","preferredDefinition":"An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Telaglenastat","conceptCode":"C114381","definition":"An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1328A097-4B29-1D46-E050-BB89AD432CC3","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1328A097-4B42-1D46-E050-BB89AD432CC3","beginDate":"2015-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-07","modifiedBy":"ONEDATA","dateModified":"2015-04-07","deletedIndicator":"No"},{"value":"Oprozomib","valueDescription":"Oprozomib","ValueMeaning":{"publicId":"4740632","version":"1","preferredName":"Oprozomib","longName":"4740632","preferredDefinition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oprozomib","conceptCode":"C91388","definition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10D8E2A9-2FD8-D0DE-E050-BB89AD435EC5","latestVersionIndicator":"Yes","beginDate":"2015-03-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10D8E2A9-2FF1-D0DE-E050-BB89AD435EC5","beginDate":"2015-03-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-09","modifiedBy":"ONEDATA","dateModified":"2015-03-09","deletedIndicator":"No"},{"value":"Pomalidomide","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10D8E2A9-2FFB-D0DE-E050-BB89AD435EC5","beginDate":"2015-03-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-09","modifiedBy":"ONEDATA","dateModified":"2015-03-09","deletedIndicator":"No"},{"value":"Lenvatinib Mesylate","valueDescription":"Lenvatinib Mesylate","ValueMeaning":{"publicId":"4828174","version":"1","preferredName":"Lenvatinib Mesylate","longName":"4828174","preferredDefinition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenvatinib Mesylate","conceptCode":"C48636","definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16714A24-91CD-6277-E050-BB89AD433DE7","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"16714A24-91E6-6277-E050-BB89AD433DE7","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"ONEDATA","dateModified":"2015-05-19","deletedIndicator":"No"},{"value":"Binimetinib","valueDescription":"Binimetinib","ValueMeaning":{"publicId":"4828187","version":"1","preferredName":"Binimetinib","longName":"4828187","preferredDefinition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Binimetinib","conceptCode":"C84865","definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49B7-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"16717093-49D0-6644-E050-BB89AD434C5B","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"ONEDATA","dateModified":"2015-05-19","deletedIndicator":"No"},{"value":"Alectinib","valueDescription":"Alectinib","ValueMeaning":{"publicId":"4828189","version":"1","preferredName":"Alectinib","longName":"4828189","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alectinib","conceptCode":"C101790","definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49DD-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"16717093-49F6-6644-E050-BB89AD434C5B","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"ONEDATA","dateModified":"2015-05-19","deletedIndicator":"No"},{"value":"Glembatumumab Vedotin","valueDescription":"Glembatumumab Vedotin","ValueMeaning":{"publicId":"4925571","version":"1","preferredName":"Glembatumumab Vedotin","longName":"4925571","preferredDefinition":"An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glembatumumab Vedotin","conceptCode":"C78449","definition":"An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C162452-F30A-BD65-E050-BB89AD4325CB","latestVersionIndicator":"Yes","beginDate":"2015-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C162452-F323-BD65-E050-BB89AD4325CB","beginDate":"2015-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-07-30","modifiedBy":"ONEDATA","dateModified":"2015-07-30","deletedIndicator":"No"},{"value":"Donor Cellular Infusion","valueDescription":"Donor Cellular Infusion","ValueMeaning":{"publicId":"4926573","version":"1","preferredName":"Donor Cellular Infusion","longName":"4926573","preferredDefinition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C69AAD8-76B5-DEDC-E050-BB89AD434FD9","latestVersionIndicator":"Yes","beginDate":"2015-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C69AAD8-76CE-DEDC-E050-BB89AD434FD9","beginDate":"2015-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-08-03","modifiedBy":"ONEDATA","dateModified":"2015-08-03","deletedIndicator":"No"},{"value":"Tretinoin","valueDescription":"Tretinoin (ATRA)","ValueMeaning":{"publicId":"4763631","version":"1","preferredName":"Tretinoin (ATRA)","longName":"4763631","preferredDefinition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1273ABD3-1D1F-6F1B-E050-BB89AD434A27","latestVersionIndicator":"Yes","beginDate":"2015-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1273ABD3-1D38-6F1B-E050-BB89AD434A27","beginDate":"2015-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-29","modifiedBy":"ONEDATA","dateModified":"2015-03-29","deletedIndicator":"No"},{"value":"Obinutuzumab","valueDescription":"Obinutuzumab","ValueMeaning":{"publicId":"5096860","version":"1","preferredName":"Obinutuzumab","longName":"5096860","preferredDefinition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obinutuzumab","conceptCode":"C70741","definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-4750-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28ACEAFB-4769-6667-E050-BB89AD432DA7","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"ONEDATA","dateModified":"2016-01-06","deletedIndicator":"No"},{"value":"ATR Kinase Inhibitor VX-970","valueDescription":"ATR Kinase Inhibitor VX-970","ValueMeaning":{"publicId":"5260852","version":"1","preferredName":"ATR Kinase Inhibitor VX-970","longName":"5260852","preferredDefinition":"An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Berzosertib","conceptCode":"C116355","definition":"An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32BBE309-5EB8-5BC3-E050-BB89AD432ACF","latestVersionIndicator":"Yes","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32BBE309-5ED1-5BC3-E050-BB89AD432ACF","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"ONEDATA","dateModified":"2016-05-13","deletedIndicator":"No"},{"value":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","valueDescription":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","ValueMeaning":{"publicId":"5260854","version":"1","preferredName":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","longName":"5260854","preferredDefinition":"A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Davamotecan Pegadexamer","conceptCode":"C62600","definition":"A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration of davamotecan pegadexamer, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32BBE309-5EDE-5BC3-E050-BB89AD432ACF","latestVersionIndicator":"Yes","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32BBE309-5EF7-5BC3-E050-BB89AD432ACF","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"ONEDATA","dateModified":"2016-05-13","deletedIndicator":"No"},{"value":"Multitargeted Tyrosine Kinase Inhibitor PLX3397","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor PLX3397","ValueMeaning":{"publicId":"5260856","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor PLX3397","longName":"5260856","preferredDefinition":"A capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor PLX3397 binds to and inhibits phosphorylation of stem cell factor receptor (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), which may result in the inhibition of tumor cell proliferation and down-modulation of macrophages, osteoclasts and mast cells involved in the osteolytic metastatic disease. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pexidartinib","conceptCode":"C88303","definition":"A small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32BBE309-5F04-5BC3-E050-BB89AD432ACF","latestVersionIndicator":"Yes","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32BBE309-5F1D-5BC3-E050-BB89AD432ACF","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"ONEDATA","dateModified":"2016-05-13","deletedIndicator":"No"},{"value":"Osimertinib","valueDescription":"Osimertinib","ValueMeaning":{"publicId":"5305951","version":"1","preferredName":"Osimertinib","longName":"5305951","preferredDefinition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osimertinib","conceptCode":"C116377","definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35DFF1EC-FEBB-8034-E050-BB89AD435383","latestVersionIndicator":"Yes","beginDate":"2016-06-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"35DFF1EC-FED4-8034-E050-BB89AD435383","beginDate":"2016-06-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-22","modifiedBy":"ONEDATA","dateModified":"2016-06-22","deletedIndicator":"No"},{"value":"Liposomal Cytarabine","valueDescription":"Liposomal Cytarabine","ValueMeaning":{"publicId":"5255884","version":"1","preferredName":"Liposomal Cytarabine","longName":"5255884","preferredDefinition":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Cytarabine","conceptCode":"C2388","definition":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8D15-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32936C88-8D2E-BF10-E050-BB89AD436D35","beginDate":"2016-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-11","modifiedBy":"ONEDATA","dateModified":"2016-05-11","deletedIndicator":"No"},{"value":"Prior therapy, NOS","valueDescription":"Prior Therapy Not Otherwise Specified ","ValueMeaning":{"publicId":"5579092","version":"1","preferredName":"Prior Therapy Not Otherwise Specified ","longName":"5579092","preferredDefinition":"Not characterized in any other way.: An indicator that a person has been previously treated for the same condition or with the same therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41989304-D053-2E19-E053-F662850A5F5B","latestVersionIndicator":"Yes","beginDate":"2016-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41989304-D06C-2E19-E053-F662850A5F5B","beginDate":"2016-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-18","modifiedBy":"ONEDATA","dateModified":"2016-11-18","deletedIndicator":"No"},{"value":"Epratuzumab","valueDescription":"Epratuzumab","ValueMeaning":{"publicId":"3438598","version":"1","preferredName":"Epratuzumab","longName":"3438598","preferredDefinition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epratuzumab","conceptCode":"C1887","definition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3E82-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41E5AA84-9F77-5B55-E053-F662850A271C","beginDate":"2016-11-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-22","modifiedBy":"ONEDATA","dateModified":"2016-11-22","deletedIndicator":"No"},{"value":"Chimeric antigen receptor T cells","valueDescription":"Chimeric Antigen Receptor T-Lymphocyte","ValueMeaning":{"publicId":"5578587","version":"1","preferredName":"Chimeric Antigen Receptor T-Lymphocyte","longName":"5578587","preferredDefinition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.: A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4194B6C9-01F8-3377-E053-F662850AA9AA","latestVersionIndicator":"Yes","beginDate":"2016-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4194B6C9-0211-3377-E053-F662850AA9AA","beginDate":"2016-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-18","modifiedBy":"ONEDATA","dateModified":"2016-11-18","deletedIndicator":"No"},{"value":"Doxorubicin Hydrochloride Liposome","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"2576633","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"2576633","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F866-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EC978F3-4E4B-5473-E053-F662850A012C","beginDate":"2017-05-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"Vintafolide","valueDescription":"Vintafolide","ValueMeaning":{"publicId":"5808439","version":"1","preferredName":"Vintafolide","longName":"5808439","preferredDefinition":"A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vintafolide","conceptCode":"C62525","definition":"A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ECA34E6-3DC2-0F97-E053-F662850A62A8","latestVersionIndicator":"Yes","beginDate":"2017-05-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4ECA34E6-3DDD-0F97-E053-F662850A62A8","beginDate":"2017-05-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"PNC-27","valueDescription":"PNC-27","ValueMeaning":{"publicId":"5887266","version":"1","preferredName":"PNC-27","longName":"5887266v1.00","preferredDefinition":"A human double minute 2 (HDM2)-binding peptide comprised of a carboxy terminal p53 leader sequence (amino acids 12-26) linked to a membrane residency peptide (MRP), which facilitates penetration of the tumor cell plasma membrane, with potential antineoplastic activity. HDM2-binding peptide PNC-27 binds to HDM2, which is expressed in the plasma membrane of certain cancer cells, and induces transmembrane pore formation, resulting in tumor cell necrosis that is independent of p53 activity. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed by cancer cells and has been implicated in cancer cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HDM2-binding Peptide PNC-27","conceptCode":"C136515","definition":"A human double minute 2 (HDM2)-binding peptide comprised of a carboxy terminal p53 leader sequence (amino acids 12-26) linked to a membrane residency peptide (MRP), which facilitates penetration of the tumor cell plasma membrane, with potential antineoplastic activity. HDM2-binding peptide PNC-27 binds to HDM2, which is expressed in the plasma membrane of certain cancer cells, and induces transmembrane pore formation, resulting in tumor cell necrosis that is independent of p53 activity. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed by cancer cells and has been implicated in cancer cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52A27F77-F166-201B-E053-F662850A3F7F","latestVersionIndicator":"Yes","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-06-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"52A27F77-F17F-201B-E053-F662850A3F7F","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-06-23","modifiedBy":"ONEDATA","dateModified":"2017-06-23","deletedIndicator":"No"},{"value":"Tremelimumab","valueDescription":"Tremelimumab","ValueMeaning":{"publicId":"3185137","version":"1","preferredName":"Tremelimumab","longName":"3185137","preferredDefinition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A317-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4CFD0718-5F25-7D12-E053-F662850AD37E","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"ONEDATA","dateModified":"2017-04-12","deletedIndicator":"No"},{"value":"Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4CFD0718-5F4B-7D12-E053-F662850AD37E","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"ONEDATA","dateModified":"2017-04-12","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4CFD0718-5F57-7D12-E053-F662850AD37E","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"ONEDATA","dateModified":"2017-04-12","deletedIndicator":"No"},{"value":"Radium Ra 223 Dichloride","valueDescription":"Radium Chloride Ra-223","ValueMeaning":{"publicId":"3788420","version":"1","preferredName":"Radium Chloride Ra-223","longName":"3788420","preferredDefinition":"A radiopharmaceutic of short-lived radium-223 with potential anti-tumor activity. Radium preferentially binds to and accumulates in bone tissue. The radioisotope radium-223 may kill bone cancer cells through the local emission of high energy alpha particles, thereby potentially decreasing tumor progression in the skeleton.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radium Ra 223 Dichloride","conceptCode":"C62535","definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB3D-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"51C3DC75-145A-5D00-E053-F662850A0253","beginDate":"2017-06-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-06-12","modifiedBy":"ONEDATA","dateModified":"2017-06-12","deletedIndicator":"No"},{"value":"PF-04136309","valueDescription":"CCR2 Antagonist PF-04136309","ValueMeaning":{"publicId":"5777017","version":"1","preferredName":"CCR2 Antagonist PF-04136309","longName":"5777017","preferredDefinition":"An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CCR2 Antagonist PF-04136309","conceptCode":"C97507","definition":"An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D6388AF-D58A-422C-E053-F662850AA641","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D6388AF-D5A3-422C-E053-F662850AA641","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"ONEDATA","dateModified":"2017-04-17","deletedIndicator":"No"},{"value":"IDH305","valueDescription":"IDH1(R132) Inhibitor IDH305","ValueMeaning":{"publicId":"5777019","version":"1","preferredName":"IDH1(R132) Inhibitor IDH305","longName":"5777019","preferredDefinition":"An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IDH1(R132) Inhibitor IDH305","conceptCode":"C121457","definition":"An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D6388AF-D5B0-422C-E053-F662850AA641","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D6388AF-D5C9-422C-E053-F662850AA641","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"ONEDATA","dateModified":"2017-04-17","deletedIndicator":"No"},{"value":"FOLFIRINOX","valueDescription":"Folfirinox Regimen","ValueMeaning":{"publicId":"5153133","version":"1","preferredName":"Folfirinox Regimen","longName":"5153133","preferredDefinition":"A regimen consisting of fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin used for the treatment of pancreatic cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Folfirinox Regimen","conceptCode":"C11764","definition":"A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, ampullary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA15D94-7F52-85A7-E050-BB89AD437035","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D6388AF-D5DD-422C-E053-F662850AA641","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"ONEDATA","dateModified":"2017-04-17","deletedIndicator":"No"},{"value":"CCX872-B","valueDescription":"CCR2 Antagonist CCX872-B","ValueMeaning":{"publicId":"5777021","version":"1","preferredName":"CCR2 Antagonist CCX872-B","longName":"5777021","preferredDefinition":"An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CCR2 Antagonist CCX872-B","conceptCode":"C120302","definition":"An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D6388AF-D5EA-422C-E053-F662850AA641","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D6388AF-D603-422C-E053-F662850AA641","beginDate":"2017-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-17","modifiedBy":"ONEDATA","dateModified":"2017-04-17","deletedIndicator":"No"},{"value":"Trifluridine/Tipiracil Hydrochloride","valueDescription":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","ValueMeaning":{"publicId":"5831612","version":"1","preferredName":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","longName":"5831612","preferredDefinition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trifluridine and Tipiracil Hydrochloride","conceptCode":"C102554","definition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-07CE-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"597AB32A-5FA5-239B-E053-F662850A6FA2","beginDate":"2017-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-18","modifiedBy":"ONEDATA","dateModified":"2017-09-18","deletedIndicator":"No"},{"value":"Capecitabine/Oxaliplatin","valueDescription":"Capecitabine/Oxaliplatin","ValueMeaning":{"publicId":"5981301","version":"1","preferredName":"Capecitabine/Oxaliplatin","longName":"5981301","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine/Oxaliplatin","conceptCode":"C11635","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"597AB32A-5FB2-239B-E053-F662850A6FA2","latestVersionIndicator":"Yes","beginDate":"2017-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"597AB32A-5FCD-239B-E053-F662850A6FA2","beginDate":"2017-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-18","modifiedBy":"ONEDATA","dateModified":"2017-09-18","deletedIndicator":"No"},{"value":"Capecitabine/Irinotecan","valueDescription":"XELIRI Regimen","ValueMeaning":{"publicId":"5981303","version":"1","preferredName":"XELIRI Regimen","longName":"5981303","preferredDefinition":"A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"XELIRI Regimen","conceptCode":"C11602","definition":"A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"597AB32A-5FDA-239B-E053-F662850A6FA2","latestVersionIndicator":"Yes","beginDate":"2017-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"597AB32A-5FF5-239B-E053-F662850A6FA2","beginDate":"2017-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-18","modifiedBy":"ONEDATA","dateModified":"2017-09-18","deletedIndicator":"No"},{"value":"Pimasertib","valueDescription":"Pimasertib","ValueMeaning":{"publicId":"6024061","version":"1","preferredName":"Pimasertib","longName":"6024061","preferredDefinition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pimasertib","conceptCode":"C84864","definition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D19D58D-9E06-66C6-E053-F662850A0684","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D19D58D-9E21-66C6-E053-F662850A0684","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"ONEDATA","dateModified":"2017-11-03","deletedIndicator":"No"},{"value":"Anti-CEA BiTE","valueDescription":"Anti-CEA BiTE Monoclonal Antibody AMG211","ValueMeaning":{"publicId":"6024059","version":"1","preferredName":"Anti-CEA BiTE Monoclonal Antibody AMG211","longName":"6024059","preferredDefinition":"A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CEA BiTE Monoclonal Antibody AMG211","conceptCode":"C95728","definition":"A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D19D58D-9DDD-66C6-E053-F662850A0684","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D19D58D-9DF9-66C6-E053-F662850A0684","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"ONEDATA","dateModified":"2017-11-03","deletedIndicator":"No"},{"value":"Evofosfamide","valueDescription":"Evofosfamide","ValueMeaning":{"publicId":"6024063","version":"1","preferredName":"Evofosfamide","longName":"6024063","preferredDefinition":"A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evofosfamide","conceptCode":"C71722","definition":"A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D19D58D-9E2E-66C6-E053-F662850A0684","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D19D58D-9E4A-66C6-E053-F662850A0684","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"ONEDATA","dateModified":"2017-11-03","deletedIndicator":"No"},{"value":"Bavituximab/Placebo","valueDescription":"Bavituximab/Placebo","ValueMeaning":{"publicId":"6046295","version":"1","preferredName":"Bavituximab/Placebo","longName":"6046295","preferredDefinition":"A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.: An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bavituximab","conceptCode":"C49088","definition":"A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61D0F87D-1F22-739E-E053-F662850A43FA","latestVersionIndicator":"Yes","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D12681-D23B-3E06-E053-F662850AB78E","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Immunoglobulin","valueDescription":"Immunoglobulin","ValueMeaning":{"publicId":"5143295","version":"1","preferredName":"Immunoglobulin","longName":"5143295","preferredDefinition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C581-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1EB0-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":"Ponatinib","ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1EBA-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Elotuzumab","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1EC4-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Daratumumab","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1ED8-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Marizomib","valueDescription":"Marizomib","ValueMeaning":{"publicId":"5621726","version":"1","preferredName":"Marizomib","longName":"5621726","preferredDefinition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marizomib","conceptCode":"C64634","definition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC0F-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1EEC-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Nintedanib","valueDescription":"Nintedanib","ValueMeaning":{"publicId":"3718802","version":"1","preferredName":"Nintedanib","longName":"3718802","preferredDefinition":"An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nintedanib","conceptCode":"C62765","definition":"An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E013E4-E74A-2A0B-E040-BB89AD431A04","latestVersionIndicator":"Yes","beginDate":"2013-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1F00-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Buparlisib","valueDescription":"PI3K Inhibitor BKM120","ValueMeaning":{"publicId":"3788416","version":"1","preferredName":"PI3K Inhibitor BKM120","longName":"3788416","preferredDefinition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buparlisib","conceptCode":"C90565","definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CAD3-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61D0F87D-1F15-739E-E053-F662850A43FA","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"Necitumumab","valueDescription":"Necitumumab","ValueMeaning":{"publicId":"6084996","version":"1","preferredName":"Necitumumab","longName":"6084996","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necitumumab","conceptCode":"C88281","definition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66217E39-C8D2-01DB-E053-F662850AFD24","latestVersionIndicator":"Yes","beginDate":"2018-02-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-26","modifiedBy":"COOPERM","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665BB794-4C13-4788-E053-F662850A6EB2","beginDate":"2018-03-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"},{"value":"Mirvetuximab Soravtansine","valueDescription":"Mirvetuximab Soravtansine","ValueMeaning":{"publicId":"6199771","version":"1","preferredName":"Mirvetuximab Soravtansine","longName":"6199771","preferredDefinition":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mirvetuximab Soravtansine","conceptCode":"C102566","definition":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F92C-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F945-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Epacadostat","valueDescription":"Epacadostat","ValueMeaning":{"publicId":"6199773","version":"1","preferredName":"Epacadostat","longName":"6199773","preferredDefinition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epacadostat","conceptCode":"C92582","definition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F952-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F96B-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Ustekinumab","valueDescription":"Ustekinumab","ValueMeaning":{"publicId":"6199775","version":"1","preferredName":"Ustekinumab","longName":"6199775","preferredDefinition":"An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ustekinumab","conceptCode":"C84237","definition":"An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F978-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F991-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F99B-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Antibody-drug Conjugate PF-06647020","valueDescription":"Antibody-drug Conjugate PF-06647020","ValueMeaning":{"publicId":"6199777","version":"1","preferredName":"Antibody-drug Conjugate PF-06647020","longName":"6199777","preferredDefinition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of PF-06647020 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cofetuzumab Pelidotin","conceptCode":"C123828","definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F9A8-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F9C1-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"Prexasertib","valueDescription":"Prexasertib","ValueMeaning":{"publicId":"6199779","version":"1","preferredName":"Prexasertib","longName":"6199779","preferredDefinition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prexasertib","conceptCode":"C91392","definition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F9CE-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69FA0151-F9E7-2B31-E053-F662850A82BD","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"T-VEC","valueDescription":"Talimogene Laherparepvec","ValueMeaning":{"publicId":"6365953","version":"1","preferredName":"Talimogene Laherparepvec","longName":"6365953","preferredDefinition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talimogene Laherparepvec","conceptCode":"C61314","definition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7171C6E5-4544-56AE-E053-F662850A2A3A","latestVersionIndicator":"Yes","beginDate":"2018-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-07-20","modifiedBy":"COOPERM","dateModified":"2018-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7171C6E5-455D-56AE-E053-F662850A2A3A","beginDate":"2018-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-07-20","modifiedBy":"ONEDATA","dateModified":"2018-07-20","deletedIndicator":"No"},{"value":"Instiladrin","valueDescription":"Nadofaragene Firadenovec/Syn3","ValueMeaning":{"publicId":"6661769","version":"1","preferredName":"Nadofaragene Firadenovec/Syn3","longName":"6661769","preferredDefinition":"A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN alpha-2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nadofaragene Firadenovec/Syn3","conceptCode":"C104743","definition":"A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec/Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN alpha-2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835CDA4D-14EE-6408-E053-F662850A7720","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"COOPERM","dateModified":"2019-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"835CDA4D-1507-6408-E053-F662850A7720","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","deletedIndicator":"No"},{"value":"Napabucasin","valueDescription":"Napabucasin","ValueMeaning":{"publicId":"6148644","version":"1","preferredName":"Napabucasin","longName":"6148644","preferredDefinition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Napabucasin","conceptCode":"C96429","definition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-4292-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"835CDA4D-151B-6408-E053-F662850A7720","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","deletedIndicator":"No"},{"value":"DPX-Survivac","valueDescription":"Survivin Antigen Vaccine DPX-Survivac","ValueMeaning":{"publicId":"6687978","version":"1","preferredName":"Survivin Antigen Vaccine DPX-Survivac","longName":"6687978","preferredDefinition":"A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the survivin antigen vaccine DPX-Survivac, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maveropepimut-S","conceptCode":"C97951","definition":"A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of Maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86084999-6371-7CF3-E053-F662850ABF0E","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-638A-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Ipafricept","valueDescription":"Ipafricept","ValueMeaning":{"publicId":"6687980","version":"1","preferredName":"Ipafricept","longName":"6687980","preferredDefinition":"A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipafricept","conceptCode":"C102565","definition":"A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86084999-6397-7CF3-E053-F662850ABF0E","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-63B0-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Metformin","valueDescription":"Metformin","ValueMeaning":{"publicId":"3189685","version":"1","preferredName":"Metformin","longName":"3189685v1.00","preferredDefinition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin","conceptCode":"C61612","definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BB1D0F5-1252-2360-E040-BB89AD4328D8","latestVersionIndicator":"Yes","beginDate":"2011-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-02-07","modifiedBy":"MMADDINENI","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-63C4-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Cemiplimab","valueDescription":"Cemiplimab","ValueMeaning":{"publicId":"6687982","version":"1","preferredName":"Cemiplimab","longName":"6687982","preferredDefinition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cemiplimab","conceptCode":"C121540","definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86084999-63D2-7CF3-E053-F662850ABF0E","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-63EB-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":"Venetoclax","ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-63F5-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Abemaciclib","valueDescription":"Abemaciclib","ValueMeaning":{"publicId":"6148605","version":"1","preferredName":"Abemaciclib","longName":"6148605","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abemaciclib","conceptCode":"C97660","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-77AE-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86084999-63FF-7CF3-E053-F662850ABF0E","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"PolyPEPI1018","valueDescription":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","ValueMeaning":{"publicId":"6688090","version":"1","preferredName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","longName":"6688090","preferredDefinition":"A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","conceptCode":"C154278","definition":"A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860B82C9-418F-1D98-E053-F662850A5514","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860B82C9-41A8-1D98-E053-F662850A5514","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Humanized High-chimeric Antibody CD47","valueDescription":"Chimeric Humanized Anti-CD47 Antibody","ValueMeaning":{"publicId":"6688526","version":"1","preferredName":"Chimeric Humanized Anti-CD47 Antibody","longName":"6688526","preferredDefinition":"A humanized, high-chimeric antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, chimeric humanized anti-CD47 antibody selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Humanized Anti-CD47 Antibody","conceptCode":"C122397","definition":"A humanized, high-chimeric antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, chimeric humanized anti-CD47 antibody selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"861A2145-F6A4-644A-E053-F662850A8FC3","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"861A2145-F6BD-644A-E053-F662850A8FC3","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","deletedIndicator":"No"},{"value":"Anti-CD47 MAb SRF-231","valueDescription":"Anti-CD47 Monoclonal Antibody SRF231","ValueMeaning":{"publicId":"6688528","version":"1","preferredName":"Anti-CD47 Monoclonal Antibody SRF231","longName":"6688528","preferredDefinition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SRF231 selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urabrelimab","conceptCode":"C155976","definition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"861A2145-F6CA-644A-E053-F662850A8FC3","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"861A2145-F6E3-644A-E053-F662850A8FC3","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","deletedIndicator":"No"},{"value":"Anti-CD47 MAb IBI-188","valueDescription":"Anti-CD47 Monoclonal Antibody IBI188","ValueMeaning":{"publicId":"6688530","version":"1","preferredName":"Anti-CD47 Monoclonal Antibody IBI188","longName":"6688530","preferredDefinition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD47 monoclonal antibody IBI188 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letaplimab","conceptCode":"C157385","definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, letaplimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"861A2145-F6F0-644A-E053-F662850A8FC3","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"861A2145-F709-644A-E053-F662850A8FC3","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","deletedIndicator":"No"},{"value":"Anti-CD47 MAb CC-90002","valueDescription":"Anti-CD47 Monoclonal Antibody CC-90002","ValueMeaning":{"publicId":"6688532","version":"1","preferredName":"Anti-CD47 Monoclonal Antibody CC-90002","longName":"6688532","preferredDefinition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD47 Monoclonal Antibody CC-90002","conceptCode":"C121211","definition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"861A2145-F716-644A-E053-F662850A8FC3","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"861A2145-F72F-644A-E053-F662850A8FC3","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","deletedIndicator":"No"},{"value":"Anti-CD47 Hu5F9-G4","valueDescription":"Anti-CD47 Monoclonal Antibody Hu5F9-G4","ValueMeaning":{"publicId":"6688534","version":"1","preferredName":"Anti-CD47 Monoclonal Antibody Hu5F9-G4","longName":"6688534","preferredDefinition":"A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody Hu5F9-G4 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magrolimab","conceptCode":"C117730","definition":"A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"861A2145-F73C-644A-E053-F662850A8FC3","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"861A2145-F755-644A-E053-F662850A8FC3","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","deletedIndicator":"No"},{"value":"Carboplatin/Pemetrexed","valueDescription":"Carboplatin/Pemetrexed Regimen","ValueMeaning":{"publicId":"6774796","version":"1","preferredName":"Carboplatin/Pemetrexed Regimen","longName":"6774796","preferredDefinition":"A chemotherapy regimen consisting of carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Pemetrexed Regimen","conceptCode":"C136284","definition":"A regimen consisting of carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC), and malignant peritoneal and pleural mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A82DF3B-7FCB-22E7-E053-F662850A406F","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A82DF3B-7FE4-22E7-E053-F662850A406F","beginDate":"2019-06-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","deletedIndicator":"No"},{"value":"CD70+CAR-T","valueDescription":"Anti-CD70 CAR-expressing T Lymphocytes (CD70 CAR-T)","ValueMeaning":{"publicId":"6841671","version":"1","preferredName":"Anti-CD70 CAR-expressing T Lymphocytes (CD70 CAR-T)","longName":"6841671v1.00","preferredDefinition":"A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD70 CAR-expressing T Lymphocytes","conceptCode":"C162699","definition":"A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFF20A8-FB3A-7092-E053-F662850AA47F","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-31","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFF20A8-FB53-7092-E053-F662850AA47F","beginDate":"2019-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"Romidepsin","valueDescription":"Romidepsin","ValueMeaning":{"publicId":"5342172","version":"1","preferredName":"Romidepsin","longName":"5342172","preferredDefinition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romidepsin","conceptCode":"C1544","definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-39D0-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C6B4-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":"Abatacept","ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C6C0-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Ixazomib","valueDescription":"Ixazomib","ValueMeaning":{"publicId":"5944043","version":"1","preferredName":"Ixazomib","longName":"5944043","preferredDefinition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixazomib","conceptCode":"C97940","definition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FED1-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C6CA-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Photodynamic therapy","valueDescription":"Photodynamic therapy","ValueMeaning":{"publicId":"2569057","version":"1","preferredName":"Photodynamic therapy","longName":"2569057","preferredDefinition":"Use of light activated drugs (photosensitizing agents) to kill cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Photodynamic Therapy","conceptCode":"C15300","definition":"Use of light activated drugs (photosensitizing agents) to treat cancer and other conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DACE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-04-06","modifiedBy":"COOPERM","dateModified":"2015-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C6D4-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"HPV vaccine","valueDescription":"Human Papilloma Virus Vaccine","ValueMeaning":{"publicId":"6847006","version":"1","preferredName":"Human Papilloma Virus Vaccine","longName":"6847006","preferredDefinition":"A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Papilloma Virus Vaccine","conceptCode":"C1951","definition":"A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C6E0-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C6FB-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Indole 3 carbinol","valueDescription":"Indole-3-Carbinol","ValueMeaning":{"publicId":"6847008","version":"1","preferredName":"Indole-3-Carbinol","longName":"6847008","preferredDefinition":"A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indole-3-Carbinol","conceptCode":"C1135","definition":"A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C708-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C723-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"PBSCT, Allogeneic","valueDescription":"Allogeneic Peripheral Blood Stem Cell Transplantation","ValueMeaning":{"publicId":"6847009","version":"1","preferredName":"Allogeneic Peripheral Blood Stem Cell Transplantation","longName":"6847009","preferredDefinition":"Taken from different individuals of the same species.: Similar to bone marrow transplantation, peripheral stem cell transplantation is a method of replacing the blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells. Certain immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.  Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic","conceptCode":"C28343","definition":"Taken from different individuals of the same species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Peripheral Blood Stem Cell Transplantation","conceptCode":"C15430","definition":"A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C730-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C74B-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"CDX1127-01","valueDescription":"Varlilumab","ValueMeaning":{"publicId":"6847011","version":"1","preferredName":"Varlilumab","longName":"6847011","preferredDefinition":"A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Varlilumab","conceptCode":"C99127","definition":"A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C758-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C773-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"RO6958688","valueDescription":"Cibisatamab","ValueMeaning":{"publicId":"6847013","version":"1","preferredName":"Cibisatamab","longName":"6847013","preferredDefinition":"An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cibisatamab","conceptCode":"C120097","definition":"An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C780-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C79B-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Apremilast","valueDescription":"Apremilast","ValueMeaning":{"publicId":"6847015","version":"1","preferredName":"Apremilast","longName":"6847015v1.00","preferredDefinition":"An orally bioavailable, small molecule inhibitor of phosphodiesterase 4 (PDE4), with potential anti-inflammatory activity. Upon oral administration, apremilast targets, binds to and inhibits the activity of PDE4, thereby blocking cyclic adenosine monophosphate (cAMP) degradation and increasing intracellular cAMP levels. This may decrease the production of the proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha). PDE4 is an enzyme that plays an important role in the degradation of cAMP and in cytokine production in inflammatory cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apremilast","conceptCode":"C147044","definition":"An orally bioavailable, small molecule inhibitor of phosphodiesterase 4 (PDE4), with potential anti-inflammatory activity. Upon oral administration, apremilast targets, binds to and inhibits the activity of PDE4, thereby blocking cyclic adenosine monophosphate (cAMP) degradation and increasing intracellular cAMP levels. This may decrease the production of the proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha). PDE4 is an enzyme that plays an important role in the degradation of cAMP and in cytokine production in inflammatory cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6751D8-C7A8-1B8D-E053-F662850ACA89","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C7C3-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"TCHP","valueDescription":"Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen","ValueMeaning":{"publicId":"6005249","version":"1","preferredName":"Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen","longName":"6005249","preferredDefinition":"A chemotherapy regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCHP Regimen","conceptCode":"C138047","definition":"A regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-4FF9-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F6751D8-C7CF-1B8D-E053-F662850ACA89","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"ETBX-051","valueDescription":"Adenoviral Brachyury Vaccine ETBX-051","ValueMeaning":{"publicId":"6856470","version":"1","preferredName":"Adenoviral Brachyury Vaccine ETBX-051","longName":"6856470","preferredDefinition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral Brachyury Vaccine ETBX-051","conceptCode":"C143034","definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"903DFDCE-4822-679E-E053-F662850AB095","latestVersionIndicator":"Yes","beginDate":"2019-08-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-16","modifiedBy":"ONEDATA","dateModified":"2019-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"903DFDCE-483D-679E-E053-F662850AB095","beginDate":"2019-08-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-16","modifiedBy":"ONEDATA","dateModified":"2019-08-16","deletedIndicator":"No"},{"value":"ETBX-061","valueDescription":"Adenoviral MUC1 Vaccine ETBX-061","ValueMeaning":{"publicId":"6856472","version":"1","preferredName":"Adenoviral MUC1 Vaccine ETBX-061","longName":"6856472","preferredDefinition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral MUC1 Vaccine ETBX-061","conceptCode":"C143035","definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"903DFDCE-484A-679E-E053-F662850AB095","latestVersionIndicator":"Yes","beginDate":"2019-08-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-16","modifiedBy":"ONEDATA","dateModified":"2019-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"903DFDCE-4865-679E-E053-F662850AB095","beginDate":"2019-08-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-16","modifiedBy":"ONEDATA","dateModified":"2019-08-16","deletedIndicator":"No"},{"value":"Cisplatin/Pemetrexed","valueDescription":"Pemetrexed-Cisplatin Regimen","ValueMeaning":{"publicId":"3557952","version":"1","preferredName":"Pemetrexed-Cisplatin Regimen","longName":"3557952","preferredDefinition":"A regimen consisting of pemetrexed and cisplatin used for the treatment of malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Pemetrexed Regimen","conceptCode":"C63788","definition":"A regimen consisting of pemetrexed and cisplatin that may be used for the treatment of malignant peritoneal and pleural mesothelioma, and non-small cell lung cancer (NSCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7502A41-7F0F-66C6-E040-BB89AD43459A","latestVersionIndicator":"Yes","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C64DCCB-1155-39FF-E053-F662850A8458","beginDate":"2019-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-06-28","modifiedBy":"ONEDATA","dateModified":"2019-06-28","deletedIndicator":"No"},{"value":"MVA/FPV-Brachyury-TRICOM","valueDescription":"MVA-BN-Brachyury-TRICOM Vaccine And FPV-Brachyury-TRICOM Vaccine Treatment Regimen","ValueMeaning":{"publicId":"6753165","version":"1","preferredName":"MVA-BN-Brachyury-TRICOM Vaccine And FPV-Brachyury-TRICOM Vaccine Treatment Regimen","longName":"6753165","preferredDefinition":"A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury vaccine, the vector expresses the brachyury protein. The expressed brachyury protein may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against bra","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MVA-BN-Brachyury-TRICOM Vaccine","conceptCode":"C148400","definition":"A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury vaccine, the vector expresses the brachyury protein. The expressed brachyury protein may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"FPV-Brachyury-TRICOM Vaccine","conceptCode":"C148402","definition":"A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8864D9EF-584E-3B67-E053-F662850A88EA","latestVersionIndicator":"Yes","beginDate":"2019-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-08","modifiedBy":"ONEDATA","dateModified":"2019-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8864D9EF-5867-3B67-E053-F662850A88EA","beginDate":"2019-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-08","modifiedBy":"ONEDATA","dateModified":"2019-05-08","deletedIndicator":"No"},{"value":"Guadecitabine","valueDescription":"Guadecitabine","ValueMeaning":{"publicId":"6753167","version":"1","preferredName":"Guadecitabine","longName":"6753167","preferredDefinition":"A dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. Following metabolic activation by phosphorylation and incorporation into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing genome-wide and non-specific hypomethylation, and inducing cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, hence may result in gradual release of decitabine both extra and intracellularly, leading to more prolonged exposures to decitabine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guadecitabine","conceptCode":"C95209","definition":"A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8864D9EF-5874-3B67-E053-F662850A88EA","latestVersionIndicator":"Yes","beginDate":"2019-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-08","modifiedBy":"ONEDATA","dateModified":"2019-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8864D9EF-588D-3B67-E053-F662850A88EA","beginDate":"2019-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-08","modifiedBy":"ONEDATA","dateModified":"2019-05-08","deletedIndicator":"No"},{"value":"Cyclophosphamide/Vincristine/Cisplatin/Etoposide","valueDescription":"COPE Regimen","ValueMeaning":{"publicId":"7070277","version":"1","preferredName":"COPE Regimen","longName":"7070277","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, vincristine, cisplatin, and etoposide that may be used in the treatment of small cell lung cancer (SCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COPE Regimen","conceptCode":"C9714","definition":"A chemotherapy regimen consisting of cyclophosphamide, vincristine, cisplatin, and etoposide that may be used in the treatment of small cell lung cancer (SCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-6246-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-625F-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"CCNU/Bevacizumab","valueDescription":"Bevacizumab/Lomustine Regimen","ValueMeaning":{"publicId":"7070275","version":"1","preferredName":"Bevacizumab/Lomustine Regimen","longName":"7070275","preferredDefinition":"A regimen consisting of bevacizumab and lomustine that can be used for the treatment of glioblastoma (GBM).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab/Lomustine Regimen","conceptCode":"C160526","definition":"A regimen consisting of bevacizumab and lomustine that can be used for the treatment of certain central nervous system (CNS) cancers including oligodendroglioma, astrocytoma, glioblastoma (GBM) and gliosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-620C-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-6225-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"Chemotherapy (NOS)","valueDescription":"Not Otherwise Specified Chemotherapy","ValueMeaning":{"publicId":"6617617","version":"1","preferredName":"Not Otherwise Specified Chemotherapy","longName":"6617617","preferredDefinition":"Not characterized in any other way.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FC591D6-92B8-36E8-E053-F662850AEFC2","latestVersionIndicator":"Yes","beginDate":"2019-01-18","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-18","modifiedBy":"ONEDATA","dateModified":"2019-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-6239-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"Cisplatin/Cyclophosphamide/Etoposide","valueDescription":"Cisplatin/Cyclophosphamide/Etoposide Regimen","ValueMeaning":{"publicId":"7070278","version":"1","preferredName":"Cisplatin/Cyclophosphamide/Etoposide Regimen","longName":"7070278","preferredDefinition":"A regimen consisting of Cisplatin, Cyclophosphamide, and Etoposide that can be used for the treatment of extensive-stage small cell lung cancer.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-6269-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-6282-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"Vismodegib","valueDescription":"Vismodegib","ValueMeaning":{"publicId":"3438593","version":"1","preferredName":"Vismodegib","longName":"3438593","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vismodegib","conceptCode":"C74038","definition":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3DE1-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-628C-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"GSK2256098","valueDescription":"FAK Inhibitor GSK2256098","ValueMeaning":{"publicId":"7070279","version":"1","preferredName":"FAK Inhibitor GSK2256098","longName":"7070279","preferredDefinition":"A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FAK Inhibitor GSK2256098","conceptCode":"C88346","definition":"A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-6298-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-62B1-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"HuMax-IL8","valueDescription":"Anti-IL-8 Monoclonal Antibody HuMax-IL8","ValueMeaning":{"publicId":"7070281","version":"1","preferredName":"Anti-IL-8 Monoclonal Antibody HuMax-IL8","longName":"7070281","preferredDefinition":"A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, HuMax-IL8 directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, HuMax-IL8 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adakitug","conceptCode":"C124227","definition":"A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-62BE-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-62D7-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"MVA Brachyury-TRICOM vaccine","valueDescription":"Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine","ValueMeaning":{"publicId":"7070283","version":"1","preferredName":"Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine","longName":"7070283","preferredDefinition":"A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine","conceptCode":"C116777","definition":"A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F6CDCF-62E4-4842-E053-F662850A0E27","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F6CDCF-62FD-4842-E053-F662850A0E27","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"BXQ-350","valueDescription":"BXQ-350 Nanovesicle Formulation","ValueMeaning":{"publicId":"7071769","version":"1","preferredName":"BXQ-350 Nanovesicle Formulation","longName":"7071769","preferredDefinition":"A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BXQ-350 Nanovesicle Formulation","conceptCode":"C131491","definition":"A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98FD79FC-6512-366E-E053-F662850A8BD8","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98FD79FC-652B-366E-E053-F662850A8BD8","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"Utomilumab","valueDescription":"Utomilumab","ValueMeaning":{"publicId":"7154920","version":"1","preferredName":"Utomilumab","longName":"7154920","preferredDefinition":"A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Utomilumab","conceptCode":"C116619","definition":"A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D3B26CC-6D8B-05B2-E053-F662850ACBE5","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D3B26CC-6DA6-05B2-E053-F662850ACBE5","beginDate":"2020-01-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"hATG (Horse Anti-thymocyte)","valueDescription":"Equine Thymocyte Immune Globulin","ValueMeaning":{"publicId":"7094883","version":"1","preferredName":"Equine Thymocyte Immune Globulin","longName":"7094883","preferredDefinition":"A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T-lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equine Thymocyte Immune Globulin","conceptCode":"C80824","definition":"A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T-lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99F001B8-7302-1CA6-E053-F662850AAF09","latestVersionIndicator":"Yes","beginDate":"2019-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-17","modifiedBy":"ONEDATA","dateModified":"2019-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99F001B8-731B-1CA6-E053-F662850AAF09","beginDate":"2019-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-17","modifiedBy":"ONEDATA","dateModified":"2019-12-17","deletedIndicator":"No"},{"value":"Siltuximab","valueDescription":"Siltuximab","ValueMeaning":{"publicId":"5621734","version":"1","preferredName":"Siltuximab","longName":"5621734","preferredDefinition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siltuximab","conceptCode":"C61084","definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BCF0-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99F001B8-7325-1CA6-E053-F662850AAF09","beginDate":"2019-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-17","modifiedBy":"ONEDATA","dateModified":"2019-12-17","deletedIndicator":"No"},{"value":"Cisplatin/Lomustine/Cytoxan/Mesna","valueDescription":"Cisplatin/Lomustine/Cyclophosphamide/Mesna","ValueMeaning":{"publicId":"7070292","version":"1","preferredName":"Cisplatin/Lomustine/Cyclophosphamide/Mesna","longName":"7070292","preferredDefinition":"A regimen consisting of Cisplatin, Loumustine, Cyclophosphamide (Cytoxan), and Mesna.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F824B1-B636-0755-E053-F662850A1F98","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98F824B1-B64F-0755-E053-F662850A1F98","beginDate":"2019-12-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","deletedIndicator":"No"},{"value":"Anti-KRAS G12V PBL","valueDescription":"Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes","ValueMeaning":{"publicId":"7235715","version":"1","preferredName":"Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes","longName":"7235715","preferredDefinition":"Autologous peripheral blood lymphocytes (PBLs) transduced with an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine to valine point mutation at position 12 (G12V) variant of K-RAS, with potential antineoplastic activity. HLA-A1101 positive PBLs are harvested from a K-RAS G12V-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12V mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12V mTCR-expressing PBLs target and bind to K-RAS G12V-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes","conceptCode":"C142888","definition":"Autologous peripheral blood lymphocytes (PBLs) transduced with an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine to valine point mutation at position 12 (G12V) variant of K-RAS, with potential antineoplastic activity. HLA-A1101 positive PBLs are harvested from a K-RAS G12V-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12V mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12V mTCR-expressing PBLs target and bind to K-RAS G12V-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A23C8922-50DC-26EF-E053-F662850A66F7","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-01","modifiedBy":"ONEDATA","dateModified":"2020-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A23C8922-50F5-26EF-E053-F662850A66F7","beginDate":"2020-04-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-01","modifiedBy":"ONEDATA","dateModified":"2020-04-01","deletedIndicator":"No"},{"value":"Anti-KRAS G12D PBL","valueDescription":"Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes","ValueMeaning":{"publicId":"7235717","version":"1","preferredName":"Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes","longName":"7235717","preferredDefinition":"Autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine (Gly, G) to aspartic acid (Asp, D) point mutation at position 12 (G12D) variant of K-RAS (KRAS), with potential immunomodulating and antineoplastic activities. HLA-A1101-positive PBLs are harvested from a K-RAS G12D-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12D mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12D mTCR-expressing PBLs target and bind to K-RAS G12D-overexpressing tumor cells, which results in both cytokine secretion, including interferon-gamma (IFN-g), and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes","conceptCode":"C156889","definition":"Autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine (Gly, G) to aspartic acid (Asp, D) point mutation at position 12 (G12D) variant of K-RAS (KRAS), with potential immunomodulating and antineoplastic activities. HLA-A1101-positive PBLs are harvested from a K-RAS G12D-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12D mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12D mTCR-expressing PBLs target and bind to K-RAS G12D-overexpressing tumor cells, which results in both cytokine secretion, including interferon-gamma (IFN-g), and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A23C8922-5102-26EF-E053-F662850A66F7","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-01","modifiedBy":"ONEDATA","dateModified":"2020-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A23C8922-511B-26EF-E053-F662850A66F7","beginDate":"2020-04-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-01","modifiedBy":"ONEDATA","dateModified":"2020-04-01","deletedIndicator":"No"},{"value":"Midostaurin","valueDescription":"Midostaurin","ValueMeaning":{"publicId":"5805895","version":"1","preferredName":"Midostaurin","longName":"5805895","preferredDefinition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midostaurin","conceptCode":"C1872","definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4464-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"COOPERM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4864AF7-A629-3D9F-E053-F662850AD1FB","beginDate":"2020-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-30","modifiedBy":"ONEDATA","dateModified":"2020-04-30","deletedIndicator":"No"},{"value":"CD19/CD22 CAR-T","valueDescription":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells","ValueMeaning":{"publicId":"7347497","version":"1","preferredName":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells","longName":"7347497","preferredDefinition":"A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120","conceptCode":"C142834","definition":"A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells CT120 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9760881-6D49-7026-E053-4EBD850A3498","latestVersionIndicator":"Yes","beginDate":"2020-07-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-02","modifiedBy":"COOPERM","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9760881-6D62-7026-E053-4EBD850A3498","beginDate":"2020-07-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-02","modifiedBy":"ONEDATA","dateModified":"2020-07-02","deletedIndicator":"No"},{"value":"Treosulfan","valueDescription":"Treosulfan","ValueMeaning":{"publicId":"3922372","version":"1","preferredName":"Treosulfan","longName":"3922372","preferredDefinition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treosulfan","conceptCode":"C1257","definition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8F0C244-B505-23D8-E040-BB89AD430966","latestVersionIndicator":"Yes","beginDate":"2013-10-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-17","modifiedBy":"COOPERM","dateModified":"2020-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9760881-6D6C-7026-E053-4EBD850A3498","beginDate":"2020-07-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-02","modifiedBy":"ONEDATA","dateModified":"2020-07-02","deletedIndicator":"No"},{"value":"Inotuzumab","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-38B8-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"Erwinia","valueDescription":"Asparaginase Erwinia chrysanthemi","ValueMeaning":{"publicId":"7331406","version":"1","preferredName":"Asparaginase Erwinia chrysanthemi","longName":"7331406","preferredDefinition":"An enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora). Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting leukemic cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  This agent also induces apoptosis in tumor cells. The Erwinia-derived product is often used for those patients who have experienced a hypersensitivity reaction to the E. Coli formulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase Erwinia chrysanthemi","conceptCode":"C64260","definition":"A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-38C5-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":"2023.6.28 Alt VM added per ticket request CADSR0002550. ak 2022.12.1 Alt VM added for ticket CADSR0001748. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-38DE-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"CAR T-cell infusion with Kymriah","valueDescription":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","ValueMeaning":{"publicId":"5621736","version":"1","preferredName":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","longName":"5621736","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD2A-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-38F2-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"CD19CAR","valueDescription":"Autologous CD19/CD22 Chimeric Antigen Receptor T-cells","ValueMeaning":{"publicId":"7331408","version":"1","preferredName":"Autologous CD19/CD22 Chimeric Antigen Receptor T-cells","longName":"7331408","preferredDefinition":"A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120","conceptCode":"C142834","definition":"A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells CT120 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-38FF-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-3918-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"Thymoglobulin","valueDescription":"Lapine T-Lymphocyte Immune Globulin","ValueMeaning":{"publicId":"7331410","version":"1","preferredName":"Lapine T-Lymphocyte Immune Globulin","longName":"7331410","preferredDefinition":"A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapine T-Lymphocyte Immune Globulin","conceptCode":"C80833","definition":"A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-3925-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-393E-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"Marquibo","valueDescription":"Vincristine Sulfate Liposome","ValueMeaning":{"publicId":"7331412","version":"1","preferredName":"Vincristine Sulfate Liposome","longName":"7331412","preferredDefinition":"A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine Sulfate Liposome","conceptCode":"C2702","definition":"A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-394B-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-3964-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"CAR-T Infusion","valueDescription":"Chimeric Antigen Receptor T-Cell Therapy","ValueMeaning":{"publicId":"7331413","version":"1","preferredName":"Chimeric Antigen Receptor T-Cell Therapy","longName":"7331413","preferredDefinition":"A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is being studied in the treatment of some types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor T-Cell Therapy","conceptCode":"C126102","definition":"Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-396E-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D4A25B-3987-566A-E053-4EBD850AA9EA","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"MSB0011359C","valueDescription":"Bintrafusp Alfa","ValueMeaning":{"publicId":"7405919","version":"1","preferredName":"Bintrafusp Alfa","longName":"7405919","preferredDefinition":"A bifunctional fusion protein composed of avelumab, an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the TGFbetaRII moiety of bintrafusp alfa binds to and neutralizes TGFbeta while the avelumab moiety simultaneously binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bintrafusp Alfa","conceptCode":"C124229","definition":"A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD63C989-8500-2DA7-E053-4EBD850A8CE1","latestVersionIndicator":"Yes","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD63C989-8519-2DA7-E053-4EBD850A8CE1","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"ONEDATA","dateModified":"2020-08-21","deletedIndicator":"No"},{"value":"CV301","valueDescription":"CEA-MUC-1-TRICOM Vaccine CV301","ValueMeaning":{"publicId":"7405921","version":"1","preferredName":"CEA-MUC-1-TRICOM Vaccine CV301","longName":"7405921","preferredDefinition":"A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CEA-MUC-1-TRICOM Vaccine CV301","conceptCode":"C131129","definition":"A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD63C989-8526-2DA7-E053-4EBD850A8CE1","latestVersionIndicator":"Yes","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"ONEDATA","dateModified":"2020-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD63C989-853F-2DA7-E053-4EBD850A8CE1","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"ONEDATA","dateModified":"2020-08-21","deletedIndicator":"No"},{"value":"Prostvac","valueDescription":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","ValueMeaning":{"publicId":"7405923","version":"1","preferredName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","longName":"7405923","preferredDefinition":"A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","conceptCode":"C132990","definition":"A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD63C989-854C-2DA7-E053-4EBD850A8CE1","latestVersionIndicator":"Yes","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"ONEDATA","dateModified":"2020-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD63C989-8565-2DA7-E053-4EBD850A8CE1","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"ONEDATA","dateModified":"2020-08-21","deletedIndicator":"No"},{"value":"Cabiralizumab","valueDescription":"Cabiralizumab","ValueMeaning":{"publicId":"7431039","version":"1","preferredName":"Cabiralizumab","longName":"7431039","preferredDefinition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabiralizumab","conceptCode":"C123831","definition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFFCF37C-F97F-084C-E053-4EBD850ACB9C","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFFCF37C-F998-084C-E053-4EBD850ACB9C","beginDate":"2020-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Samrotamab Vedotin","valueDescription":"Samrotamab Vedotin","ValueMeaning":{"publicId":"7431041","version":"1","preferredName":"Samrotamab Vedotin","longName":"7431041","preferredDefinition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-085 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Samrotamab Vedotin","conceptCode":"C124134","definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFFCF37C-F9A5-084C-E053-4EBD850ACB9C","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFFCF37C-F9BE-084C-E053-4EBD850ACB9C","beginDate":"2020-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","deletedIndicator":"No"},{"value":"Pegaspargase","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2D4ABE5-14A2-6B4D-E053-4EBD850A1573","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B623F8EC-6735-7EFF-E053-4EBD850A0CAB","beginDate":"2020-12-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-10","modifiedBy":"ONEDATA","dateModified":"2020-12-10","deletedIndicator":"No"},{"value":"Duvelisib","valueDescription":"Duvelisib","ValueMeaning":{"publicId":"7464061","version":"1","preferredName":"Duvelisib","longName":"7464061","preferredDefinition":"An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duvelisib","conceptCode":"C99225","definition":"An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1945CB5-8C5E-5064-E053-4EBD850AF60F","latestVersionIndicator":"Yes","beginDate":"2020-10-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-13","modifiedBy":"ONEDATA","dateModified":"2020-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1945CB5-8C77-5064-E053-4EBD850AF60F","beginDate":"2020-10-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-13","modifiedBy":"ONEDATA","dateModified":"2020-10-13","deletedIndicator":"No"},{"value":"AVD","valueDescription":"AVD Regimen","ValueMeaning":{"publicId":"6002270","version":"1","preferredName":"AVD Regimen","longName":"6002270","preferredDefinition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AVD Regimen","conceptCode":"C140093","definition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CD9-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"COOPERM","dateModified":"2020-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6202B4D-4297-1F08-E053-4EBD850A8971","beginDate":"2020-12-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-10","modifiedBy":"ONEDATA","dateModified":"2020-12-10","deletedIndicator":"No"},{"value":"Aminocaproic Acid","valueDescription":"Aminocaproic Acid","ValueMeaning":{"publicId":"3128754","version":"1","preferredName":"Aminocaproic Acid","longName":"3128754","preferredDefinition":"A synthetic lysine derivative with antifibrinolytic activity. Aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Aminocaproic acid competitively reduces the conversion of plasminogen to plasmin by plasminogen activators. It directly inhibits proteolytic activity of plasmin, but higher doses are required than are needed to reduce plasmin formation. Aminocaproic acid is used in the treatment of hemorrhage and prophylactically against hemorrhage, including hyperfibrinolysis-induced hemorrhage and postsurgical hemorrhage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminocaproic Acid","conceptCode":"C47391","definition":"A synthetic lysine derivative with antifibrinolytic activity. Aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Aminocaproic acid competitively reduces the conversion of plasminogen to plasmin by plasminogen activators. It directly inhibits proteolytic activity of plasmin, but higher doses are required than are needed to reduce plasmin formation. Aminocaproic acid is used in the treatment of hemorrhage and prophylactically against hemorrhage, including hyperfibrinolysis-induced hemorrhage and postsurgical hemorrhage.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F92-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CF8693-9635-1AF6-E053-4EBD850ADCE8","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Meloxicam","valueDescription":"Meloxicam","ValueMeaning":{"publicId":"2578284","version":"1","preferredName":"Meloxicam","longName":"2578284","preferredDefinition":"An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meloxicam","conceptCode":"C61439","definition":"An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":"Updated definition with current NCIt concept. 10.29.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CF8693-963F-1AF6-E053-4EBD850ADCE8","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Polysulfated Glycosaminoglycan","valueDescription":"Polysulfated Glycosaminoglycan (Adequan Canine, PSGAG)","ValueMeaning":{"publicId":"7485295","version":"1","preferredName":"Polysulfated Glycosaminoglycan (Adequan Canine, PSGAG)","longName":"7485295","preferredDefinition":"A semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from bovine tracheal cartilage and consisting of mostly chondroitin sulfate, with anti-arthritic activities in animals including dogs. Upon administration, polysulfated GAG (PSGAG), a proteolytic enzyme inhibitor, may inhibit various processes that lead to the loss of cartilaginous mucopolysaccharides. This may include the inhibition of interleukin-1 (IL-1)-mediated inflammation and degradation of cartilage proteoglycans and collagen. PSGAG may also stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid, which may improve joint function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polysulfated Glycosaminoglycan","conceptCode":"C175559","definition":"A semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from bovine tracheal cartilage and consisting of mostly chondroitin sulfate, with anti-arthritic activities in animals including dogs. Upon administration, polysulfated GAG (PSGAG), a proteolytic enzyme inhibitor, may inhibit various processes that lead to the loss of cartilaginous mucopolysaccharides. This may include the inhibition of interleukin-1 (IL-1)-mediated inflammation and degradation of cartilage proteoglycans and collagen. PSGAG may also stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid, which may improve joint function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CF8693-964B-1AF6-E053-4EBD850ADCE8","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CF8693-9664-1AF6-E053-4EBD850ADCE8","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Isatuximab","valueDescription":"Isatuximab","ValueMeaning":{"publicId":"6618086","version":"1","preferredName":"Isatuximab","longName":"6618086","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isatuximab","conceptCode":"C90578","definition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801EA03E-93F2-7862-E053-F662850A4F83","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"COOPERM","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C081A415-8DD0-738E-E053-4EBD850A54EE","beginDate":"2021-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"Dubermatinib","valueDescription":"Dubermatinib","ValueMeaning":{"publicId":"7656772","version":"1","preferredName":"Dubermatinib","longName":"7656772","preferredDefinition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dubermatinib","conceptCode":"C127116","definition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2261746-979E-6E4D-E053-4EBD850A048B","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2261746-97B7-6E4D-E053-4EBD850A048B","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","deletedIndicator":"No"},{"value":"Sotorasib","valueDescription":"Sotorasib (AMG510)","ValueMeaning":{"publicId":"7656774","version":"1","preferredName":"Sotorasib (AMG510)","longName":"7656774","preferredDefinition":"An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sotorasib","conceptCode":"C154287","definition":"An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2261746-97C4-6E4D-E053-4EBD850A048B","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"COOPERM","dateModified":"2021-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2261746-97DD-6E4D-E053-4EBD850A048B","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","deletedIndicator":"No"},{"value":"Eltrombopag","valueDescription":"Eltrombopag","ValueMeaning":{"publicId":"3173720","version":"1","preferredName":"Eltrombopag","longName":"3173720","preferredDefinition":"An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eltrombopag","conceptCode":"C71634","definition":"An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97EE67EB-72DA-3463-E040-BB89AD4305CD","latestVersionIndicator":"Yes","beginDate":"2010-12-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2C6FE1F-8BB8-64B2-E053-4EBD850ABEB7","beginDate":"2021-05-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-05-20","modifiedBy":"ONEDATA","dateModified":"2021-05-20","deletedIndicator":"No"},{"value":"Encorafenib","valueDescription":"Encorafenib","ValueMeaning":{"publicId":"7679543","version":"1","preferredName":"Encorafenib","longName":"7679543","preferredDefinition":"An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Encorafenib","conceptCode":"C98283","definition":"An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4351C00-9939-1CEA-E053-4EBD850AE305","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-07","modifiedBy":"ONEDATA","dateModified":"2021-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4351C00-9952-1CEA-E053-4EBD850AE305","beginDate":"2021-06-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-07","modifiedBy":"ONEDATA","dateModified":"2021-06-07","deletedIndicator":"No"},{"value":"Mogamulizumab","valueDescription":"Mogamulizumab","ValueMeaning":{"publicId":"5944042","version":"1","preferredName":"Mogamulizumab","longName":"5944042","preferredDefinition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mogamulizumab","conceptCode":"C62510","definition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FE7C-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFF619BE-FFDF-1A7C-E053-4EBD850AF3D8","beginDate":"2021-04-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","deletedIndicator":"No"},{"value":"HiDAC","valueDescription":"High-Dose Cytarabine Regimen","ValueMeaning":{"publicId":"7775255","version":"1","preferredName":"High-Dose Cytarabine Regimen","longName":"7775255","preferredDefinition":"A chemotherapy regimen consisting of high-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML) and primary central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High-Dose Cytarabine Regimen","conceptCode":"C160046","definition":"A chemotherapy regimen consisting of high-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML) and primary central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CADFBC77-398E-3205-E053-4EBD850A6B44","latestVersionIndicator":"Yes","beginDate":"2021-08-31","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADFBC77-39A7-3205-E053-4EBD850A6B44","beginDate":"2021-08-31","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Enfortumab Vedotin","valueDescription":"Enfortumab Vedotin","ValueMeaning":{"publicId":"7775224","version":"1","preferredName":"Enfortumab Vedotin","longName":"7775224","preferredDefinition":"An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enfortumab Vedotin","conceptCode":"C114500","definition":"An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CACCEDA3-F159-49C4-E053-4EBD850A830B","latestVersionIndicator":"Yes","beginDate":"2021-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-30","modifiedBy":"ONEDATA","dateModified":"2021-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CACCEDA3-F172-49C4-E053-4EBD850A830B","beginDate":"2021-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-30","modifiedBy":"ONEDATA","dateModified":"2021-08-30","deletedIndicator":"No"},{"value":"Erdafitinib","valueDescription":"Erdafitinib","ValueMeaning":{"publicId":"7775226","version":"1","preferredName":"Erdafitinib","longName":"7775226","preferredDefinition":"An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erdafitinib","conceptCode":"C103273","definition":"An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CACCEDA3-F17F-49C4-E053-4EBD850A830B","latestVersionIndicator":"Yes","beginDate":"2021-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-30","modifiedBy":"ONEDATA","dateModified":"2021-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CACCEDA3-F198-49C4-E053-4EBD850A830B","beginDate":"2021-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-08-30","modifiedBy":"ONEDATA","dateModified":"2021-08-30","deletedIndicator":"No"},{"value":"Sacituzumab","valueDescription":"Sacituzumab","ValueMeaning":{"publicId":"7792993","version":"1","preferredName":"Sacituzumab","longName":"7792993","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sacituzumab","conceptCode":"C152280","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD3B2027-565B-2D74-E053-4EBD850A2E11","latestVersionIndicator":"Yes","beginDate":"2021-09-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-09-30","modifiedBy":"ONEDATA","dateModified":"2021-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD3B2027-5674-2D74-E053-4EBD850A2E11","beginDate":"2021-09-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-09-30","modifiedBy":"ONEDATA","dateModified":"2021-09-30","deletedIndicator":"No"},{"value":"TEDDI-R","valueDescription":"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R)","ValueMeaning":{"publicId":"7740110","version":"1","preferredName":"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R)","longName":"7740110","preferredDefinition":"A chemoimmunotherapy regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, ibrutinib, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide Regimen","conceptCode":"C180769","definition":"A chemoimmunotherapy regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, ibrutinib, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C71B135C-D0D3-2F51-E053-4EBD850AC975","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-14","modifiedBy":"HARTLEYG","dateModified":"2021-07-20","changeDescription":"Added concept when loaded into caDSR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C71B3028-2BCB-44D0-E053-4EBD850A170F","beginDate":"2021-07-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-14","modifiedBy":"ONEDATA","dateModified":"2021-07-14","deletedIndicator":"No"},{"value":"Idelalisib","valueDescription":"Idelalisib","ValueMeaning":{"publicId":"5096863","version":"1","preferredName":"Idelalisib","longName":"5096863","preferredDefinition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idelalisib","conceptCode":"C78825","definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-479D-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C790FF9E-C243-1A66-E053-4EBD850A6E50","beginDate":"2021-07-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-20","modifiedBy":"ONEDATA","dateModified":"2021-07-20","deletedIndicator":"No"},{"value":"Polatuzumab Vedotin","valueDescription":"Polatuzumab Vedotin","ValueMeaning":{"publicId":"7739453","version":"1","preferredName":"Polatuzumab Vedotin","longName":"7739453","preferredDefinition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polatuzumab Vedotin","conceptCode":"C104153","definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7072988-11DF-4C09-E053-4EBD850A2A72","latestVersionIndicator":"Yes","beginDate":"2021-07-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-13","modifiedBy":"ONEDATA","dateModified":"2021-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7072988-11F8-4C09-E053-4EBD850A2A72","beginDate":"2021-07-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-13","modifiedBy":"ONEDATA","dateModified":"2021-07-13","deletedIndicator":"No"},{"value":"SIRPa-IgG4-Fc Fusion Protein TTI-622","valueDescription":"SIRPa-IgG4-Fc Fusion Protein TTI-622","ValueMeaning":{"publicId":"7739455","version":"1","preferredName":"SIRPa-IgG4-Fc Fusion Protein TTI-622","longName":"7739455","preferredDefinition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, the SIRPa-IgG4-Fc fusion protein TTI-622 selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maplirpacept","conceptCode":"C150756","definition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7072988-1205-4C09-E053-4EBD850A2A72","latestVersionIndicator":"Yes","beginDate":"2021-07-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-13","modifiedBy":"ONEDATA","dateModified":"2021-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7072988-121E-4C09-E053-4EBD850A2A72","beginDate":"2021-07-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-13","modifiedBy":"ONEDATA","dateModified":"2021-07-13","deletedIndicator":"No"},{"value":"TEDD-R","valueDescription":"Temozolomide, Etoposide, Doxil, Dexamethasone and Rituximab (TEDD-R)","ValueMeaning":{"publicId":"7736635","version":"1","preferredName":"Temozolomide, Etoposide, Doxil, Dexamethasone and Rituximab (TEDD-R)","longName":"7736635","preferredDefinition":"A chemoimmunotherapy regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone/Liposomal Doxorubicin/Etoposide/Rituximab/Temozolomide Regimen","conceptCode":"C180731","definition":"A chemoimmunotherapy regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F2E6C6-DE3D-5F40-E053-4EBD850AA801","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-12","modifiedBy":"HARTLEYG","dateModified":"2021-07-20","changeDescription":"Added concept once loaded.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7072211-6600-3E49-E053-4EBD850A65F3","beginDate":"2021-07-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-07-13","modifiedBy":"ONEDATA","dateModified":"2021-07-13","deletedIndicator":"No"},{"value":"Lurbinectedin","valueDescription":"Lurbinectedin","ValueMeaning":{"publicId":"7685533","version":"1","preferredName":"Lurbinectedin","longName":"7685533","preferredDefinition":"A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lurbinectedin","conceptCode":"C82382","definition":"A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4C130C1-723A-52D1-E053-4EBD850A849B","latestVersionIndicator":"Yes","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4BEEB0F-0258-6A88-E053-4EBD850A9289","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","deletedIndicator":"No"},{"value":"Avapritinib","valueDescription":"Avapritinib","ValueMeaning":{"publicId":"7685535","version":"1","preferredName":"Avapritinib","longName":"7685535","preferredDefinition":"An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avapritinib","conceptCode":"C123827","definition":"An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4C130C1-7260-52D1-E053-4EBD850A849B","latestVersionIndicator":"Yes","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4BEEB0F-026C-6A88-E053-4EBD850A9289","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","deletedIndicator":"No"},{"value":"Ripretinib","valueDescription":"Ripretinib","ValueMeaning":{"publicId":"7685537","version":"1","preferredName":"Ripretinib","longName":"7685537","preferredDefinition":"An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ripretinib","conceptCode":"C124067","definition":"An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4C130C1-7288-52D1-E053-4EBD850A849B","latestVersionIndicator":"Yes","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4BEEB0F-0280-6A88-E053-4EBD850A9289","beginDate":"2021-06-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-14","modifiedBy":"ONEDATA","dateModified":"2021-06-14","deletedIndicator":"No"},{"value":"Acalabrutinib","valueDescription":"Acalabrutinib","ValueMeaning":{"publicId":"6028593","version":"1","preferredName":"Acalabrutinib","longName":"6028593","preferredDefinition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acalabrutinib","conceptCode":"C113442","definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1C8E98-260C-503F-E053-F662850A8F36","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D30ABC1F-CDCF-724C-E053-4EBD850A8A9F","beginDate":"2021-12-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-12-13","modifiedBy":"ONEDATA","dateModified":"2021-12-13","deletedIndicator":"No"},{"value":"Antiandrogen Therapy (ADT)","valueDescription":"Antiandrogen Therapy","ValueMeaning":{"publicId":"5053421","version":"1","preferredName":"Antiandrogen Therapy","longName":"5053421","preferredDefinition":"Treatment with drugs used to block production or interfere with the action of male sex hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiandrogen Therapy","conceptCode":"C15481","definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"253EB018-6267-7E8E-E050-BB89AD43347B","latestVersionIndicator":"Yes","beginDate":"2015-11-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D30ABC1F-CDE3-724C-E053-4EBD850A8A9F","beginDate":"2021-12-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-12-13","modifiedBy":"ONEDATA","dateModified":"2021-12-13","deletedIndicator":"No"},{"value":"Rilimogene Glafolivec","valueDescription":"Rilimogene Glafolivec","ValueMeaning":{"publicId":"8024222","version":"1","preferredName":"Rilimogene Glafolivec","longName":"8024222","preferredDefinition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilimogene Glafolivec","conceptCode":"C29560","definition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6FBF4AD-47AF-7BCF-E053-4EBD850A595A","latestVersionIndicator":"Yes","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"HARTLEYG","dateModified":"2022-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6FBF4AD-47C8-7BCF-E053-4EBD850A595A","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"ONEDATA","dateModified":"2022-02-01","deletedIndicator":"No"},{"value":"Rilimogene Galvacirepvec","valueDescription":"Rilimogene Galvacirepvec","ValueMeaning":{"publicId":"6159909","version":"1","preferredName":"Rilimogene Galvacirepvec","longName":"6159909","preferredDefinition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilimogene Galvacirepvec","conceptCode":"C38681","definition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5BA8-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"HARTLEYG","dateModified":"2022-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6FBF4AD-47DC-7BCF-E053-4EBD850A595A","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"ONEDATA","dateModified":"2022-02-01","deletedIndicator":"No"},{"value":"CXCR1/2 Inhibitor SX-682","valueDescription":"CXCR1/2 Inhibitor SX-682","ValueMeaning":{"publicId":"8049068","version":"1","preferredName":"CXCR1/2 Inhibitor SX-682","longName":"8049068","preferredDefinition":"An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CXCR1/2 Inhibitor SX-682","conceptCode":"C150389","definition":"An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D84F133C-A559-6205-E053-4EBD850A468B","latestVersionIndicator":"Yes","beginDate":"2022-02-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-18","modifiedBy":"ONEDATA","dateModified":"2022-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D84F1BB6-DB60-6207-E053-4EBD850ACFFC","beginDate":"2022-02-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-18","modifiedBy":"ONEDATA","dateModified":"2022-02-18","deletedIndicator":"No"},{"value":"Ivosidenib","valueDescription":"Ivosidenib","ValueMeaning":{"publicId":"6429532","version":"1","preferredName":"Ivosidenib","longName":"6429532","preferredDefinition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivosidenib","conceptCode":"C114383","definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AC7369-E7A7-1EBD-E053-F662850A1EEE","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB7234CD-AA1A-07C4-E053-4EBD850A7EDA","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"ONEDATA","dateModified":"2022-03-30","deletedIndicator":"No"},{"value":"ALT-803","valueDescription":null,"ValueMeaning":{"publicId":"6004367","version":"1","preferredName":"Nogapendekin Alfa","longName":"6004367","preferredDefinition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nogapendekin Alfa","conceptCode":"C107503","definition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAAA573-85ED-197B-E053-F662850A215E","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"KUMMEROA","dateModified":"2022-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF254FDB-10CB-0788-E053-731AD00A68DE","beginDate":"2022-05-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-05-17","modifiedBy":"KUMMEROA","dateModified":"2022-05-17","deletedIndicator":"No"},{"value":"CALGB 10403 Regimen","valueDescription":null,"ValueMeaning":{"publicId":"10694589","version":"1","preferredName":"CALGB 10403 Regimen","longName":"10694589v1.00","preferredDefinition":"CALGB 10403 Regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E456632F-85CE-214F-E053-731AD00ABAD8","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-21","modifiedBy":"GDEEN","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E456632F-85CF-214F-E053-731AD00ABAD8","beginDate":"2022-07-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-21","modifiedBy":"GDEEN","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"Apalutamide","valueDescription":null,"ValueMeaning":{"publicId":"5811375","version":"1","preferredName":"Apalutamide","longName":"5811375","preferredDefinition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apalutamide","conceptCode":"C92574","definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26D5-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7107C52-4535-5D39-E053-731AD00A141E","beginDate":"2022-08-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-25","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","deletedIndicator":"No"},{"value":"Darolutamide","valueDescription":null,"ValueMeaning":{"publicId":"6159883","version":"1","preferredName":"Darolutamide","longName":"6159883v1.00","preferredDefinition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darolutamide","conceptCode":"C104748","definition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4B98-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7107C52-4536-5D39-E053-731AD00A141E","beginDate":"2022-08-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-25","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","deletedIndicator":"No"},{"value":"Belumosudil","valueDescription":null,"ValueMeaning":{"publicId":"7614732","version":"1","preferredName":"Belumosudil","longName":"7614732","preferredDefinition":"An orally administered inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belumosudil","conceptCode":"C128786","definition":"An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A44-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F4-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"11289980","version":"1","preferredName":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"11289980v1.00","preferredDefinition":"A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C173644","definition":"A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFAF-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F5-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Dolutegravir Sodium/Rilpivirine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"11289984","version":"1","preferredName":"Dolutegravir Sodium/Rilpivirine Hydrochloride","longName":"11289984v1.00","preferredDefinition":"A fixed two-agent combination of the sodium salt form of dolutegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI) and the hydrochloride salt form of rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon oral administration of dolutegravir sodium/rilpivirine hydrochloride, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolutegravir Sodium/Rilpivirine Hydrochloride","conceptCode":"C189974","definition":"A fixed two-agent combination of the sodium salt form of dolutegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI and the hydrochloride salt form of rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon oral administration of dolutegravir sodium/rilpivirine hydrochloride, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9389882-E553-5E85-E053-731AD00A5B1E","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F6-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Molnupiravir","valueDescription":null,"ValueMeaning":{"publicId":"8062014","version":"1","preferredName":"Molnupiravir","longName":"8062014","preferredDefinition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molnupiravir","conceptCode":"C172633","definition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3F95-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F7-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Imipenem-Cilastatin-Relebactam","valueDescription":null,"ValueMeaning":{"publicId":"11289981","version":"1","preferredName":"Imipenem-Cilastatin-Relebactam","longName":"11289981v1.00","preferredDefinition":"A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem-Cilastatin-Relebactam","conceptCode":"C181013","definition":"A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFB0-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F8-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Tedizolid","valueDescription":null,"ValueMeaning":{"publicId":"7094876","version":"1","preferredName":"Tedizolid","longName":"7094876","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tedizolid","conceptCode":"C84222","definition":"An antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99EFE66B-C6A0-1CAA-E053-F662850A8AE0","latestVersionIndicator":"Yes","beginDate":"2019-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-17","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9F9-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Meropenem Trihydrate/Vaborbactam","valueDescription":null,"ValueMeaning":{"publicId":"11289982","version":"1","preferredName":"Meropenem Trihydrate/Vaborbactam","longName":"11289982v1.00","preferredDefinition":"A fixed two-agent injectable combination of the trihydrate form of meropenem, a broad-spectrum synthetic beta-lactam carbapenem antibiotic, and vaborbactam, a cyclic boronic acid beta-lactamase inhibitor, with antibacterial activity against susceptible bacteria. Upon administration of meropenem trihydrate/vaborbactam, meropenem binds to and inactivates penicillin-binding proteins (PBPs) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Vaborbactam binds to and inhibits beta-lactamase, thereby inhibiting the breakdown of meropenem, and increases the activity and therapeutic effect of meropenem.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meropenem Trihydrate/Vaborbactam","conceptCode":"C189976","definition":"A fixed two-agent injectable combination of the trihydrate form of meropenem, a broad-spectrum synthetic beta-lactam carbapenem antibiotic, and vaborbactam, a cyclic boronic acid beta-lactamase inhibitor, with antibacterial activity against susceptible bacteria. Upon administration of meropenem trihydrate/vaborbactam, meropenem binds to and inactivates penicillin-binding proteins (PBPs) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Vaborbactam binds to and inhibits beta-lactamase, thereby inhibiting the breakdown of meropenem, and increases the activity and therapeutic effect of meropenem.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFB1-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E938D1C2-D9FA-6457-E053-731AD00AA851","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Acetaminophen/Tramadol","valueDescription":null,"ValueMeaning":{"publicId":"12093849","version":"1","preferredName":"Acetaminophen/Tramadol (Tramacet)","longName":"12093849v1.00","preferredDefinition":"A combination preparation of the non-opiate, non-salicylate analgesic acetaminophen and the centrally acting synthetic opioid analgesic tramadol, with analgesic activity. Upon oral administration, acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while tramadol exerts its analgesic activity by multiple mechanisms including the binding to the mu-opioid receptors in the central nervous system (CNS) and the weak inhibition of norepinephrine and serotonin reuptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Tramadol","conceptCode":"C190844","definition":"A combination preparation of the non-opiate, non-salicylate analgesic acetaminophen and the centrally acting synthetic opioid analgesic tramadol, with analgesic activity. Upon oral administration, acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while tramadol exerts its analgesic activity by multiple mechanisms including the binding to the mu-opioid receptors in the central nervous system (CNS) and the weak inhibition of norepinephrine and serotonin reuptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A64-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB51BC1-4A01-0825-E053-731AD00A8F92","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Enclomiphene Citrate","valueDescription":null,"ValueMeaning":{"publicId":"12093850","version":"1","preferredName":"Enclomiphene Citrate (Androxal)","longName":"12093850v1.00","preferredDefinition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enclomiphene Citrate","conceptCode":"C61745","definition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A65-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB51BC1-4A02-0825-E053-731AD00A8F92","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Ibutamoren Mesylate","valueDescription":null,"ValueMeaning":{"publicId":"12093851","version":"1","preferredName":"Ibutamoren Mesylate (Nutrobal)","longName":"12093851v1.00","preferredDefinition":"The mesylate salt form of ibutamoren, an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS). Upon administration, ibutamoren promotes the release of growth hormone (GH) from the pituitary gland, thereby increasing plasma GH levels. This may counteract GH deficiency. GH plays an important role in many biological processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibutamoren Mesylate","conceptCode":"C97489","definition":"The mesylate salt form of ibutamoren, an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS). Upon administration, ibutamoren promotes the release of growth hormone (GH) from the pituitary gland, thereby increasing plasma GH levels. This may counteract GH deficiency. GH plays an important role in many biological processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A66-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB51BC1-4A03-0825-E053-731AD00A8F92","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection","valueDescription":null,"ValueMeaning":{"publicId":"12093852","version":"1","preferredName":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection (Lipo-B (MIC) injection)","longName":"12093852v1.00","preferredDefinition":"An injectable preparation composed of the four ingredients methionine, inositol, choline chloride and cyanocobalamin, with potential lipotropic activity. Upon administration of methionine/inositol/choline chloride/cyanocobalamin injection, the active ingredients may exert lipotropic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection","conceptCode":"C190845","definition":"An injectable preparation composed of the four ingredients methionine, inositol, choline chloride and cyanocobalamin, with potential lipotropic activity. Upon administration of methionine/inositol/choline chloride/cyanocobalamin injection, the active ingredients may exert lipotropic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A67-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB51BC1-4A04-0825-E053-731AD00A8F92","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Cobalamin","valueDescription":null,"ValueMeaning":{"publicId":"2577835","version":"1","preferredName":"Vitamin B12","longName":"2577835","preferredDefinition":"A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobalamin","conceptCode":"C939","definition":"An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB54000-483B-0CCC-E053-731AD00A2257","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Copanlisib","valueDescription":null,"ValueMeaning":{"publicId":"12117784","version":"1","preferredName":"Copanlisib Hydrochloride (Aliqopa)","longName":"12117784v1.00","preferredDefinition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copanlisib Hydrochloride","conceptCode":"C138994","definition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA771CA-4F81-4CFD-E053-731AD00A43EC","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-29","modifiedBy":"GDEEN","dateModified":"2022-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEA77FA7-5CCB-4F25-E053-731AD00A0F27","beginDate":"2022-11-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-29","modifiedBy":"GDEEN","dateModified":"2022-11-29","deletedIndicator":"No"},{"value":"Vortioxetine Hydrobromide","valueDescription":null,"ValueMeaning":{"publicId":"12127874","version":"1","preferredName":"Vortioxetine Hydrobromide (Trintellix)","longName":"12127874v1.00","preferredDefinition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vortioxetine Hydrobromide","conceptCode":"C125653","definition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF354FFA-1174-5D37-E053-731AD00AFA66","latestVersionIndicator":"Yes","beginDate":"2022-12-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-06","modifiedBy":"GDEEN","dateModified":"2022-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF3F463C-A156-0E95-E053-731AD00A0803","beginDate":"2022-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-07","modifiedBy":"GDEEN","dateModified":"2022-12-07","deletedIndicator":"No"},{"value":"Carboxymethylcellulose Sodium-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"3777004","version":"1","preferredName":"Carboxymethylcellulose Sodium-containing Eye Drop","longName":"3777004","preferredDefinition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose Sodium-containing Eye Drop","conceptCode":"C106410","definition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DECE2246-538B-B502-E040-BB89AD4311C4","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-10","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F033061F-C75C-3CB8-E053-731AD00A4947","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"12173256","version":"1","preferredName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop (Systane)","longName":"12173256v1.00","preferredDefinition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","conceptCode":"C191779","definition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F032E55A-3C26-2E85-E053-731AD00A95DF","latestVersionIndicator":"Yes","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F033061F-C75D-3CB8-E053-731AD00A4947","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Oportuzumab Monatox","valueDescription":null,"ValueMeaning":{"publicId":"12187520","version":"1","preferredName":"Oportuzumab Monatox (Vicinium)","longName":"12187520v1.00","preferredDefinition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oportuzumab Monatox","conceptCode":"C61307","definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0462917-59F7-3A52-E053-731AD00A9E56","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-20","modifiedBy":"GDEEN","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F0463C24-2475-3C23-E053-731AD00AA05C","beginDate":"2022-12-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-20","modifiedBy":"GDEEN","dateModified":"2022-12-20","deletedIndicator":"No"},{"value":"Alfuzosin Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12203720","version":"1","preferredName":"Alfuzosin Hydrochloride","longName":"12203720v1.00","preferredDefinition":"The hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alfuzosin Hydrochloride","conceptCode":"C53408","definition":"The hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F05B5464-85DA-3DE6-E053-731AD00AE613","latestVersionIndicator":"Yes","beginDate":"2022-12-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-21","modifiedBy":"GDEEN","dateModified":"2022-12-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F05B5464-85DB-3DE6-E053-731AD00AE613","beginDate":"2022-12-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-21","modifiedBy":"GDEEN","dateModified":"2022-12-21","deletedIndicator":"No"},{"value":"Mepivacaine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12267130","version":"1","preferredName":"Mepivacaine Hydrochloride (Carbocaine)","longName":"12267130v1.00","preferredDefinition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mepivacaine Hydrochloride","conceptCode":"C47602","definition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10F9205-BC32-2765-E053-731AD00A55C5","latestVersionIndicator":"Yes","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F10FB1A6-ADBF-3328-E053-731AD00A9A11","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","deletedIndicator":"No"},{"value":"Vedolizumab","valueDescription":null,"ValueMeaning":{"publicId":"8115529","version":"1","preferredName":"Vedolizumab","longName":"8115529v1.00","preferredDefinition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vedolizumab","conceptCode":"C95798","definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3E8E-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"GDEEN","dateModified":"2023-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4123A16-0271-4D3E-E053-731AD00AB231","beginDate":"2023-02-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-06","modifiedBy":"GDEEN","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"Retifanlimab","valueDescription":null,"ValueMeaning":{"publicId":"13314837","version":"1","preferredName":"Retifanlimab (Zynyz)","longName":"13314837v1.00","preferredDefinition":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retifanlimab","conceptCode":"C142168","definition":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89A827A-EB4E-7DEE-E053-731AD00A0CF8","latestVersionIndicator":"Yes","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F89A827A-EB4F-7DEE-E053-731AD00A0CF8","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","deletedIndicator":"No"},{"value":"Bleomycin, Etoposide and Platinum","valueDescription":null,"ValueMeaning":{"publicId":"13336614","version":"1","preferredName":"BEP Regimen","longName":"13336614v1.00","preferredDefinition":"A chemotherapy regimen consisting of bleomycin, etoposide and cisplatin used for the treatment of ovarian and testicular germ cell tumors (GCTs).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BEP Regimen","conceptCode":"C63488","definition":"A regimen consisting of bleomycin, etoposide and cisplatin that may be used for the treatment of gestational trophoblastic neoplasia (GTN),  malignant sex cord-stromal tumors, ovarian and testicular cancer, including ovarian and testicular germ cell tumors (GCTs).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FEB340-8D9D-675F-E053-731AD00A73C6","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-10","modifiedBy":"GDEEN","dateModified":"2023-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8FEB340-8D9E-675F-E053-731AD00A73C6","beginDate":"2023-04-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-10","modifiedBy":"GDEEN","dateModified":"2023-04-10","deletedIndicator":"No"},{"value":"Abacavir sulfate","valueDescription":null,"ValueMeaning":{"publicId":"2576888","version":"1","preferredName":"Abacavir Sulfate","longName":"2576888","preferredDefinition":"A synthetic carbocyclic nucleoside analog.  In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles.  This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate","conceptCode":"C28804","definition":"A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F965-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033717-07D4-023F-E053-731AD00AE7D9","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Abacavir sulfate/Lamivudine regimen","valueDescription":null,"ValueMeaning":{"publicId":"13763492","version":"1","preferredName":"Abacavir Sulfate/Lamivudine","longName":"13763492v1.00","preferredDefinition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate/Lamivudine","conceptCode":"C157405","definition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033717-07D3-023F-E053-731AD00AE7D9","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033717-07D5-023F-E053-731AD00AE7D9","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Cobicistat","valueDescription":null,"ValueMeaning":{"publicId":"13763495","version":"1","preferredName":"Cobicistat","longName":"13763495v1.00","preferredDefinition":"A cytochrome P450 3A (CYP3A) inhibitor that can be used to enhance the pharmacokinetic profile of certain anti-HIV-1 agents. Upon administration, cobicistat inhibits the liver enzyme CYP3A4 and limits the breakdown of co-administered agents that are metabolized by CYP3A4, and increases the concentration, systemic exposure and efficacy of the co-administered agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobicistat","conceptCode":"C97360","definition":"A cytochrome P450 3A (CYP3A) inhibitor that can be used to enhance the pharmacokinetic profile of certain anti-HIV-1 agents. Upon administration, cobicistat inhibits the liver enzyme CYP3A4 and limits the breakdown of co-administered agents that are metabolized by CYP3A4, and increases the concentration, systemic exposure and efficacy of the co-administered agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8A-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033CFE-0D93-0308-E053-731AD00A79BE","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Darunavir ethanolate","valueDescription":null,"ValueMeaning":{"publicId":"13763496","version":"1","preferredName":"Darunavir Ethanolate","longName":"13763496v1.00","preferredDefinition":"The ethanolate form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir Ethanolate","conceptCode":"C77389","definition":"The ethanolate form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8B-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033CFE-0D94-0308-E053-731AD00A79BE","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Emtricitabine/Tenofovir alafenamide fumarate regimen","valueDescription":null,"ValueMeaning":{"publicId":"13763498","version":"1","preferredName":"Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"13763498v1.00","preferredDefinition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C157538","definition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8D-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033CFE-0D96-0308-E053-731AD00A79BE","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Dolutegravir sodium","valueDescription":null,"ValueMeaning":{"publicId":"13763499","version":"1","preferredName":"Dolutegravir Sodium","longName":"13763499v1.00","preferredDefinition":"The sodium salt form of dolutegravir, an orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolutegravir Sodium","conceptCode":"C148408","definition":"The sodium salt form of dolutegravir, an orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8E-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033CFE-0D97-0308-E053-731AD00A79BE","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Doravirine","valueDescription":null,"ValueMeaning":{"publicId":"13763500","version":"1","preferredName":"Doravirine","longName":"13763500v1.00","preferredDefinition":"A pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), that is used to treat HIV infection. Upon oral administration, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doravirine","conceptCode":"C171848","definition":"A pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), that is used to treat HIV infection. Upon oral administration, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8F-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD033CFE-0D98-0308-E053-731AD00A79BE","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763503","version":"1","preferredName":"Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate","longName":"13763503v1.00","preferredDefinition":"A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate","conceptCode":"C157403","definition":"A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD034144-C29C-03ED-E053-731AD00A62FB","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD034144-C29E-03ED-E053-731AD00A62FB","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Elvitegravir","valueDescription":null,"ValueMeaning":{"publicId":"13763504","version":"1","preferredName":"Elvitegravir","longName":"13763504v1.00","preferredDefinition":"A modified quinolone antibiotic with activity against human immunodeficiency virus 1. Elvitegravir is an inhibitor of viral integrase and retains activity against integrase mutants that are resistant to Raltegravir.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elvitegravir","conceptCode":"C76493","definition":"A modified quinolone antibiotic with activity against human immunodeficiency virus 1. Elvitegravir is an inhibitor of viral integrase and retains activity against integrase mutants that are resistant to Raltegravir.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD034144-C29D-03ED-E053-731AD00A62FB","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD034144-C29F-03ED-E053-731AD00A62FB","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Emtracitabine/Tenofovir disoproxil fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763505","version":"1","preferredName":"Emtricitabine/Tenofovir Disoproxil Fumarate","longName":"13763505v1.00","preferredDefinition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine/Tenofovir Disoproxil Fumarate","conceptCode":"C157535","definition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0342EF-45C8-0412-E053-731AD00A27EC","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45CD-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Etravirine","valueDescription":null,"ValueMeaning":{"publicId":"3380178","version":"1","preferredName":"Etravirine","longName":"3380178","preferredDefinition":"A diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etravirine","conceptCode":"C73195","definition":"A diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D4D9-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45CE-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Atazanavir/Cobicistat","valueDescription":null,"ValueMeaning":{"publicId":"13763507","version":"1","preferredName":"Atazanavir/Cobicistat","longName":"13763507v1.00","preferredDefinition":"A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV-1 infection. Upon oral administration, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of atazanavir and increasing its systemic exposure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atazanavir/Cobicistat","conceptCode":"C157541","definition":"A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV-1 infection. Upon oral administration, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of atazanavir and increasing its systemic exposure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0342EF-45CA-0412-E053-731AD00A27EC","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45D0-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Fostemsavir tromethamine","valueDescription":null,"ValueMeaning":{"publicId":"13763508","version":"1","preferredName":"Fostemsavir Tromethamine","longName":"13763508v1.00","preferredDefinition":"The tromethamine salt form of fostemsavir, an orally bioavailable phosphonooxymethyl prodrug of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir, with activity against HIV. Upon oral administration, fostemsavir is hydrolyzed to the active moiety temsavir. Temsavir targets and binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160. This selectively inhibits the interaction between HIV-1 virus and host cellular CD4 receptors, thereby preventing HIV-1 virus attachment. This also inhibits gp120-dependent post-attachment steps that are needed for HIV-1 viral entry into host cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fostemsavir Tromethamine","conceptCode":"C166604","definition":"The tromethamine salt form of fostemsavir, an orally bioavailable phosphonooxymethyl prodrug of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir, with activity against HIV. Upon oral administration, fostemsavir is hydrolyzed to the active moiety temsavir. Temsavir targets and binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160. This selectively inhibits the interaction between HIV-1 virus and host cellular CD4 receptors, thereby preventing HIV-1 virus attachment. This also inhibits gp120-dependent post-attachment steps that are needed for HIV-1 viral entry into host cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0342EF-45CB-0412-E053-731AD00A27EC","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45D1-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide fumarate","valueDescription":null,"ValueMeaning":{"publicId":"8024216","version":"1","preferredName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"8024216","preferredDefinition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C157537","definition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6FBE51D-09C0-33FD-E053-4EBD850A5B32","latestVersionIndicator":"Yes","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45D2-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Ibalizumab-uiyk","valueDescription":null,"ValueMeaning":{"publicId":"13763509","version":"1","preferredName":"Ibalizumab-uiyk (Trogarzo)","longName":"13763509v1.00","preferredDefinition":"A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for HIV, thereby inhibiting HIV entry into CD4-positive T-cells. This leads to a reduction in viral load.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibalizumab","conceptCode":"C88612","definition":"A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for HIV, thereby inhibiting HIV entry into CD4-positive T-cells. This leads to a reduction in viral load.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0342EF-45CC-0412-E053-731AD00A27EC","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0342EF-45D3-0412-E053-731AD00A27EC","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Lamivudine","valueDescription":null,"ValueMeaning":{"publicId":"3378060","version":"1","preferredName":"Lamivudine","longName":"3378060","preferredDefinition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B900BC0D-BE49-CD46-E040-BB89AD434DBB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C1-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Lamivudine/Zidovudine","valueDescription":null,"ValueMeaning":{"publicId":"2577823","version":"1","preferredName":"Lamivudine/Zidovudine","longName":"2577823","preferredDefinition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine/Zidovudine","conceptCode":"C28939","definition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C2-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Lenacapavir sodium","valueDescription":null,"ValueMeaning":{"publicId":"13763543","version":"1","preferredName":"Lenacapavir Sodium","longName":"13763543v1.00","preferredDefinition":"The sodium salt form of lenacapavir, an inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function, with activity against HIV. Upon administration, lenacapavir targets and binds to the interface between HIV capsid protein (p24) subunits in hexamers. This inhibits capsid function, including capsid-mediated nuclear uptake of preintegration complexes, virion production and proper capsid core formation, thereby inhibiting HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenacapavir Sodium","conceptCode":"C186395","definition":"The sodium salt form of lenacapavir, an inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function, with activity against HIV. Upon administration, lenacapavir targets and binds to the interface between HIV capsid protein (p24) subunits in hexamers. This inhibits capsid function, including capsid-mediated nuclear uptake of preintegration complexes, virion production and proper capsid core formation, thereby inhibiting HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5BC-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C3-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Maraviroc","valueDescription":null,"ValueMeaning":{"publicId":"6429534","version":"1","preferredName":"Maraviroc","longName":"6429534","preferredDefinition":"A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maraviroc","conceptCode":"C73144","definition":"A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-492C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C4-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Emtricitabine/Rilpivirine/Tenofovir alafenamide fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763544","version":"1","preferredName":"Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate","longName":"13763544v1.00","preferredDefinition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a diarylpyrimidine derivative and non-nucleoside RT inhibitor (NNRTI); and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Rilpivirine, a non-competitive NNRTI binds to RT and inhibits RNA and DNA-dependent polymerase activities, including viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate","conceptCode":"C157539","definition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a diarylpyrimidine derivative and non-nucleoside RT inhibitor (NNRTI); and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Rilpivirine, a non-competitive NNRTI binds to RT and inhibits RNA and DNA-dependent polymerase activities, including viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5BD-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C5-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Raltegravir potassium","valueDescription":null,"ValueMeaning":{"publicId":"13763545","version":"1","preferredName":"Raltegravir Potassium","longName":"13763545v1.00","preferredDefinition":"The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltegravir Potassium","conceptCode":"C73823","definition":"The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5BE-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C6-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Darunavir/Cobicistat","valueDescription":null,"ValueMeaning":{"publicId":"13763546","version":"1","preferredName":"Darunavir/Cobicistat","longName":"13763546v1.00","preferredDefinition":"A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir/Cobicistat","conceptCode":"C157536","definition":"A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5BF-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C7-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Rilpivirine","valueDescription":null,"ValueMeaning":{"publicId":"13763547","version":"1","preferredName":"Rilpivirine","longName":"13763547v1.00","preferredDefinition":"A second-generation non-nucleoside reverse transcriptase inhibitor. Rilpivirine is a diarylpyrimidine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilpivirine","conceptCode":"C76929","definition":"A second-generation non-nucleoside reverse transcriptase inhibitor. Rilpivirine is a diarylpyrimidine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5C0-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5C8-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763548","version":"1","preferredName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate","longName":"13763548v1.00","preferredDefinition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate","conceptCode":"C157404","definition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D1-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5D4-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Tenofovir alafenamide","valueDescription":null,"ValueMeaning":{"publicId":"13763549","version":"1","preferredName":"Tenofovir Alafenamide","longName":"13763549v1.00","preferredDefinition":"A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tenofovir Alafenamide","conceptCode":"C148276","definition":"A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D2-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5D5-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Abacavir/Dolutegravir/Lamivudine","valueDescription":null,"ValueMeaning":{"publicId":"13763550","version":"1","preferredName":"Abacavir/Dolutegravir/Lamivudine","longName":"13763550v1.00","preferredDefinition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir/Dolutegravir/Lamivudine","conceptCode":"C157543","definition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D3-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5D6-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Zidovudine","valueDescription":null,"ValueMeaning":{"publicId":"3128742","version":"1","preferredName":"Zidovudine","longName":"3128742","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zidovudine","conceptCode":"C947","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E76-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0345A9-D5D7-049D-E053-731AD00A7FA4","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","deletedIndicator":"No"},{"value":"Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13795017","version":"1","preferredName":"Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"13795017v1.00","preferredDefinition":"An orally bioavailable fixed combination of bictegravir sodium, the sodium salt form of the human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) bictegravir, emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of bictegravir/emtricitabine/tenofovir alafenamide, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C199579","definition":"An orally bioavailable fixed combination of bictegravir sodium, the sodium salt form of the human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) bictegravir, emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of bictegravir/emtricitabine/tenofovir alafenamide, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD2873BC-5D20-6A5C-E053-731AD00A0FF7","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD2873BC-5D24-6A5C-E053-731AD00A0FF7","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","deletedIndicator":"No"},{"value":"Cabotegravir and Rilpivirine Injections","valueDescription":null,"ValueMeaning":{"publicId":"13795018","version":"1","preferredName":"Cabotegravir/Rilpivirine","longName":"13795018v1.00","preferredDefinition":"An extended-release injectable formulation of cabotegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon intramuscular administration of cabotegravir/rilpivirine, cabotegravir binds to and blocks the active site of HIV integrase, an HIV-1 coded enzyme that is necessary for viral replication, thereby inhibiting its activity. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabotegravir/Rilpivirine","conceptCode":"C199583","definition":"An extended-release injectable formulation of cabotegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon intramuscular administration of cabotegravir/rilpivirine, cabotegravir binds to and blocks the active site of HIV integrase, an HIV-1 coded enzyme that is necessary for viral replication, thereby inhibiting its activity. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD2873BC-5D21-6A5C-E053-731AD00A0FF7","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD2873BC-5D25-6A5C-E053-731AD00A0FF7","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","deletedIndicator":"No"},{"value":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13795019","version":"1","preferredName":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","longName":"13795019v1.00","preferredDefinition":"An orally bioavailable fixed combination of doravirine, a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, and the fumarate salt form of the prodrug tenofovir disoproxil, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of doravirine/lamivudine/tenofovir disoproxil, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication. Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), that competes for incorporation into viral DNA, and tenofovir disoproxil, upon conversion into tenofovir, also competes with natural deoxyribonucleosides for incorporation into the growing viral DNA chain, thereby inhibiting the HIV RT competitively and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","conceptCode":"C199582","definition":"An orally bioavailable fixed combination of doravirine, a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, and the fumarate salt form of the prodrug tenofovir disoproxil, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of doravirine/lamivudine/tenofovir disoproxil, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication. Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), that competes for incorporation into viral DNA, and tenofovir disoproxil, upon conversion into tenofovir, also competes with natural deoxyribonucleosides for incorporation into the growing viral DNA chain, thereby inhibiting the HIV RT competitively and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD2873BC-5D22-6A5C-E053-731AD00A0FF7","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD2873BC-5D26-6A5C-E053-731AD00A0FF7","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","deletedIndicator":"No"},{"value":"Dolutegravir/Lamivudine","valueDescription":null,"ValueMeaning":{"publicId":"13795020","version":"1","preferredName":"Dolutegravir Sodium/Lamivudine","longName":"13795020v1.00","preferredDefinition":"An orally bioavailable fixed combination of the sodium salt form of dolutegravir, an integrase strand-transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of dolutegravir/lamivudine, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Lamivudine is phosphorylated into its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), which inhibits the HIV reverse transcriptase (RT) enzyme competitively and acts as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolutegravir Sodium/Lamivudine","conceptCode":"C199581","definition":"An orally bioavailable fixed combination of the sodium salt form of dolutegravir, an integrase strand-transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of dolutegravir/lamivudine, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Lamivudine is phosphorylated into its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), which inhibits the HIV reverse transcriptase (RT) enzyme competitively and acts as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD2873BC-5D23-6A5C-E053-731AD00A0FF7","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD2873BC-5D27-6A5C-E053-731AD00A0FF7","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","deletedIndicator":"No"},{"value":"Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13795037","version":"1","preferredName":"Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate","longName":"13795037v1.00","preferredDefinition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a non-nucleoside RT inhibitor (NNRTI); and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate","conceptCode":"C157408","definition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a non-nucleoside RT inhibitor (NNRTI); and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD288385-9A6F-6C2A-E053-731AD00AF294","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD288385-9A70-6C2A-E053-731AD00AF294","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","deletedIndicator":"No"},{"value":"PRGN-2009","valueDescription":null,"ValueMeaning":{"publicId":"13966077","version":"1","preferredName":"Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine","longName":"13966077v1.00","preferredDefinition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 16 and 18 E6/E7 antigens, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus expressing HPV-16/18 E6/E7 vaccine PRGN-2009, the adenovirus infects and expresses the HPV-16/18 E6/E7 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV-16/18 E6/E7 antigens, thereby inducing tumor cell lysis. HPV oncoproteins play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine","conceptCode":"C172914","definition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 16 and 18 E6/E7 antigens, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus expressing HPV-16/18 E6/E7 vaccine PRGN-2009, the adenovirus infects and expresses the HPV-16/18 E6/E7 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV-16/18 E6/E7 antigens, thereby inducing tumor cell lysis. HPV oncoproteins play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA99C1E-696B-78F2-E053-731AD00A730A","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEA99C1E-696D-78F2-E053-731AD00A730A","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","deletedIndicator":"No"},{"value":"PRGN-2012","valueDescription":null,"ValueMeaning":{"publicId":"13966078","version":"1","preferredName":"Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012","longName":"13966078v1.00","preferredDefinition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 6 and 11, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012, the adenovirus infects and expresses the HPV-6/11 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against cells infected with HPV-6/11, thereby inducing tumor cell lysis. HPV6/11 play a key role in the development of recurrent respiratory papillomatosis (RRP).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012","conceptCode":"C177305","definition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 6 and 11, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012, the adenovirus infects and expresses the HPV-6/11 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against cells infected with HPV-6/11, thereby inducing tumor cell lysis. HPV6/11 play a key role in the development of recurrent respiratory papillomatosis (RRP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA99C1E-696C-78F2-E053-731AD00A730A","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEA99C1E-696E-78F2-E053-731AD00A730A","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","deletedIndicator":"No"},{"value":"Anti-CCR8 Monoclonal Antibody LM-108","valueDescription":null,"ValueMeaning":{"publicId":"13971232","version":"1","preferredName":"Anti-CCR8 Monoclonal Antibody LM-108","longName":"13971232v1.00","preferredDefinition":"A monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody LM-108 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CCR8 Monoclonal Antibody LM-108","conceptCode":"C186374","definition":"A monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody LM-108 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEC09367-0425-05FF-E053-731AD00AA41C","latestVersionIndicator":"Yes","beginDate":"2023-06-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-22","modifiedBy":"GDEEN","dateModified":"2023-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEC09367-0426-05FF-E053-731AD00AA41C","beginDate":"2023-06-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-22","modifiedBy":"GDEEN","dateModified":"2023-06-22","deletedIndicator":"No"},{"value":"Alvimopan","valueDescription":null,"ValueMeaning":{"publicId":"14056144","version":"1","preferredName":"Alvimopan","longName":"14056144v1.00","preferredDefinition":"A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvimopan","conceptCode":"C49096","definition":"A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"004092B1-9F08-616F-E063-731AD00A826C","latestVersionIndicator":"Yes","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"004092B1-9F09-616F-E063-731AD00A826C","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","deletedIndicator":"No"},{"value":"Bedaquiline fumurate","valueDescription":null,"ValueMeaning":{"publicId":"14056247","version":"1","preferredName":"Bedaquiline Fumarate","longName":"14056247v1.00","preferredDefinition":"The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bedaquiline Fumarate","conceptCode":"C142949","definition":"The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"004BD7C4-7F6D-105A-E063-731AD00AF4DE","latestVersionIndicator":"Yes","beginDate":"2023-07-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"004BD7C4-7F6E-105A-E063-731AD00AF4DE","beginDate":"2023-07-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-12","modifiedBy":"GDEEN","dateModified":"2023-07-12","deletedIndicator":"No"},{"value":"Lifitegrast","valueDescription":null,"ValueMeaning":{"publicId":"14059580","version":"1","preferredName":"Lifitegrast (Xiidra)","longName":"14059580v1.00","preferredDefinition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lifitegrast","conceptCode":"C175726","definition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0061E597-02DE-1CCA-E063-731AD00AED08","latestVersionIndicator":"Yes","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0061E597-02DF-1CCA-E063-731AD00AED08","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"GDEEN","dateModified":"2023-07-13","deletedIndicator":"No"},{"value":"Gilteritinib","valueDescription":null,"ValueMeaning":{"publicId":"6429350","version":"1","preferredName":"Gilteritinib","longName":"6429350","preferredDefinition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gilteritinib","conceptCode":"C116722","definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D70B-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00EFECB8-779F-12C6-E063-731AD00A8A11","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-07-20","deletedIndicator":"No"},{"value":"Witch Hazel Rectal Pads","valueDescription":null,"ValueMeaning":{"publicId":"14114585","version":"1","preferredName":"Witch Hazel-containing Anti-Hemorroidal Formulation Rectal Pad Dosage Form","longName":"14114585v1.00","preferredDefinition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue._Of or pertaining to the rectum._A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Witch Hazel-containing Anti-Hemorroidal Formulation","conceptCode":"C29525","definition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rectal","conceptCode":"C25224","definition":"Of or pertaining to the rectum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pad Dosage Form","conceptCode":"C69016","definition":"A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00EFECB8-779E-12C6-E063-731AD00A8A11","latestVersionIndicator":"Yes","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00EFECB8-77A0-12C6-E063-731AD00A8A11","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-07-20","deletedIndicator":"No"},{"value":"Asciminib","valueDescription":null,"ValueMeaning":{"publicId":"13597046","version":"1","preferredName":"Asciminib","longName":"13597046v1.00","preferredDefinition":"An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asciminib","conceptCode":"C114494","definition":"An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC0A8EF3-70C6-52F5-E053-731AD00A2404","latestVersionIndicator":"Yes","beginDate":"2023-05-19","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-19","modifiedBy":"DWARZEL","dateModified":"2023-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01D04A57-B57C-1F2B-E063-731AD00A12A8","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","deletedIndicator":"No"},{"value":"Bebtelovimab","valueDescription":null,"ValueMeaning":{"publicId":"14256422","version":"1","preferredName":"Bebtelovimab","longName":"14256422v1.00","preferredDefinition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bebtelovimab","conceptCode":"C182122","definition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F8D7F5-2EF9-29FD-E063-731AD00A3BDB","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F8DC35-A43C-2AAB-E063-731AD00AE71F","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"HER2 Tri-specific Natural Killer Cell Engager DF1001","valueDescription":null,"ValueMeaning":{"publicId":"13660287","version":"1","preferredName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","longName":"13660287v1.00","preferredDefinition":"An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2 tri-specific NK cell engager DF1001 targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","conceptCode":"C172279","definition":"An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2 tri-specific NK cell engager DF1001 targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC7D49B7-933E-4F54-E053-731AD00A4379","latestVersionIndicator":"Yes","beginDate":"2023-05-24","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-24","modifiedBy":"GDEEN","dateModified":"2023-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"025CCBB4-0B4C-5592-E063-731AD00A02A2","beginDate":"2023-08-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-07","modifiedBy":"GDEEN","dateModified":"2023-08-07","deletedIndicator":"No"},{"value":"Docusate Sodium-Senna","valueDescription":null,"ValueMeaning":{"publicId":"7130497","version":"1","preferredName":"Docusate Sodium-Senna ","longName":"7130497v1.00","preferredDefinition":"A combination preparation composed of a standardized senna concentrate and the sodium salt form of the emollient laxative docusate, with laxative and stool softening activity. Senna concentrate consists of the anthraquinone glycosides sennosides extracted from senna leaves. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement and relief of constipation. Docusate, an anionic surfactant, decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. This softens the stool for smoother and easier evacuation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docusate Sodium-Senna","conceptCode":"C29450","definition":"A combination preparation composed of a standardized senna concentrate and the sodium salt form of the emollient laxative docusate, with laxative and stool softening activity. Senna concentrate consists of the anthraquinone glycosides sennosides extracted from senna leaves. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement and relief of constipation. Docusate, an anionic surfactant, decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. This softens the stool for smoother and easier evacuation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BA5935F-F5F8-2EF6-E053-F662850A9D24","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5881-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Melatonin/Magnesium Citrate","valueDescription":null,"ValueMeaning":{"publicId":"14318387","version":"1","preferredName":"Melatonin/Magnesium Citrate","longName":"14318387v1.00","preferredDefinition":"A combination agent containing melatonin, a serotonin-derived neurohormone, and the citrate salt of the element magnesium, that could potentially be used to promote relaxation and sleep. Upon oral administration, melatonin is involved in numerous biological functions including circadian rhythm, sleep, and the stress response. Magnesium may promote relaxation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melatonin/Magnesium Citrate","conceptCode":"C200662","definition":"A combination agent containing melatonin, a serotonin-derived neurohormone, and the citrate salt of the element magnesium, that could potentially be used to promote relaxation and sleep. Upon oral administration, melatonin is involved in numerous biological functions including circadian rhythm, sleep, and the stress response. Magnesium may promote relaxation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF48-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5882-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Escitalopram","valueDescription":null,"ValueMeaning":{"publicId":"7460883","version":"1","preferredName":"Escitalopram","longName":"7460883","preferredDefinition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Escitalopram","conceptCode":"C61754","definition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D4A7-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5883-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Beclomethasone Dipropionate","valueDescription":null,"ValueMeaning":{"publicId":"2577726","version":"1","preferredName":"Beclomethasone Dipropionate","longName":"2577726","preferredDefinition":"The dipropionate salt of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone Dipropionate","conceptCode":"C299","definition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5884-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Potassium Citrate","valueDescription":null,"ValueMeaning":{"publicId":"7060586","version":"1","preferredName":"Potassium Citrate","longName":"7060586","preferredDefinition":"The potassium salt form of citrate with alkalinizing property. Following absorption, potassium citrate causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts the alkalizing and anti-urolithic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Citrate","conceptCode":"C29372","definition":"The potassium salt form of citrate, with alkalinizing activity and that can be used for potassium supplementation. Upon oral administration, potassium citrate provides potassium. Potassium maintains normal fluid and electrolyte balance, regulates the proper functioning of heart and muscle contractions, supports healthy bone density and blood pressure. It also plays an important role in the transmission of nerve impulses and energy production. Amino acid chelated minerals are highly bioavailable and better absorbed than non-amino acid-chelated minerals. Potassium citrate also causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts alkalizing and anti-urolithic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A4DC41-3760-447D-E053-F662850AC4BA","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5885-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14318388","version":"1","preferredName":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","longName":"14318388v1.00","preferredDefinition":"A formulation composed of the phytosterol beta-sitosterol, cholecalciferol, calcium, zinc, selenium, copper, manganese, chromium, molybdenum and boron, that can potentially be used to support a healthy prostate. Upon oral administration, the formulation may help support and maintain prostate function and promote less urges to urinate and improve bladder emptying.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","conceptCode":"C200663","definition":"A formulation composed of the phytosterol beta-sitosterol, cholecalciferol, calcium, zinc, selenium, copper, manganese, chromium, molybdenum and boron, that can potentially be used to support a healthy prostate. Upon oral administration, the formulation may help support and maintain prostate function and promote less urges to urinate and improve bladder emptying.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF49-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5886-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Omega-3-containing Krill Oil Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14318389","version":"1","preferredName":"Omega-3-containing Krill Oil Supplement","longName":"14318389v1.00","preferredDefinition":"A supplement composed of omega-3 fatty acids derived from krill oil, that can be used for omega-3 fatty acid supplementation. Upon oral administration, omega-3 containing krill oil supplement provides omega-3 fatty acids. Omega-3 fatty acids get incorporated into and are a critical part of cellular membranes where they influence membrane fluidity and deformability. Omega-3 fatty acids play an important role in the proper functioning of heart, brain, blood vessels, lungs, immune system, and endocrine system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omega-3-containing Krill Oil Supplement","conceptCode":"C200664","definition":"A supplement composed of omega-3 fatty acids derived from krill oil, that can be used for omega-3 fatty acid supplementation. Upon oral administration, omega-3 containing krill oil supplement provides omega-3 fatty acids. Omega-3 fatty acids get incorporated into and are a critical part of cellular membranes where they influence membrane fluidity and deformability. Omega-3 fatty acids play an important role in the proper functioning of heart, brain, blood vessels, lungs, immune system, and endocrine system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4A-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5887-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Cholecalciferol","valueDescription":null,"ValueMeaning":{"publicId":"3237531","version":"1","preferredName":"Cholecalciferol","longName":"3237531","preferredDefinition":"A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholecalciferol","conceptCode":"C48194","definition":"A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F86C65-82A9-B0DA-E040-BB89AD435E50","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-23","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5888-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Magnesium Malate","valueDescription":null,"ValueMeaning":{"publicId":"14318390","version":"1","preferredName":"Magnesium Malate","longName":"14318390v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Malate","conceptCode":"C87336","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4B-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5889-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Zinc Oxide-containing Paste","valueDescription":null,"ValueMeaning":{"publicId":"14318391","version":"1","preferredName":"Zinc Oxide-containing Paste","longName":"14318391v1.00","preferredDefinition":"A topical paste containing zinc oxide, that can be used to protect the skin. Upon application to the affected area(s), zinc oxide forms a thick, protective barrier to help heal and soothe the diaper rash discomfort.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Oxide-containing Paste","conceptCode":"C200665","definition":"A topical paste containing zinc oxide, that can be used to protect the skin. Upon application to the affected area(s), zinc oxide forms a thick, protective barrier to help heal and soothe the diaper rash discomfort.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4C-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588A-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Amlodipine","valueDescription":null,"ValueMeaning":{"publicId":"7060445","version":"1","preferredName":"Amlodipine","longName":"7060445","preferredDefinition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine","conceptCode":"C61635","definition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66EB-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588B-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Atorvastatin","valueDescription":null,"ValueMeaning":{"publicId":"14318392","version":"1","preferredName":"Atorvastatin","longName":"14318392v1.00","preferredDefinition":"A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atorvastatin","conceptCode":"C61527","definition":"A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4D-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588C-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Ciclesonide","valueDescription":null,"ValueMeaning":{"publicId":"14295565","version":"1","preferredName":"Ciclesonide (Omnaris)","longName":"14295565v1.00","preferredDefinition":"A nonhalogenated, synthetic, inhaled corticosteroid (ICS) with anti-inflammatory and potential antiviral activities. Upon administration by oral inhalation into the lungs, ciclesonide (CIC) is converted by local esterases to its active metabolite desisobutyryl-ciclesonide (des-CIC), which binds to intracellular glucocorticoid receptors (GRs). The ligand-bound GRs regulate gene expressions, which lead to inhibitory activities against multiple cell types, such as mast cells, eosinophils, basophils, lymphocytes, macrophages and neutrophils, and various mediators associated with inflammation, such as histamine, eicosanoids, leukotrienes and cytokines. In addition, ciclesonide may suppress the replication of human coronavirus by targeting viral nonstructural protein 15 (NSP15).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciclesonide","conceptCode":"C65326","definition":"A nonhalogenated, synthetic, inhaled corticosteroid (ICS) with anti-inflammatory and potential antiviral activities. Upon administration by oral inhalation into the lungs, ciclesonide (CIC) is converted by local esterases to its active metabolite desisobutyryl-ciclesonide (des-CIC), which binds to intracellular glucocorticoid receptors (GRs). The ligand-bound GRs regulate gene expressions, which lead to inhibitory activities against multiple cell types, such as mast cells, eosinophils, basophils, lymphocytes, macrophages and neutrophils, and various mediators associated with inflammation, such as histamine, eicosanoids, leukotrienes and cytokines. In addition, ciclesonide may suppress the replication of human coronavirus by targeting viral nonstructural protein 15 (NSP15).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0258701B-CFB9-15EE-E063-731AD00A911E","latestVersionIndicator":"Yes","beginDate":"2023-08-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-07","modifiedBy":"GDEEN","dateModified":"2023-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588D-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Efineptakin alpha","valueDescription":null,"ValueMeaning":{"publicId":"14318393","version":"1","preferredName":"Efineptakin alfa","longName":"14318393v1.00","preferredDefinition":"A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efineptakin alfa","conceptCode":"C151927","definition":"A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4E-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588E-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Liposomal Doxorubicin/Pomalidomide Regimen","valueDescription":null,"ValueMeaning":{"publicId":"14318394","version":"1","preferredName":"Liposomal Doxorubicin/Pomalidomide Regimen","longName":"14318394v1.00","preferredDefinition":"A regimen consisting of liposomal doxorubicin and pomalidomide that may be used in the treatment of Kaposi sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Doxorubicin/Pomalidomide Regimen","conceptCode":"C200666","definition":"A regimen consisting of liposomal doxorubicin and pomalidomide that may be used in the treatment of Kaposi sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4F-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-588F-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Lutetium Lu 177 Dotatate","valueDescription":null,"ValueMeaning":{"publicId":"13689512","version":"1","preferredName":"Lutetium Lu 177 Dotatate","longName":"13689512v1.00","preferredDefinition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lutetium Lu 177 Dotatate","conceptCode":"C95020","definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC8A7A8A-B4B7-7512-E053-731AD00AC851","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5890-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Talazoparib","valueDescription":null,"ValueMeaning":{"publicId":"6159964","version":"1","preferredName":"Talazoparib","longName":"6159964","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talazoparib","conceptCode":"C95733","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-0031-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5891-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Vepdegestrant","valueDescription":null,"ValueMeaning":{"publicId":"13961725","version":"1","preferredName":"Vepdegestrant","longName":"13961725v1.00","preferredDefinition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vepdegestrant","conceptCode":"C165420","definition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE4692A3-4D05-32AE-E053-731AD00A1782","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"FINCHAMB","dateModified":"2023-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FB094-5892-737B-E063-731AD00A8B65","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"PDS0101","valueDescription":null,"ValueMeaning":{"publicId":"13679605","version":"1","preferredName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","longName":"13679605v1.00","preferredDefinition":"A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","conceptCode":"C111688","definition":"A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC899B2A-6AC3-51EF-E053-731AD00A4A70","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-25","modifiedBy":"DWARZEL","dateModified":"2023-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05554F75-C109-7E30-E063-731AD00A402F","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"Monalizumab","valueDescription":null,"ValueMeaning":{"publicId":"6159859","version":"1","preferredName":"Monalizumab","longName":"6159859","preferredDefinition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monalizumab","conceptCode":"C120208","definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-52E4-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05554F75-C10A-7E30-E063-731AD00A402F","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"LN-145","valueDescription":null,"ValueMeaning":{"publicId":"13606187","version":"1","preferredName":"Autologous Tumor Infiltrating Lymphocytes LN-145","longName":"13606187v1.00","preferredDefinition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Tumor Infiltrating Lymphocytes LN-145","conceptCode":"C135634","definition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC16EBB5-0428-7A8A-E053-731AD00A5644","latestVersionIndicator":"Yes","beginDate":"2023-05-19","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-19","modifiedBy":"DWARZEL","dateModified":"2023-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05554F75-C10B-7E30-E063-731AD00A402F","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"CDX-1140","valueDescription":null,"ValueMeaning":{"publicId":"13596647","version":"1","preferredName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","longName":"13596647v1.00","preferredDefinition":"A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","conceptCode":"C150558","definition":"A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC055485-4EC7-6C23-E053-731AD00AAAA9","latestVersionIndicator":"Yes","beginDate":"2023-05-19","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-19","modifiedBy":"DWARZEL","dateModified":"2023-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05554F75-C10C-7E30-E063-731AD00A402F","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"Fluorouracil/Leucovorin/Oxaliplatin/Docetaxel","valueDescription":null,"ValueMeaning":{"publicId":"13456564","version":"1","preferredName":"FLOT Regimen","longName":"13456564v1.00","preferredDefinition":"A regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel that can be used in the treatment of gastric, esophageal and esophagogastric junction cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLOT Regimen","conceptCode":"C160565","definition":"A regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel that can be used in the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA5252CC-0E13-77A9-E053-731AD00A46C2","latestVersionIndicator":"Yes","beginDate":"2023-04-27","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-27","modifiedBy":"GDEEN","dateModified":"2023-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05554F75-C10D-7E30-E063-731AD00A402F","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"Doxycycline","valueDescription":null,"ValueMeaning":{"publicId":"3874894","version":"1","preferredName":"Doxycycline","longName":"3874894","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E595BB41-EE07-FBF1-E040-BB89AD435381","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05E8C3F2-ED76-5208-E063-731AD00A8981","beginDate":"2023-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-21","modifiedBy":"GDEEN","dateModified":"2023-09-21","deletedIndicator":"No"},{"value":"Lutetium Lu 177 Vipivotide Tetraxetan","valueDescription":null,"ValueMeaning":{"publicId":"13961776","version":"1","preferredName":"Lutetium Lu 177 Vipivotide Tetraxetan","longName":"13961776v1.00","preferredDefinition":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lutetium Lu 177 Vipivotide Tetraxetan","conceptCode":"C148145","definition":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE46D580-B1DB-4302-E053-731AD00A64F4","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"065FFB72-2668-6A9C-E063-731AD00AF3AF","beginDate":"2023-09-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-27","modifiedBy":"GDEEN","dateModified":"2023-09-28","deletedIndicator":"No"},{"value":"Anakinra","valueDescription":null,"ValueMeaning":{"publicId":"7092700","version":"1","preferredName":"Anakinra","longName":"7092700","preferredDefinition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anakinra","conceptCode":"C38717","definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB90-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"070DAD1C-941E-4328-E063-731AD00AB71A","beginDate":"2023-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-06","modifiedBy":"KUMMEROA","dateModified":"2023-10-06","deletedIndicator":"No"},{"value":"Apoaequorin/Vitamin D Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14540948","version":"1","preferredName":"Apoaequorin/Vitamin D Supplement","longName":"14540948v1.00","preferredDefinition":"A dietary supplement composed of synthetic form of the naturally-occurring protein apoaequorin and vitamin D, that may potentially be used to improve memory. Upon oral administration of apoaequorin/vitamin D supplement, apoaequorin, a calcium binding protein naturally found in luminescent jellyfish (Aequorea victoria), may potentially improve memory through the regulation of intracellular calcium in neuronal cells, though it has not been shown to be able to cross the blood brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apoaequorin/Vitamin D Supplement","conceptCode":"C201815","definition":"A dietary supplement composed of synthetic form of the naturally-occurring protein apoaequorin and vitamin D, that may potentially be used to improve memory. Upon oral administration of apoaequorin/vitamin D supplement, apoaequorin, a calcium binding protein naturally found in luminescent jellyfish (Aequorea victoria), may potentially improve memory through the regulation of intracellular calcium in neuronal cells, though it has not been shown to be able to cross the blood brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08012B85-3FF9-6E00-E063-731AD00A17F7","latestVersionIndicator":"Yes","beginDate":"2023-10-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-18","modifiedBy":"GDEEN","dateModified":"2023-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08013F22-5295-70F3-E063-731AD00A1AF4","beginDate":"2023-10-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-18","modifiedBy":"GDEEN","dateModified":"2023-10-18","deletedIndicator":"No"},{"value":"Liraglutide","valueDescription":null,"ValueMeaning":{"publicId":"14554869","version":"1","preferredName":"Liraglutide","longName":"14554869v1.00","preferredDefinition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liraglutide","conceptCode":"C82239","definition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345B-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830D5EC-9478-0DC5-E063-731AD00ADFD2","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","valueDescription":null,"ValueMeaning":{"publicId":"14554870","version":"1","preferredName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","longName":"14554870v1.00","preferredDefinition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","conceptCode":"C173741","definition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345C-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830D5EC-9479-0DC5-E063-731AD00ADFD2","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":null,"ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"086A20E1-8A1F-3AF6-E063-731AD00AAFD9","beginDate":"2023-10-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-23","modifiedBy":"GDEEN","dateModified":"2023-10-23","deletedIndicator":"No"},{"value":"CAR NK Cells (PD-L1 CAR-NK cells)","valueDescription":null,"ValueMeaning":{"publicId":"14588665","version":"1","preferredName":"Chimeric Antigen Receptor Natural Killer Cells","longName":"14588665v1.00","preferredDefinition":"A preparation of natural killer (NK) cells that are engineered to contain a chimeric antigen receptor (CAR).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor Natural Killer Cells","conceptCode":"C201933","definition":"A preparation of natural killer (NK) cells that are engineered to contain a chimeric antigen receptor (CAR).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08F17AB6-EFF9-3C94-E063-731AD00AF4FD","latestVersionIndicator":"Yes","beginDate":"2023-10-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-30","modifiedBy":"GDEEN","dateModified":"2023-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08F17AB6-EFFA-3C94-E063-731AD00AF4FD","beginDate":"2023-10-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-30","modifiedBy":"GDEEN","dateModified":"2023-10-30","deletedIndicator":"No"},{"value":"Epcoritamab","valueDescription":null,"ValueMeaning":{"publicId":"13634215","version":"1","preferredName":"Epcoritamab","longName":"13634215v1.00","preferredDefinition":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epcoritamab","conceptCode":"C163022","definition":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC697A36-1D6E-49BE-E053-731AD00AF95D","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"DWARZEL","dateModified":"2023-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09BCFC46-B6CE-0710-E063-731AD00AAA03","beginDate":"2023-11-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-09","modifiedBy":"KUMMEROA","dateModified":"2023-11-09","deletedIndicator":"No"},{"value":"Zanubrutinib","valueDescription":null,"ValueMeaning":{"publicId":"13744151","version":"1","preferredName":"Zanubrutinib","longName":"13744151v1.00","preferredDefinition":"An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zanubrutinib","conceptCode":"C141428","definition":"An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA48EFB-3E13-1288-E053-731AD00A60D7","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09BD8B49-3E26-23AA-E063-731AD00AE84B","beginDate":"2023-11-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-09","modifiedBy":"KUMMEROA","dateModified":"2023-11-09","deletedIndicator":"No"},{"value":"Mosunetuzumab","valueDescription":null,"ValueMeaning":{"publicId":"13699255","version":"1","preferredName":"Mosunetuzumab","longName":"13699255v1.00","preferredDefinition":"A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mosunetuzumab","conceptCode":"C129691","definition":"A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC8E8B2A-E939-327A-E053-731AD00A1FC9","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-25","modifiedBy":"DWARZEL","dateModified":"2023-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B2C169E-BC44-6901-E063-731AD00A8DA3","beginDate":"2023-11-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-11-27","modifiedBy":"GDEEN","dateModified":"2023-11-27","deletedIndicator":"No"},{"value":"Tafasitamab","valueDescription":null,"ValueMeaning":{"publicId":"13743975","version":"1","preferredName":"Tafasitamab","longName":"13743975v1.00","preferredDefinition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tafasitamab","conceptCode":"C95768","definition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA388EB-9E6F-631D-E053-731AD00ADE4C","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B2C169E-BC45-6901-E063-731AD00A8DA3","beginDate":"2023-11-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-11-27","modifiedBy":"GDEEN","dateModified":"2023-11-27","deletedIndicator":"No"},{"value":"Loncastuximab","valueDescription":null,"ValueMeaning":{"publicId":"14623885","version":"1","preferredName":"Loncastuximab","longName":"14623885v1.00","preferredDefinition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the tumor-associated antigen (TAA) CD19, with potential antineoplastic activity. Upon administration, loncastuximab targets and binds to CD19 expressed on tumor cells. This may inhibit the proliferation of CD19-overexpressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loncastuximab","conceptCode":"C174770","definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the tumor-associated antigen (TAA) CD19, with potential antineoplastic activity. Upon administration, loncastuximab targets and binds to CD19 expressed on tumor cells. This may inhibit the proliferation of CD19-overexpressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B2C169E-BC43-6901-E063-731AD00A8DA3","latestVersionIndicator":"Yes","beginDate":"2023-11-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-11-27","modifiedBy":"GDEEN","dateModified":"2023-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B2C169E-BC46-6901-E063-731AD00A8DA3","beginDate":"2023-11-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-11-27","modifiedBy":"GDEEN","dateModified":"2023-11-27","deletedIndicator":"No"},{"value":"Bictegravir","valueDescription":null,"ValueMeaning":{"publicId":"14650182","version":"1","preferredName":"Bictegravir","longName":"14650182v1.00","preferredDefinition":"A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used to treat HIV infection. Upon oral administration, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bictegravir","conceptCode":"C171719","definition":"A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used to treat HIV infection. Upon oral administration, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BEFE112-ED61-0704-E063-731AD00A6637","latestVersionIndicator":"Yes","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BEFE112-ED63-0704-E063-731AD00A6637","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Tetracaine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14650183","version":"1","preferredName":"Tetracaine Hydrochloride","longName":"14650183v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetracaine Hydrochloride","conceptCode":"C75104","definition":"The hydrochloride salt form of tetracaine, a benzoate ester, with anesthetic properties. Upon administration, tetracaine reversibly binds voltage-gated sodium ion channels in neuronal cell membranes and inhibits sodium influx. This prevents the initiation and conduction of nerve impulses, and stabilizes neuronal membranes. This results in a loss of sensation, and thereby provides analgesia and anesthesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BEFE112-ED62-0704-E063-731AD00A6637","latestVersionIndicator":"Yes","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BEFE112-ED64-0704-E063-731AD00A6637","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Potassium Phosphate/Sodium Phosphate","valueDescription":null,"ValueMeaning":{"publicId":"3282731","version":"1","preferredName":"Potassium Phosphate/Sodium Phosphate","longName":"3282731","preferredDefinition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate/Sodium Phosphate","conceptCode":"C29288","definition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D768-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BEFE112-ED65-0704-E063-731AD00A6637","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Dupilumab","valueDescription":null,"ValueMeaning":{"publicId":"13634130","version":"1","preferredName":"Dupilumab","longName":"13634130v1.00","preferredDefinition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dupilumab","conceptCode":"C162455","definition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC6948FB-949D-4130-E053-731AD00A325E","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BEFE112-ED66-0704-E063-731AD00A6637","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Alpha-1-Proteinase Inhibitor Human","valueDescription":null,"ValueMeaning":{"publicId":"7631837","version":"1","preferredName":"Alpha-1-Proteinase Inhibitor Human","longName":"7631837","preferredDefinition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1-Proteinase Inhibitor Human","conceptCode":"C82258","definition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC87F2A-1385-74AF-E053-4EBD850AEF21","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DFB1814-8C9B-761B-E063-731AD00A2F7C","beginDate":"2024-01-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-02","modifiedBy":"GDEEN","dateModified":"2024-01-02","deletedIndicator":"No"},{"value":"Nitazoxanide","valueDescription":null,"ValueMeaning":{"publicId":"3944878","version":"1","preferredName":"Nitazoxanide","longName":"3944878","preferredDefinition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitazoxanide","conceptCode":"C47637","definition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F0FE-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DFB1814-8C9C-761B-E063-731AD00A2F7C","beginDate":"2024-01-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-02","modifiedBy":"GDEEN","dateModified":"2024-01-02","deletedIndicator":"No"},{"value":"Vibegron","valueDescription":null,"ValueMeaning":{"publicId":"14672740","version":"1","preferredName":"Vibegron (Gemtesa)","longName":"14672740v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vibegron","conceptCode":"C152872","definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing activity. Upon oral administration, vibegron targets, binds to and activates ADRB3, which leads to relaxation of the detrusor smooth muscle during bladder filling. This increases bladder capacity and provides symptomatic relief, including urge urinary incontinence, urgency, and urinary frequency, for overactive bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E216A81-6533-0B42-E063-731AD00A51FA","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E216A81-6534-0B42-E063-731AD00A51FA","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","deletedIndicator":"No"},{"value":"5-Hydroxytryptophan, DL-","valueDescription":null,"ValueMeaning":{"publicId":"14675155","version":"1","preferredName":"5-Hydroxytryptophan, DL-","longName":"14675155v1.00","preferredDefinition":"A racemic mixture of 5-hydroxytryptophan (5-HTP), a precursor to the neurotransmitter serotonin with anti-depressant, analgesic and appetite-suppressant activities. DL-5-HTP is decarboxylated to serotonin by aromatic-L-amino-acid decarboxylase, and results in increased serotonin levels within the brain. Mediated through serotonin receptors, elevated levels of serotonin causes increased serotonin neurotransmissions, hence leading to release of depression, pain and appetite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5-Hydroxytryptophan, DL-","conceptCode":"C61712","definition":"A racemic mixture of 5-hydroxytryptophan (5-HTP), a precursor to the neurotransmitter serotonin with anti-depressant, analgesic and appetite-suppressant activities. DL-5-HTP is decarboxylated to serotonin by aromatic-L-amino-acid decarboxylase, and results in increased serotonin levels within the brain. Mediated through serotonin receptors, elevated levels of serotonin causes increased serotonin neurotransmissions, hence leading to release of depression, pain and appetite.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03C-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04A-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Activated Charcoal","valueDescription":null,"ValueMeaning":{"publicId":"5206952","version":"1","preferredName":"Activated Charcoal","longName":"5206952v1.00","preferredDefinition":"Carbon that has been treated to create small, low-volume pores that increase the surface area available for adsorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Activated Charcoal","conceptCode":"C77524","definition":"Carbon that has been treated to create small, low-volume pores that increase the surface area available for adsorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F39E58E-6B52-3234-E050-BB89AD43210C","latestVersionIndicator":"Yes","beginDate":"2016-03-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04B-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Cultured Lentinula edodes Mycelia Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675156","version":"1","preferredName":"Cultured Lentinula edodes Mycelia Extract","longName":"14675156v1.00","preferredDefinition":"An orally bioavailable capsule-based formulation of a standardized extract of cultured Lentinula edodes (Shiitake mushroom) mycelia (ECLM), which is high in the polysaccharides beta- and alpha-glucans, with potential antioxidant, immunomodulating and antineoplastic activities. Upon oral administration, the cultured Lentinula edodes mycelia extract activates the immune system, by binding to toll-like receptors (TLRs), specifically TLR-4, and induces the activation of dendritic cells (DCs), natural killer (NK) cells, macrophages and T-cells and the release of cytokines. This may clear human papillomavirus (HPV) infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cultured Lentinula edodes Mycelia Extract","conceptCode":"C179283","definition":"An orally bioavailable capsule-based formulation of a standardized extract of cultured Lentinula edodes (Shiitake mushroom) mycelia (ECLM), which is high in the polysaccharides beta- and alpha-glucans, with potential antioxidant, immunomodulating and antineoplastic activities. Upon oral administration, the cultured Lentinula edodes mycelia extract activates the immune system, by binding to toll-like receptors (TLRs), specifically TLR-4, and induces the activation of dendritic cells (DCs), natural killer (NK) cells, macrophages and T-cells and the release of cytokines. This may clear human papillomavirus (HPV) infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03D-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04C-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675157","version":"1","preferredName":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","longName":"14675157v1.00","preferredDefinition":"An orally bioavailable herbal combination formulation containing garlic (Allium sativum) bulb extract, olive (Olea europaea) leaf extract, elderberry (Sambucus nigra), oregano (Origanum vulgare) oil, arabinogalactans from the Larch tree (Larix laricina), and rosemary (Rosmarinus officinalis) oil.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","conceptCode":"C203501","definition":"An orally bioavailable herbal combination formulation containing garlic (Allium sativum) bulb extract, olive (Olea europaea) leaf extract, elderberry (Sambucus nigra), oregano (Origanum vulgare) oil, arabinogalactans from the Larch tree (Larix laricina), and rosemary (Rosmarinus officinalis) oil.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03E-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04D-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Vitamin A/C/E-Zinc/Copper-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675158","version":"1","preferredName":"Vitamin A/C/E-Zinc/Copper-based Supplement","longName":"14675158v1.00","preferredDefinition":"An orally bioavailable combination formulation containing the vitamins A, C and E, as well as the minerals zinc and copper.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin A/C/E-Zinc/Copper-based Supplement","conceptCode":"C203503","definition":"An orally bioavailable combination formulation containing the vitamins A, C and E, as well as the minerals zinc and copper.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03F-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04E-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Artemisinin","valueDescription":null,"ValueMeaning":{"publicId":"14675159","version":"1","preferredName":"Artemisinin","longName":"14675159v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Artemisinin","conceptCode":"C78093","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C040-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C04F-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Berberine","valueDescription":null,"ValueMeaning":{"publicId":"14675160","version":"1","preferredName":"Berberine","longName":"14675160v1.00","preferredDefinition":"A quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation. In addition, berberine modulates lipid and glucose metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Berberine","conceptCode":"C83551","definition":"A quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation. In addition, berberine modulates lipid and glucose metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C041-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C050-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","valueDescription":null,"ValueMeaning":{"publicId":"14675161","version":"1","preferredName":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","longName":"14675161v1.00","preferredDefinition":"An injectable formulation composed of the hydrochloride (HCl) salt form of papaverine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically, and the mesylate salt form of phentolamine, a synthetic imidazoline and alpha-adrenergic antagonist, that can be used in the treatment of erectile dysfunction (ED). Upon injection of the papaverine HCl/phentolamine mesylate injectable formulation directly into the corpus cavernosum, the two active ingredients work synergistically. Papaverine non-selectively inhibits phosphodiesterases (PDE), increases cyclic adenosine monophosphate (cAMP) production, relaxes penile smooth muscles, causes vasodilation, and increases blood flow to the penis. This causes an erection. Phentolamine binds to and inhibits alpha-1 and alpha-2 adrenergic receptors, resulting in a decrease in peripheral vascular resistance, relaxes penile smooth muscles, causes vasodilatation, and increases blood flow to the penis, thereby simultaneously causing an erection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","conceptCode":"C203505","definition":"An injectable formulation composed of the hydrochloride (HCl) salt form of papaverine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically, and the mesylate salt form of phentolamine, a synthetic imidazoline and alpha-adrenergic antagonist, that can be used in the treatment of erectile dysfunction (ED). Upon injection of the papaverine HCl/phentolamine mesylate injectable formulation directly into the corpus cavernosum, the two active ingredients work synergistically. Papaverine non-selectively inhibits phosphodiesterases (PDE), increases cyclic adenosine monophosphate (cAMP) production, relaxes penile smooth muscles, causes vasodilation, and increases blood flow to the penis. This causes an erection. Phentolamine binds to and inhibits alpha-1 and alpha-2 adrenergic receptors, resulting in a decrease in peripheral vascular resistance, relaxes penile smooth muscles, causes vasodilatation, and increases blood flow to the penis, thereby simultaneously causing an erection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C042-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C051-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil","valueDescription":null,"ValueMeaning":{"publicId":"5511068","version":"1","preferredName":"Mycophenolate Mofetil (MMF)","longName":"5511068v1.00","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A77-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C052-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Cinacalcet Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"13633926","version":"1","preferredName":"Cinacalcet Hydrochloride","longName":"13633926v1.00","preferredDefinition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cinacalcet Hydrochloride","conceptCode":"C47450","definition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC666493-8747-4554-E053-731AD00A0758","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C053-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Clomipramine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14675162","version":"1","preferredName":"Clomipramine Hydrochloride","longName":"14675162v1.00","preferredDefinition":"The hydrochloride salt form of clomipramine, a tertiary amine salt derivative of dibenzazepine. Clomipramine hydrochloride is a tricyclic antidepressant that acts by reducing the re-uptake of norepinephrine and serotonin in the central nervous system, thereby enhancing the effects of these neurotransmitters. This drug also binds to alpha-adrenergic, histaminergic, and cholinergic receptors which are responsible for the many side effects seen with this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clomipramine Hydrochloride","conceptCode":"C47458","definition":"The hydrochloride salt form of clomipramine, a tertiary amine salt derivative of dibenzazepine. Clomipramine hydrochloride is a tricyclic antidepressant that acts by reducing the re-uptake of norepinephrine and serotonin in the central nervous system, thereby enhancing the effects of these neurotransmitters. This drug also binds to alpha-adrenergic, histaminergic, and cholinergic receptors which are responsible for the many side effects seen with this agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C043-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C054-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","valueDescription":null,"ValueMeaning":{"publicId":"14675163","version":"1","preferredName":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","longName":"14675163v1.00","preferredDefinition":"An ophthalmic combination agent composed of the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase II, and the maleate salt form of timolol, a propanolamine derivative and a non-selective beta-adrenergic antagonist, with intraocular pressure-reducing activity. Upon topical administration of dorzolamide hydrochloride/timolol maleate ophthalmic solution, dorzolamide targets, binds to and inhibits carbonic anhydrase II, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions, in the eye. This decreases aqueous humor secretion, and reduces sodium and fluid transport. Although the precise mechanism of action of timolol is not clearly established, timolol targets, binds to and inhibits beta adrenoceptors in the ciliary body of the eye which may decrease aqueous humor production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","conceptCode":"C203504","definition":"An ophthalmic combination agent composed of the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase II, and the maleate salt form of timolol, a propanolamine derivative and a non-selective beta-adrenergic antagonist, with intraocular pressure-reducing activity. Upon topical administration of dorzolamide hydrochloride/timolol maleate ophthalmic solution, dorzolamide targets, binds to and inhibits carbonic anhydrase II, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions, in the eye.  This decreases aqueous humor secretion, and reduces sodium and fluid transport. Although the precise mechanism of action of timolol is not clearly established, timolol targets, binds to and inhibits beta adrenoceptors in the ciliary body of the eye which may decrease aqueous humor production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C044-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C055-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Docusate Sodium","valueDescription":null,"ValueMeaning":{"publicId":"2576789","version":"1","preferredName":"Docusate Sodium","longName":"2576789","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docusate Sodium","conceptCode":"C29000","definition":"The sodium salt of docusate, a dioctyl salt and an emollient laxative with stool-softening activity. Docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F902-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C056-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sacubitril/Valsartan","valueDescription":null,"ValueMeaning":{"publicId":"13961838","version":"1","preferredName":"Sacubitril/Valsartan","longName":"13961838v1.00","preferredDefinition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sacubitril/Valsartan","conceptCode":"C162629","definition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE474EC3-FB58-54FC-E053-731AD00A91F1","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C057-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Azelaic Acid","valueDescription":null,"ValueMeaning":{"publicId":"14675164","version":"1","preferredName":"Azelaic Acid","longName":"14675164v1.00","preferredDefinition":"A naturally occurring dicarboxylic acid produced by Malassezia furfur and found in whole grain cereals, rye, barley and animal products.  Azelaic acid possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. Azelaic acid is bactericidal against Proprionibacterium acnes and Staphylococcus epidermidis due to its inhibitory effect on the synthesis of microbial cellular proteins. Azelaic acid exerts its keratolytic and comedolytic effects by reducing the thickness of the stratum corneum and decreasing the number of keratohyalin granules by reducing the amount and distribution of filaggrin in epidermal layers. Azelaic acid also possesses a direct anti-inflammatory effect due to its scavenger activity of free oxygen radical. This drug is used topically to reduce inflammation associated with acne and rosacea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azelaic Acid","conceptCode":"C47407","definition":"A naturally occurring dicarboxylic acid produced by Malassezia furfur and found in whole grain cereals, rye, barley and animal products.  Azelaic acid possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. Azelaic acid is bactericidal against Proprionibacterium acnes and Staphylococcus epidermidis due to its inhibitory effect on the synthesis of microbial cellular proteins. Azelaic acid exerts its keratolytic and comedolytic effects by reducing the thickness of the stratum corneum and decreasing the number of keratohyalin granules by reducing the amount and distribution of filaggrin in epidermal layers. Azelaic acid also possesses a direct anti-inflammatory effect due to its scavenger activity of free oxygen radical. This drug is used topically to reduce inflammation associated with acne and rosacea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C045-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C058-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Ginger","valueDescription":null,"ValueMeaning":{"publicId":"14675165","version":"1","preferredName":"Ginger","longName":"14675165v1.00","preferredDefinition":"A fresh, dried or processed form of the rhizome of the Asian perennial plant Zingiber officinale (ginger) with potential anti-emetic activity. Ginger is mainly used in cooking due to its unique fragrance and flavor and has been studied for its use in the treatment of nausea and vomiting. The gingeroles and shoagoles found in ginger may be responsible for ginger's anti-emetic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ginger","conceptCode":"C66725","definition":"A fresh, dried or processed form of the rhizome of the Asian perennial plant Zingiber officinale (ginger) with potential anti-emetic activity. Ginger is mainly used in cooking due to its unique fragrance and flavor and has been studied for its use in the treatment of nausea and vomiting. The gingeroles and shoagoles found in ginger may be responsible for ginger's anti-emetic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C046-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C059-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Arginine","valueDescription":null,"ValueMeaning":{"publicId":"3256941","version":"1","preferredName":"Arginine","longName":"3256941","preferredDefinition":"An essential amino acid in juvenile humans, Arginine is a complex amino acid, often found at active site in proteins and enzymes due to its amine-containing side chain. Arginine may prevent or treat heart and circulatory diseases, combat fatigue, and stimulate the immune system. It also boosts production of nitric oxide, relaxing blood vessels, and treating angina and other cardiovascular problems. Arginine is also an important intermediate in the urea cycle and in detoxification of nitrogenous wastes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arginine","conceptCode":"C62008","definition":"An essential amino acid in juvenile humans, Arginine is a complex amino acid, often found at active site in proteins and enzymes due to its amine-containing side chain. Arginine may prevent or treat heart and circulatory diseases, combat fatigue, and stimulate the immune system. It also boosts production of nitric oxide, relaxing blood vessels, and treating angina and other cardiovascular problems. Arginine is also an important intermediate in the urea cycle and in detoxification of nitrogenous wastes. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A896758E-4FC7-97BE-E040-BB89AD435115","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-21","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C05A-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Levomilnacipran Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14675166","version":"1","preferredName":"Levomilnacipran Hydrochloride","longName":"14675166v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levomilnacipran Hydrochloride","conceptCode":"C166646","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C047-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C05B-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Zinc Monomethionine/Copper-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675167","version":"1","preferredName":"Zinc Monomethionine/Copper-based Supplement","longName":"14675167v1.00","preferredDefinition":"An orally bioavailable combination of the minerals zinc, which is complexed with the essential amino acid methionine, and copper.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Monomethionine/Copper-based Supplement","conceptCode":"C203506","definition":"n orally bioavailable combination of the minerals zinc, which is complexed with the essential amino acid methionine, and copper.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C048-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C05C-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Marigold Extract/Saffron Extract-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675168","version":"1","preferredName":"Marigold Extract/Saffron Extract-based Supplement","longName":"14675168v1.00","preferredDefinition":"An orally bioavailable combination of saffron (Crocus sativus) stigma extract and Marigold (Tagetes erecta) flower extract which provides lutein, (meso-)zeaxanthin, phospholipids, and mixed carotenoids, including alpha-carotene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marigold Extract/Saffron Extract-based Supplement","conceptCode":"C203507","definition":"An orally bioavailable combination of saffron (Crocus sativus) stigma extract and Marigold (Tagetes erecta) flower extract which provides lutein, (meso-)zeaxanthin, phospholipids, and mixed carotenoids, including alpha-carotene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C049-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA05E61-C05D-55F4-E063-731AD00A696E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Dronedarone Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12399014","version":"1","preferredName":"Dronedarone Hydrochloride","longName":"12399014v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dronedarone Hydrochloride","conceptCode":"C65486","definition":"The hydrochloride salt form of dronedarone, an orally bioavailable benzofuran derivative, with anti-arrhythmic activity. Upon oral administration, and although the exact mechanism of action through which dronedarone exerts its anti-arrhythmic effect has not been fully elucidated, it inhibits multiple voltage-gated ion channels, including sodium, potassium, and calcium ion channels, and restores the normal sinus rhythm and reduces heart rate in atrial fibrillation. It also non-competitively antagonizes adrenergic receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2900C2F-B833-39F8-E053-731AD00A559E","latestVersionIndicator":"Yes","beginDate":"2023-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7EE-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium Borate","valueDescription":null,"ValueMeaning":{"publicId":"14675169","version":"1","preferredName":"Sodium Borate","longName":"14675169v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Borate","conceptCode":"C77496","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E5-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7EF-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Nattokinase/Serrapeptase-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675170","version":"1","preferredName":"Nattokinase/Serrapeptase-based Supplement","longName":"14675170v1.00","preferredDefinition":"A dietary supplement formulation composed of two proteolytic enzymes nattokinase, a serine protease derived fromBacillus subtilis and produced during nattos fermentation process, and serrapeptase, which is derived from the non-pathogenic enterobacteriaSerratia E15.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nattokinase/Serrapeptase-based Supplement","conceptCode":"C203502","definition":"A dietary supplement formulation composed of two proteolytic enzymes nattokinase, a serine protease derived from Bacillus subtilis and produced during natto's fermentation process, and serrapeptase, which is derived from the non-pathogenic enterobacteria Serratia E15.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E6-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F0-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Nicotine Gum","valueDescription":null,"ValueMeaning":{"publicId":"3276683","version":"1","preferredName":"Nicotine Gum","longName":"3276683","preferredDefinition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicotine Gum","conceptCode":"C15663","definition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACFBB39A-964C-633A-E040-BB89AD436C25","latestVersionIndicator":"Yes","beginDate":"2011-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F1-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Ocrelizumab","valueDescription":null,"ValueMeaning":{"publicId":"13714642","version":"1","preferredName":"Ocrelizumab","longName":"13714642v1.00","preferredDefinition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocrelizumab","conceptCode":"C66250","definition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9B4A16-F173-71DC-E053-731AD00A42F0","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F2-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Pomegranate","valueDescription":null,"ValueMeaning":{"publicId":"14675171","version":"1","preferredName":"Pomegranate","longName":"14675171v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomegranate","conceptCode":"C73929","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E7-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F3-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675172","version":"1","preferredName":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","longName":"14675172v1.00","preferredDefinition":"A dietary supplement formulation composed of saw palmetto berry extract, lycopene, beta-sitosterol, vitamin D3, zinc, selenium, and quercetin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","conceptCode":"C203500","definition":"A dietary supplement formulation composed of saw palmetto berry extract, lycopene, beta-sitosterol, vitamin D3, zinc, selenium, and quercetin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E8-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F4-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Pygeum Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675173","version":"1","preferredName":"Pygeum Extract","longName":"14675173v1.00","preferredDefinition":"An herbal extract derived from the African prune treePygeum africanum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pygeum Extract","conceptCode":"C203499","definition":"An herbal extract derived from the African prune tree Pygeum africanum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E9-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F5-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Red Yeast Rice Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675174","version":"1","preferredName":"Red Yeast Rice Extract","longName":"14675174v1.00","preferredDefinition":"An extract derived from rice that has been fermented with the yeast Monascus purpureus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Red Yeast Rice Extract","conceptCode":"C203498","definition":"An extract derived from rice that has been fermented with the yeast Monascus purpureus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EA-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F6-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Resveratrol","valueDescription":null,"ValueMeaning":{"publicId":"3630009","version":"1","preferredName":"Resveratrol","longName":"3630009","preferredDefinition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resveratrol","conceptCode":"C1215","definition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF2CE395-C15E-016C-E040-BB89AD437110","latestVersionIndicator":"Yes","beginDate":"2012-11-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-23","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F7-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Riboflavin","valueDescription":null,"ValueMeaning":{"publicId":"14675175","version":"1","preferredName":"Riboflavin","longName":"14675175v1.00","preferredDefinition":"An essential human nutrient that is a heat-stable and water-soluble flavin belonging to the vitamin B family. Riboflavin is a precursor of the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are of vital importance in normal tissue respiration, pyridoxine activation, tryptophan to niacin conversion, fat, carbohydrate, and protein metabolism, and glutathione reductase mediated detoxification. Riboflavin may also be involved in maintaining erythrocyte integrity. This vitamin is essential for healthy skin, nails, and hair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Riboflavin","conceptCode":"C808","definition":"An essential human nutrient that is a heat-stable and water-soluble flavin belonging to the vitamin B family. Riboflavin is a precursor of the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are of vital importance in normal tissue respiration, pyridoxine activation, tryptophan to niacin conversion, fat, carbohydrate, and protein metabolism, and glutathione reductase mediated detoxification. Riboflavin may also be involved in maintaining erythrocyte integrity. This vitamin is essential for healthy skin, nails, and hair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EB-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F8-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675176","version":"1","preferredName":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","longName":"14675176v1.00","preferredDefinition":"A dietary supplement formulation composed of fermented organic mushroom blend, including Maitake (Grifola frondosa) mycelia, Shiitake (Lentinula eddoes) mycelia and Reishi (Ganoderma lucidum) mycelia, selenium, and Uncaria tomentosa (cats claw) bark.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","conceptCode":"C203497","definition":"A dietary supplement formulation composed of fermented organic mushroom blend, including Maitake (Grifola frondosa) mycelia, Shiitake (Lentinula eddoes) mycelia and Reishi (Ganoderma lucidum) mycelia, selenium, and Uncaria tomentosa (cat's claw) bark.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EC-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7F9-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Zopiclone","valueDescription":null,"ValueMeaning":{"publicId":"14675177","version":"1","preferredName":"Zopiclone","longName":"14675177v1.00","preferredDefinition":"The racemic form of a nonbenzodiazepine, cyclopyrrolone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, zopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zopiclone","conceptCode":"C80279","definition":"The racemic form of a nonbenzodiazepine, cyclopyrrolone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, zopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7ED-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FA-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Mushroom Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675364","version":"1","preferredName":"Mushroom Extract","longName":"14675364v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mushroom Extract","conceptCode":"C71949","definition":"An extract of Agaricus bisporus, also known as cultivated mushroom, button mushroom and common mushroom.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EB42A15-FA65-7040-E063-731AD00A8C57","latestVersionIndicator":"Yes","beginDate":"2024-01-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-11","modifiedBy":"GDEEN","dateModified":"2024-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EB42A15-FA66-7040-E063-731AD00A8C57","beginDate":"2024-01-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-11","modifiedBy":"GDEEN","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Prebiotic supplements","valueDescription":null,"ValueMeaning":{"publicId":"14688620","version":"1","preferredName":"Synbiotic Supplement","longName":"14688620v1.00","preferredDefinition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synbiotic Supplement","conceptCode":"C99230","definition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3B2DD9-E62A-795A-E063-731AD00A62FC","latestVersionIndicator":"Yes","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E62F-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Alrizomadlin","valueDescription":null,"ValueMeaning":{"publicId":"13961798","version":"1","preferredName":"Alrizomadlin","longName":"13961798v1.00","preferredDefinition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alrizomadlin","conceptCode":"C132991","definition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE470C61-592F-4CA4-E053-731AD00ADDA6","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E630-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Alogliptin","valueDescription":null,"ValueMeaning":{"publicId":"2945212","version":"1","preferredName":"Lactation Disorder","longName":"2945212","preferredDefinition":"A disorder not necessarily related to pregnancy that is observed in females and males. It is characterized by disturbances of milk secretion. Causes include damage to the breast parenchyma due to inflammation, medications, pituitary tumors, and hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactation Disorder","conceptCode":"C79606","definition":"A disorder not necessarily related to pregnancy that is observed in females and males. It is characterized by disturbances of milk secretion. Causes include damage to the breast parenchyma due to inflammation, medications, pituitary tumors, and hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"745580E8-43D5-8FA9-E040-BB89AD433702","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E631-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Zotiraciclib Citrate","valueDescription":null,"ValueMeaning":{"publicId":"13746575","version":"1","preferredName":"Zotiraciclib Citrate","longName":"13746575v1.00","preferredDefinition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zotiraciclib Citrate","conceptCode":"C105851","definition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA66669-55B6-6FE3-E053-731AD00A12E6","latestVersionIndicator":"Yes","beginDate":"2023-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-27","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-193C-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"NovoTTF-100A Device","valueDescription":null,"ValueMeaning":{"publicId":"7717906","version":"1","preferredName":"NovoTTF-100A Device","longName":"7717906","preferredDefinition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NovoTTF-100A Device","conceptCode":"C125103","definition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68E0707-A38D-1753-E053-4EBD850AA75A","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-193D-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Valproic Acid","valueDescription":null,"ValueMeaning":{"publicId":"7460887","version":"1","preferredName":"Valproic Acid","longName":"7460887","preferredDefinition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valproic Acid","conceptCode":"C29536","definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D54F-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-193E-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Topical Leptospermum Honey","valueDescription":null,"ValueMeaning":{"publicId":"14737557","version":"1","preferredName":"Topical Leptospermum Honey","longName":"14737557v1.00","preferredDefinition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Leptospermum Honey","conceptCode":"C203678","definition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"102FFBCF-5CF7-046F-E063-731AD00AD14D","latestVersionIndicator":"Yes","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-193F-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"DRD2 Antagonist/ClpP Agonist ONC206","valueDescription":null,"ValueMeaning":{"publicId":"14483679","version":"1","preferredName":"DRD2 Antagonist/ClpP Agonist ONC206","longName":"14483679v1.00","preferredDefinition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DRD2 Antagonist/ClpP Agonist ONC206","conceptCode":"C176975","definition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05BC7C2E-28A5-5471-E063-731AD00AEA2B","latestVersionIndicator":"Yes","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-1940-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Protein Phosphatase 2A Inhibitor LB-100","valueDescription":null,"ValueMeaning":{"publicId":"13724985","version":"1","preferredName":"Protein Phosphatase 2A Inhibitor LB-100","longName":"13724985v1.00","preferredDefinition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protein Phosphatase 2A Inhibitor LB-100","conceptCode":"C106430","definition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9F3F8C-ECF4-2D42-E053-731AD00AFB41","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFCD6-1941-049E-E063-731AD00A0B2E","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Galcanezumab-gnlm","valueDescription":null,"ValueMeaning":{"publicId":"14741291","version":"1","preferredName":"Galcanezumab","longName":"14741291v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galcanezumab","conceptCode":"C166816","definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"105629E4-1268-7709-E063-731AD00A5990","latestVersionIndicator":"Yes","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10563426-F170-78B1-E063-731AD00AFB50","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","deletedIndicator":"No"},{"value":"Pamiparib","valueDescription":null,"ValueMeaning":{"publicId":"13715000","version":"1","preferredName":"Pamiparib","longName":"13715000v1.00","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamiparib","conceptCode":"C120553","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9CCF12-BD7C-3766-E053-731AD00A3FED","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A647ED-A163-2390-E063-731AD00AC30C","beginDate":"2024-02-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-05","modifiedBy":"GDEEN","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Lirafugratinib","valueDescription":null,"ValueMeaning":{"publicId":"13961738","version":"1","preferredName":"Lirafugratinib","longName":"13961738v1.00","preferredDefinition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lirafugratinib","conceptCode":"C174208","definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE469A97-14A0-338C-E053-731AD00A7EAE","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"FINCHAMB","dateModified":"2023-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A9B0EC-D9C3-70BF-E063-731AD00A0CEC","beginDate":"2024-02-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-05","modifiedBy":"GDEEN","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Devimistat","valueDescription":null,"ValueMeaning":{"publicId":"13634059","version":"1","preferredName":"Devimistat","longName":"13634059v1.00","preferredDefinition":"A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Devimistat","conceptCode":"C80039","definition":"A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC66B732-474D-5005-E053-731AD00A2E4C","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"DWARZEL","dateModified":"2023-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11372CA5-AACD-7964-E063-731AD00A5FE7","beginDate":"2024-02-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-12","modifiedBy":"GDEEN","dateModified":"2024-02-12","deletedIndicator":"No"},{"value":"Brinzolamide","valueDescription":null,"ValueMeaning":{"publicId":"14770128","version":"1","preferredName":"Brinzolamide (Azopt)","longName":"14770128v1.00","preferredDefinition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brinzolamide","conceptCode":"C47420","definition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11EB7D48-1049-3ACB-E063-731AD00AF3DC","latestVersionIndicator":"Yes","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11EB84CB-F9AF-3C65-E063-731AD00A268F","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","deletedIndicator":"No"},{"value":"Pexastimogene Devacirepvec","valueDescription":null,"ValueMeaning":{"publicId":"13722187","version":"1","preferredName":"Pexastimogene Devacirepvec","longName":"13722187v1.00","preferredDefinition":"An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pexastimogene Devacirepvec","conceptCode":"C71533","definition":"An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9DC172-1566-6312-E053-731AD00A533C","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11FF5E95-F80D-6074-E063-731AD00AEAA4","beginDate":"2024-02-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-22","modifiedBy":"GDEEN","dateModified":"2024-02-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2939029","version":"1","preferredName":"Prior Therapy Agent Name","preferredDefinition":"No value exists.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C16124:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4AB7-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"ONEDATA","dateModified":"2009-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4AC8-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"GDEEN","dateModified":"2024-02-22","changeDescription":"2021-12-29 ak Added PV alt name NHS-IL12 to C97961.","administrativeNotes":"2023.9.22 Updated some missing PV concepts. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000584","version":"1","longName":"Prior Treatment","context":"ECOG-ACRIN"}]},{"publicId":"7283431","version":"1","longName":"CRF CDEs","context":"AMC","ClassificationSchemeItems":[{"publicId":"7283432","version":"1","longName":"Eligibility Checklist","context":"AMC"}]}],"AlternateNames":[{"name":"AMC","type":"USED_BY","context":"AMC"},{"name":"PRLNE1","type":"OID, AMC","context":"AMC"}],"ReferenceDocuments":[{"name":"Prior first line therapy rece","type":"Preferred Question Text","description":"Prior first line therapy received","url":null,"context":"ECOG-ACRIN"},{"name":"AMC Question Text","type":"Alternate Question Text","description":"1st line of therapy name","url":null,"context":"AMC"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"68EA3C2F-67C8-6F1C-E053-F662850A1B2C","latestVersionIndicator":"Yes","beginDate":"2018-04-03","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-03","modifiedBy":"COLLIED","dateModified":"2022-02-22","changeDescription":"Created for EA5162, 04/03/2018 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}